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General introduction
The topic of this thesis is focused on alterations in endothelial function in different stages 
of cardiovascular disease with special attention to the microcirculation. Due to its enormous 
surface, the microcirculation is regarded as the largest organ in the body. Moreover, evidence 
is accumulating that the microcirculation plays a major role in coronary artery disease (CAD), 
a common and potentially life-threatening disease. Not only is (micro)vascular endothelial 
dysfunction involved in the development of CAD, it also has been reported as an adverse 
side-effect of the treatment of CAD with percutaneous coronary interventions (PCI), as this 
thesis will address. Diabetes Mellitus (DM), a disease of epidemic proportions nowadays, is 
an independent and strong predictor of CAD.1 (Micro)vascular endothelial dysfunction is 
one of the most important contributors to the cardiovascular complications of DM, with an 
important role for the activated renin-angiotensin-aldosterone system (RAAS), as this thesis 
will demonstrate. A better understanding of (micro)vascular endothelial dysfunction will aid 
in better understanding the pathogenesis of cardiovascular disease and thereby provide novel 
treatment targets ultimately resulting in further improvement of treatment, or even prevention 
of cardiovascular disease.
In this general introduction, topics important for this thesis will be briefly explained. This thesis 
is subdivided into three parts with part I focusing on endothelial dysfunction in the development 
of CAD; part II focusing on endothelial dysfunction after PCI; and part III focusing on endothelial 
dysfunction in relation to DM and the RAAS. For a more detailed introduction into each of these 
three research parts, the reader is referred to chapters 3, 9 and 14, respectively. Finally, this 
thesis is the result of translational research combining both clinical and preclinical studies.
Coronary artery disease
Cardiovascular disease is still one of the leading causes of morbidity and mortality in the 
industrialized world. In the Netherlands, in the year 2015 alone, 20.757 women and 18.543 men 
died of cardiovascular disease; this translates to the death of, on average, 57 women and 51 men 
per day. Within cardiovascular disease, CAD plays an important role (29% as a cause of death 
in men and 18% in women).2 CAD is caused by atherosclerosis with endothelial dysfunction as 
an important initiator and contributor to the disease process.3 When atherosclerosis proceeds, 
together with thrombosis, it can result in occlusive CAD, causing severe morbidity and mortality.
Atherosclerosis
Atherosclerosis is the principal cause of CAD and is considered to be a generalized inflammatory 
disease occurring in large and medium-sized arteries. Inflammation and highly specific cellular 
and molecular responses result in the accumulation of plasma lipids within the artery wall 
causing atherosclerotic lesions.4 These lesions may be present throughout a person’s lifetime. 
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1The earliest type of lesion, the fatty streak, is already common in children.5 These early lesions 
can progress over time, destabilize at a certain moment to result in a clinical manifestation of the 
disease: i.e. occlusive CAD resulting in a myocardial infarction. The initial changes that precede 
the formation of atherosclerotic lesions take place in the endothelium, the barrier between the 
blood and the vascular wall. The vascular wall of arteries is composed of three layers: the intima 
consisting of a single layer of endothelial cells, the media consisting predominantly of vascular 
smooth muscle cells, and the adventitia made of connective tissue, containing nerves as well as 
nutrient capillaries that supply the vessel.
Endothelium 
The endothelium participates in numerous physiological processes including the regulation of 
vascular tone by the release of vasoactive molecules.6 Vasodilation refers to arterial widening 
and vasoconstriction to arterial narrowing, both resulting from relaxation or constriction of 
smooth muscle cells within the vascular wall. The vasomotor response may be intrinsic, due 
to local processes, or extrinsic due to systemic processes. In this way, organ perfusion can be 
regulated, coupling perfusion to tissue metabolism.7
Changes in the vasomotor properties of the endothelium may represent the earliest manifestation 
of endothelial dysfunction, characterised for example by exaggerated vasoconstriction. 
Endothelial dysfunction has been implicated in the pathological process of atherosclerosis: early 
in the process of atherogenesis; later in the control of dynamic plaque burden, and eventually 
in the clinical manifestation of CAD. Even PCI strategies, developed to resolve obstructive CAD, 
have been associated with endothelial dysfunction (see chapter 9).
By secreting relaxing and contracting factors, the endothelium itself can induce vasodilation 
or vasoconstriction in response to shear stress and to a variety of endogenous vasoactive 
substances that are produced systemically or generated locally by vascular tissue or circulating 
blood cells. The major endothelium-derived relaxing factor is nitric monoxide (NO), which 
reduces intracellular calcium within the vascular smooth muscle cells resulting in vasodilation.8 
The endothelium also secretes endothelium derived hyperpolarizing factors (EDHFs),9 and 
the potent vasoconstrictor endothelin-1 (ET-1).10 Furchgott et al have demonstrated that the 
endothelium plays an obligatory role in the relaxation of arteries induced by acetylcholine 
in humans or by bradykinin in swine. They identified NO as the released factor and cyclic 
guanoside monophosphate (cGMP) as its key second messenger. Since then, methods have 
been developed to assess endothelium dependent vasomotor function.11-13 The measurement 
of endothelial dysfunction has been used as a potential predictor of cardiovascular disease 3. 
Indeed, prospective studies have demonstrated that endothelial dysfunction is highly predictive 
of future cardiovascular disease.14
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Coronary interventions
PCI with stents is an important treatment option for obstructive CAD. The choice ranges from 
conventional bare metal stents (BMS), to first and second generation drug-eluting stents 
(DES) that are widely used in clinical practice.15 DES are nowadays the preferred treatment for 
local occlusive CAD, because DES locally release high concentrations of immunosuppressive, 
cytostatic, or cytotoxic drugs at the coronary injury site in order to prevent vascular smooth 
muscle cell proliferation and therefore limiting in-stent restenosis, as seen with BMS.16 The DES 
that have been approved include, in chronological order, the first generation DES like sirolimus-
eluting stent, paclitaxel-eluting stent (PES), and tacrolimus-eluting stent; and second generation 
DES like zotarolimus-eluting stent and everolimus-eluting stent. For third generation DES, the 
structural backbone has been optimised with use of the same drugs as for second generation 
DES. DES drugs can profoundly inhibit the development of neointimal formation after stenting. 
Indeed, DES treatment resulted in a reduction of restenosis rates and showed significant long-
term reduction in the number of target lesion revascularisation procedures as compared to 
BMS.17-21 However, DES have also been associated with increased risk of stent thrombosis, the 
most feared complication of coronary stenting due to its high mortality rates.22-25 As an underlying 
mechanism of thrombosis, impaired re-endothelialisation and delayed vascular healing have 
been identified.26,27 
Subsequently PCI technology has been further developed and now goes in the direction already 
indicated in 1990 by prof. W.J. van der Giessen: “The next generation of coronary stents will have 
to be a combination of a biodegradable device with either drug eluting properties or a device 
seeded with normal or by DNA-technology transformed endothelial cells. The next years will 
learn which approach, will be the most effective.”28 Recently, as a fourth generation of DES, the 
bioresorbable vascular scaffold (BVS) with drug-eluting properties has been introduced with the 
aim to provide temporary vessel scaffolding and to be subsequently resorbed over time with 
restoration of vasomotion. This could be the solution to the permanent presence of a metallic 
cage of conventional DES and BMS. Clinical trials have demonstrated efficacy for the treatment 
of CAD with some restoration of vasomotion.29-32 However, paradoxical vasoconstriction has also 
been observed, indicating persisting impairment of endothelial function.29,30 In addition, higher 
rates of scaffold thrombosis have been reported compared to second generation DES with 
related morbidity and mortality.33-35 Therefore, the problem of endothelial dysfunction after 
PCI still remains, requiring further study (see part II of this thesis). Interventional therapy will 
never be the ideal treatment on its own, since it only targets the consequences of CAD, i.e. the 
coronary obstruction, but not the atherosclerotic disease process itself. Therefore, knowledge 
of early disease development is of the utmost importance.
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1Animal models
Experimental disease models have been instrumental in enhancing our understanding of 
the pathogenesis of atherosclerosis development.36,37 However, atherosclerosis is a disease 
influenced by a multitude of environmental factors. The different animal models which have 
been used differ in disease initiation and disease manifestation and represent only a part of the 
heterogeneous clinical situation. Prof. W.J. van der Giessen stated in his thesis: “No single animal 
model will give definite answers but each one provides new insights or contributes to the study 
of a particular problem concerning the cause, the pathogenesis or the consequences”.28 Small 
animal models, like mice and rats, have the advantage of low costs, availability, and easy usability. 
Due to genetic modification and cross-breeding, specific strains can be generated and used to 
unravel mechanisms involved in the cardiovascular disease process. When size becomes more 
important, small animal models need to be complemented by large animal models. Indeed, for 
the study of CAD and related diagnostic and therapeutic interventions, an animal model that 
closely resembles the human situation with lesions at similar anatomical locations is necessary, 
e.g. a porcine model with CAD (see chapter 3).
Coronary circulation
The coronary vasculature has traditionally been divided into large conduit arteries, which are 
prone to atherosclerosis development, and the microcirculation, which represents the major 
locus of resistance to flow. Direct measurements of microvascular pressures in beating hearts 
have demonstrated that during basal conditions, up to 40% of total coronary resistance resides 
in small arteries between 100 and 400 μm in diameter. During vasodilation, these vessels 
contribute to an even greater fraction of total coronary resistance,38 making these small 
arteries important participants of the coronary circulation. These arteries are capable of active 
vasomotion by a myriad of vasodilator and vasoconstrictor signals exerted by neurohormonal 
influences, the endothelium, and metabolic signals form the myocardium. In this way, these 
vasomotor influences allow the myocardium to match the coronary blood supply with oxygen 
and nutrients, while maintaining a consistently high level of oxygen extraction.39
As described above, the endothelium is an important regulator of vasomotion and has been 
studied in part I of this thesis during different development stages of CAD: in both animal 
models and in patients. However, in small animals and in humans, the coronary circulation is 
more difficult to study. Since CAD is a representation of generalised cardiovascular disease, 
the study of endothelial function of the peripheral circulation can be relevant for CAD, and is 
translatable to the coronary circulation.40
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In vitro vascular function assessment
In this thesis (micro)vascular endothelial function was studied in vitro in isolated arterial 
segments (see chapters 5, 6, 7, 9, 10, 11, 13 and 16). For these in vitro studies, organ chambers 
and wire myographs were used. Organ chambers are suitable for segments of conduit arteries 
up to 1-4 mm in diameter. Mulvany and Halpern have developed a technique to study the 
vascular response of isolated segments of small resistance arteries (100-300 μm in diameter), 
called the Mulvany wire myograph.41 For both types of set-ups, arteries are quickly removed 
from freshly obtained organs and placed in cooled, oxygenated Krebs’ buffer solution, which has 
physiological similarities to plasma. An arterial segment is then mounted on hooks or wires and 
set to the appropriate diameter via coupling of the hooks / wires to an isometric force transducer 
on one side and to a micro-meter on the other side. This will allow for precise measurement of 
the separation of the hooks / wires and the increasing passive force when stretching the vessel. 
A mounted segment is stabilised at 37°C before undergoing a passive normalisation procedure, 
which determines a passive length-tension curve up to 90% of the circumference that would 
occur at a predetermined transmural pressure. Having set the segment to a normalised passive 
stretch, the active force developed by a constrictor stimulus is measured as the increase in 
pressure against which the vessel will contract. Different concentrations of vasoactive stimuli 
with or without specific blockers can now be applied and the changes in force / pressure can be 
measured and presented as a percentage of vasodilation or vasoconstriction in concentration-
response curves. Endothelial vasodilators are for example NO, EDHF, bradykinin, acetylcholine 
and prostaglandins generated by cyclooxygenase 1 or 2 (COX-2). Examples of vasoconstrictors are 
ET-1, angiotensin II (Ang II), phenylephrine and endothelium derived contractile factors (EDCF). 
All above mentioned substances have been used to cause in vitro vasomotor responses in the 
experiments of this thesis (see chapters 5, 6, 7, 10, 11, 13, 16). With multiple set-ups and many 
vessel segments per artery, vascular function can be studied in parallel and in great detail, which 
in vivo would be hampered by the potential systemic side effects of these vasoactive substances 
and by the interaction with each other caused by the long half-life of some substances.
Diabetes mellitus
The prevalence of DM, as well as its precursor the metabolic syndrome, is increasing worldwide 
and is reaching epidemic proportions.42,43 Cardiovascular disease, including CAD, accounts for 
most of the morbidity and mortality in patients with DM.44 CAD in DM patients is described as 
being diffuse and typically rapid in progression.45 Revascularisation procedures in DM patients 
are usually associated with worse outcomes than those performed in patients without DM.46 
This is related to multiple factors including the numerous metabolic disturbances which affect 
these high-risk patients and ultimately determine their tendency towards an increased pro-
atherothrombotic status.47 While the most common metabolic abnormality associated with DM 
is hyperglycemia, there are also abnormalities in fat metabolism resulting in hyperlipidemia, 
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1increased inflammation and oxidative stress, decreased vascular availability of NO, and an 
activated RAAS leading to endothelial dysfunction and subsequently to both macrovascular and 
microvascular injury.44,48-51 This results in the extensive generalised cardiovascular disease of DM 
with typical end organ damage in kidneys, eyes and coronary circulation.
Renin-angiotensin-aldosterone system
The RAAS is an important physiological regulator of blood pressure, fluid and electrolyte 
homeostasis, as well as cardiovascular regulation and remodeling. It controls the circulating 
volume and electrolyte balances through coordinated effects on the heart, blood vessels and 
kidneys via a cascade of hormones. The kidneys can regulate, in reaction to reduced renal blood 
flow, the synthesis of renin via conversion of its precursor prorenin. Remarkably, both renin 
and prorenin are released into the circulation. Plasma renin then carries out the conversion of 
angiotensinogen, released by the liver, to angiotensin I. Angiotensin I is subsequently converted 
to Ang II by the enzyme angiotensin-converting enzyme (ACE), mainly located in the endothelium 
of the lungs, although many other tissues can also form Ang II. Ang II is the primary effector 
hormone of the RAAS, acting as a strong vasoconstrictor, that can work either systemically or 
locally.52 Ang II stimulates the secretion of aldosterone from the adrenals and has its effects on 
fluid and electrolyte balance in the kidney, closing the feedback loop. If the systemic RAAS is 
overactive, blood pressure will be too high with subsequent adverse events. In addition, also 
‘local’ overactive RAAS has been linked to specific tissue damage.53 Inhibition of the RAAS, with 
ACE-inhibitors, Ang II type 1 receptor blockers and mineralocorticoid receptor antagonists, 
not only improves blood pressure control but also ameliorates endothelial function and 
cardiovascular outcomes in patients with DM.54-56 These downstream blockers of the RAAS result 
in an increase of plasma renin via a feedback loop.57 Previously, this was regarded as irrelevant, 
as long as the downstream RAAS was being blocked. However, the discovery of the (pro)renin 
receptor has shed a different light on the matter,58 suggesting that elevated plasma renin levels 
could result in the increased tissue uptake of renin, possibly inducing deleterious effects. This 
discovery has resulted in the development of more upstream RAAS inhibition with a direct renin 
inhibitor, which has become possible since 2007 with the clinical approval of aliskiren.59 Renin is 
the first and rate-limiting step of the RAAS, and therefore a logical therapeutic target. However, 
its clinical benefit for cardiovascular disease still needs to be proven.
It is clear that an overactive RAAS, either systemic or local, is a major contributor to cardiovascular 
complications, especially in the context of DM.50,51 The exact mechanisms of RAAS induced 
cardiovascular pathology in DM are still incompletely understood, but in specific tissues a 
discordant RAAS has been postulated as an explanation for disease, as exemplified in part III of 
this thesis.
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Aim and outline of the thesis
The general aim of this thesis is to study the role of endothelium-dependent (micro)vascular 
alterations in cardiovascular disease, specifically in (I) CAD development, (II) after PCI and (III) 
in relation to DM and RAAS over-activation. We investigated the specific research questions in 
both patients and experimental animal models. This thesis is divided in three parts.
Part I Endothelial dysfunction in the development of coronary artery disease
In chapter 2, a patient study regarding the role of generalised microvascular endothelial 
dysfunction in CAD development is presented. In this study, we used a validated method of 
peripheral microvascular endothelial function assessment, as a possible surrogate of the coronary 
microcirculation. Our objective was to assess the predictive value of peripheral microvascular 
endothelial dysfunction as an initial test to detect the presence or absence of obstructive CAD. 
For more in detail study of the pathological process especially in early CAD, experimental 
studies with animals are necessary. In the remaining chapters of part I, large animal models 
have been used for the different stages of the CAD process, ranging from generalised early 
atherosclerosis to specific coronary microvascular endothelial dysfunction. In chapter 3, a 
short review regarding animal models of CAD is given, focusing on the possibilities of invasive 
coronary imaging modalities in these models. In this review the diabetic, atherosclerotic pig 
model is being introduced. This model has been subsequently used in chapter 4 for a dietary 
intervention study. This study characterizes and compares the pathogenic effects of different 
diets in DM pigs. In this study we focused on aortic atherosclerosis development. This model 
of early macrovascular disease was subsequently used to study CAD in more detail. In chapter 
5, the diabetic atherosclerotic pig model has been used to examine coronary function early 
in the process of CAD development. This study specifically focuses on in vitro coronary 
endothelial function via NO and ET-1 systems, with separate evaluation of coronary conduit and 
small arterial function. To study these alterations over time, the diabetic atherosclerotic pigs 
were also studied at a later time point (see chapter 6). This study showed the possibilities of 
invasive coronary imaging techniques to assess more advanced CAD within this model and also 
assessed in vitro coronary macrovascular endothelial function. In chapter 7, in vitro coronary 
microvascular endothelial function, was studied in detail, in this model of more advanced 
CAD, again focusing on NO and ET-1 systems. Finally, in chapter 8, a study of the same diabetic 
atherosclerotic pigs with more advanced CAD, showed the effects of generalized microvascular 
dysfunction on specific end-organs including the kidney.
Part II Endothelial dysfunction after percutaneous coronary interventions
In chapter 9, a review regarding endothelial dysfunction after coronary interventions, in 
particular after DES implantation is given. In this overview, we described different methods, 
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1including patient examinations and animal models, of both in vivo and in vitro measurements 
of endothelial function after PCI, focusing on different aspects of endothelial dysfunction. 
Again, the porcine model is introduced as the most suitable model because of its similarities 
to human coronary anatomy. In chapter 10, the healthy porcine model is used to study the 
early endothelial response within the stent after different DES and BMS implantations, as well 
as the response of the microcirculation distal to the stent. In chapter 11, coronary endothelial 
function after different DES and BMS is being further examined with the focus on the NO- and 
EDHF-mediated mechanisms of coronary macro- and microvascular function distal to the stent.
However, the healthy porcine heart is not a disease model, possibly hampering the translation 
to the patient situation with CAD. Therefore, the atherosclerotic, diabetic pig model with more 
advanced CAD was used to study a novel type of coronary intervention, the BVS (see chapter 
12). Finally, coronary endothelial function of both the coronary macro- and microcirculation 
distal to BVS implantation was studied within this model in chapter 13.
Part III Endothelial dysfunction related to diabetes mellitus and the renin-angiotensin-
aldosterone system
In this part, the problem of increased cardiovascular disease development in DM is studied 
in more detail with focus on an overactive RAAS.  In particular the role of prorenin is studied, 
since diabetic patients have greatly elevated prorenin levels.60 In addition, these elevated 
prorenin levels are an early predictor of microvascular complications in DM.61,62 In chapter 14, 
we discussed the concept of a discordant tissue RAAS as a mediator of endothelial dysfunction 
leading to the cardiovascular complications of DM. In particular, the concept of the prorenin - 
(pro)renin receptor interaction, inducing inflammation and fibrosis resulting in cardiovascular 
disease, is being postulated, stating that interference in this axis might be a next logical step 
in the search for new therapeutic regimes to reduce DM-related cardiovascular morbidity and 
mortality. To examine this concept, we performed a patient study and a study in a rat model of 
cardiovascular disease (see part III). In chapter 15, we described which RAAS component best 
reflects renal RAAS activity in DM and therefore could indicate a discordant tissue RAAS in DM. 
In this study, we measured RAAS markers as well as markers of kidney function in urinary and 
plasma samples of diabetic and non-diabetic patients, with or without hypertension.
To study the prorenin - (pro)renin receptor interaction in more detail, a small animal model with 
cardiovascular disease was used: the diabetic hypertensive transgenic (mRen2)27 rat model. 
These diabetic rats express the mouse renin gene; have hypertension and elevated prorenin 
levels. This is therefore an ideal model of DM and an overactive RAAS to study cardiovascular 
dysfunction. In chapter 16 we evaluated endothelial dysfunction in diabetic, transgenic rats 
treated with a specific RAAS blocker: the renin inhibitor aliskiren, or aliskiren plus the putative 
(pro)renin receptor antagonist ‘handle region peptide’ (HRP). For this purpose, we studied 
detailed vascular function in both conduit and small arteries in vitro. In chapter 17 and in 
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chapter 18 the effects of RAAS blockade combined with (pro)renin receptor antagonism on 
damage to specific end organs, the kidneys and the eyes, were evaluated within the same rat 
model.
Finally, in chapter 19 all studies of these three parts are summarised and in chapter 20 a 
discussion of the studies and the clinical perspectives are given.
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ZHUH QRW VLJQL¿FDQWO\ GLIIHUHQW EHWZHHQ QRUPDO DQG LVFK-
aemic X-ECG groups. In addition RHI and AIx were simi-
lar between low risk as compared with intermediate-to-high 
risk, based on risk algorithms (RHI: 1.98 (0.67) vs 1.94 
(0.78); AIx: 0.0 (21) vs 5.0 (25); p = NS), or CCS and CTA 
5+,YV$,[íYV
p 16 )LQDOO\ 5+, DQG$,[ IDLOHG WR SUHGLFW UHYDVFX-
larisation (RHI: OR 1.42, CI 0.65–3.1; AIx: OR 1.02, CI 
0.98–1.05).
Conclusions 3$7FDQQRWGHWHFWDORZULVNRI&$'SRVVLEO\
because RHI and AIx versus X-ECG, CCS and CTA repre-
sent independent processes.
Keywords Coronary artery disease ·  
3HULSKHUDOYDVFXODUIXQFWLRQā1RQLQYDVLYHWHVWLQJ
Introduction
Chest pain is a common symptom that may be caused by 
obstructive coronary artery disease (CAD) and requires 
ULVN VWUDWL¿FDWLRQ WR DVVHVV WKH SUREDELOLW\ RI &$' >1]. 
Risk algorithms have been developed based on combina-
WLRQVRIULVNIDFWRUV>2, 3]. However, these models tend to 
RYHUHVWLPDWHWKHSUHYDOHQFHRI&$'>4], and are based on 
SRSXODWLRQ FDOFXODWLRQV UDWKHU WKDQ D GLUHFW DVVHVVPHQW RI
the atherosclerotic process within an individual. Diagnos-
tic testing with exercise electrocardiography (X-ECG) is 
FRQVLGHUHGWREHKLJKO\GLVFULPLQDWLYH>5@KRZHYHULVRIWHQ
inconclusive. Alternative tests using pharmacological stress 
are usually not immediately available. Computed tomogra-
SK\ &7 LV H[SDQGLQJ LQ WKHZRUNXS >1], using coronary 
FDOFLXPVFRULQJ&&6>6] and computed tomographic angi-
RJUDSK\&7$>7]. However, there are associated disadvan-
tages such as costs, radiation exposure and administration 
Abstract
Background (QGRWKHOLDOG\VIXQFWLRQSUHFHGHVFRURQDU\DU-
tery disease (CAD) and can be measured by peripheral arte-
ULDOWRQRPHWU\3$7:HH[DPLQHGWKHDSSOLFDELOLW\RI3$7
WRGHWHFWDORZULVNRI&$'LQDFKHVWSDLQFOLQLF
Methods ,Q  SDWLHQWV 3$7 ZDV SHUIRUPHG UHVXOWLQJ LQ
reactive hyperaemia (RHI) and augmentation (AIx) indi-
FHV3DWLHQWVZHUH ULVNFODVVL¿HGDFFRUGLQJ WR+HDUW6FRUH
Diamond and Forrester pretest probability (DF), exercise 
testing (X-ECG), and computed tomography calcium scor-
ing (CCS) and angiography (CTA). Correlations, risk group 
GLIIHUHQFHVDQGSUHGLFWLRQRIUHYDVFXODULVDWLRQZLWKLQ\HDU
were calculated.
Results RHI correlated with HeartScore (r í
p = 0.05), AIx with DF (r = 0.26, p = 0.01). However, both 
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RIFRQWUDVWDJHQW>8@7KHUHIRUHDEHWWHUGLVFULPLQDWLRQRI
SDWLHQWVDWORZULVNRIFOLQLFDOO\UHOHYDQW&$'ZLOOIDFLOLWDWH
PRUHHI¿FLHQWXVHRIVXEVHTXHQWGLDJQRVWLFV
(QGRWKHOLDOG\VIXQFWLRQSUHFHGHVDQGFRQWULEXWHVWRWKH
atherosclerotic disease process. Peripheral arterial tonom-
etry (PAT) has emerged as an easy, noninvasive test to study 
HQGRWKHOLDOIXQFWLRQDWWKH¿QJHUWLS>9, 10]. From one sin-
gle PAT measurement both the reactive hyperaemia index 
5+,LQGLFDWLQJHQGRWKHOLXPGHSHQGHQWYDVRGLODWLRQ>11], 
DQGWKHDXJPHQWDWLRQLQGH[$,[LQGLFDWLQJDUWHULDOVWLII-
QHVV>12], can be derived. RHI and AIx have shown to be 
DOWHUHG LQ WKHSUHVHQFHRI&$'>12–15], and can be used 
LQ &$' ULVN VWUDWL¿FDWLRQ >16]. However, although PAT 
appears promising in research settings, validation in the 
clinical setting beside conventional measures has only been 
OLPLWHG>11@7KHUHIRUHWKHREMHFWLYHRIWKLVFURVVVHFWLRQDO
VWXG\ZDV WRDVVHVV WKHDSSOLFDELOLW\RI3$7WRGHWHFW ORZ
ULVNRIFOLQLFDOO\UHOHYDQW&$'LQXQVHOHFWHGSDWLHQWVYLVLW-
ing a rapid-access outpatient chest pain clinic.
Methods
Study population
From September 2009 to February 2010, 93 consecutive 
patients with new onset stable chest pain without evidence 
RI RQJRLQJ LVFKDHPLD DQG QR SULRU KLVWRU\ RI &$' JDYH
ZULWWHQFRQVHQWWRXQGHUJR¿QJHUSOHWK\VPRJUDSK\WRPHD-
sure PAT at the same time as their chest pain evaluation, 
DIWHUVWXG\DSSURYDOE\WKH0HGLFDO(WKLFV&RPPLWWHH7KH
sample size was comparable with previous PAT validation 
VWXGLHV >11, 12, 16@ DQG VXI¿FLHQWO\ ODUJH WRREVHUYHGLV-
FULPLQDWLQJ WHQGHQFLHV >17]. There were no exclusion cri-
teria. All patients were scheduled to undergo conventional 
GLDJQRVWLFV%DVHG RQ FXWRII YDOXHV RI WKHVH GLDJQRVWLFV
SDWLHQWVDWORZULVNRIFOLQLFDOO\UHOHYDQW&$'ZHUHLGHQWL-
¿HG7KLVZDVYHUL¿HGE\HYDOXDWLQJUHYDVFXODULVHGSDWLHQWV
by percutaneous coronary intervention (PCI) or coronary 
DUWHU\E\SDVVJUDIWLQJ&$%*IRUXSWR\HDU
5LVNSUR¿OLQJ
&DUGLRYDVFXODU ULVN IDFWRUV ZHUH VXPPDULVHG XVLQJ WKH
+HDUW6FRUHULVNDOJRULWKP>3@WRDVVHVVWKHULVNRI\HDU
PRUWDOLW\ RI &$' DQG WKH'LDPRQG DQG )RUUHVWHUPRGHO
')>2, 4@WRDVVHVVWKHSUHWHVWSUREDELOLW\RI&$'
Exercise electrocardiography
;(&*ZDVSHUIRUPHGE\VWDQGDUGLVHGSURWRFRO>5]. A non-
GLDJQRVWLF UHVXOW ZDV GH¿QHG DV GLVFRQWLQXDWLRQ ZLWKRXW
HYLGHQFHRIP\RFDUGLDOLVFKDHPLDEHIRUHUHDFKLQJRI
the target heart rate. Results were described as being non-
ischaemic, inconclusive or ischaemic. Only non-ischaemic 
and ischaemic groups were taken into comparative anal.
Cardiac computed tomography
$ QRQHQKDQFHG &7 VFDQ ZDV SHUIRUPHG WR DVVHVV WKH
DPRXQW RI FRURQDU\ FDOFLXP IROORZHG E\ D FRQWUDVW
HQKDQFHG VFDQ WR DVVHVV SODTXH EXUGHQ DQG SUHVHQFH RI
stenotic CAD. Image acquisition was conducted using a 
128-slice dual-source CT (Siemens Flash, Forchheim, Ger-
many). Coronary arteries were quantitatively evaluated per
FRURQDU\VHJPHQWIRUSUHVHQFHRIDWKHURVFOHURWLFSODTXHDQG
!VWHQRVLV>7@&&6DQGWRWDOQXPEHURISODTXHVDQG
stenoses per patient were included in the analysis.
Peripheral arterial tonometry
The PAT response was measured with the EndoPAT 2000 
device (Itamar Medical Ltd., Caesarea, Israel), according to 
a standardised protocol allowing simultaneous determina-
WLRQRIERWK5+,DQG$,[$QLQGH[RISXOVHZDYHDPSOLWXGH
at rest and during reactive hyperaemia resulted in RHI, a 
PHDVXUHRIHQGRWKHOLXPGHSHQGHQWYDVRGLODWLRQ>9–11, 13, 
16@ $XJPHQWDWLRQ RI WKH FHQWUDO SXOVH SUHVVXUH DOORZHG
GHWHUPLQDWLRQRI$,[UHSUHVHQWLQJHQGRWKHOLXPGHSHQGHQW
DUWHULDOVWLIIQHVV>12, 18].
Statistical analysis
Summary data are presented as numbers (proportion) or 
expressed as mean ± standard deviation or median (inter-
TXDUWLOH UDQJH ,Q FDVH RI QRQQRUPDO GLVWULEXWLRQ GDWD
ZHUHORJDULWKPLFDOO\WUDQVIRUPHGEHIRUHDQDO\VLV&RUUHOD-
tions between RHI, AIx and conventional diagnostics were 
DQDO\VHG XVLQJ 3HDUVRQ¶V FRUUHODWLRQ FRHI¿FLHQW 'LIIHU-
ences between two groups were assessed by t-testing. The 
SUHGLFWLYHYDOXHRI5+,DQG$,[IRUUHYDVFXODULVDWLRQZDV
analysed using logistic regression and described as odds 
UDWLR 25 ZLWK FRUUHVSRQGLQJ  FRQ¿GHQFH LQWHUYDO
(CI). Two-tailed pZDVFRQVLGHUHGVLJQL¿FDQW
Results
Conventional diagnostic characteristics
Overall, patients were middle aged with equal distribution 
between genders (Table 11RQHKDGDKLVWRU\RI&$'EXW
FDUGLRYDVFXODUULVNIDFWRUVZHUHDEXQGDQWDQGWKUHHTXDUWHUV
used cardiovascular medication. In all, conventional diag-
QRVWLFVEHVLGHV3$7ZHUHSHUIRUPHGWRH[DPLQHFOLQLFDOO\
relevant CAD (Table 2). This allowed us to examine corre-
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Digital pulse arterial tonometry testing
With regard to risk algorithms, RHI correlated weakly with 
HeartScore (r íp = 0.05, Fig. 1a), whereas AIx did 
not (r = 0.15, p = NS, Fig. 1b). Surprisingly, RHI did not 
correlate with DF (r = 0.05, p = NS, Fig. 1c), whereas AIx 
did modestly (r = 0.26, p < 0.05, Fig. 1d). With regard to CT 
SDUDPHWHUV QR VLJQL¿FDQW FRUUHODWLRQV EHWZHHQ 5+, DQG
CCS (r íp = NS), plaque (r íp = NS, Fig. 1e) 
or stenosis (r íp 16ZHUHIRXQG$OVRQRVLJQL¿-
cant associations between AIx and CCS (r = 0.06, p = NS), 
plaque (r = 0.11, p = NS, Fig. I) or stenosis (r = 0.03, p = NS) 
were observed.
7RDQDO\VHORZULVNRIFOLQLFDOO\UHOHYDQW&$'PRUHVSH-
FL¿FDOO\SDWLHQWVZHUHGLYLGHGLQWRORZRULQWHUPHGLDWHWR
KLJKULVNJURXSVEDVHGRQWKHRXWFRPHVRIULVNVFRUHV;(&*
and CT. According to the risk algorithms, patients at low 
risk (n GH¿QHGDVORZULVNRIERWK')DQG+HDUW6FRUH
outcomes) showed similar RHI and AIx values as compared 
with intermediate-to-high risk (n GH¿QHGDVLQWHUPHGL-
DWHWRKLJKULVNRI')RU+HDUW6FRUHRXWFRPHUHVSHFWLYHO\
(RHI: 1.98 (0.67) vs 1.94 (0.78); AIx: 0.00 (21) vs 5.0 (25); 
all p = NS; Fig. 2a, b). According to X-ECG results, low risk 
(n GH¿QHGDVDQHJDWLYH;(&*RXWFRPHDOVRGLGQRW
VLJQL¿FDQWO\GLIIHUIURPKLJKULVNn GH¿QHGDVDSRVL-
tive outcome), respectively (RHI: 1.97 (0.72) vs 1.58 (0.61); 
$,[íYVDOOp = NS). According to CT 
outcomes, low risk (n GH¿QHGDVDEVHQFHRIFDOFLXP
plaque and stenosis) resembled intermediate-to-high risk 
(n GH¿QHGDVSUHVHQFHRIFDOFLXPSODTXHRUVWHQRVLV
5+,YV$,[íYV
all p = NS; Fig. 2c, d).
Finally, both RHI and AIx could not predict revasculari-
sation within 1 year (RHI: OR 1.42, CI 0.65–3.1; AIx: OR 
1.02, CI 0.98–1.05). Although RHI was lower in the revas-
FXODULVHGJURXSWKLVZDVQRWVLJQL¿FDQWO\GLIIHUHQWUHYDV-
cularisation + (n YVUHYDVFXODULVDWLRQín = 79): 1.94 
(1.06) vs 1.96 (0.70), p = NS; Fig. 3a). Also AIx showed a 
tendency towards an altered response in the revascularised 
JURXS KRZHYHU DJDLQ QRW VWDWLVWLFDOO\ VLJQL¿FDQW UHYDV-
cularisation + (n  YV UHYDVFXODULVDWLRQ í n = 81): 4.0 
(27) vs 2.0 (23), p = NS; Fig. 3b). This is in contrast to
conventional diagnostics: the revascularised group (n = 7) 
VKRZHG VLJQL¿FDQWO\ PRUH LVFKDHPLF ;(&* RXWFRPHV
than the non-revascularised group (n = 46) (0.71 ± 0.18 vs 
0.09 ± 0.04; p < 0.01); CCS showed a modest prediction
(OR 1.01, CI 1.00–1.03), whereas CTA-assessed plaque
(OR 1.11, CI 1.05–1.17) and stenosis (OR 2.8, CI 1.60–4.8)
VKRZHGVWURQJSUHGLFWLRQVRIUHYDVFXODULVDWLRQ
lations between PAT and conventional diagnostics, as well 
DVVXEJURXSDQDO\VLVIRUWKHVHRXWFRPHVDQGSUHGLFWLRQRI
revascularisation within 1 year.
Table 1 Patient characteristics
Demographics
Age (years) 56 ± 11
Women 
Risk factors
Nicotine abuse 
Hypertension 
Diabetes mellitus 
Dyslipidaemia 
Body mass index (kg/m2) 28 ± 5
)DPLO\KLVWRU\RIFDUGLRYDVFXODUGLVHDVH 
+LVWRU\RIYDVFXODUGLVHDVH 
Cardiovascular medication use 
Revascularisation
PCI 
CABG 
PCI percutaneous coronary intervention, CABG coronary artery 
E\SDVVJUDIWLQJ
Table 2 Diagnostic characteristics
Risk scores
+HDUW6FRUHORZLQWHUPHGLDWHULVN 
+HDUW6FRUHKLJKULVN 
Median HeartScore 4 (6)
')ORZSUHWHVWSUREDELOLW\ 
')LQWHUPHGLDWHSUHWHVWSUREDELOLW\± 
')KLJKSUHWHVWSUREDELOLW\! 
Median DF pretest probability 55 (51)
X-ECG
X-ECG 
Inconclusive 
Non-ischaemic 
Ischaemic 
CT
CCS 
Median CCS 6.1 (94)
CTA 
Median plaques 6.0 (14)
Median stenosis 0 (1)
PAT
RHI 
Median RHI 1.95 (0.76)
AIx 
Median Aix 3.0 (23)
DF Diamond and Forrester model, X-ECG exercise 
electrocardiography, CT computed tomography, CCS coronary 
calcium scoring, CTA computed tomography angiography, PAT 
peripheral arterial tonometry, RHI reactive hyperaemia index, AIx 
augmentation index.
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low risk based on conventional diagnostics showed non-dis-
criminative RHI and AIx outcomes. (iv) Finally, both RHI 
DQG$,[IDLOHGWRSUHGLFWUHYDVFXODULVDWLRQZLWKLQ\HDU
&OLQLFDODSSOLFDELOLW\RI3$7
L:HFRQ¿UPHGWKHPRGHVWUHODWLRQRI5+,ZLWKWUDGLWLRQDO
ULVNIDFWRUVDVUHSRUWHGSUHYLRXVO\>13]. AIx showed a weak 
Discussion
7KH SUHVHQW VWXG\ H[DPLQHG WKH DSSOLFDELOLW\ RI 3$7
GHULYHG5+,DQG$,[WRLGHQWLI\SDWLHQWVDWORZULVNRIFOLQL-
FDOO\ UHOHYDQW&$'7KHPRVW LPSRUWDQW¿QGLQJVZHUH L
that although RHI and AIx correlated weakly with CAD 
risk estimates, (ii) both RHI and AIx were not related with 
X-ECG or CT-imaged parameters. (iii) Most importantly, 
fe
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Fig. 1 &RUUHODWLRQJUDSKVRI
reactive hyperaemia index (RHI) 
(panels a, c, e) and augmenta-
WLRQLQGH[$,[SDQHOVEGI
with HeartScore (panels a, b), 
Diamond and Forrester pretest 
probability (DF) (panels c, d) 
DQGWRWDODPRXQWRISODTXHDV-
sessed by computed tomographic 
DQJLRJUDSK\&7$SDQHOVHI
Regression equation and R2 cor-
UHODWLRQFRHI¿FLHQWDUHGHSLFWHG
SHUSDQHO6LJQL¿FDQWDVVRFLDWLRQV
were observed between RHI and 
HeartScore as well as between 
AIx and DF, *P
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SUHVHQW LQ UHYDVFXODULVHG SDWLHQWV RI WKH SUHVHQW VWXG\
whereas RHI was non-discriminative, making an indepen-
dent relation likely. In addition, RHI and AIx did not sig-
QL¿FDQWO\ FRUUHODWHZLWK&&6 LQ FRQWUDVW WR DSULRU VWXG\
RI VHOHFWHG SDWLHQWV >19@ +DQ HW DO >20] also showed no 
DVVRFLDWLRQEHWZHHQ FRURQDU\ HQGRWKHOLDO G\VIXQFWLRQ DQG
FDOFL¿FDWLRQUHÀHFWLQJWKDWERWKFDQUHSUHVHQWVHSDUDWHGLV-
ease stages. In addition, brachial AIx was not independently 
DVVRFLDWHGZLWK&&6 >21], supporting our results. Indeed, 
FRUUHODWLRQZLWK WKH SUHWHVW SUREDELOLW\ RI &$' 3DWYDUG-
KDQ HW DO >12] reported a strong association between AIx 
DQGDJHPRVW OLNHO\ WKHEDVLV IRU WKLV FRUUHODWLRQ LL1R
VLJQL¿FDQWGLIIHUHQFHVLQHLWKHU5+,RU$,[ZHUHREVHUYHG
based on X-ECG outcome. This is remarkable since X-ECG 
is considered to be highly discriminative in patients at risk 
RIREVWUXFWLYH&$'>5], and also RHI has shown to be able 
WRGLVFULPLQDWHEHWZHHQSUHVHQFHRUDEVHQFHRI&$'>11]. 
,QGHHGLVFKDHPLF;(&*RXWFRPHVZHUHPRUHIUHTXHQWO\
Fig. 3 'LIIHUHQFHVRIUHDFWLYH
hyperaemia index (RHI) (panel 
a) and augmentation index 
(AIx) (panel b) between patients 
with and without revascu-
ODULVDWLRQXSWR\HDUDIWHU3$7
measurement. Horizontal bars 
depict the median value. No 
VLJQL¿FDQWGLIIHUHQFHVEHWZHHQ
the groups were observed. 
5HYDVFí no revascularisation; 
Revasc + revascularisation
 
Fig. 2 'LIIHUHQFHVRIUHDFWLYH
hyperaemia index (RHI) (panels 
a, c) and augmentation index 
(AIx) (panels b, d) between 
patients at low and intermedi-
DWHWRKLJKULVNRIFOLQLFDOO\
relevant CAD based on the 
FRPELQHGRXWFRPHRIULVN
scores (a, b), and CCS and CTA 
assessed plaque and stenosis (c, 
d). Horizontal bars depict the 
PHGLDQYDOXH1RVLJQL¿FDQW
GLIIHUHQFHVEHWZHHQWKHJURXSV
were observed. RFULVNIDFWRUV
X-ECG exercise ECG, CT com-
puted tomography, low low risk, 
int-hi intermediate-to-high risk
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RIFDUGLRYDVFXODUGLVHDVHDQGGLDEHWHV&LUF-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±
20. Han SH, Gerber TC, Suwaidi JA, et al. Relationship between coro-
QDU\HQGRWKHOLDOIXQFWLRQDQGFRURQDU\FDOFL¿FDWLRQLQHDUO\DWK-
erosclerosis. Atherosclerosis. 2010;209:197–200.
21. Park JS, Choi UJ, Lim HS, et al. The relationship between coronary 
DUWHU\FDOFL¿FDWLRQDVDVVHVVHGE\PXOWLGHWHFWRUFRPSXWHGWRPRJ-
UDSK\DQGDUWHULDOVWLIIQHVV&OLQ([S+\SHUWHQV±
RWKHU YDVFXODU IXQFWLRQ WHVWV KDYH SUHYLRXVO\ LQGLFDWHG
WKDWHQGRWKHOLDOG\VIXQFWLRQPD\UHSUHVHQWDQLQGHSHQGHQW
UHVSRQVHLQWKHSURJUHVVLRQRI&$'ZKHUHDVDUHODWLRQZLWK
WKHGHYHORSPHQWRIDWKHURVFOHURVLVH[LVWV>22–26]. RHI and 
$,[ ZHUH QRW VLJQL¿FDQWO\ DVVRFLDWHG ZLWK &7$LPDJHG
plaque or stenosis. This is contrary to previous studies with 
LPDJHG &$' GHVFULELQJ VSHFL¿F VXEJURXSV ZLWK SURYHQ
&$'>11, 12@GLDEHWHV >14@RUZRPHQ>15] although the 
SUHVHQFHRI&$'ZDVQRWYHUL¿HGZLWK&7$LQDQ\RIWKHP
LLL$OVR5+,DQG$,[ZHUHQRWDEOH WRGLIIHUHQWLDWH ORZ
ULVN RI FOLQLFDOO\ UHOHYDQW &$' LQ FRQWUDVW WR UHVXOWV LQ
VHOHFWHGSRSXODWLRQV>11, 12, 16], complicating comparison 
with our unselected population. (iv) Finally, RHI and AIx 
IDLOHGWRSUHGLFWUHYDVFXODULVDWLRQZLWKLQ\HDUFRQWUDU\WR
Rubinshtein, who showed that RHI independently predicted 
UHYDVFXODULVDWLRQ>27]. Also radial AIx predicted revascular-
LVDWLRQ>28@DOWKRXJKIRUGLJLWDO$,[QRVXFKVWXGLHVH[LVWWR
our knowledge. However, again selected patients were eval-
XDWHGZLWKDGYHUVHHYHQWVRFFXUULQJDWORQJWHUPIROORZXS
ZKLFK LV GLI¿FXOW WR FRPSDUHZLWK RXU \HDU HYDOXDWLRQ
,QGHHG SDWLHQW VHOHFWLRQPD\ VWURQJO\ LQÀXHQFH RXWFRPH
EHFDXVHVSHFL¿FULVNIDFWRUVKDYHDGGLWLRQDOHIIHFWVRQWKH
PHDVXUHPHQW LWVHOI EHVLGHV RQ WKH&$'SURFHVV DV KLJK-
OLJKWHGE\WKHVWXG\RI*DUJLXOR>14].
Conclusions
,QVSLWHRIWKHSDWKRSK\VLRORJLFDOEDVLVRIHQGRWKHOLDOG\V-
IXQFWLRQ LQ &$' DQG WKH SURPLVLQJ UHVXOWV ZLWK 3$7 LQ
VHOHFWHGSRSXODWLRQVXQGHUFRQWUROOHGFRQGLWLRQVZHIRXQG
no evidence to support PAT as a diagnostic tool to detect low 
ULVNRIFOLQLFDOO\UHOHYDQW&$'LQDQXQVHOHFWHGRXWSDWLHQW
population.
Acknowledgements 7KHDUWLFOHLVGHGLFDWHGWR3URIHVVRU'U:-YDQ
der Giessen who sadly passed away on 6 June 2011.
Funding 7KHSUHVHQWVWXG\ZDVIXQGHGE\WKH(UDVPXV0HGLFDO&HQ-
ter as a pilot study.
&RQÀLFWRILQWHUHVWV None reported.
Open Access 7KLVDUWLFOHLVGLVWULEXWHGXQGHUWKHWHUPVRIWKH&UHDWLYH
Commons Attribution License which permits any use, distribution, and 
reproduction in any medium, provided the original author(s) and the 
source are credited.
References
 1. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guide-
OLQHVRQWKHPDQDJHPHQWRIVWDEOHFRURQDU\DUWHU\GLVHDVHWKH7DVN
)RUFHRQWKHPDQDJHPHQWRIVWDEOHFRURQDU\DUWHU\GLVHDVHRIWKH
(XURSHDQ6RFLHW\RI&DUGLRORJ\(XU+HDUW-±
Chapter 2
32
474
1 3
Neth Heart J (2015) 23:468–474
26. Asselbergs FW, Monnink SH, Jessurun GA, et al. Assessing 
WKH SURJQRVWLF YDOXH RI FRURQDU\ HQGRWKHOLDO IXQFWLRQ LQ SD-
WLHQWV UHIHUUHG IRU D ¿UVW FRURQDU\ DQJLRJUDP $P - &DUGLRO
2004;94:1063–7.
5XELQVKWHLQ5.XYLQ-76RIÀHU0HWDO$VVHVVPHQWRIHQGRWKH-
OLDOIXQFWLRQE\QRQLQYDVLYHSHULSKHUDODUWHULDOWRQRPHWU\SUHGLFWV
late cardiovascular adverse events. Eur Heart J. 2010;31:1142–8.
28. Weber T, Auer J, O’Rourke MF, et al. Increased arterial wave 
UHÀHFWLRQV SUHGLFW VHYHUH FDUGLRYDVFXODU HYHQWV LQ SDWLHQWV XQ-
dergoing percutaneous coronary interventions. Eur Heart J. 
2005;26:2657–63.
 -DPEULN=9HQQHUL/9DUJD$HWDO3HULSKHUDOYDVFXODUHQGRWKH-
OLDO IXQFWLRQWHVWLQJIRU WKHGLDJQRVLVRIFRURQDU\DUWHU\GLVHDVH
Am Heart J. 2004;148:684–9.
)ULFN06XHVVHQEDFKHU$$OEHU+) HW DO3URJQRVWLFYDOXHRI
EUDFKLDODUWHU\HQGRWKHOLDOIXQFWLRQDQGZDOOWKLFNQHVV-$P&ROO
Cardiol. 2005;46:1006–10.
9HQQHUL/3RJJLDQWL(-DPEULN=HWDO7KHHOXVLYHSURJQRVWLF
YDOXHRIV\VWHPLFHQGRWKHOLDOIXQFWLRQLQSDWLHQWVZLWKFKHVWSDLQ
syndrome. Int J Cardiol. 2007;119:109–11.
25. Nishimura RA, Lerman A, Chesebro JH, et al. Epicardial vasomo-
tor responses to acetylcholine are not predicted by coronary ath-
erosclerosis as assessed by intracoronary ultrasound. J Am Coll 
Cardiol. 1995;26:41–9.

.
.Invasive coronary imaging in animal models 
of atherosclerosis
van Ditzhuijzen N.S.*, van den Heuvel M.*, Sorop O., van Duin R.W., Krabbendam-Peters I., 
van Haeren R., Ligthart J.M., Witberg K.T., Duncker D.J., Regar E., 
van Beusekom H.M. and van der Giessen W.J.
*Shared first authorship
Neth Heart J. 2011 Oct;19(10):442-6
3
Chapter 3
36
Invasive coronary imaging in animal models
of atherosclerosis
N. S. van Ditzhuijzen & M. van den Heuvel & O. Sorop & R. W. B. van Duin &
I. Krabbendam–Peters & R. van Haeren & J. M. R. Ligthart & K. T. Witberg &
D. J. Duncker & E. Regar & H. M. M. van Beusekom & W. J. van der Giessen
Published online: 9 September 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Experimental disease models have enhanced our understand-
ing of the pathogenesis of atherosclerosis development. For
example, insight has been gained into the role of the
endothelium, lipids, platelets and inflammation, as well as
into potential diagnostic and therapeutic interventions. More-
over, transgenic and knock-out technologies have become a
widespread approach and this is a growing field to assess the
role of individual genes in vascular biology and pathology.
However, atherosclerosis is most of all a multifactorial
disease, influenced by a multitude of environmental factors.
Therefore, it is important to also study non-transgenic animal
models that closely resemble the human situation with
atherosclerotic lesions at anatomical locations that mimic the
clinical manifestation of the disease, e.g. coronary artery
disease (CAD). Although no model completely mimics
human atherosclerosis, much can be learned from existing
models in the study of this disease, also with respect to the
development of new interventions. Here, we describe the most
relevant animal models of atherosclerosis, while focusing on
CAD development and the use of coronary diagnostic and
therapeutic interventions. In addition, we show examples of
features of a large animal model of CAD including pictures of
invasive coronary imaging.
Small versus large animal models
Small animal models, primarily small rodents and rabbits,
have been used extensively in atherosclerosis research.
Some of the reasons include low costs, availability, and
easy usability (Table 1). However, mice do not spontane-
ously develop atherosclerosis without genetic manipulation
since they have a lipid profile that is different from humans.
Yet, due to genetic modification and cross-breeding specific
strains can be generated and used to unravel molecular
mechanisms involved in the atherosclerosis process [1].
However transgenic mouse models do not typically develop
advanced lesions, including plaque rupture and thrombosis
[2], which is typical in patients presenting with symptom-
atic disease. When size becomes more important, small
animal models need to be complemented by larger animal
models in which vessel characteristics are more similar to
human arteries. The rabbit model on a high cholesterol diet
has been widely used in the study of experimental
atherosclerosis (Table 1). Combined with arterial wall
injury, lesions at least partly resembling human plaque
will develop in the aorta or iliac arteries of this model
[3]. However, when coronary atherosclerosis is the object
of study, pigs seem to be the most representative model
(Table 1). Pigs have a highly similar anatomy and
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physiology of the coronary system as compared to humans
[4]. In addition, with use of toxin-mediated pancreatic
damage and a high fat diet, human diabetes mellitus
(DM)-like metabolic alterations will develop [5], followed
by coronary lesions resembling the human condition
closely with even some characteristics of vulnerable
plaque [6, 7]. Historically monkeys have also been
considered to be a good model of human atherosclerosis
(Table 1); in particular the effects of hormones and the role
of behaviour can be studied with this model [8, 9].
However, nowadays monkeys are not widely used due to
obvious species-specific ethical concerns and costs [2].
In the validation process of coronary interventional
devices and therapies for diagnosis and treatment of
human CAD, both healthy rabbit [10] and pig models
[11] have been used extensively, although the rat model
has also been used occasionally [12] (Table 1). In these
models, arterial overstretch injury with stenting will result
in a restenosis process with re-endothelialisation, inflam-
mation and neointima formation. However, these are
healthy animal models in which the vascular healing
response occurs faster than in diseased humans [10, 11].
Therefore, the USA Food and Drug Administration has
proposed a guidance that new coronary diagnostic and
therapeutic interventional devices need to be tested in
more clinically relevant animal models of disease
(6255companion.doc, 2008). Since the porcine model is
Table 1 Animal models of atherosclerosis
Animal model Advantages Limitations
Mouse 1 Rapid development of atherosclerotic plaque 1 Limited resemblance to humans
2 Short reproductive cycle+large litters 2 Limited complex atherosclerotic lesion formation
3 Well-known genome+genome manipulation possible 3 Very high levels of blood lipids+different lipid profile
4 Cheap
Rat 1 Useful as restenosis model 1 No development of atherosclerotic lesions
2 Cheap
Rabbit 1 Fibroatheroma lesions 1 Need for high plasma cholesterol levels to develop atherosclerosis
2 Useful as restenosis model 2 No plaque rupture model
3 Affordable 3 Model for neointima formation+re-endothelialisation rather than
atherosclerosis
4 Coronary evaluation difficult
Pig 1 Atherosclerotic lesions similar to human disease 1 Expensive
2 Blood lipids in human range 2 Difficult to handle due to size
3 Invasive coronary imaging possible 3 Limited genomic tools
4 Useful as restenosis model post-intervention
5 Useful for detailed coronary endothelial function studies
Monkey 1 Atherosclerotic lesions similar to human disease 1 Ethical concerns
2 Influence of behavioural factors, e.g. psychosocial
stress
2 Very expensive
3 Influence of hormonal status 3 Difficult to handle
Table 2 Plasma characteristics
Plasma markers Diabetic pigs Non-diabetic
pigs
Two-way
ANOVA
Glucose (mmol/l) P<0.01a
9 months 15±2.9* 4.1±0.27
12 months 13±2.3* 4.5±0.47
15 months 18±4.5* 5.1±0.42
Triglycerides (mmol/l) P=0.02a
9 months 1.15±0.26 0.64±0.27
12 months 0.95±0.25 0.44±0.08
15 months 1.26±0.50 0.64±0.19
Cholesterol (mmol/l) P=0.86
9 months 20±2.0 20±2.6
12 months 18±1.8 19±2.0
15 months 17±1.7 18±2.7
LDL cholesterol (mmol/l) P=0.75
9 months 17±1.9 16±2.2
12 months 15±1.6 15±1.9
15 months 14±1.7 15±2.5
HDL cholesterol (mmol/l) P=0.13
9 months 5.2±0.22 5.8±0.21
12 months 5.7±0.31 5.7±0.31
15 months 5.1±0.40 5.7±0.35
Values are mean±SEM,
*P<0.05 diabetic vs. non-diabetic pigs at corresponding time points,
a diabetic vs. non-diabetic pigs over time
LDL low density lipoprotein, HDL high density lipoprotein
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the only model in which CAD can be truly studied and
catheters and coronary interventional devices can be
applied to the vascular bed they are designed for, this
model might be considered the most suitable [13]. New
types of invasive coronary imaging techniques have
already been applied in the pig model, e.g. optical
coherence tomography (OCT) in healthy porcine coronar-
ies [14] and intravascular ultrasound (IVUS) in diseased
porcine coronaries [7].
Present animal model
In light of the considerations outlined above, the present study
was undertaken to investigate coronary atherosclerosis devel-
opment over time with the use of a diseased porcine model.
The study was performed in accordance with the Guide for the
Care and Use of Laboratory Animals (NIH Publication No.
85-23, revised 1996), and with approval of the Erasmus MC
Animal Care committee. For this purpose, diabetes was
induced in a subgroup of male crossbred (Yorkshire x
Landrace) pigs by single dose injection of streptozotocin
(140 mg/kg) to give a subtotal destruction of pancreatic beta-
cells, as described previously [5]. After 2 weeks of stable DM
induction, a high fat atherogenic diet was introduced to all
pigs. The pigs (diabetic: n=8; non-diabetic: n=7) were
adjusted to this diet and followed up to study atherosclerosis
development over time up to 15 months. Similar growth
patterns were achieved in all pigs via adjustment of
individual caloric intake. Moreover, blood glucose levels
were monitored in diabetic pigs and insulin therapy was
Fig. 1 Typical example of the
development of an atherosclerotic
plaque over time on OCT and
IVUS in a diabetic pig; a OCT of
intimal hyperplasia at 9 months
(*); b IVUS of the same cross
section as shown in a fails to
clearly detect the early lesion;
c+d OCT and IVUS of the
growing plaque at 12 months (*);
e+f OCT and IVUS of the same
growing plaque at 15 months (*)
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started only when plasma ketones appeared, to prevent
severe DM-related complications. Anaesthetised pigs were
imaged at 9, 12 and 15 months of study duration by two
invasive coronary imaging modalities. Moreover, arterial
blood samples were taken at these time points. A subgroup
of pigs (n=5) was sacrificed at 12 months, the remaining
animals (n=10) at 15 months to obtain coronary tissue for
histology. Afterwards, plasma concentrations of glucose,
total cholesterol, and low and high density lipoprotein
(LDL and HDL) cholesterol were measured at the clinical
chemical laboratory of the Erasmus MC using standard
protocols.
Imaging modalities
Two invasive coronary imaging modalities were used in the
present study: OCT and gray-scale IVUS. OCT, using an
infrared light source, has an imaging depth of approximately
1.5 mm into tissue, an axial resolution of 10–15 μm and a
lateral resolution of 25–40 μm. This image resolution of
OCT offers the potential to assess coronary atherosclerosis
in detail [15, 16]. Evaluation of atherosclerosis by OCT was
performed in vivo in all pigs at 9, 12 and 15 months using
the C7 XR Fourier-Domain OCT system (St. Jude Medical,
Westford, MA, USA). Cross-sectional images were acquired
at 100 frames per second with an automatic pullback speed
of 20 mm/s.
The limited penetration depth of OCT is a shortcom-
ing for the assessment of the total vessel wall, particu-
larly in case of a diseased vessel. Therefore, in case of a
plaque thickness >1.5 mm, evaluation of the plaque was
done by gray-scale IVUS using an automated pullback
speed of 0.5 mm/s (Atlantis SR Pro, Boston Scientific
Corp., Natick, MA, USA). During pullback acquisition,
images were obtained at a rate of 30 frames/s. This technique,
using sound instead of light, has an axial resolution of 80–
200 μm and a lateral resolution of 200–400 μm. The
penetration depth is 4–8 mm, which permits visualisation
of the total vessel wall and therefore precise assessment of
the extent of atherosclerosis within a segment of a
coronary artery [17].
Preliminary results
In diabetic pigs, plasma glucose levels were elevated at
every measured time point as compared with the non-
diabetic pigs (Table 2, P<0.05). Moreover in this group
of pigs, plasma triglycerides were increased over time
(Table 2, P<0.05) as well. Since both groups were fed an
atherogenic diet, both showed elevated total cholesterol,
LDL and HDL levels, which were not different over time
(Table 2). In summary, diabetic pigs showed human-like DM
characteristics of hyperglycaemia and triglyceridaemia,
whereas all pigs showed evidence of hypercholesterolaemia.
These metabolic alterations were accompanied by
coronary atherosclerosis development. Indeed, at
9 months small early lesions could be detected in the
coronary arteries of most pigs, specifically seen with
OCT imaging (Fig. 1a). With IVUS this early stage of
atherosclerosis was not visible (Fig. 1b). Over time (12
and 15 months), these lesions showed progression, both in
size and in quantity as exemplified with OCT and IVUS
(Fig. 1c - f). Histology at 12 months confirmed the
formation of more complex coronary atherosclerosis at
this time point, consisting of lipid accumulation and
calcification also seen on IVUS (Fig. 2a - c). All pigs
Fig. 2 Typical example of IVUS (a) and histology (b, c) of a
coronary atherosclerotic plaque in a diabetic pig. a IVUS of the same
plaque as seen in b and c with deep calcium (white arrow). b and c
show an overview and detail of the plaque with circumferential lipid
accumulation (stained red) and deep calcification (Ca, remaining rim
stained blue). The coronary plaque even shows the presence of a thin
fibrous cap (black arrow) overlying the superficial lipid-rich tissue,
showing a likeness to a thin cap fibrous atheroma [18]. Oil-red-O
stain, bar in b is 700 μm, bar in c is 200 μm
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were sacrificed at 15 months because of the attained
body weight and related handling difficulties (diabetic vs.
non-diabetic: 97±3 vs. 96±1 kg).
Conclusion
Different animal models are useful to study different
aspects in the process of atherosclerosis development
(Table 1). However, for the study of CAD and related
diagnostic and therapeutic interventions, a porcine disease
model seems most suitable. In the presence of several
metabolic alterations, lesions develop within 9 to 12 months,
closely resembling human coronary atherosclerotic plaques
upon examination by histology.
In addition, examples from this model show that OCT
and gray-scale IVUS appear to be highly complementary
imaging modalities for the evaluation of the development of
coronary atherosclerotic plaque over time. The present
preliminary results indicate that these modalities can be
used for plaque characterisation in vivo, making this large
diseased animal model ideal for studying new coronary
diagnostic and therapeutic interventions.
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Dietary saturated fat/cholesterol, but not
unsaturated fat or starch, induces C-reactive
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ectopic fat deposition in diabetic pigs
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Abstract
Background: Diabetes is thought to accelerate cardiovascular disease depending on the type of diet. This study in
diabetic subjects was performed to investigate the metabolic, inflammatory and cardiovascular effects of nutritional
components typically present in a Western, Mediterranean or high glycaemic diet.
Methods: Streptozotocin-diabetic pigs (~45 kg) were fed for 10 weeks supplemental (40% of dietary energy)
saturated fat/cholesterol (SFC), unsaturated fat (UF) or starch (S) in an eucaloric dietary intervention study.
Results: Fasting plasma total, LDL and HDL cholesterol concentrations were 3-5 fold higher (p < 0.01) in SFC
compared to UF and S pigs. Fasting plasma NEFA concentrations (mmol/L) were highest (p < 0.05) in SFC (1.09 ±
0.17), intermediate in UF (0.80 ± 0.14) and lowest in S pigs (0.58 ± 0.14) whereas plasma glucose (~13 mmol/L),
triglyceride (~0.5 mmol/L) and insulin (~24 pmol/L) concentrations were comparable among SFC, UF and S pigs.
The postprandial response area under the curves (AUC, 0-4 h) for glucose but not for insulin and triglyceride
responses were intermediate in SFC (617 ± 144) and lowest (p < 0.05) in UF (378 ± 157) compared to S pigs
(925 ± 139). Fasting hepatic glucose production, hepatic and peripheral insulin sensitivity and blood pressure were
not different among pigs. C-reactive protein (CRP) concentrations (mg/L) were highest (p < 0.05) in SFC (25 ± 4),
intermediate in S (21 ± 3) and lowest in UF pigs (14 ± 2). Liver weights, liver and muscle triglyceride
concentrations, and the surface area of aorta fatty streaks were highest (p < 0.01) in SFC pigs. A positive
correlation between postprandial plasma CRP and aorta fatty streaks was observed in SFC pigs (R2 = 0.95).
Retroperitoneal fat depot weight (g) was intermediate in SFC (260 ± 72), lowest in S (135 ± 51) and highest
(p < 0.05) in UF (571 ± 95) pigs.
Conclusion: Dietary saturated fat/cholesterol induces inflammation, atherosclerosis and ectopic fat deposition
whereas an equally high dietary unsaturated fat load does not induce these abnormalities and shows beneficial
effects on postprandial glycaemia in diabetic pigs.
Keywords: Diabetes, Insulin, Diet, Unsaturated fat, Saturated fat, Cholesterol, Inflammation, C-reactive protein,
Atherosclerosis, Pigs
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Background
The impact of an excess in dietary fats and carbohy-
drates on metabolic control, inflammation and cardio-
vascular disease has been studied and discussed in
normal and (pre)diabetic subjects in both human [1-4]
and animal studies [5-7]. In general, excessive dietary
saturated fats and cholesterol increase the risk for the
development of obesity, diabetes and cardiovascular dis-
eases [6,8-10] while dietary unsaturated fats are consid-
ered less harmful and do not impose an increased risk
for the development of diabetes and cardiovascular dis-
eases [1,2,6]. Dietary carbohydrates, in the form of
starches, have a high glycaemic load and thereby worsen
postprandial glucose, stimulate insulin secretion and de
novo lipogenesis [11-14].
Most studies on the longer term (months) effects of
dietary components have been carried out in normal or
glucose intolerant individuals but limited information is
available in diabetic subjects on metabolic control,
inflammation, cardiovascular abnormalities and body
composition [2,12,13,15].
Longer term studies in diabetic humans are difficult to
perform because adherence to the prescribed diets has
proven to be extremely difficult [16] and because dietary
effects on the pathophysiology of diabetes are usually
small with respect to metabolic control, insulin sensitiv-
ity, inflammation and cardiovascular diseases [17,18]. In
addition, longer term studies are usually necessary to
disclose any dietary effects on the pathophysiology of
diabetes because part of the dietary effects are caused by
changes in body composition. This can partly be over-
come by studying animal models which are representa-
tive for the human situation, are highly homogenous
and are kept under strictly standardized experimental
conditions.
We have developed a pig model for diabetes mellitus
type 2 in humans which is characterized by insulin resis-
tance, hyperglycaemia as well as elevated plasma trigly-
ceride and NEFA concentrations. The diabetic pigs are
non-ketotic, anabolic and do not require insulin therapy
[19]. Pigs are like humans omnivores and as such, the
functionality of the gastrointestinal tract is comparable
between pigs and man and therefore the pig is an useful
animal model for the study of dietary components
[20,21]. This makes the pig particular useful when the
effect of diets is studied on diabetes accelerated dyslipi-
daemia and atherosclerosis [22-24]. Furthermore, coron-
ary arteries of diabetic pigs have been shown to express
low grade inflammation [25], a condition also described
in humans with type 2 diabetes mellitus [13,26,27].
The aim of this dietary intervention study was to char-
acterize and compare the medium/long-term (10 weeks)
pathogenic effects of eucaloric diets 1) both high in
supplemental fat, but differing in fat composition as
reflected by mainly saturated fats and cholesterol (SFC)
versus mainly unsaturated fats (UF) and 2) differing in
supplemental fat (SFC or UF) versus supplemental car-
bohydrate (starch, S), on pre- and postprandial hypergly-
caemia, lipidaemia and insulinaemia, on insulin
sensitivity, blood pressure, circulating pro-inflammatory
markers, retroperitoneal fat weight and on muscle, liver
and aorta lipid deposits in diabetic pigs.
Methods
The performed research is in compliance with the
ARRIVE guidelines on animal research [28]. Experimen-
tal protocols describing the management, surgical proce-
dures, and animal care were reviewed and approved by
the ASG-Lelystad Animal Care and Use Committee
(Lelystad, The Netherlands).
Animals, housing, diets and surgery
Domestic (Landrace × Yorkshire, D-line) pigs (barrows
with an initial age and body weight of ~11 weeks and
~30 kg, respectively) were obtained (Bastiaanse, Espel,
The Netherlands) and kept in specially designed meta-
bolic pens (1.15 × 1.35 m) and adapted to the light/dark
cycle (lights on at 05:00 h and off at 19:00 h) and a feed-
ing schedule. Pigs were weighed weekly and the meal size
was adjusted to the individual pig’s weight. The pigs were
fed 2.5-fold maintenance requirements for gross energy
(GE) as established in a normal pig. This corresponded
with a feeding level of 1045 kJ GE kg-1 BW0.75 (metabolic
weight of the pigs) per day and is sufficient to ensure
moderate growth in normal pigs [29].
The pigs were fed a commercial pig diet (5% crude fat,
16% crude protein, 41% starch and sugars, 20% non-starch
polysaccharides, 6% ash and 12% water; Startbrok; Agri-
firm, Meppel, The Netherlands) twice daily (at 06:00 and
16:00 h). Water was always available ad libitum. After
1 week, pigs were provided with a permanent blood vessel
catheter in the jugular vein, as previously described by us
[29,30]. One week after surgery, 21 pigs were treated with
streptozotocin (140 mg/kg) as described previously [19].
Two weeks thereafter, 3 pigs showed fasting plasma glu-
cose concentrations <10 mmol/L and were excluded from
the study. The remaining 18 pigs were balanced over the 3
diet groups, based on fasting hyperglycaemia. Composition
of the saturated fat/cholesterol, unsaturated fat and starch
enriched diets is shown in Table 1. The experimental
meals were fed twice daily (at 1045 kJ GE kg-1 BW0.75 per
day) for a duration of 10 weeks. In practical terms this
means that the pigs on the starch-enriched diet were fed
1.31-fold the amount (on weight basis, but equal in caloric
content) compared to the pigs on the fat-enriched diets in
order to match the energy intake of pigs among diets.
Koopmans et al. Cardiovascular Diabetology 2011, 10:64
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Supplemental saturated fat plus cholesterol (SFC),
unsaturated fat (UF), or starch (S) content was 40% of
total dietary energy. SFC was derived from beef tallow
(i.e. ~55% saturated, ~35% mono-unsaturated, and ~10%
poly-unsaturated fatty acids) plus 1% cholesterol, UF
was derived from sunflower and rape oil (i.e. ~65%
poly-unsaturated, ~25% mono-unsaturated, and 10%
saturated fatty acids) and S was derived from pea starch,
representing components of a Western, Mediterranean
or high glycaemic diet, respectively.
Timeline
The timeline of the study is represented schematically in
Figure 1. In short, the 3 diets were fed to the pigs (n = 6
per diet group) for 10 weeks comprising the following
techniques and measurements: 1) daily food intake, 2)
weekly body weight, 3) quantitative collection of urine
(for determination of 24-h urinary glucose excretion) on
Mondays, Wednesdays and Fridays during the dietary
treatment, 4) at week 7, the pigs were provided with
permanent catheters in the jugular vein and carotid
artery, 5) at week 8, a meal tolerance test was performed
and intra-arterial blood pressure was recorded, 6) at
week 9, a hyperinsulinaemic euglycaemic clamp study
using 6,6-2H2-glucose infusion was performed and 7) at
week 10, pigs were killed by intravenous injection of
barbiturate (administered via the jugular catheter) for
tissue collection.
Meal tolerance test and blood pressure
During the one-week recovery period after surgery, the
pigs were habituated to the blood sampling and experi-
mental procedures. The carotid artery catheter was used
for blood sampling and registration of blood pressure.
During the blood sampling procedure, the catheters
were flushed with physiological saline and sealed off
with physiological saline containing 5 IU heparin per
mL. From experience we know that this sampling proce-
dure does not affect plasma NEFA concentrations.
Blood was sampled repeatedly before, during and after
the morning meal (-15, 0, 30, 60, 120, 240, 360, and 480
minutes from the start of feeding). Per sampling time
point, approximately 5 ml blood was sampled. The
responses of insulin, glucose and triglycerides were
assessed. In addition, the pre-and post-prandial levels of
C-reactive protein (CRP), haptoglobin, IL-6 and TNF-a
were determined on samples taken 15 minutes before
and 180 minutes after the start of feeding. Subsequent
to the meal tolerance test, the blood pressure and heart
rate were determined five hours post-prandially on a
Digital Electromanometer, Type 330 (Hugo Sachs Elek-
tronik KG, March-Hugstetten, Germany).
Hyperinsulinaemic euglycaemic clamp and 6,6-
2H2-glucose infusion
The jugular vein catheter was used for the infusion of
fluids and the carotid artery catheter was used for blood
Table 1 Composition of the experimental diets
Food ingredients Saturated fat diet plus cholesterol Unsaturated fat diet Starch diet
Milk protein (caseinate) 23.2 23.2 17.7
Fructose 9.2 9.2 7.1
Maltodextrin DE 19 30.8 30.8 23.6
Native pea starch 0.0 0.0 41.4
Total sugar and starch 40.0 40.0 72.1
Soy bean oil 0.0 0.0 2.7
Lecithin 0.0 1.5 0.0
Canola oil (rape oil/Lear) 0.0 2.7 0.0
Trisun 80, high oleic sunflower oil 0.0 23.0 0.0
Beef tallow 27.2 0.0 0.0
Total fat 27.2 27.2 2.7
Fiber: Fibrim 2000 9.4 9.4 7.3
Premix1 0.20 0.20 0.15
Cholesterol2 1.0 0.0 0.0
Total (%) 100.0 100.0 100.0
Gross Energy (GE; MJ/kg) 23.4 23.4 17.9
The per-cent of each ingredient contributing to the total amount of diet (= 100%) is listed. Energy intake was matched among dietary groups and therefore pigs
receiving the Starch diet were fed 1.32 times the amount of the high fat diet groups. Therefore the diets were homogenous except for starch or fat.
1 This vitamin and trace mineral premix contained per kg diet: vit. A (retinol) - 1750 IU; vit. D3 (cholecalciferol) - 200 IU; vit. E (tocopherol) - 11 IU; vit. K1
(phylloquinone) - 0.5 mg; vit. B1 (thiamin) - 1.0 mg; vit. B2 (riboflavin) - 4 mg; d-pantothenic acid - 9 mg; niacin (vit. B3, nicotinic acid) - 12.5 mg (available); biotin
(vit. H) - 50 μg; vit. B12 (cyanocobalamin) - 15 μg; folic acid (folacin) - 0.3 mg; vit. B6 (pyridoxin) - 1.5 mg; choline - 400 mg; Fe - 80 mg; Zn - 54 mg; Mn - 30 mg;
Co - 0.15 mg; I - 0.14 mg; Se - 0.25 mg; antioxidants (E310,320,321) - 50 mg; with maize starch as carrier.
2 Cholesterol has no energetic value and therefore 1 kg cholesterol was supplemented per 100 kg diet.
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sampling during the hyperinsulinaemic clamp study.
Preceding the insulin clamp, overnight fasting blood
samples were collected for determining the concentra-
tions of fructosamine, glucagon, cortisol, NEFA, total
cholesterol, LDL and HDL cholesterol and background
glucose enrichment.
After baseline samples, a prime (4.8 mg/kg)-continuous
(0.08 mg.kg-1.min-1) infusion of 6,6-2H2-glucose was admi-
nistered for 150 min. After an equilibration time, blood
samples were taken at 110, 120, 130, 140 and 150 min for
determination of glucose, 6,6-2H2-glucose enrichment (to
estimate fasting hepatic glucose production) and insulin.
Subsequently, insulin was infused (prime (34 mU/kg)-con-
tinuous (2 mU.kg-1.min-1)) for 6 hours. A variable infusion
of a 33% D-glucose solution was started to maintain
plasma glucose at euglycaemia (~5 mmol/L). Steady state
calculations were carried out during the last 40 minutes of
the clamp (t = 320, 330, 340, 350 and 360 min) and the
coefficients of variation for the insulin and glucose con-
centrations, and for the infusion rate of glucose were
determined. During the last 3 hours of the insulin clamp, a
prime (4.8 mg/kg)-continuous (0.08 mg.kg-1.min-1) infu-
sion of 6,6-2H2-glucose was superimposed to estimate 1)
insulin stimulated whole body glucose uptake (rate of dis-
appearance = Rd) and 2) insulin-inhibited hepatic glucose
production, as described before [19]. For this purpose
blood samples were taken at t 320, 330, 340, 350 and
360 min of the clamp.
Infusates: Insulin (Actrapid MC, porcine monocompo-
nent, Novo, Copenhagen, Denmark), 6,6-2H2-glucose
(Cambridge Isotope Laboratories, Inc, MA, USA) and
D-glucose (Merck, Darmstadt, Germany) were prepared
as sterile solutions and passed through a 0.22 μm Milli-
pore filter into sterile containers before use. Insulin was
diluted in a saline solution containing pig plasma (final
plasma concentration was 3%) in order to avoid sticking
of insulin to the plastic containers and tubings. 6,6-2H2-
glucose was dissolved in a saline solution and D-glucose
was dissolved in aqua dest.
Plasma, urine and tissue collection and analyses
Blood samples collected in heparinised (150 USP. U.
Lithium Heparin, 10 mL Venoject, Terumo, Leuven,
Belgium) or EDTA (ethylenediaminetetraacetic acid,
(0.47 mol/L EDTA, 10 mL Venoject, Terumo, Leuven,
Belgium) tubes were immediately chilled at 0°C on
water with ice, and centrifuged at 4°C for 10 minutes at
3000 rpm. Plasma aliquots were stored at -80°C for later
analyses. Urine was quantitatively collected per 24 hours
in buckets containing 0.5 grams Halamid-d (sodium-p-
toluenesulfonchloramide, Akzo Nobel Chemicals,
Amersfoort, The Netherlands) to prevent microbial
breakdown of glucose. Urine samples were stored at
-20°C for later glucose analyses. Muscle (m. iliopsoasis)
and liver were snap-frozen in liquid nitrogen and stored
at -80°C. Abdominal aorta was fixed in a 4% paraformal-
dehyde solution.
Plasma samples for determination of 6,6-2H2-glucose
enrichment were analyzed as described previously [19].
In short, glucose was extracted from plasma, derivatised,
and injected into a gas chromatograph/mass spectro-
meter system (HP 6890 series GC system and 5973
Mass Selective Detector, Palo Alto, CA, USA). Separa-
tion was achieved on a J&W scientific DB 17 capillary
column (30 m × 0.25 mm × 0.25 μm; Agilent Technolo-
gies Nederland BV, Amstelveen, The Netherlands). Iso-
topic enrichment was calculated as tracer-to- tracee
ratio after subtracting the isotopic enrichment of a back-
ground plasma sample. An aliquot of the 6,6-2H2-glu-
cose infusate was analyzed for the isotope concentration
to calculate the actual infusion rate for each infusion
experiment.
Start experimental diets
Jugular catheter
Weeks0-3
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euglycaemic clamp 
9
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8
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Figure 1 Timeline of the study.
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the study per diet group (Table 2). However, liver weights
and triglyceride concentrations were higher (p < 0.01) in
SFC pigs compared to UF and S pigs. Triglyceride con-
centration in muscle was highest (p < 0.01) in SFC pigs,
intermediate in UF and lowest in S pigs. Retroperitoneal
fat depot weight was intermediate in SFC (260 ± 72 g),
lowest in S (135 ± 51 g) and highest (p < 0.05) in UF (571
± 95) pigs.
Metabolic control
At the end of the dietary intervention, fasting plasma insu-
lin, glucagon, glucose, fructosamine and triglyceride con-
centrations were similar among all diabetic pigs (Tables 3
and 4). Fasting plasma total cholesterol, HDL, LDL and
VLDL concentrations were higher (p < 0.01) in SFC pigs
compared to UF and S pigs. The ratio of HDL/LDL cho-
lesterol was unchanged but the ratio of HDL/total choles-
terol was reduced (p < 0.05) in SFC and UF pigs compared
to S pigs (Table 4). Fasting plasma NEFA concentrations
were highest (p < 0.05) in SFC pigs, intermediate in UF
pigs and lowest S pigs (Table 4). Fasting hepatic glucose
production, insulin-inhibited hepatic glucose production
and insulin-stimulated whole body glucose uptake were
similar among diabetic pigs (Table 3). Coefficients of var-
iation of clamp plasma glucose, plasma insulin and glucose
infusion rate in SFC versus UF versus S pigs were 5 ±
2 versus 7 ± 3 versus 3 ± 1%, 11 ± 5 versus 7 ± 2 versus
8 ± 3% and 2 ± 1 versus 3 ± 1 versus 2 ± 1%, respectively.
The postprandial response area under the curves (0-4 h or
0-8 h) for glucose but not for insulin and triglyceride
responses were intermediate in SFC (617 ± 144 or 471 ±
122), lowest (p < 0.05) in UF (378 ± 157 or 292 ± 133) and
highest in S pigs (925 ± 139 or 724 ± 92 (Figures 2 and 3).
Inflammation
The fasting plasma concentrations of cortisol, haptoglo-
bin, IL-6 and TNF-a were not statistically different
between the diet groups (Table 4). By contrast, both
fasting and postprandial plasma C-reactive protein
(CRP) concentrations and meal-induced CRP responses
(Δ) were higher (p < 0.05) in SFC pigs compared to UF
pigs but not always higher compared to S pigs, i.e. fast-
ing plasma CRP concentration was similar in SFC and S
pigs (Figure 4).
Atherosclerosis and blood pressure
The surface area of aorta fatty streaks was higher (p <
0.001) in SFC pigs compared to UF and S pigs (Table 2).
Visualization of the fatty streaks in the abdominal aortas
of the three groups of pigs is presented in Figure 5. In
SFC pigs, a positive correlation between surface area of
aorta fatty streaks and postprandial plasma CRP concen-
tration was observed (R2 = 0.95, p < 0.001) (Figure 6).
Mean arterial, systolic and diastolic blood pressures were
Koopmansetal.CardiovascularDiabetology2011,10:64
http://www.cardiab.com/content/10/1/64
PlasmaglucosewasanalyzedwiththeGlucose liquiUV
monokit (Human,Wiesbaden,Germany),plasmanon-
esterified fattyacidswereanalyzedwith theWAKOkit
(Neuss,Germany)andplasmatriglycerideswithakitfrom
Human(Wiesbaden,Germany).Total,LDLandHDLcho-
lesterolconcentrations inplasmaweredeterminedwith
liquicolorkits(Human,Wiesbaden,Germany)andVLDL
cholesterolwascalculatedastotalcholesterolminusLDL
andHDLcholesterol.Plasma insulinconcentrationwas
measuredusingaDelfiaassay (testkitbyPerkinElmer
LifeSciencesTrustbyWallacOy,Turku,Finland).This
specificpig insulinassaywasvalidatedusingpig insulin
standards,as indicatedbefore[30].Plasmaglucagonwas
measuredwithakitfromEuro-Diagnostica(Arnhem,The
Netherlands),plasmacortisolwith theCount-A-Count
Cortisolkit(DPC,LosAngeles,USA)andfructosamineby
akitfromSpinreact(SantEsteveDeBas,Spain).Plasma
C-reactiveprotein(CRP), interleukin-6(IL-6)andtumor
necrosis factoralpha (TNF-a)wereanalyzedwithkits
(CRP-hs,Human,Wiesbaden,Germany;Haptoglobin,
Instruchemie,Delfzijl,TheNetherlands;SWInterleukin6,
IBL,Hamburg,GermanyandSWTNF-alphaElisaKit,
BiosourceInt,Camarillo,USA),respectively.
Ketones (acetoacetic acid)were determined in fresh
urinebyareagentstrip test (Ketostix,BayerDiagnostics,
Mijdrecht,TheNetherlands).
Triglycerideconcentrationsinmuscleandliversamples
weredeterminedwiththesamekitasusedfortheplasma
samples,aftersaponificationwithanalkalinalcoholsolu-
tionaspreviouslydescribed[31].
Aortic fatty streaks,asamarkerofearlyatherosclero-
sis [22,24], (AHA class 2 lesion [32]),were quantified
withuseofSudan IV fat stain in sectionsof theabdom-
inal aorta ranging from the bifurcation of the renal
arteries to the bifurcation of the iliac arteries. The
stained aortaswere then photographed and analyzed
withamicroscopy imageanalysis system (Clemex tech-
nologies Inc.,Quebec,Canada) as ratioof stained area
to totalarea.
Statisticalanalyses
Resultsareexpressedasmeans±SEMand thecriterion
of statistical significancewas set atp< 0.05.Thedata
were subjected to the analysis of variance procedure
(ANOVA) (for repeatedmeasurementswhenapplicable)
followed by the unpaired or paired student’s t-test of 
Genstat5 [33] fordeterminationofdifferencesbetween
orwithin the threedietarygroups,respectively.
Results
Bodycomposition
FinalbodyweightswerecomparableamongSFC,UFand
Spigs indicating thataverage food intakeandurinary
glucoseexcretionwere inbalanceduring thecourseof
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not statistically different between the diet groups
(Table 5).
Discussion
Main findings
Pigs on dietary SFC showed a more atherogenic plasma
profile with higher plasma NEFA concentrations, higher
liver weights and liver triglyceride concentrations, and
increased aorta fatty streak area compared to pigs on
dietary UF and S. The postprandial glucose, but not insu-
lin and triglyceride responses were intermediate in SFC
pigs, lowest in UF pigs and highest in S pigs, whereas
hepatic and whole body insulin sensitivities for glucose
metabolism were not significantly affected by the diets.
This indicates that the postprandial glucose intolerance
of S pigs compared to SFC and UF pigs is caused by an
increased systemic influx of dietary glucose after starch
digestion and not by insulin resistance. The mechanisms
behind the relative postprandial glucose intolerance in
SFC pigs compared to UF pigs are unknown. However,
several non-significant factors may contribute to the dif-
ference in postprandial glucose tolerance. Fasting and
insulin-inhibited hepatic glucose production during the
clamp were elevated by 16% (p = NS) and 50% (p = NS)
and early (30 min) postprandial insulin secretion was 2-
fold reduced (p = NS) in SFC pigs compared to UF pigs.
For the latter, it has been suggested that the degree of
saturation of fatty acids may have a negative influence on
insulin release by beta-cells in vitro [34]. Taken together,
these factors may add-up and act in concert to both
impair non-insulin-dependent and insulin-dependent
glucose tolerance in SFC pigs compared to UF pigs.
With respect to body composition, SFC pigs showed
increased muscle, liver and aorta fat deposits and a
reduced amount of retroperitoneal fat. The latter non-
ectopic depot of adipose tissue was largest in UF pigs,
indicating that body composition is most favourably
affected by the UF diet compared to the SFC diet in this
non-obese diabetic pig model. The UF diet is mainly
stored in adipose tissue and to a lesser extent in organs
and the vascular system. By contrast, the S pigs showed
the lowest muscle and liver fat deposits and a low
amount of retroperitoneal fat. This indicates that energy
storage in the form of fat is low from dietary S, both in
adipose and non-adipose tissue. The baseline markers of
systemic inflammation tended to be higher in SFC pigs,
but only baseline and postprandial CRP concentrations
reached levels of statistical significance. A strong correla-
tion was observed between postprandial plasma CRP and
aorta fatty streak area (R2 = 0.95, p < 0.001), suggesting
that postprandial CRP is a biomarker for atherosclerosis
in this diabetic pig model. This is one of the few pieces of
Table 2 Food intake, urinary glucose excretion, final body weights and tissue data of diabetic pigs fed saturated fat/
cholesterol or unsaturated fat or starch enriched diets
Saturated fat plus cholesterol diet Unsaturated fat diet Starch diet
Factual average food intake (MJ/day) 23.9 ± 1.3 25.0 ± 2.0 27.7 ± 0.9
Average urinary glucose excretion (MJ/day) 8.5 ± 1.0A 9.1 ± 1.1A 15.8 ± 2.1B
Final body weight (kg) 41 ± 3 45 ± 5 48 ± 7
Liver weight (kg) 1.47 ± 0.08A 1.12 ± 0.03B 1.11 ± 0.03B
Liver triglyceride concentration (g/kg) 49 ± 11A 27 ± 1B 21 ± 3B
Muscle triglyceride concentration (g/kg) 21 ± 4A 13 ± 3AB 8 ± 1B
Retroperitoneal fat weight (g) 260 ± 72AB 571 ± 95A 135 ± 51B
Surface area aorta fatty steaks (%) 17.9 ± 4.4A 0.03 ± 0.02B 0.14 ± 0.07B
A, B , data with different superscripts in the same row differ at p < 0.05.
Table 3 Fasting hepatic glucose production, insulin-stimulated whole body glucose uptake, insulin-inhibited hepatic
glucose production and plasma concentrations of metabolites and insulin in diabetic pigs fed saturated fat/cholesterol
or unsaturated fat or starch enriched diets
Saturated fat plus cholesterol diet Unsaturated fat diet Starch diet
Fasting plasma fructosamine (μmol/L) 449 ± 25 494 ± 62 558 ± 103
Fasting plasma glucose (mmol/L) 12.4 ± 0.4 14.4 ± 0.7 12.7 ± 1.6
Fasting plasma insulin (pmol/L) 23 ± 7 26 ± 7 22 ± 4
Fasting hepatic glucose production (mg.kg-1.min-1) 7.4 ± 0.8 6.4 ± 0.5 8.2 ± 2.0
Clamp plasma glucose (steady state, mmol/L) 5.7 ± 0.2 5.4 ± 0.2 5.4 ± 0.2
Clamp plasma insulin (steady state, pmol/L) 320 ± 27 409 ± 33 327 ± 33
Insulin-stimulated whole body glucose uptake (mg.kg-1.min-1) 10.0 ± 2.3 9.5 ± 2.1 10.8 ± 2.8
Insulin-inhibited hepatic glucose production
(mg.kg-1.min-1)
1.8 ± 0.2 1.2 ± 0.3 1.8 ± 0.1
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evidence that the inflammatory marker CRP is secondary
to the atheromatous process itself.
Taken together, these main findings indicate that diet-
ary saturated fat/cholesterol induces CRP associated
early atherosclerosis and ectopic fat deposition whereas
eucaloric unsaturated fat or starch do not induce these
abnormalities and unsaturated fat shows beneficial
effects on postprandial glycaemia in diabetic pigs.
Insulin resistance
After a 10-week intervention study, dietary composition
had no significant effect on insulin sensitivity in diabetic
pigs. This is in line with a 2-week intervention study in
type 2 diabetic patients [35]. In non-diabetic rodents
however, it is widely accepted that long-term feeding of
dietary saturated fats induces insulin resistance whereas
unsaturated fats increase insulin sensitivity [6]. This dis-
crepancy may be caused by the fact that insulin resistance
is already a prominent feature of diabetic humans [27]
and pigs [19] and any modest dietary effect on insulin
sensitivity does not come to expression in insulin resis-
tant individuals. For example, both liver [6] and skeletal
muscle [36] triglyceride concentrations have been shown
to affect insulin sensitivity but in the present study, the
diet-induced 2-fold variation in liver and skeletal muscle
triglyceride concentrations is insufficient to further mod-
ulate insulin resistance in diabetic pigs.
Inflammation
Fasting plasma concentrations of the acute phase protein
CRP were higher in diabetic pigs which were fed the SFC
diet compared to the UF diet but not to the S diet. This
underlines the anti-inflammatory effect of dietary UF
[37,38]. The pro-inflammatory effect of a diet rich in
saturated fats and cholesterol has been shown before in
Table 4 Fasting plasma concentrations of lipid metabolites, hormones and inflammatory markers in diabetic pigs fed
saturated fat/cholesterol or unsaturated fat or starch enriched diets
Saturated fat plus cholesterol diet Unsaturated fat diet Starch diet
NEFA (mmol/L) 1.09 ± 0.17A 0.80 ± 0.14AB 0.58 ± 0.14B
Triglycerides (mmol/L) 0.58 ± 0.17 0.51 ± 0.05 0.43 ± 0.11
Total cholesterol (mmol/L) 9.9 ± 1.2A 2.0 ± 0.1 B 1.7 ± 0.2 B
HDL cholesterol (mmol/L) 2.1 ± 0.2A 0.4 ± 0.0 B 0.5 ± 0.0 B
LDL cholesterol (mmol/L) 3.3 ± 0.3A 1.3 ± 0.1 B 1.1 ± 0.1 B
VLDL cholesterol (mmol/L) 4.5 ± 0.8A 0.2 ± 0.1 B 0.1 ± 0.0 B
Ratio HDL/LDL cholesterol 0.64 ± 0.08 0.35 ± 0.05 0.46 ± 0.03
Ratio HDL/total cholesterol 0.21 ± 0.01A 0.23 ± 0.02A 0.29 ± 0.01 B
Glucagon (pmol/L) 131 ± 25 114 ± 35 83 ± 10
Cortisol (nmol/L) 334 ± 44 284 ± 69 262 ± 50
Haptoglobin (pg/mL) 251 ± 132 394 ± 100 236 ± 52
IL-6 (pg/mL) 2224 ± 1102 818 ± 664 459 ± 270
TNF-a (pg/mL) 610 ± 289 394 ± 248 384 ± 135
A, B , data with different superscripts in the same row differ at p < 0.05.
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Figure 2 Postprandial curves (0-8 h) of plasma glucose (A),
triglycerides (B) and insulin (C) are shown for diabetic pigs
which were fed diets supplemented with starch (open circles),
unsaturated fats (black squares) or saturated fats with
cholesterol (black circles).
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non-diabetic humans [8,10] and in non-diabetic pigs
[39,40]. In our study, postprandial plasma CRP, but not
haptoglobin, IL-6 or TNF-a, positively correlated with
the severity of beginning atherosclerosis. It seems there-
fore that postprandial CRP concentrations, which were
increased 2-fold compared to fasting concentrations,
react strongly to vascular damage and/or atherosclerosis
[41]. Indeed, CRP has been proposed as a putative clinical
biomarker for atherosclerosis [42,43] serving a possible
protective role in the atherogenic process [44]. In diabetic
pigs which were fed a diet rich in UF, no increase in post-
prandial CRP was observed. This corresponds with the
absence of atherosclerosis in these diabetic pigs. The
beneficial mechanism of action of UF, but not SFC, may
be related to the affinity to bind to the nuclear peroxi-
some proliferator-activated receptor (PPAR), the same
pathway which is activated by the anti-diabetic drug thia-
zolidinedione (TZD) [27,45-47]. Therefore, dietary UF
can be regarded as a therapeutic agent to prevent some
of the abnormalities of type 2 diabetes.
Diabetic pig model
Fasting plasma insulin (~25 pmol/L), glucose (~13
mmol/L) and triglyceride (~0.5 mmol/L) concentrations
and a positive energy balance (body weight gain of
~1.5 kg/week) without the occurrence of ketosis indi-
cated a mild form of diabetes in the pigs. In a previous
paper we argued that the present insulin resistant pig
model resembled type 2 diabetes [19]. In addition to
these observations, we now showed that, after streptozo-
tocin treatment, the residual beta-cells of the pancreas
were able to increase insulin secretion ~5-7 fold upon a
meal-challenge. This indicates that a substantial endo-
genous insulin secretion capacity is still present in this
diabetic pig model.
Conclusion
When comparing dietary SFC, UF and S, dietary SFC
induces CRP-associated early atherosclerosis and ectopic
fat deposition whereas isoenergetic UF shows beneficial
effects on postprandial glycaemia, inflammation and
body composition in diabetic pigs.
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Figure 3 The postprandial response areas under the curve (Δ0-4
h) are depicted for plasma glucose (A), triglycerides (B) and
insulin (C) for supplemental starch (open bars), unsaturated fats
(striped bars) or saturated fats with cholesterol (black bars).
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Figure 4 Overnight fasting and postprandial (3 h) plasma C-
reactive protein (CRP) concentrations and the meal response
over fasting (Δ) are depicted for diabetic pigs which were fed
diets supplemented with starch (open bars), unsaturated fats
(striped bars) or saturated fats with cholesterol (black bars).
Means ± SEM. *p < 0.05.
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Figure 5 Images of typical examples of abdominal aorta Sudan IV fat staining of diabetic pigs, which were fed diets supplemented
with starch (top picture), unsaturated fats (middle), or saturated fats with cholesterol (bottom). Red intra-luminal staining indicates
presence of fatty streaks. Insert in bottom picture shows histological detail (hematoxylin-eosin staining) of fatty streak (4 × magnification). The
intimal area of this part of the vessel wall consists of multiple cellular layers with empty little spaces where fat was deposited.
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Detailed evaluation of coronary function early in diabetes 
mellitus (DM)-associated coronary artery disease (CAD) 
development is difficult in patients. Therefore, we investigated 
coronary conduit and small artery function in a preatherosclerotic 
DM porcine model with type 2 characteristics. Streptozotocin-
induced DM pigs on a saturated fat/cholesterol (SFC) diet (SFC  
DM) were compared with control pigs on SFC and standard 
(control) diets. SFC   DM pigs showed DM-associated 
metabolic alterations and early atherosclerosis development in 
the aorta. Endothelium-dependent vasodilation to bradykinin 
(BK), with or without blockade of nitric oxide (NO) synthase, 
endothelium-independent vasodilation to an exogenous NO-donor 
(S-nitroso-N-acetylpenicillamine), and vasocon-striction to 
endothelin (ET)-1 with blockade of receptor subtypes, were 
assessed in vitro. Small coronary arteries, but not conduit 
vessels, showed functional alterations including impaired BK-
induced vasodilatation due to loss of NO (P  0.01 vs. SFC and 
control) and reduced vasoconstriction to ET-1 (P  0.01 vs. SFC 
and control), due to a decreased ETA receptor dominance. Other 
vasomotor responses were unaltered. In conclusion, this model 
demonstrates specific coronary microvascular alterations with re-
gard to NO and ET-1 systems in the process of early atheroscle-
rosis in DM. In particular, the altered ET-1 system correlated 
with hyperglycemia in atherogenic conditions, emphasizing the 
importance of this system in DM-associated CAD development.
coronary circulation; diabetes mellitus; endothelial function; endothe-
lin-1
DIABETES MELLITUS (DM) IS widespread in industrialized coun-
tries, and the incidence of type 2 is rapidly increasing world-
wide. DM is an independent and strong predictor of coronary
artery disease (CAD) (26), characterized by atherosclerosis of
the conduit arteries (16, 23) and dysfunction of the microcir-
culation (51). Endothelial dysfunction is an important determi-
nant of altered vascular reactivity and plays a major role in the
genesis of DM-induced macro- and microvascular complica-
tions (51). Impaired coronary vasodilation, which is present
well before the development of angiographically visible ath-
erosclerosis in DM patients, is known to be at least partially
due to impairment of the nitric oxide (NO) system (45). On the
other hand, it is less clear whether and how the vasoconstrict-
ing endothelin (ET)-1 system is affected. Evidence of an
altered ET-1 system in DM patients is predominantly coming
from studies in the peripheral circulation in advanced stages of
disease (30), and details on coronary alterations in relation to
ET-1 in DM subjects are scarce (48, 62), in particular in early
CAD development. Moreover, the pathological significance of
the ET-1 system is still not completely established and is
complicated by interactions with other vasoregulatory systems
such as the NO system (57). Given that the regulation of endo-
thelial function may vary in different vascular beds, additional re-
search on alterations in NO and ET-1 systems in the coronary
circulation during early CAD development is needed (20).
Knowledge of early coronary endothelial dysfunction is
highly relevant, as it is an independent predictor of cardiovas-
cular events (46), and its reversal might even result in the
prevention of events. Such detailed evaluation is difficult to
achieve in humans, since the precise onset of DM and CAD is
usually unknown. Therefore, suitable animal models focusing
on early disease development are necessary. Because of the
highly similar anatomy and physiology of the cardiovascular
system, porcine models with toxin-mediated pancreatic dam-
age in combination with an atherogenic diet have been previ-
ously used to study DM and cardiovascular complications (16,
17, 23, 37, 41, 42, 63). However, most of these models have
focused on advanced CAD with clear presence of atheroscle-
rotic plaque.
In light of these considerations, the present study was
undertaken to study coronary function early in the process of
atherosclerosis development in a DM type 2-like porcine
model (35) with focus on endothelial function via NO and
ET-1 systems. For this purpose, we examined vasomotion in
vitro of both coronary conduit and coronary small arteries of
DM pigs after 10 wk on a saturated fat/cholesterol diet (SFC
DM) compared with control pigs on the same SFC diet (SFC)
and to controls on a standard low fat diet (control). Because a
previous study (34) indicated that there were minimal effects of
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DM combined with unsaturated fat or starch diets on plasma
cholesterol and central atherosclerosis development after 10
wk, a group of DM pigs on the standard diet was omitted.
MATERIALS AND METHODS
All experiments were performed in accordance with the American
Physiological Society’s Guiding Principles in the Care and Use of
Vertebrate Animals in Research and Training and with approval of
the Local Animal Ethics Committee of Lelystad, The Netherlands.
Animal Experiments
Before the start of the study period of 10 wk, 16 male crossbred
pigs (Yorkshire  Landrace) were housed in three groups. Initially,
the first group (control group, n  5) was fed a standard diet for
growing pigs, and the second and third groups (SFC, n  5; and SFC 
DM, n  6) were fed a diet complemented with 25% of saturated fats
and 1% of cholesterol (SFC diet). All pigs started the prestudy phase
at 30 kg of body wt and were fed ad libitum with free access to
water. At 70 kg of body wt, the pigs were individually housed in
metabolism cages and fed two meals a day, during which the pigs had
ad libitum access to food for 1 h. The food in the study period
consisted of control diet in the case of the control pigs and of SFC diet
in the case of the SFC and the SFC  DM pigs. Details of the
composition of the study diets are given in Table 1.
In the first study week, pigs were anesthetized with intramuscular
2 mg/kg azaperone (Stressnil; Janssen, Tilburg, The Netherlands),
followed by intravenous 15 mg/kg thiopental (Nesdonal; Rhone
Merieux, Lyon, France). A permanent blood vessel catheter (Secalon
Seldy, 16-G polyurethane; Becton Dickinson, Franklin Lakes, NJ)
was inserted in the ear vein and fixed firmly to the ear. DM was
induced in pigs of the SFC  DM group by slow titrated injection of
streptozotocin (STZ; 80 mg/kg; Pharmacia and Upjohn, Kalamazoo,
MI) in the ear vein to produce subtotal destruction of pancreatic
-cells, as described previously (34, 35). The following STZ injec-
tions (respectively on days 3, 5, and 8 after the first dose) depended on
the level of urinary glucose excretion (total STZ dose per pig ranged
from 110 to 150 mg/kg), as we know from experience that urinary
glucose excretion of 400 g/day corresponded with a fasting plasma
glucose concentration of 15–20 mmol/l. In the week of DM induction,
the SFC  DM pigs had free access to food all day to avoid
hypoglycemia. After 1 wk of DM settlement, the SFC  DM pigs
were also placed on the twice daily feeding regime, as outlined above,
until the end of the study.
In the seventh week of the study period, all pigs were sedated with
2 mg/kg of intramuscular azaperone (Stressnil), and anesthetized with
15 mg/kg of intravenous thiopental (Nesdonal). Pigs were intubated
and anesthesia was maintained by inhalation of 3% sevoflurane
combined with 40% oxygen and room air. All pigs were equipped
with two permanent polyethylene blood vessel catheters (Tygon;
Norton, Akron, OH), which were placed in the external jugular vein
and in the carotid artery for blood sampling procedures and hemody-
namic measurements during the study. The catheters were fixed firmly
at the site of insertion, tunneled subcutaneously to the back of the pig
and exteriorized between the shoulder blades. The catheters were
filled and sealed off with saline containing heparin and penicillin
(Procpen, Cuijk, The Netherlands) and kept in a backpack and glued
to the skin. In the first week after surgery, pigs were habituated to
stress-free blood sampling. In the eighth week of the study period,
fasting blood samples for determination of glucose, fructosamine,
insulin, -hydroxybutyrate, nonesterified fatty acids, triglycerides,
total cholesterol, very-low-density lipoprotein, low-density lipopro-
tein, high-density lipoprotein, tumor necrosis factor-, and markers of
liver function (aspartate aminotransferase) and kidney function (cre-
atinine) were collected and analyzed. Moreover, at this time point a
meal tolerance test was performed to assess DM metabolic character-
istics. Blood was sampled repeatedly before, during, and up to 8 h
after a morning meal. Per sampling time point, small amounts of
blood (5 ml) were collected to monitor the responses of glucose,
insulin, and triglycerides to the meal. Subsequently, blood pressure
and heart rate were determined 5 h postprandially via the carotid
artery using a digital electro-manometer (Type 330; Hugo Sachs
Elektronik, March-Hugstetten, Germany). At the end of the study
(after 10 wk), blood samples were collected for determination of
plasma concentrations of ET-1. Then, all pigs were killed stress free
by intravenous injection of an overdose of pentobarbital via the
jugular vein catheter. Hearts were immediately excised and placed in
cold, oxygenated Krebs bicarbonate buffer solution of the following
composition (103 mol/l): 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4,
1.2 KH2PO4, 25 NaHCO3, and 8.3 glucose, pH 7.4. Coronary conduit
and small arteries were isolated from the territory of the left anterior
descending coronary artery for in vitro functional studies (5, 6).
Furthermore, specimens of left anterior descending coronary artery
and related coronary small arteries, liver, pancreas, and abdominal
aorta were fixed for histology.
Vascular Function
Segments of conduit arteries (4 mm length) were suspended in
large organ baths containing Krebs bicarbonate solution aerated with
95% O2-5% CO2 (43). In this way, the buffer solution has a chemical
composition with highest resemblance to that naturally occurring in
blood and the oxygen content of the solution is high enough to
compensate for lack of oxygen carriers in the in vitro setup (Radnoti
tissue-organ bath principles; ADinstruments). Segments of small ar-
teries (2 mm length) were mounted in wire myographs (J. P.
Trading, Aarhus, Denmark) and both conduit and small arteries were
maintained at 37°C (5, 6). Both vessel types were subjected to the
same protocol with vascular responses reflected in changes in isomet-
ric force as recorded with a Harvard isometric transducer. Following
a 30-min stabilization period, the internal diameter was set to a tension
equivalent to 0.9 times the estimated diameter at 100 mmHg of
effective transmural pressure (27). After this normalization procedure,
segments were exposed to depolarization by 101 mol/l potassium
chloride (KCl; Sigma-Aldrich, Zwijndrecht, The Netherlands) to de-
termine maximal contractile responses. Upon washout, in a first set of
segments, endothelium-dependent vasodilation to bradykinin (BK;
1010 to 106 mol/l; Sigma-Aldrich) was recorded upon preconstric-
tion with the thromboxane-A2 analog U46619 (107 mol/l). To
quantify contributions of non-NO vasodilator substances to BK-
induced dilation, the concentration-response curve (CRC) to BK
Table 1. Composition of the experimental diets: each
ingredient contributing to the total amount of diet is listed
Raw Material Control Diet SFC Diet
Soy beans, extracted – 164.5
Potato protein 50.0 50.0
Animal fat (lard) – 250.0
Barley 396.2 –
Wheat 500.0 –
Wheat glutenmeal 8.7 106.0
Sucrose – 200.0
Fructose – 200.0
Soy oil 17.3 –
Limestone 13.0 9.6
Monocalcium phosphate 6.9 10.8
Sodium chloride 4.0 4.7
Mineral/vitamin-premix 2.0 2.0
L-lysine hydrochloride 1.9 2.4
Cholesterol (extra) – 10.0
Total, g/kg 1,000.0 1,010.0
Gross energy, MJ/kg 17.3 23.5
Ingredients are in g/kg. SFC, saturated fat/cholesterol.
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(1010 to 106 mol/l) was constructed upon 30 min of preincubation
with 104 mol/l of the NO-synthase inhibitor N-nitro-L-arginine
methyl ester HCl (L-NAME; Sigma-Aldrich) in a second set of
experiments. CRCs to ET-1 (1010 to 107 mol/l; Sigma-Aldrich)
were constructed from a third set of segments. In this set, endothelium-
independent but NO-mediated vasodilation to the exogenous NO-
donor S-nitroso-N-acetylpenicillamine (SNAP; 107 and 106 mol/l;
Sigma-Aldrich) was also examined. To investigate the specific con-
tributions of ETA and ETB receptors to the ET-1 response, CRCs to
ET-1 (1010 to 107 mol/l) were constructed after 30 min of prein-
cubation with 106 mol/l ETA receptor antagonist BQ123 (Sigma-
Aldrich) or 108 mol/l ETB receptor antagonist BQ788 (Sigma-
Aldrich), as described previously (59).
Baseline diameters of the coronary small arteries of the functional
experiments could not be accurately assessed because segments were
isolated under nonpressurized conditions. However, using the mea-
sured optimal tension and point of passive stretch according to the
Laplace formula obtained during the normalization procedure, the
passive baseline inner-diameters were calculated (2, 27). To ex-
amine whether the small arteries had undergone changes in their
passive tension characteristics, the values of the relaxed steady-
state diameters at each wall tension of the normalization procedure
(n  24 –29 vessels/group) were fitted by an exponential equation
according to Halpern et al. (27).
Protein expression of ETA and ETB receptors was examined by
Western blotting. Lysates of segments of coronary small arteries were
loaded on gel and blotted. ETA and ETB expression was determined
using specific primary antibodies (1:1000; sc-21193 and sc-21199;
Santa Cruz Biotechnology, Heidelberg, Germany) and corrected for
-actin expression (1:100,000; A5441 Sigma-Aldrich).
Histology
Fresh sections of coronary conduit and small arteries, pancreas,
liver, and abdominal aorta were fixed in 4% buffered formaldehyde
for further histological analysis. Sections of paraffin-embedded coro-
nary arteries were stained with resorcin fuchsin stain and hematoxylin
eosin stain to assess the presence of intimal hyperplasia and vascular
cell nuclei, respectively. In sections of pancreatic tissue, insulin
content was assessed using a primary antibody against insulin (Sigma-
Aldrich). Staining was visualized using a horseradish peroxidase-
labeled secondary antibody and diaminobenzidine as a chromogen
(DakoPatts, Amsterdam, The Netherlands). Insulin stained areas were
measured using Clemex Vision PE (Clemex Technologies, Longueuil,
Quebec, Canada) and are presented as a percentage of total analyzed
area. Sections of liver tissue were stained with hematoxylin eosin
stain. Lobular steatosis was scored (0  fat accumulation in 0–5% of
the hepatocytes per lobule; 1  5–33%; 2  33–66%; and 3 
66%; Ref. 14). In the formaldehyde-fixed abdominal aorta, the
amount of fatty streaks as a marker of early atherosclerosis develop-
ment (AHA type II lesion; Ref. 60) was quantified as percentage of
total area after Sudan IV fat staining (Sigma-Aldrich; Ref. 17).
Data Analysis
Comparison of normally distributed model characteristics was
performed by one-way ANOVA. For skewed data, median values
with interquartile ranges were calculated and the Kruskal Wallis test
was used. Vasodilator responses were expressed as percentage of
preconstriction to U46619 (BK) or ET-1 (SNAP). Vasoconstrictor
responses to U46619, L-NAME and ET-1 were normalized to 101
mol/l KCl. Statistical analysis of CRCs was performed using two-way
ANOVA for repeated measures, followed by Bonferroni’s post hoc
correction. For each CRC reaching a plateau, the concentration nec-
essary to produce 50% of its maximal response was determined using
logistic function (5, 6). The maximal response (Emax) of a vasoactive
substance was assessed when appropriate. Associations between uni-
variate data were evaluated by either Pearson or Spearman rank
correlation. StatView 5.0 (SAS Institute) and SPSS 17.0 (IBM) were
used for the analyses. Data are given as means  SE or as median
with interquartile ranges. Two-tailed P  0.05 was considered statis-
tically significant.
RESULTS
Model Characteristics
Gross energy intake was highest in SFC pigs, intermediate in
control pigs, and lowest in SFC DM pigs (54 3.9 vs. 48
1.7 vs. 44  4.9 MJ/day; P  0.05) without differences in
hemodynamic parameters (Table 2). Although SFC DM pigs
had the lowest intake, they had a positive energy balance
Table 2. Model characteristics
Control (n  5) SFC (n  5) SFC  DM (n  6)
Anatomical parameters
Body weight, kg 123  4 131  5 103  8*
Corrected liver weight, % 1.37  0.04 1.90  0.08 2.4  0.19*
Hemodynamic parameters
Heart rate, beats/min 100  4 103  7 98  12
Systolic blood pressure, mmHg 134  5 145  9 128  7
Diastolic blood pressure, mmHg 88  4 92  7 84  8
Plasma parameters
Glucose, mmol/l 4.7 (4.6–4.8) 6.0 (5.5–6.0) 14 (10–23)*
Fructosamine, mol/l 97 (77–100) 72 (64–78) 390 (154–588)*
Insulin, ng/ml 0.12 (0.08–0.26) 0.22 (0.13–0.32) 0.14 (0.06–0.25)
-Hydroxybutyrate, mol/l 25 25 165  77*
NEFA, mmol/l 0.13 (0.12–0.18) 0.17 (0.16–0.23) 0.55 (0.21–0.58)*
Triglycerides, mmol/l 0.23 (0.18–0.25) 0.22 (0.18–0.23) 0.32 (0.16–0.47)
Total cholesterol, mmol/l 2.1  0.05 9.9  2.4 14  2.7*
VLDL, mmol/l 0.08  0.02 4.2  1.59 6.9  1.83*
HDL-to-LDL ratio 0.76  0.07 0.23  0.03 0.27  0.05*
TNF, pg/ml 46 (38–57) 49 (16–86) 82 (49–102)
Tissue parameters
Pancreatic insulin staining, % 1.65 (1.38–2.12) 2.7 (1.88–2.8) 0.16 (0.13–0.26)*
Liver steatosis (grade) 0.00  0.00 0.60  0.25 1.33  0.21*
Aortic fatty streak staining, % 0.04 (0.01–0.11) 0.66 (0.20–3.2) 11 (2.9–22)*
Values are means SE or median with interquartile ranges. NEFA, nonesterified fatty acids. *P  0.05 SFC  diabetes mellitus (DM) vs. SFC or control.
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during the whole study period with no signs of urinary ketone
body excretion. Therefore, the SFC  DM pigs did not show
severe body wasting or signs of dehydration and did not require
insulin therapy. In line with the lower levels of food intake,
bodyweight at death was lowest in the SFC  DM group (P 
0.05). In contrast, relative liver weight of these pigs was
significantly higher, with pronounced steatosis on histology
(P 0.01). Moreover, the abdominal aorta of SFC DM pigs
showed augmented fat staining (P  0.02). The percentage of
fatty streaks was increased 10-fold compared with SFC pigs,
while control pigs demonstrated little fat staining. These fatty
streaks consisted of several intimal cell layers with fat deposits
(data not shown). In contrast, intimal hyperplasia was not
observed in either coronary conduit or small arteries in any of
the groups (Fig. 1). In summary, SFC  DM pigs showed a
positive energy balance without insulin therapy, pronounced
liver steatosis, and early atherosclerosis development only in
the central aorta.
Plasma analysis showed significantly increased fasting glu-
cose and fructosamine levels in SFC  DM pigs (P  0.01),
indicative of elevated glucose levels over the preceding week
(Table 2). In contrast, fasting insulin concentrations were not
altered. Therefore, a DM state was created with no absolute
insulin deficiency. However, the ketone body -hydroxybu-
tyrate (which was below detection limit in control and SFC
pigs) was significantly increased in SFC  DM pigs (P 
0.02), indicating a functional shortage of insulin in these
animals. Indeed, immunohistochemistry confirmed a reduction
in pancreatic insulin producing -cells (P  0.01). Also,
nonesterified fatty acids levels were elevated in SFC  DM
pigs (P  0.04), again indicative of reduced insulin function-
ality. Although triglyceride levels tended to be highest in SFC 
DM pigs, statistical significance was not reached. SFC  DM
pigs also showed the most profound changes in lipid profile,
characterized by significantly elevated total cholesterol and
very low density lipoprotein levels and a reduced low-density
lipoprotein-to-high-density lipoprotein ratio (all P  0.02).
Furthermore, these pigs showed a trend towards an in-
creased inflammatory response with tumor necrosis factor-
(P  0.07). In addition, the meal tolerance test showed
sustained elevated postprandial plasma glucose levels in
SFC  DM pigs together with a markedly reduced post-
prandial insulin response and a tendency toward an elevated
triglyceride response as shown in Fig. 2. Taken together,
SFC  DM pigs showed a markedly increased set point for
plasma glucose, postprandial hypoinsulinemia with evi-
dence of reduced insulin functionality, and dyslipidemia. No
signs of liver or renal toxicity were observed between
control, SFC and SFC  DM pigs (aspartate aminotransfer-
ase: 19  1.6 vs. 19  1.5 vs. 18  2.0 U/l, P  NS;
creatinine: 117  5.0 vs. 124  8.5 vs. 101  6.4 106
mol/l, P  NS). Therefore, DM was safely induced, as
previously described (28).
Coronary Vasomotor Function
Conduit arteries. SFC  DM and SFC groups showed
similar baseline contractile responses to KCl and preconstric-
tion to U46619 (both, P  NS). Segments from both groups
dilated similarly to BK in a concentration-dependent manner
(pEC50 SFC  DM vs. SFC: 7.9  0.2 vs. 7.5  0.3).
Relaxations amounted up to 50% of the preconstriction level
Fig. 1. Representative histological sections of coronary arteries of control (n  5), saturated fat/cholesterol (SFC; n  5), and SFC-diabetes mellitus (SFC 
DM; n  6) groups: conduit arteries (resorcin fuchsin stain; top; bar  700 m) and small arteries (hematoxylin eosin stain; bottom; bar  100 m).
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(Fig. 3A). Pretreatment with L-NAME almost completely abol-
ished dilation to BK in both groups (P  0.01, CRC L-NAME
vs. no L-NAME), so that the effect of L-NAME was not
different between both groups (Fig. 3B). ET-1 produced vaso-
constriction in a concentration-dependent manner up to 125%
of the response to KCl (pEC50 SFC  DM vs. SFC: 7.7  0.2
vs. 7.5  0.1) that was similar in both groups (Fig. 3C).
Finally, the exogenous NO-donor SNAP induced identical
vasodilator responses in both groups (Fig. 3D). These data are
highly similar to those previously observed in control pigs (5).
Small arteries. The passive baseline inner-diameters of the
coronary small arteries were similar (SFC  DM vs. SFC vs.
control: 364  19 vs. 333  26 vs. 337  19 m; P  NS).
Moreover, the small arteries showed similar baseline contrac-
tile responses to KCl and preconstriction to U46619, indicating
equal vasoconstrictor potential between the groups (KCl SFCDM
vs. SFC vs. control: 3.6  0.4 vs. 2.8  0.5 vs. 2.8  0.3 g;
U46619: 2.5  0.4 vs. 1.9  0.3 vs. 2.4  0.4 g; both, P 
NS). Small arteries dilated to BK in a concentration-dependent
manner in all groups. Relaxations amounted up to 90% of the
preconstriction level but differed significantly between the
groups (Fig. 4A). SFC DM pigs showed a right-ward shift of
the BK CRC (pEC50 SFC DM vs. SFC vs. control: 8.0 0.3
vs. 8.6 0.2 vs. 8.5 0.3; P 0.01 CRC SFC DM vs. SFC
and control) without altering its maximal effect. After prein-
cubation with L-NAME, the BK CRC of all groups was shifted
to the right (P 0.01, CRC L-NAME vs. no L-NAME), and the
three curves were no longer significantly different. These
findings indicate that the non-NO component of BK-induced
vasodilation was identical in all three groups (Fig. 4B) and that
the diminished response to BK in the absence of L-NAME was
due to decreased NO production rather than a decrease in
non-NO vasodilating substances, such as prostaglandins and
endothelium-derived hyperpolarizing factors. The effect of
L-NAME in the small arteries was more modest than in the
conduit arteries, indicating a smaller NO component and a
more pronounced non-NO component of the BK response, in
agreement with previous results (5, 6). ET-1 induced vasocon-
striction in a concentration-dependent manner (Fig. 4C). How-
ever, only SFC  DM pigs showed a clear downward shift of
the ET-1 CRC (P  0.01, SFC  DM vs. SFC vs. control),
with a greatly diminished maximal response to the highest
concentration of ET-1 (Emax: SFC  DM vs. SFC vs. control:
53  16 vs. 136  19 vs. 109  8; P  0.05). The exogenous
NO-donor SNAP induced similar vasodilator responses in all
groups, indicating intact vascular smooth muscle cell function
(Fig. 4D).
ET receptor subtypes. In both SFC and control groups, ETA
receptor blockade, but not ETB receptor blockade, attenuated
the vasoconstrictor responses to ET-1 (P  0.05 CRC ETA vs.
ET-1 and ETB), indicating a predominant role for ETA recep-
tors in response to exogenous ET-1 (Fig. 5). However, for the
SFC  DM pigs only a trend for ETA receptor contribution
could be noted (P 0.07 CRC ETA vs. ET-1), indicating a loss
of ETA dominance. Systemic ET-1 plasma levels were not
different between the groups [SFC  DM vs. SFC vs. control:
1.26 (1.08–1.35) vs. 1.10 (0.96–1.28) vs. 1.07 (0.93–1.29)
pg/ml; P  NS].
ET receptor expression. To examine whether altered expres-
sion of ETA and ETB receptors contributes to the reduced ET-1
responsiveness of small coronary arteries of the SFC  DM
pigs, expression of ETA and ETB receptor protein in small
arteries of the three groups were compared. No differences in
ETA expression were noted between the groups (P  0.26; Fig.
6A). Similarly, no alterations in ETB expression were observed
(P  0.62; Fig. 6B).
Arterial stiffness. The relaxed wall tension-strain relations of
small arterial segments revealed no significant differences in
optimal circumference among the three groups. However, the
stiffness coefficient  was significantly higher in SFC  DM
pigs compared with control pigs (SFC  DM vs. SFC vs.
control: 8.1  0.4 vs. 7.1  0.4 vs. 6.6  0.4; P  0.01 SFC 
Fig. 2. Meal tolerance test: fasting levels and postprandial responses of plasma
glucose (A), insulin (B), and triglycerides (C). Area under the curve (AUC) of
the glucose response of SFC  DM pigs (n  6) was significantly higher
compared with both SFC (n  5) and control (n  5) pigs (A: *P  0.01). In
contrast, the AUC of the insulin response was least in these animals compared
with control pigs (B: †P  0.05). AUCs of the triglyceride response of the 3
groups were not significantly different.
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DM vs. control), suggesting an increase in stiffness in the SFC
DM pigs.
Correlation of vascular responses to metabolic alterations.
The small sample size in the present study does not allow firm
conclusions regarding correlations between vascular responses
in vitro and metabolic abnormalities in vivo and should there-
fore be considered to be hypothesis generating only. Neverthe-
less, it is of interest to note that the maximal ET-1 response of
coronary small artery function (ET-1 Emax) correlated well
with the overall BK responsiveness (BK pEC50; r  0.53; P 
0.05), i.e., a reduced ET-1 response was associated with a
reduced BK response. Moreover, ET-1 Emax correlated with
the model characteristic of hyperglycemia: e.g., fructosamine
(r  0.49; P  0.05), in contrast to BK pEC50 (r  0.19;
P  NS).
DISCUSSION
The principal findings of this study of coronary function
early in the process of diabetic atherosclerosis development are
as follows: 1) BK-induced endothelium-dependent vasodilata-
tion was impaired in small coronary arteries of SFC  DM
pigs, which was attributable to a loss of NO-mediated vasodi-
lation. 2) Although plasma ET-1 levels were not significantly
changed, coronary small vessels of these pigs showed reduced
ET-1-induced vasoconstriction, due to a decreased ETA recep-
tor dominance. 3) Moreover, these vessels showed signs of
structural changes reflected in an increased stiffness coeffi-
cient. 4) In contrast to these observations in small arteries, the
coronary conduit arteries of SFC  DM pigs did not show any
alterations in vascular function at this stage of the disease.
Coronary endothelial dysfunction plays a key role in the
pathogenesis of DM-associated cardiovascular events (46, 51).
However, the affected vascular processes are not well under-
stood and difficult to study in humans, hence requiring relevant
animal models. Although small animal models are highly
relevant to unravel disease mechanisms, their ability to fully
mimic human disease is limited (64). Furthermore, while
isolated vessels from other vascular beds, such as aorta, basilar
and mesenteric arteries (12, 55, 56), or total heart perfusion (8,
61), have been studied in rodents, separate evaluation of
coronary conduit vs. small artery function is difficult in small
animals. Since human and porcine coronary anatomy and
physiology are highly similar (19), a pig model to study CAD
development with focus on vascular function appears to be
highly relevant.
Coronary vascular alterations have been studied extensively
in high-fat-fed prediabetic large animal models, including both
dogs (33, 36, 58) and pigs (9, 10, 44), the results of which
could be of value for patients with the metabolic syndrome
(32). Also, atherosclerotic DM porcine models have been
developed and successfully employed (16, 17, 23, 37, 41, 63).
However, limited data on coronary endothelial function are
available from these DM models and usually only in the
presence of advanced CAD. Dixon et al. (17) studied DM
minipigs, fed a high-fat, high-cholesterol diet, as early as 12
wk after DM induction and noted an increased percentage of
Fig. 3. Coronary conduit function of SFC and SFC DM groups: endothelium-dependent vasodilation to bradykinin (BK; A) and to BK after preincubation with
N-nitro-L-arginine methyl ester HCl (L-NAME; B), vasoconstriction to endothelin (ET-1; C), and endothelium-independent vasodilation to S-nitroso-N-
acetylpenicillamine (SNAP; D). There were no significant differences between SFC and SFC  DM groups.
Fig. 4. Coronary small artery function of control, SFC, and SFC  DM groups: endothelium-dependent vasodilation to BK (A), and to BK after preincubation
with L-NAME (B), vasoconstriction to ET-1 (C), and endothelium-independent vasodilation to SNAP (D). *†P  0.01, SFC  DM vs. SFC and control.
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contractile oscillations of coronary conduit arteries with unaf-
fected endothelium-dependent vasodilation. Unfortunately, po-
tential alterations in coronary microvascular function were not
studied. Mokelke et al. (42) examined a specific aspect of
coronary dysfunction at 20 wk of study duration in a diabetic,
dyslipidemic swine model. Differential regulation of potassium
currents in both coronary conduit and microvessels was stud-
ied, but the development of overall coronary endothelial dys-
function was not assessed. Therefore, information regarding
the exact nature of endothelial alterations early in DM-associ-
ated coronary atherosclerosis is still incomplete and therefore
new, well-characterized DM models continue to be of interest.
Using a recently developed DM type 2-like pig model (34,
35), we created conditions of hyperglycemia, hypoinsulinemia
with reduced insulin functionality and dyslipidemia without
requiring insulin replacement therapy and without signs of
STZ-induced liver or kidney toxicity. These metabolic condi-
tions mimic the human presentation of DM (11), in particular
of advanced stage DM type 2 with hypoinsulinemia, dyslipi-
demia, and secondary pathology including liver steatosis and
central atherosclerosis formation. We acknowledge that the
model characteristics do not fully meet human DM type 2 or
type 1 criteria. However, increased CAD risk caused by micro-
and macrovascular complications is seen in both types of
human DM. Therefore, classification may be less important
than understanding the vascular alterations that mediate this
complication (7). In the present DM model, we separately
studied in vitro coronary function of both conduit and small
sized arteries. The coronary arteries showed no signs of ath-
erosclerosis yet. In addition, endothelium-dependent vasodila-
tion of these arteries was unaltered and we observed no
contractile oscillations during preconstruction, which contrasts
with the results of Dixon et al. (17). However, we studied
vascular function in normal sized pigs after 10 wk instead of 12
wk of study duration. The coronary small arteries showed
changes towards increased vascular stiffness, comparable to
human hypertensive DM type 2 pathology (54). Of notice, our
results indicate that this process already starts before the onset
of hypertension (25). Moreover, in these small arteries we
confirmed the presence of endothelial dysfunction due to im-
paired NO-mediated vasodilation, in accordance with observa-
tions in the coronary microcirculation of DM patients (47), as
well as in the coronary microcirculation (1) and the peripheral
circulation (12, 49) of other large animal models of DM. This
impaired endothelium-mediated, NO-dependent coronary mi-
crovascular dilation might be caused by reduced NO produc-
tion, although we did not observe differences in total endothe-
lial NO synthase expression in the small coronary arteries of
the three groups (unpublished data). Alternatively, endothelial
NO synthase uncoupling or NO scavenging, for example, by
oxygen-derived free radicals, may have reduced NO bioavail-
ability, as observed shortly after DM induction (1) or after
long-term high-fat feeding (36) in dogs.
Interestingly, our results also demonstrate unaltered ET-1
plasma levels together with a reduction in coronary microvas-
cular vasoconstriction to exogenous ET-1. ET-1 plasma levels
have been reported to be either unchanged or elevated in DM
patients, depending on disease duration and complications
(30). The unaltered response to U46619 indicates that a general
abnormality in vasoconstriction was not responsible for the
reduced ET-1 response that we observed. In addition, evidence
for a reduced responsiveness to ET-1 has been shown previ-
ously in the peripheral circulation of DM type 2 patients (15,
21, 38, 53, 54). However, such information specifically focus-
ing on the coronary circulation of DM patients is not available.
Only altered coronary responses to ET-1 have been reported
after ischemia reperfusion in the specific setting of coronary
intervention in DM type 2 patients with advanced CAD (22,
48, 62). In agreement with the present findings of control and
SFC pigs, unaltered vasoconstriction to ET-1 was found be-
tween control and prediabetic dogs on a high-fat diet (33). In
addition, unpublished data of our group show unaltered ET-1
responses in small coronary arteries of diabetic pigs fed an
unsaturated fat rich diet for 10 wk. Therefore, specifically the
combination of DM and an atherogenic diet appears to alter
ET-1 responsiveness. In contrast, other DM animal models
have reported enhanced ET-1 vascular responsiveness (31, 55,
56), also in the coronary circulation (8, 61). These differences
between DM models are not readily explained but may involve
differences in vascular beds (55, 56), genetically modified
strains (8, 55, 56), and different temporal stages of DM-
induction with subsequent other metabolic alterations (31, 61).
Fig. 5. Coronary small artery function: ET-1 responses after specific ET-1 receptor blockade (A  control; B  SFC; C  SFC  DM). ETA receptor blockade
resulted in impaired ET-1 induced vasoconstriction. *†P 0.01 ETA vs. ET-1 and ETB; ‡P 0.10 ETA vs. ET-1. ETB receptor blockade had no significant effect
on the ET-1 response in all groups.
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In the present model, ET-1 reactivity strongly correlated with
hyperglycemia in atherogenic conditions, suggesting a mutual
interaction between metabolic and vascular aspects. However,
future studies are required to investigate these correlations in
more detail.
The hyperglycemic state is thought to affect endothelial
function via several biochemical pathways (3), unified by
Brownlee (13) and Giacco and Brownlee (24). According to
this mechanism the production of reactive oxygen species
generated by mitochondrial uncoupling causes increased
polyol pathway flux, increased intracellular formation of ad-
vanced glycation end-products (AGEs), increased expression
of the receptor for AGEs and its activating ligands, activation
of protein kinase C, and overactivity of the hexosamine path-
way (3). High glucose levels also cause the formation of
extracellular AGEs, which may affect endothelial function
directly or via receptor-mediated mechanisms. In general,
AGEs result in altered cellular signaling, promotion of gene
expression, release of proinflammatory molecules and again
the generation of oxidative stress (4). The results of the present
study show evidence of chronic hyperglycemia, inflammation,
and coronary endothelium-dependent microvascular dysfunc-
tion making the contribution of both reactive oxygen species
and AGEs likely. Indeed, AGE-associated oxidative stress has
been shown to reduce the bioavailability of endothelium-
derived NO in several ways (4), which could result in blunted
NO-mediated dilation. In addition, both AGEs (52) and oxida-
tive stress (18) result in increased ET-1 expression, which via
increased interstitial ET-1 concentrations and subsequent re-
ceptor desensitization could explain the reduced ET-1-medi-
ated microvascular constriction of the present study.
In healthy humans and pigs, ET-1 contributes to basal
coronary vascular tone mainly via the ETA receptor (40, 50). In
contrast, in our model of early DM-related atherosclerosis
development, ETA-receptor-mediated vasoconstriction was
markedly reduced, indicating a switch in ET-1 receptor sub-
type contribution. Since both ETA and ETB receptor expres-
sions were not significantly different between the three groups
of pigs, specific ETA receptor desensitization possibly played a
role. However, the signaling cascade of ET-1 via the ETA
receptor involves several steps, culminating in an increase in
intracellular calcium concentrations (29). Hence specific post-
receptor signaling mechanisms associated with altered vaso-
constrictor responses may be involved. Clinical studies (15, 21,
39) have reported unaltered, enhanced, and decreased ETA
receptor mediated responses in the peripheral circulation,
which might be explained by differences in disease duration of
the populations studied. Also, in animal models differences in
receptor expression have been reported. High-fat-fed predia-
betic dogs showed a decrease in ETA receptor transcription of
both coronary conduit and small arteries, although ET-1 re-
sponsiveness was still unaltered (33). An advanced atheroscle-
rotic DM pig model demonstrated a switch in ET-1 receptor
contribution with reduced ETA dominance in vascular smooth
muscle cells of coronary conduit arteries (37). Moreover,
although a DM type 2 mouse model showed increased ET-1
induced coronary vasoconstriction, ET-1 receptor subtype con-
tribution was altered with ETA reactivity depending on intra-
vascular NO availability (8). Also in the present model, coro-
nary small artery alterations in NO and ET-1 systems were
associated. Therefore, altered ET-1 responsiveness is likely to
be accompanied by altered ET-1 receptor subtype contribu-
tions, either by receptor desensitization or at postreceptor level,
and reflects the balance between both NO and ET-1 systems
within a specific vascular bed.
In conclusion, in the present model of early atherosclerosis
and DM, the loss of NO-mediated coronary microvascular
dilation may be counteracted by the blunted ET-1 constriction,
which may facilitate hyperemia. Indeed, according to the
hemodynamic hypothesis of DM microangiopathy (38), an
initial increase in microvascular blood flow followed by mi-
crovascular stiffness and disturbed autoregulation could finally
result in decreased microvascular perfusion and exaggerated
DM associated CAD development. Future studies with this
DM model are warranted to prove this concept in vitro and to
assess its relevance to the coronary vascular bed in vivo.
Fig. 6. ET-1 receptor protein expression in segments of coronary small arteries
of control (n  5), SFC (n  5), and SFC  DM (n  6) groups. No
differences in ETA (A) or ETB (B) receptor expression were observed between
the groups (P  NS). A.U., arbitrary units.
Chapter 5
66
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
M.v.d.H., O.S., S.J.K., R.D. and R.d.V. analyzed data; M.v.d.H., O.S.,
S.J.K., H.M.M.v.B., E.C.E., D.J.D., A.H.J.D., and W.J.v.d.G. interpreted
results of experiments; M.v.d.H. and O.S. prepared figures; M.v.d.H. drafted
manuscript; M.v.d.H., O.S., S.J.K., E.C.E., D.J.D., A.H.J.D., and W.J.v.d.G.
edited and revised manuscript; M.v.d.H., O.S., S.J.K., R.D. and R.d.V. per-
formed experiments; O.S., S.J.K., A.H.J.D., W.J.v.d.G. conception and design
of research; D.J.D., A.H.J.D., and W.J.v.d.G. approved final version of man-
uscript.
REFERENCES
1. Ammar RF Jr, Gutterman DD, Brooks LA, Dellsperger KC. Free
radicals mediate endothelial dysfunction of coronary arterioles in diabetes.
Cardiovasc Res 47: 595–601, 2000.
2. Angus JA, Wright CE. Techniques to study the pharmacodynamics of
isolated large and small blood vessels. J Pharmacol Toxicol Methods 44:
395–407, 2000.
3. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial
dysfunction and diabetes: roles of hyperglycemia, impaired insulin sig-
naling and obesity. Cell Tissue Res 335: 165–189, 2009.
4. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm K. A RAGE biology,
atherosclerosis and diabetes. Clin Sci (Lond) 121: 43–55, 2011.
5. Batenburg WW, de Vries R, Saxena PR, Danser AHJ. L-S-nitrosothi-
ols: endothelium-derived hyperpolarizing factors in porcine coronary
arteries? J Hypertens 22: 1927–1936, 2004.
6. Batenburg WW, Popp R, Fleming I, de Vries R, Garrelds IM, Saxena
PR, Danser AHJ. Bradykinin-induced relaxation of coronary microarter-
ies: S-nitrosothiols as EDHF? Br J Pharmacol 142: 125–135, 2004.
7. Bellinger DA, Merricks EP, Nichols TC. Swine models of type 2
diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular
complications. ILAR J 47: 243–258, 2006.
8. Bender SB, Klabunde RE. Altered role of smooth muscle endothelin
receptors in coronary endothelin-1 and 1-adrenoceptor-mediated vaso-
constriction in type 2 diabetes. Am J Physiol Heart Circ Physiol 293:
H2281–H2288, 2007.
9. Borbouse L, Dick GM, Asano S, Bender SB, Dincer UD, Payne GA,
Neeb ZP, Bratz IN, Sturek M, Tune JD. Impaired function of coronary
BK(Ca) channels in metabolic syndrome. Am J Physiol Heart Circ Physiol
297: H1629–H1637, 2009.
10. Borbouse L, Dick GM, Payne GA, Berwick ZC, Neeb ZP, Alloosh M,
Bratz IN, Sturek M, Tune JD. Metabolic syndrome reduces the contri-
bution of K channels to ischemic coronary vasodilation. Am J Physiol
Heart Circ Physiol 298: H1182–H1189, 2010.
11. Boullion RD, Mokelke EA, Wamhoff BR, Otis CR, Wenzel J, Dixon
JL, Sturek M. Porcine model of diabetic dyslipidemia: insulin and feed
algorithms for mimicking diabetes mellitus in humans. Comp Med 53:
42–52, 2003.
12. Brondum E, Nilsson H, Aalkjaer C. Functional abnormalities in isolated
arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat mod-
els. Horm Metab Res 37, Suppl 1: 56–60, 2005.
13. Brownlee M. Biochemistry and molecular cell biology of diabetic com-
plications. Nature 414: 813–820, 2001.
14. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon
BR. Nonalcoholic steatohepatitis: histologic features and clinical correla-
tions with 30 blinded biopsy specimens. Hum Pathol 35: 1070–1082,
2004.
15. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of
endogenous endothelin in patients with type II diabetes mellitus. Circu-
lation 106: 1783–1787, 2002.
16. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C,
Gerrity RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone
PH. Prediction of the localization of high-risk coronary atherosclerotic
plaques on the basis of low endothelial shear stress: an intravascular
ultrasound and histopathology natural history study. Circulation 117:
993–1002, 2008.
17. Dixon JL, Stoops JD, Parker JL, Laughlin MH, Weisman GA, Sturek
M. Dyslipidemia and vascular dysfunction in diabetic pigs fed an athero-
genic diet. Arterioscler Thromb Vasc Biol 19: 2981–2992, 1999.
18. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K,
Seals DR. Vascular endothelial dysfunction with aging: endothelin-1 and
endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 297:
H425–H432, 2009.
19. Duncker DJ, Bache RJ. Regulation of coronary blood flow during
exercise. Physiol Rev 88: 1009–1086, 2008.
20. Ergul A. Endothelin-1 and diabetic complications: Focus on the vascula-
ture. Pharmacol Res 63: 477–482, 2011.
21. Feng J, Liu Y, Khabbaz KR, Hagberg R, Robich MP, Clements RT,
Bianchi C, Sellke FW. Decreased contractile response to endothelin-1 of
peripheral microvasculature from diabetic patients. Surgery 149: 247–252,
2011.
22. Feng J, Liu Y, Khabbaz KR, Hagberg R, Sodha NR, Osipov RM,
Sellke FW. Endothelin-1-induced contractile responses of human coro-
nary arterioles via endothelin-A receptors and PKC-alpha signaling path-
ways. Surgery 147: 798–804, 2010.
23. Gerrity RG, Natarajan R, Nadler JL, Kimsey T. Diabetes-induced
accelerated atherosclerosis in swine. Diabetes 50: 1654–1665, 2001.
24. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ
Res 107: 1058–1070, 2010.
25. Grey E, Bratteli C, Glasser SP, Alinder C, Finkelstein SM, Lindgren
BR, Cohn JN. Reduced small artery but not large artery elasticity is an
independent risk marker for cardiovascular events. Am J Hypertens 16:
265–269, 2003.
26. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality
from coronary heart disease in subjects with type 2 diabetes and in
nondiabetic subjects with and without prior myocardial infarction. N Engl
J Med 339: 229–234, 1998.
27. Halpern W, Mulvany MJ, Warshaw DM. Mechanical properties of
smooth muscle cells in the walls of arterial resistance vessels. J Physiol
275: 85–101, 1978.
28. Hara H, Lin YJ, Zhu X, Tai HC, Ezzelarab M, Balamurugan AN,
Bottino R, Houser SL, Cooper DK. Safe induction of diabetes by
high-dose streptozotocin in pigs. Pancreas 36: 31–38, 2008.
29. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular
function in health and disease. J Hypertens 16: 1081–1098, 1998.
30. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic
vascular complications. Diabetologia 42: 1383–1394, 1999.
31. Hopfner RL, McNeill JR, Gopalakrishnan V. Plasma endothelin levels
and vascular responses at different temporal stages of streptozotocin
diabetes. Eur J Pharmacol 374: 221–227, 1999.
32. Knudson JD, Dincer UD, Bratz IN, Sturek M, Dick GM, Tune JD.
Mechanisms of coronary dysfunction in obesity and insulin resistance.
Microcirculation 14: 317–338, 2007.
33. Knudson JD, Rogers PA, Dincer UD, Bratz IN, Araiza AG, Dick GM,
Tune JD. Coronary vasomotor reactivity to endothelin-1 in the prediabetic
metabolic syndrome. Microcirculation 13: 209–218, 2006.
34. Koopmans SJ, Dekker R, Ackermans MT, Sauerwein HP, Serlie MJ,
van Beusekom HM, van den Heuvel M, van der Giessen WJ. Dietary
saturated fat/cholesterol, but not unsaturated fat or starch, induces C-re-
active protein associated early atherosclerosis and ectopic fat deposition in
diabetic pigs. Cardiovasc Diabetol 10: 64, 2011.
35. Koopmans SJ, Mroz Z, Dekker R, Corbijn H, Ackermans M, Sauer-
wein H. Association of insulin resistance with hyperglycemia in strepto-
zotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a
type 2-like diabetic pig model. Metabolism 55: 960–971, 2006.
36. Kume T, Kawamoto T, Okura H, Neishi Y, Hashimoto K, Hayashida
A, Watanabe N, Kanda Y, Mochizuki S, Goto M, Yoshida K. Evalu-
ation of coronary endothelial function by catheter-type NO sensor in
high-fat-diet-induced obese dogs. Circ J 73: 562–567, 2009.
37. Lee DL, Wamhoff BR, Katwa LC, Reddy HK, Voelker DJ, Dixon JL,
Sturek M. Increased endothelin-induced Ca2 signaling, tyrosine phos-
phorylation, and coronary artery disease in diabetic dyslipidemic Swine
are prevented by atorvastatin. J Pharmacol Exp Ther 306: 132–140, 2003.
38. McAuley DF, McGurk C, Nugent AG, Hanratty C, Hayes JR, John-
ston GD. Vasoconstriction to endothelin-1 is blunted in noninsulin-
dependent diabetes: a dose-response study. J Cardiovasc Pharmacol 36:
203–208, 2000.
39. McAuley DF, Nugent AG, McGurk C, Maguire S, Hayes JR, Johnston
GD. Vasoconstriction to endogenous endothelin-1 is impaired in patients
with type II diabetes mellitus. Clin Sci (Lond) 99: 175–179, 2000.
40. Merkus D, Houweling B, Mirza A, Boomsma F, van den Meiracker
AH, Duncker DJ. Contribution of endothelin and its receptors to the
regulation of vascular tone during exercise is different in the systemic,
coronary and pulmonary circulation. Cardiovasc Res 59: 745–754, 2003.
H93CORONARY MICROVASCULAR DYSFUNCTION IN A PORCINE DM MODEL
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00311.2011 • www.ajpheart.org
Downloaded from www.physiology.org/journal/ajpheart by ${individualUser.givenNames} ${individualUser.surname} (156.083.001.029) on December 26, 2017.
Copyright © 2012 American Physiological Society. All rights reserved.
Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes
67
5
41. Mohler ER III, Sarov-Blat L, Shi Y, Hamamdzic D, Zalewski A,
Macphee C, Llano R, Pelchovitz D, Mainigi SK, Osman H, Hallman T,
Steplewski K, Gertz Z, Lu MM, Wilensky RL. Site-specific atherogenic
gene expression correlates with subsequent variable lesion development in
coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol 28:
850–855, 2008.
42. Mokelke EA, Dietz NJ, Eckman DM, Nelson MT, Sturek M. Diabetic
dyslipidemia and exercise affect coronary tone and differential regulation
of conduit and microvessel K current. Am J Physiol Heart Circ Physiol
288: H1233–H1241, 2005.
43. Mulvany MJ, Halpern W. Contractile properties of small arterial resis-
tance vessels in spontaneously hypertensive and normotensive rats. Circ
Res 41: 19–26, 1977.
44. Neeb ZP, Edwards JM, Alloosh M, Long X, Mokelke EA, Sturek M.
Metabolic syndrome and coronary artery disease in Ossabaw compared
with Yucatan swine. Comp Med 60: 300–315, 2010.
45. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P.
Coronary artery responses to physiological stimuli are improved by
deferoxamine but not by L-arginine in non-insulin-dependent diabetic
patients with angiographically normal coronary arteries and no other risk
factors. Circulation 97: 736–743, 1998.
46. Nitenberg A, Valensi P, Sachs R, Cosson E, Attali JR, Antony I.
Prognostic value of epicardial coronary artery constriction to the cold
pressor test in type 2 diabetic patients with angiographically normal
coronary arteries and no other major coronary risk factors. Diabetes Care
27: 208–215, 2004.
47. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR.
Impairment of coronary vascular reserve and ACh-induced coronary
vasodilation in diabetic patients with angiographically normal coronary
arteries and normal left ventricular systolic function. Diabetes 42: 1017–
1025, 1993.
48. Papadogeorgos NO, Bengtsson M, Kalani M. Selective endothelin
A-receptor blockade attenuates coronary microvascular dysfunction after
coronary stenting in patients with type 2 diabetes. Vasc Health Risk
Manag 5: 893–899, 2009.
49. Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C.
Role of EDHF in type 2 diabetes-induced endothelial dysfunction. Am J
Physiol Heart Circ Physiol 295: H1982–H1988, 2008.
50. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent
coronary constrictor effects of endothelin-1 and big endothelin-1 in hu-
mans. Circulation 94: 2077–2082, 1996.
51. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schin-
dler TH, Sayre JW, Hsueh WA, Schelbert HR. Coronary circulatory
dysfunction in insulin resistance, impaired glucose tolerance, and type 2
diabetes mellitus. Circulation 111: 2291–2298, 2005.
52. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M,
Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP.
Endothelin 1 transcription is controlled by nuclear factor-kappaB in
AGE-stimulated cultured endothelial cells. Diabetes 49: 1561–1570, 2000.
53. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Piccoli A, Valentini U,
Cimino A, Girelli A, Salvetti M, De Ciuceis C, Tiberio GA, Giulini
SM, Sleiman I, Monteduro C, Rosei EA. Endothelial dysfunction in
small resistance arteries of patients with non-insulin-dependent diabetes
mellitus. J Hypertens 19: 913–919, 2001.
54. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A,
Girelli A, Rodella L, Bianchi R, Sleiman I, Rosei EA. Structural
alterations in subcutaneous small arteries of normotensive and hyperten-
sive patients with non-insulin-dependent diabetes mellitus. Circulation
103: 1238–1244, 2001.
55. Sachidanandam K, Elgebaly MM, Harris AK, Hutchinson JR, Mez-
zetti EM, Portik-Dobos V, Ergul A. Effect of chronic and selective
endothelin receptor antagonism on microvascular function in type 2
diabetes. Am J Physiol Heart Circ Physiol 294: H2743–H2749, 2008.
56. Sachidanandam K, Harris A, Hutchinson J, Ergul A. Microvascular
versus macrovascular dysfunction in type 2 diabetes: differences in con-
tractile responses to endothelin-1. Exp Biol Med (Maywood) 231: 1016–
1021, 2006.
57. Schmitz-Spanke S, Schipke JD. Potential role of endothelin-1 and
endothelin antagonists in cardiovascular diseases. Basic Res Cardiol 95:
290–298, 2000.
58. Setty S, Sun W, Tune JD. Coronary blood flow regulation in the
prediabetic metabolic syndrome. Basic Res Cardiol 98: 416–423, 2003.
59. Sorop O, Merkus D, de Beer VJ, Houweling B, Pistea A, McFalls EO,
Boomsma F, van Beusekom HM, van der Giessen WJ, VanBavel E,
Duncker DJ. Functional and structural adaptations of coronary microves-
sels distal to a chronic coronary artery stenosis. Circ Res 102: 795–803,
2008.
60. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld
ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A defini-
tion of initial, fatty streak, and intermediate lesions of atherosclerosis A
report from the Committee on Vascular Lesions of the Council on
Arteriosclerosis, American Heart Association. Circulation 89: 2462–2478,
1994.
61. Verma S, Arikawa E, Lee S, Dumont AS, Yao L, McNeill JH.
Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with
bosentan. Can J Physiol Pharmacol 80: 980–986, 2002.
62. Verma S, Maitland A, Weisel RD, Fedak PW, Li SH, Mickle DA, Li
RK, Ko L, Rao V. Increased endothelin-1 production in diabetic patients
after cardioplegic arrest and reperfusion impairs coronary vascular reac-
tivity: reversal by means of endothelin antagonism. J Thorac Cardiovasc
Surg 123: 1114–1119, 2002.
63. Wang YX, Fitch R, Li W, Werner M, Halks-Miller M, Lillis B,
Vergona R, Post J, Sullivan ME, Verhallen PF. Reduction of cardiac
functional reserve and elevation of aortic stiffness in hyperlipidemic
Yucatan minipigs with systemic and coronary atherosclerosis. Vascul
Pharmacol 39: 69–76, 2002.
64. Wu KK, Huan Y. Diabetic atherosclerosis mouse models. Atherosclero-
sis 191: 241–249, 2007.
H94 CORONARY MICROVASCULAR DYSFUNCTION IN A PORCINE DM MODEL
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00311.2011 • www.ajpheart.org
Downloaded from www.physiology.org/journal/ajpheart by ${individualUser.givenNames} ${individualUser.surname} (156.083.001.029) on December 26, 2017.
Copyright © 2012 American Physiological Society. All rights reserved.

Serial coronary imaging of early 
atherosclerosis development in fast-food-fed 
diabetic and nondiabetic swine
van Ditzhuijzen N.S., van den Heuvel M., Sorop O., Rossi O., Veldhof T., Bruining N., Roest S., 
Ligthart J.M.R., Witberg K.T., Dijkshoorn M.L., Nieman K., Mulder M.T., Zijlstra F., 
Duncker D.J., van Beusekom H.M.M. and Regar E.
JACC Basic to Translational Science. 2016 Oct;449-6
6
Chapter 6
70
PRECLINICAL RESEARCH
Serial Coronary Imaging of
Early Atherosclerosis Development
in Fast-Food-Fed Diabetic and
Nondiabetic Swine
Nienke S. van Ditzhuijzen, MSC,a Mieke van den Heuvel, MD,a Oana Sorop, PHD,a Alexia Rossi, MD, PHD,b
Timothy Veldhof, MSC,a Nico Bruining, PHD,a Stefan Roest, BSC,a Jurgen M.R. Ligthart, RT,a
Karen Th. Witberg, CCRN,a Marcel L. Dijkshoorn, BSC,a Koen Nieman, MD, PHD,a Monique T. Mulder, PHD,c
Felix Zijlstra, MD, PHD,a Dirk J. Duncker, MD, PHD,a Heleen M.M. van Beusekom, PHD,a Evelyn Regar, MD, PHDa
VISUAL ABSTRACT
van Ditzhuijzen, N.S. et al. J Am Coll Cardiol Basic Trans Science. 2016;1(6):449–60.
HIGHLIGHTS
In swine with and without diabetes mellitus
fed a fast-food diet:
 OCT, NIRS, CCTA, vascular function
testing, and histology can be
consecutively and longitudinally
performed to assess gradual coronary
atherosclerosis development
 OCT and NIRS enabled detailed
assessment of early coronary
atherosclerosis development, whereas
CCTA was not able to detect discrete early
atherosclerotic changes.
 OCT, NIRS, vascular function testing, and
histology demonstrated no differences in
early atherosclerosis development.
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SUMMARY
Patientswith diabetesmellitus (DM) are at increased risk for atherosclerosis-related events comparedto non-DM
(NDM) patients.With an expectedworldwide epidemic of DM, early detection of anatomicand functional coronary
atherosclerotic changes is gaining attention. To improve our understanding ofearly atherosclerosis development,
we studied a swinemodel that gradually developed coronaryatherosclerosis. Interestingly, optical coherence
tomography, near-infrared spectroscopy (NIRS), vascularfunction, and histology demonstrated no differences
between development of early atherosclerosis infast-food-fed (FF) DM swine and that in FF-NDM swine.
Coronary computed tomography angiography didnot detect early atherosclerosis, but optical coherence
tomography and near-infrared spectroscopydemonstrated coronary atherosclerosis development in FF-DM and FF-
NDM swine. (JAmCollCardiolBasicTrans Science 2016;1:449–60)©2016TheAuthors.PublishedbyElsevieron
behalfoftheAmericanCollegeofCardiologyFoundation.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
P atients with diabetes mellitus (DM)have a 2- to 6-fold increased risk ofencountering atherosclerosis-related
events compared to their non-DM (NDM) counter-
parts (1). With a worldwide DM epidemic expected,
early detection of anatomical and functional athero-
sclerotic changes in the coronary vasculature is gain-
ing attention. However, patients typically present to
the clinician with advanced atherosclerotic disease,
thus complicating the study of early atherosclerosis
development.
Animal models may provide a solution. Several
small animal models, such as a rodent model, have
been used to unravel disease mechanisms of coronary
artery disease, but their ability to mimic human cor-
onary artery disease is limited (2). The swine coronary
artery model can be especially suitable for evaluation
of human-like coronary artery disease development.
First, the anatomy and physiology of swine hearts are
similar to those of human hearts. Second, swine can
be rendered diabetic by injection of streptozotocin.
Third, patient-like spontaneous coronary atheroscle-
rosis development can be mimicked by additionally
feeding the swine a high-cholesterol, high-sugar diet
(3); and fourth, in vivo longitudinal invasive and
noninvasive imaging can be performed using imaging
techniques such as optical coherence tomography
(OCT), near-infrared spectroscopy (NIRS), and coro-
nary computed tomography angiography (CCTA) (4).
Ex vivo coronary endothelial function can be tested
to compare functional with morphological coronary
changes, and histology can be performed to assess the
magnitude of coronary and aortic atherosclerosis at
different time points (4,5).
Because there is little understanding about
whether DM affects atherosclerosis development at
the onset of coronary artery disease, the aim of our
observational study was to assess whether DM affects
early atherosclerosis development as assessed by
OCT, NIRS, and CCTA in swine fed a high-cholesterol,
high sugar (“fast-food”) diet.
METHODS
This experimental study was approved by the Eras-
mus Medical Center Animal Ethics committee and
performed in accordance with the Guide for Care and
Use of Laboratory Animals (6).
See the Supplemental Appendix for a detailed
description of all anaesthesia procedures. Thirteen
male crossbred (Yorkshire  Landrace) swine w11
weeks of age, with an average weight of w30 kg were
included. DM was induced in 8 randomly selected
anesthetized swine by streptozotocin (single-dose
intravenous injection, 140 mg/kg) (4). All swine were
given a fast-food-fed (FF) diet containing 10% su-
crose, 15% fructose, 25% (swine) lard, 1% cholesterol,
and 0.7% sodium cholate (bile salts). Follow-up
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duration was 12 months (n ¼ 8 FF-DM swine; n ¼ 5 FF-
NDM swine) or 15 months (n ¼ 5 FF-DM swine; n ¼ 3
FF-NDM swine), during which similar growth pat-
terns were achieved by adjusting individual caloric
intake. See Figure 1A for the study ﬂow chart.
Arterial access was obtained by introducing a 9-F
sheath into the carotid artery to monitor blood pres-
sure and obtain fasting blood samples to assess plasma
insulin, glucose, triglyceride, total cholesterol (TC),
low-density lipoprotein (LDL), and high-density lipo-
protein (HDL) cholesterol levels and lipoprotein pro-
ﬁles. As control, fasting blood sampleswere taken from
5 weight-, age-, and sex-matched crossbred swine fed
standard chow. In FF-DM swine, blood glucose and
ketone levels were monitored weekly by 24-h urine
samples, and insulin was administered when needed
to prevent ketoacidosis. To obtain lipoprotein proﬁles,
we used density gradient ultracentrifugation and
measured cholesterol and triglyceride concentrations
spectrophotometrically in the fractions in FF-DM
(n ¼ 7), FF-NDM (n ¼ 3), and 1 age-, weight-, and sex-
matched control swine (please see Supplemental
Appendix for detailed methodology).
To evaluate insulin sensitivity, we calculated
the quantitative insulin sensitivity check index,
(QUICKI), as [1/[(log(I0) þ log(G0)], in which I0 is the
fasting plasma insulin level in mU/ml, and G0 is the
fasting blood glucose level in mg/dl, at 9, 12, and
15 months.
IN VIVO OCT, NIRS, AND CCTA. Serial OCT (C7XR FD
system; St. Jude Medical, St. Paul, Minnesota) and
NIRS (InfraReDx; Nipro, Osaka, Japan) were per-
formed to assess the coronary arteries at 9, 12, and 15
months. The region of interest was deﬁned as the
region in which both the OCT and NIRS were avail-
able at all 2 time points (9 and 12 months) or all
3 time points (9, 12, and 15 months) and divided
FIGURE 1 Study Flow Chart and Matching of Invasive Imaging
Study ﬂow chart (A) and matching of invasive imaging (B and C). The coronary angiograms (B1 and C1)were used to match the OCT (B3 and C3) and NIRS pullbacks (B2 and
C2) within and at the various time points. Large side branches on the coronary angiogram (I to IV) were indicated on the NIRS chemogram (B2 and C2, green lines, I to IV)
and matched to the OCT cross-sections (B3 and C3, I to IV). *Guidewire. FF-DM ¼ fast-food-fed swine with diabetes mellitus; FF- NDM ¼ fast-food-fed swine
without diabetes mellitus; M ¼ month; NIRS ¼ near-infrared spectroscopy; OCT ¼ optical coherence tomography; SB ¼ side branch; W ¼ weeks.
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into 5-mm subsegments. On the NIRS chemogram,
side branches were marked during image acquisition
based on the location of the catheter in the coro-
nary angiogram. Afterwards, NIRS and angiograph-
ically determined side branches were matched to
side branches visible in the OCT pullback (Figures 1B
and 1C).
See Supplemental Appendix for the OCT acquisi-
tion methods. Mean lumen area and diameter and
minimum lumen diameter were documented for
every frame within the region of interest using
Curad vessel analysis software (Curad, Maastricht,
the Netherlands).
OCT TISSUE CLASSIFICATION. The incidence of
lesion-positive subsegments was noted, with lesions
classiﬁed as ﬁbrous intimal thickening (FIT), lipid-
laden (LL), calciﬁed, or mixed (Figure 2A), as pub-
lished previously (7,8) (see Supplemental Appendix
for lesion deﬁnitions). According to the lesion,
lesion burden was calculated as the average number
of lesion-positive quadrants (see the Supplemental
Appendix for lesion deﬁnitions).
For NIRS, the catheter was withdrawn automati-
cally with 0.5 mm/s pullback speed. Within the
region of interest, NIRS documented the probabi-
lity that lipid core plaque (LCP) was present.
The data are displayed in a 2-dimensional arterial
map, the chemogram. A summary of the results for
each 2 mm of artery is computed (block chemogram)
and mapped to a color scale with 4 discrete
FIGURE 2 Early Atherosclerosis Development in FF-DM and FF-NDM Swine
Several lesion types were assessed by OCT (A1 to A3) and matched with histology (oil-red-O stain [A4 and A5] and von Kossa stain [A6]). Intimal hyperplasia was deﬁned
as a ﬁbrous lesion >150-mm thickness on OCT (A1), a lipid-laden lesion (A2 and A5) as diffusely delineated signal-poor region (A2, arrowheads) and a mixed lesion
(A3 and A6) as a lesion containing both lipid (A3, arrowheads) and calcium, which was deﬁned as a sharply delineated signal-poor region ([A3] arrow). In histology, red
stain denotes lipid (A5), and closed bars denote calcium (A6) deposits. (B) The prevalence and burden (C and D) of disease increased from 9 to 15 months, without any
signiﬁcant differences between FF-DM and FF-NDM. *Guidewire artifact. Abbreviations as in Figure 1.
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colors. The colors correspond to the probability that
LCP is present, with red indicating low probability
and yellow high probability (red ¼ p # 0.57;
orange ¼ 0.57; # p < 0.84; tan ¼ 0.84 # p < 0.98;
yellow ¼ p $ 0.98) (9). In the current analysis,
yellow, tan, or orange blocks were considered NIRS-
positive.
See the Supplemental Appendix for description of
the CCTA acquisition methods. CCTA was performed
using the electrocardiography (ECG)-gated spiral
scan mode. Data sets with optimal image quality
were reconstructed mainly in the mid- to end-
diastolic phase, with a slice thickness of 0.75 mm
at an increment of 0.4 mm. Coronary lesions were
classiﬁed as high-density or low-density as described
previously (10). High-density was recognized as
>220 HU, low density as <220 HU.
EX VIVO ASSESSMENT. Sacriﬁce was scheduled
after imaging at 12 months (n ¼ 3 FF-DM, n ¼ 2
FF-NDM) or 15 months (n ¼ 5 FF-DM, n ¼ 3 FF-NDM).
The hearts were removed, and the coronary tree was
dissected free and placed in cold, oxygenated Krebs
bicarbonate buffer solution or ﬁxed in formalin.
Vascular funct ion . To assess coronary endoth-
elial function at 15 months, segments of coronary
arteries (w4 mm in length) were suspended in organ
baths. Vascular responses were measured as
changes in isometric force to different concentra-
tions of vasoactive substances, as described
previously using pEC50 values (11–13). Endothelium-
dependent relaxation to bradykinin (BK; 10�10 to
10�6 mol/l) was recorded upon pre-constriction with
the thromboxane analog U46619 (10�6 mol/l). Simi-
larly, endothelium-independent vasodilation to
S-nitroso-N-acetylpenicillamine (SNAP; 10�9 to
10�5 mol/l) and endothelium-dependent vasocon-
striction to endothelin-1 (10�10 to 10�7 mol/l) were
assessed.
Histo logy . The remaining coronary artery segments
were used for histological analysis. Two-millimeter
segments taken from areas that demonstrated
vascular wall changes by coronary angiography or
OCT were embedded in optimal cutting temperature
compound and then frozen. Tissue sections were cut
and stained with hematoxylin-eosin as an overview
stain, with oil-red-O (Abcam, Cambridge, United
Kingdom) for lipid, and with von Kossa for calcium.
The sections were matched with OCT and NIRS im-
ages by using angiographic images, pullback length,
and arterial landmarks. Abdominal aortae were har-
vested and stained en face by oil-red-O to assess
atherosclerotic burden, expressed as a percentage of
stained area to total area.
STATISTICAL ANALYSIS. SPSS version 20.0 software
(Chicago, Illinois) was used for statistical analysis.
Normally distributed data are mean � SD. For swine-
level analysis, an independent sample Student t test
was used, and for segment-level analysis, generalized
estimating equations modeling was used. For
swine-level repeated measures, repeated-measures
analysis of variance and for segment-level general-
ized estimating equations modeling were performed
using a linear response model with an autoregressive
(1) structure for the within-cluster correlation matrix.
A p value of <0.05 was considered statistically
signiﬁcant.
RESULTS
In all 13 swine plasma measurements were obtained.
In Figure 3A, average plasma insulin, glucose, and
cholesterol levels at the time of anesthesia were
documented at 9, 12, and 15 months. TC, LDL, HDL,
and triglyceride levels were higher in FF-DM and FF-
NDM swine than in age-, weight-, and sex-matched
control swine (TC: 2.14 � 0.6 mmol/l; HDL: 0.94 �
0.2 mmol/l; LDL: 1.22 � 0.6 mmol/l; triglycerides:
0.20 � 0.1 mmol/l). DM was successfully induced, as
indicated by higher glucose levels in FF-DM than in
FF-NDM swine (p < 0.05), and glucose levels
remained fairly stable over time (Figure 3B). Mean
arterial pressures were similar between FF-DM and
FF-NDM swine at 15 months (89 � 10 mm Hg, 85 �
5 mm Hg, respectively; p > 0.10), and, because similar
growth patterns were maintained by monitoring in-
dividual caloric intake (Figure 3C), mean ﬁnal weights
were comparable (FF-DM: 97.3 � 7.3 kg; FF-NDM: 96.5
� 3.3 kg; p ¼ 0.87). Moreover, we created hypergly-
cemic levels in FF-DM swine without evidence of
hypoglycemia.
Because lipoprotein proﬁles were comparable at 9,
12, and 15 months, all lipid proﬁles for FF-DM and
FF-NDM swine were combined. LDL and triglycerides
were higher and HDL lower in FF-DM and FF-NDM
swine compared with an age-, weight-, and sex-
matched control. Furthermore, the LDL peak was
dramatically increased and shifted to the right in
FF-DM and FF-NDM swine compared with control,
indicating a lower density of LDL (Supplemental
Figure 1).
QUICKI results were slightly lower in FF-DM swine
(0.56 � 0.10 at 9 months, 0.69 � 0.14 at 12 months,
and 0.53 � 0.03 at 15 months) than in FF-NDM swine
at 9 and 15 months (0.68 � 0.11 at 9 months; 0.72 �
0.14 at 12 months; and 0.60 � 0.04 at 15 months;
p ¼ 0.04 at 9 months; p ¼ 0.69 at 12 months; and
p ¼ 0.02 at 15 months). Compared with age-, weight-,
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and sex-matched control swine, QUICKI results were
reduced in both the FF-DM and the FF-NDM swine at
9 months (p ¼ 0.02) and 15 months (p < 0.01), sug-
gesting that insulin resistance occurred due to
experimentally induced islet dysfunction as well as
the FF diet.
OCT, NIRS, AND CCTA FINDINGS. Serial 9- and
12-month OCT and NIRS were performed in 12 of
13 swine, and additional 15-month evaluations
were performed in 7 of 8 swine. Due to techn-
ical difﬁculties, NIRS could not be performed in
1 swine at 9 months, which was excluded from
analysis. Additionally, 1 swine died during imaging
at 15 months due to a technical complication that
caused myocardial ischemia. CCTA was performed
in all 8 swine at 14 months (n ¼ 5 FF-DM, n ¼ 3
FF-NDM).
Mean and minimal lumen diameters decreased
slightly from 9 to 15 months in all swine (p > 0.10),
without a signiﬁcant difference between FF-DM and
FF-NDM swine (p > 0.10) (Supplemental Table 1).
OCT demonstrated focal lesions that were highly
variable in presence, location, and morphology.
Between FF-DM and FF-NDM, there were no differ-
ences regarding lesion type (p ¼ 0.42 for FIT;
p ¼ 0.77 for LL) or burden (p ¼ 0.17 for intimal
hyperplasia; p ¼ 0.49 for LL), except for 1 mixed
lesion that developed in an FF-DM swine with a
FIGURE 3 Plasma Measurement Results and Individual Insulin and Food Administration
Plasma measurement results (A and B) and individual insulin and food administration (C). Data are mean � SD. Animals 1 to 8 are FF-DM; 9 to 13 are FF-NDM.
9M ¼ 9-month follow-up; 12M ¼ 12-month follow-up; 15M ¼ 15-month follow-up. *p value ¼ comparison between FF-DM and FF-NDM swine.
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and sex-matched control swine, QUICKI results were
reduced in both the FF-DM and the FF-NDM swine at
9 months (p ¼ 0.02) and 15 months (p < 0.01), sug-
gesting that insulin resistance occurred due to
experimentally induced islet dysfunction as well as
the FF diet.
OCT, NIRS, AND CCTA FINDINGS. Serial 9- and
12-month OCT and NIRS were performed in 12 of
13 swine, and additional 15-month evaluations
were performed in 7 of 8 swine. Due to techn-
ical difﬁculties, NIRS could not be performed in
1 swine at 9 months, which was excluded from
analysis. Additionally, 1 swine died during imaging
at 15 months due to a technical complication that
caused myocardial ischemia. CCTA was performed
in all 8 swine at 14 months (n ¼ 5 FF-DM, n ¼ 3
FF-NDM).
Mean and minimal lumen diameters decreased
slightly from 9 to 15 months in all swine (p > 0.10),
without a signiﬁcant difference between FF-DM and
FF-NDM swine (p > 0.10) (Supplemental Table 1).
OCT demonstrated focal lesions that were highly
variable in presence, location, and morphology.
Between FF-DM and FF-NDM, there were no differ-
ences regarding lesion type (p ¼ 0.42 for FIT;
p ¼ 0.77 for LL) or burden (p ¼ 0.17 for intimal
hyperplasia; p ¼ 0.49 for LL), except for 1 mixed
lesion that developed in an FF-DM swine with a
FIGURE 3 Plasma Measurement Results and Individual Insulin and Food Administration
Plasma measurement results (A and B) and individual insulin and food administration (C). Data are mean � SD. Animals 1 to 8 are FF-DM; 9 to 13 are FF-NDM.
9M ¼ 9-month follow-up; 12M ¼ 12-month follow-up; 15M ¼ 15-month follow-up. *p value ¼ comparison between FF-DM and FF-NDM swine.
van Ditzhuijzen et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6
Coronary Atherosclerosis Imaging in FF-DM and FF-NDM Swine O C T O B E R 2 0 1 6 : 4 4 9 – 6 0
454
Chapter 6
76
FIGURE 4 Lipid-Containing Lesion Development Observed by OCT, NIRS, and Histology
The development of an eccentric LL lesion was observed by OCT (A to C, arrowheads) and NIRS (D to F, yellow) from 9 (9M) to 12 (12M) and 15 (15M) months. The OCT cross-
sections (AtoC)correspondto theregion in theNIRSchemograms (DtoF), shownbytheorange lines. At 15months, ahigh lipidburdenwasdetectedbyOCT (C, arrowheads)and
NIRS (F, yellow). Histological analysis (G andH) of sequential sections stainedwithOil red-O (G) and hematoxylin and eosin (H) stain conﬁrmed thedevelopment of an eccentric
atheromatous plaque with a large lipid pool (L in G1 and H1). The percentage of NIRS-positive segments increased over time in both FF-DM and FF-NDM swine (I). The graph
shows the mean percentage of NIRS-positive segments per swine. Dist¼ distal; Prox ¼ proximal; LCP ¼ lipid core plaque; LL¼ lipid laden; other abbreviations as in Figure 1.
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calciﬁed burden that increased from 2 lesion-
positive quadrants at 9 months to 3 lesion-positive
quadrants at 15 months. Of the 115 segments
analyzed at 9 months (n ¼ 74 FF-DM; n ¼ 41 FF-
NDM), 17% demonstrated FIT and 8% LL. From
9 to 15 months, the prevalence of disease increased
in FF-DM and FF-NDM (Figures 2B to 2D). At
12 months, 28% of subsegments displayed FIT and
18% LL. At 15 months, 40% demonstrated FIT and
21% LL. Similarly, lesion burden increased, indicated
by the increased number of lesion-positive quad-
rants (Figures 2B to 2D). Hence, lipid burden
increased, but no OCT-derived thin-cap ﬁbroather-
oma developed in any swine (mean cap thickness:
0.21 � 0.00 mm in FF-DM; 0.18 � 0.00 mm in
FF-NDM; p > 0.10; minimal cap thickness: 0.07 mm
in FF-DM; 0.10 mm in FF-NDM at 15 months).
Similar to the OCT results that demonstrated
an increase in LL appearance (7% to 21%) and
lipid burden, NIRS demonstrated an increase in
the probability that LCP was present from 9 to 15
months (3% to 12% NIRS-positive subsegments)
(Figure 4). Agreement between OCT and NIRS for
the presence of lipid-containing lesions was
moderate (k ¼ 0.56).
CCTA documented a single low-density lesion
(186.0 � 38.3 HU) in the swine that died during the
intracoronary imaging procedure at 15 months
(Supplemental Figure 2). In the remaining swine,
CCTA was unable to detect any coronary lesion,
despite the fact that OCT and NIRS showed the
development of calciﬁed lesions or lipid-containing
lesions, respectively.
EX VIVO FINDINGS. Vascu lar funct ion . The con-
tractile response to the endothelium-independent
vasoconstrictor (U46619) was not different between
FF-DM and FF-NDM at 12 months (91 � 47 mm vs. 98 �
45 mm, respectively; p > 0.10). Coronary segments
dilated to endothelium-dependent and -independent
vasodilators (BK and SNAP) in a concentration-
dependent manner. FF-DM swine demonstrated a
reduced response to the endothelium-dependent
vasodilator BK similar to that of FF-NDM swine
(pEC50: FF-DM 7.6 � 0.5 vs. FF-NDM 7.7 � 0.3;
p > 0.10). The response to the endothelium-
independent vasodilator SNAP remained unaltered
in FF-DM and FF-NDM (p > 0.10), and the response to
the endothelium-dependent vasoconstrictor ET-1
was increased (Emax FF-DM: 102 � 18 vs. FF-NDM:
102 � 22; p > 0.10) (Figure 5).
His to logy . Of the swine that died during the
imaging procedure, histological analysis demon-
strated an eccentric atherosclerotic lesion with
necrotic core in the distal left circumﬂex coronary
artery (Supplemental Figure 3). In the remaining
swine, coronary atherosclerosis was heterogeneously
divided between and within swine, ranging from
early (Figure 2A4) to more advanced atherosclerosis
(Figures 2A5 and 2A6), as was also documented by
OCT (Figure 2).
Substantial aortic atherosclerosis developed in all
swine at 12 months (72 � 6% surface area covered by
plaque in FF-DM and 58 � 12% in FF-NDM) and at
15 months (67 � 9% FF-DM and 46 � 31% FF-NDM;
p > 0.10) (Supplemental Figure 4). There was
no correlation between the percentage of aortic
FIGURE 5 Concentration Response Curves to BK, SNAP, and ET-1
Concentration response curves to BK (left), SNAP (middle), and ET-1 (right) of coronary segments of FF-DM and FF-NDM swine. No signiﬁcant differences in vasodilatory
or vasoconstrictor responses were noted. BK ¼ bradykinin; ET ¼ endothelin; SNAP ¼ S-nitroso-N-acetylpenicillamine; other abbreviations as in Figure 1.
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atherosclerosis and triglyceride (R2: 0.12; p ¼ 0.24),
TC (R2 0.26; p ¼ 0.08), LDL (R2 0.22; p ¼ 0.11) or
HDL levels (R2: 0.25; p ¼ 0.09). Furthermore, there
was no relationship between abdominal aortic
atherosclerosis and coronary atherosclerosis. The
R2 value was 0.01 (p ¼ 0.73) for aortic atheroscle-
rosis compared with that for any lesion observed
by OCT, and R2 was 0.10 (p ¼ 0.34) for aortic
atherosclerosis compared to that for NIRS-positive
lesions.
DISCUSSION
We present a longitudinal, multimodal imaging
study assessing early atherosclerosis development
in FF-DM and FF-NDM swine. OCT, NIRS, vasc-
ular function, and histology demonstrated no
differences in early atherosclerosis development
between FF-DM and FF-NDM swine. OCT and NIRS
enabled the detailed assessment of early coronary
atherosclerosis, demonstrating focal lesions that
were highly variable in presence, location, and
morphology in all swine, whereas CCTA was not
able to detect these discrete early atherosclerotic
changes.
ATHEROSCLEROSIS DEVELOPMENT IN FF-DM
VERSUS FF-NDM SWINE. As expected, coronary and
aortic atherosclerosis progressed in all swine over
time. In line with ﬁndings by Fernandez-Friera et al.
(14), who demonstrated variable distribution of sub-
clinical atherosclerosis in coronary arteries and aortae
of middle-aged patients, we observed no correlation
between aortic and coronary atherosclerosis within
swine. Furthermore, a gene expression study
demonstrated that inﬂammatory genes were mark-
edly upregulated in coronary arteries compared with
aorta from the same animal, potentially explaining
the different atherosclerosis development in the
different vascular beds (15).
Between FF-DM and FF-NDM swine, there were
no signiﬁcant differences in extent or morphology
of atherosclerosis as assessed by intracoronary
imaging, and there were no differences in
endothelium-dependent and independent vasodila-
tion. This might indicate a ﬁnal common pathway
in the atherosclerotic disease process, as has also
recently been described in a mini-pig model, with a
similar atherosclerosis development in DM and
NDM swine (16). However, Duff et al. (17) was one
of the ﬁrst to assess experimental atherosclerosis
and suggested that hyperglycemia served as a pro-
tective factor against the development of experi-
mental atherosclerosis in rabbits. The differences
between our study ﬁndings and those by Duff et al.
(17) regarding the effect of hyperglycemia on the
development of atherosclerosis may be explained
by several factors, including species differences,
duration of DM, the toxins used to induce DM,
and the type and amount of diet given to the
swine (18).
First, rabbits are highly responsive to cholesterol
manipulation and develop lesions in a fairly short
time. Lesions are generally fattier and more macro-
phage rich than human lesions (19). Swine, on the
other hand, develop spontaneous coronary athero-
sclerosis similar to humans (4). Second, follow-up by
Duff et al. (17) reached up to 4 months, whereas we
followed the FF-DM and FF-NDM swine from 9
months to either 12 or 15 months. The protective
effect of hyperglycemia might only have been
apparent in the early stages of the disease. This
observation of protection against atherosclerosis
development is in line with observations by Niccoli
et al. (20), who demonstrated that diabetic patients
experience their ﬁrst event at a later stage of
atherosclerotic disease than nondiabetic patients.
Third, Duff et al. (17) used alloxan to render the
rabbits diabetic, whereas we used a single-dose in-
jection of streptozotocin. Differences in the toxin
used to induce DM might have resulted in noncom-
parable atherosclerosis development. Fourth, we fed
our swine twice daily but monitored individual
caloric intake to maintain similar growth patterns,
whereas Duff et al. (17) fed their rabbits ad libitum.
Monitoring individual caloric intake might have
accounted for similar atherosclerosis development in
FF-DM and FF-NDM swine.
Interestingly, DM was associated with accelerated
atherogenesis under comparable conditions of
hyperlipidemia in other swine models. Moreover,
Dixon et al. (21) and Gerrity et al. (22) demonstrated
enhanced lesion development in diabetic hyper-
lipidemic swine. The differences between our ﬁnd-
ings of a similar atherosclerosis development
between FF-DM and FF-NDM swine and the ﬁndings
by Dixon et al. (21) and Gerrity et al. (22) may also be
explained by differences in species, duration of dia-
betic disease, toxins used to induce diabetes mellitus,
and type and amount of diet given to the swine (18).
Dixon et al. (21) used male Sinclair miniature swine
and induced diabetes mellitus by using alloxan,
whereas Gerrity et al. (22) used Yorkshire swine
and induced diabetes by using 50 mg/kg streptozo-
tocin each day for 3 days; we used crossbred
Yorkshire � Landrace swine and induced diabetes by
a single-dose injection of 140 mg/kg streptozotocin.
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Furthermore, Gerrity et al. (22) fed the swine ad
libitum in the beginning of the study, whereas we fed
our swine twice daily and monitored individual
caloric intake to achieve similar growth patterns. This
might have resulted in similar atherosclerosis devel-
opment in the FF-DM and FF-NDM swine in our
study.
Because our swine demonstrated lipid proﬁles
similar to those of the swine studied by Gerrity
et al. (22) and Dixon et al. (21) but demonstrated
different patterns of atherosclerosis development,
we believe that hypercholesterolemia, with or
without hyperglycemia, is not the only factor
contributing to the development of atherosclerosis
in these animal models.
Factors such as duration of DM and hypert-
ension may attribute to the severity of atherosclerotic
disease. Moreover, hypertension, not present in the
current study, has been associated with adverse
atherosclerosis-related events in DM patients (23).
Future studies in atherosclerotic swine should
consider using older-aged swine and include risk
factors such as hypertension to accurately evaluate
development of advanced coronary atherosclerosis.
COMPARISON OF IMAGING TECHNIQUES. Over
time, the prevalence and extent of disease
increased in FF-DM and FF-NDM swine as detected
by OCT and NIRS. OCT demonstrated increasing LL
appearance and lipid burden (Figure 2), and NIRS
demonstrated an increase in the probability that
LCP was present from 9 to 15 months (Figure 4).
Interestingly, a moderate agreement was observed
between OCT and NIRS for the detection of lipid.
This ﬁnding is in line with a previously published
study that demonstrated a moderate correlation
between OCT and NIRS for detection of lipid and
measurement of lipid contents (24). In contrast to
OCT, which visualizes vessel structure and thus
lipid morphology directly, NIRS provides calculated
values of the probability of lipid in each pixel on
the vessel surface (9). This difference in data
acquisition may contribute to the moderate corre-
lation between the 2 modalities.
CCTA did not detect any of the lesions docu-
mented by OCT or NIRS. Subtle differences in tissue
contrast were not noted because most of the lesions
were small, nonobstructive, and noncalciﬁed, with a
lesion burden of 1 to 2 lesion-positive quadrants.
Moreover, the small nonobstructive coronary pla-
ques observed in our swine appeared to be beyond
the resolution of the technology (25). In previous
studies, CT emerged as a noninvasive technique to
exclude coronary artery disease and demonstrated
good accuracy for detection of coronary artery ste-
nosis and assessment of high-density and low-
density lesions (10,26). However, CCTA is limited
by the fact that the image contrast between plaque
and other soft tissues (e.g., FIT) is small (27). This
may affect identiﬁcation and sizing of coronary
plaque and most likely explains the inability of
CCTA to detect the mainly noncalciﬁed lesions in the
present study.
OCT, NIRS, and CCTA acquire data differently and
thus provide different types of information, which
can be complementary and highly valuable for eval-
uating atherosclerosis development (28).
STUDY LIMITATIONS. Sample size was relatively
small, especially at 15 months. To study differences
in vascular function and histology over several
time points, sacriﬁce of a small number of swine
was mandatory. Furthermore, differences remain
between swine and human. Although swine, like
humans, develop spontaneous coronary atheroscle-
rosis, in the present study, swine were relatively
young and thus did not develop advanced athero-
sclerosis, as can be observed in older-aged patients
who suffer from hypercholesterolemia and/or DM for
a longer time period. However, the aim of our study
was to assess the effect of DM on early atherosclerosis
development.
CONCLUSIONS
Our swine model allowed assessment of early coro-
nary atherosclerosis development using intracoronary
OCT and NIRS. CCTA could not detect early athero-
sclerotic lesions, but OCT and NIRS demonstrated a
similar gradual development of early atherosclerosis
in FF-DM and FF-NDM swine. Moreover, OCT,
NIRS, vascular function, and histology demon-
strated no differences in early atherosclerosis devel-
opment between FF-DM and FF-NDM swine up to
15 months.
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Sorop O, van den Heuvel M, van Ditzhuijzen NS, de Beer VJ,
Heinonen I, van Duin RW, Zhou Z, Koopmans SJ, Merkus D, van 
der Giessen WJ, Danser AH, Duncker DJ. Coronary microvascular 
dysfunction after long-term diabetes and hypercholesterolemia. Am J 
Physiol Heart Circ Physiol 311: H1339–H1351, 2016. First published
September 2, 2016; doi:10.1152/ajpheart.00458.2015.—Coronary mi-
crovascular dysfunction (CMD) has been proposed as an important 
component of diabetes mellitus (DM)- and hypercholesterolemia-
associated coronary artery disease (CAD). Previously we observed 
that 2.5 mo of DM and high-fat diet (HFD) in swine blunted brady-
kinin (BK)-induced vasodilation and attenuated endothelin (ET)-1-
mediated vasoconstriction. Here we studied the progression of CMD 
after 15 mo in the same animal model of CAD. Ten male swine were
fed a HFD in the absence (HFD, n  5) or presence of streptozotocin-
induced DM (DM  HFD, n  5). Responses of small (300-m-
diameter) coronary arteries to BK, ET-1, and the nitric oxide (NO) 
donor S-nitroso-N-acetylpenicillamine were examined in vitro and 
compared with those of healthy (Normal) swine (n   12). Blood 
glucose was elevated in DM  HFD (17.6  4.5 mmol/l) compared 
with HFD (5.1   0.4 mmol/l) and Normal (5.8   0.6 mmol/l) swine,
while cholesterol was markedly elevated in DM  HFD (16.8  1.7 
mmol/l) and HFD (18.1  2.6 mmol/l) compared with Normal (2.1  
0.2 mmol/l) swine (all P   0.05). Small coronary arteries showed 
early atherosclerotic plaques in HFD and DM  HFD swine. Surpris-
ingly, DM   HFD and HFD swine maintained BK responsiveness 
compared with Normal swine due to an increase in NO availability 
relative to endothelium-derived hyperpolarizing factors. However, 
ET-1 responsiveness was greater in HFD and DM   HFD than 
Normal swine (both P  0.05), resulting mainly from ETB receptor-
mediated vasoconstriction. Moreover, the calculated vascular stiffness
coefﬁcient was higher in DM  HFD and HFD than Normal swine 
(both P  0.05). In conclusion, 15 mo of DM  HFD, as well as HFD 
alone, resulted in CMD. Although the overall vasodilation to BK was 
unperturbed, the relative contributions of NO and endothelium-de-
rived hyperpolarizing factor pathways were altered. Moreover, the 
vasoconstrictor response to ET-1 was enhanced, involving the ETB
receptors. In conjunction with our previous study, these ﬁndings
highlight the time dependence of the phenotype of CMD.
coronary microvascular dysfunction; diabetes; endothelin-1; hyper-
cholesterolemia; swine
NEW & NOTEWORTHY
Coronary microvascular dysfunction (CMD) is an increasingly
recognized feature of coronary artery disease. We found that
progression of CMD in diabetic  hypercholesterolemic swine
from 2.5 to 15 mo of follow-up involved a shift from impaired
endothelium-dependent vasodilation to bradykinin to exagger-
ated vasoconstriction to endothelin, highlighting the time de-
pendence of the phenotype of CMD.
DIABETES MELLITUS (DM) and hypercholesterolemia are wide-
spread risk factors for ischemic heart disease, and their prev-
alence continues to increase worldwide (3, 4, 6, 48). A large
contribution to morbidity and mortality of diabetic patients can
be attributed to the accelerated development of obstructive
proximal coronary artery disease (CAD) (11). However, it is
also increasingly recognized that coronary microvascular dys-
function (CMD) is an early feature of DM and hypercholes-
terolemia that may precede macrovascular disease and consti-
tutes a major component of DM-associated CAD (18, 19, 52,
57, 66). Although the pathogenesis of CMD is incompletely
understood, DM-induced progressive endothelial dysfunc-
tion is thought to be a key player in this process. This
endothelial dysfunction encompasses a shift in the secretion
of endothelium-derived relaxing factors from nitric oxide
(NO) to endothelium-derived hyperpolarizing factor
(EDHF), as well as an imbalance between these relaxing
factors and endothelium-derived constricting factors such as
endothelin (ET)-1 (35, 52, 71).
In a recent study we demonstrated impaired coronary mi-
crovascular NO bioavailability and reduced ET-1 responsive-
ness in diabetic swine fed a high-fat diet (HFD) during 2.5 mo
of follow-up (71). The present study was undertaken to char-
acterize the progression of CMD in this model. Speciﬁcally, we
tested the hypothesis that prolonged exposure to hyperglyce-
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mia and hypercholesterolemia leads to further impairment of
NO availability and to increased ET-1-mediated vasoconstric-
tion. For this purpose, vascular function of small coronary
arteries was studied in vitro at 15 mo of follow-up in DM 
HFD swine and compared with vascular function in HFD, as
well as healthy (Normal), swine.
MATERIALS AND METHODS
The study was performed in a total of 16 swine in accordance with
the “Guiding Principles in the Care and Use of Laboratory Animals,”
as approved by the Council of the American Physiological Society,
and with approval of the Animal Care Committee at Erasmus Uni-
versity Medical Center Rotterdam; an additional 12 swine hearts were
obtained from a slaughterhouse.
Animals
Ten castrated male Yorkshire  Landrace swine (18.2  0.4 kg
body wt) were studied. In five animals, DM was induced by strepto-
zotocin injection (140–180 mg/kg iv) to destroy 80% of the pan-
creatic -cell islets (36, 71). At 4 wk after DM induction, a HFD
consisting of 10% sucrose, 15% fructose, 25% saturated fats, 1%
cholesterol, and 0.7% sodium cholate (bile salts) was gradually
introduced to DM (DM  HFD group) and non-DM (HFD group)
animals (71). Swine were housed in metabolic cages and fed two
meals a day, during each of which they had access to food for 1 h.
Food intake was monitored for each animal separately and titrated to
maintain growth at 1.5 kg/wk. All 10 animals completed the 15-mo
study duration. The diabetic status of the DM  HFD swine was
regularly monitored by measurements of urinary and venous blood
glucose and ketone levels.
Six weight-matched Yorkshire  Landrace normal control (Nor-
mal) swine were studied for comparison of heart rate, blood pressure,
and plasma characteristics, while three of these animals were also
used for vascular function experiments. In addition, 12 fresh healthy
normal hearts were obtained from slaughterhouse swine of similar
body weight (100 kg at euthanization) for comparison of vascular
function characteristics. Since in a separate study no differences in the
small artery functional responses to bradykinin (BK), ET-1, and
S-nitroso-N-acetylpenicillamine (SNAP) were observed between male
(n  8) and female (n  9) swine of this size (Fig. 1), data from
normal, control animals of both sexes were included.
Plasma Characteristics
At euthanization, animals were sedated with Zoletil (tiletamine/
zolazepam, 5 mg/kg), Rompun (xylazine, 2.25 mg/kg), and atropine (2
ml im), anesthetized with pentobarbital sodium (20 mg·kg1·h1 iv),
and artificially ventilated. Arterial access was obtained by introduc-
tion of a 9F sheath into the carotid artery to monitor blood pressure
and heart rate and to collect fasting arterial blood samples. Plasma
levels of glucose, triglycerides, total cholesterol, LDL, HDL, aspartate
aminotransferase, alanine aminotransferase, and creatinine were mea-
sured using standardized protocols at the clinical chemical laboratory
of the Erasmus Medical Center. Arterial plasma concentrations of
insulin (Mercodia, Uppsala, Sweden), ET-1, (ELISA, Enzo Life
Sciences, Lausen, Switzerland), and TNF (R & D Systems Europe,
Abingdon, UK) were determined using ELISA kits.
Vascular Function In Vitro
After all blood samples had been obtained and following thoracot-
omy, hearts were arrested and immediately excised and placed in cold,
oxygenated Krebs bicarbonate buffer solution. For the HFD and
DM  HFD swine, small (300 m diameter) epicardial coronary
arteries were isolated from the perfusion areas of the left anterior
descending, left circumflex, or right coronary artery such that, in both
groups, vessels from all three perfusion areas were evenly distributed.
In the Normal swine, vessels were isolated from the apical part of the
heart, so that vessels originating from both left and right coronary
artery perfusion areas were included. The isolated segments were
studied in vitro in a Mulvany wire myograph (DMT, Aarhus, Den-
mark), as previously described (71). Briefly, during the vascular
function experiments, vessel segments (2 mm long) were main-
tained at 37°C in 103 M Krebs buffer (in mM: 118 NaCl, 4.7 KCl,
2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25, NaHCO3, and 8.3 glucose;
pH 7.4). After a 30-min stabilization period, the normalization pro-
cedure was started; during this procedure, the internal diameter was
set to a tension equivalent to 90% of the estimated diameter at 100
mmHg effective transmural pressure (27). Thereafter, the vascular
segments were depolarized by 100 mM KCl (Sigma-Aldrich, Zwijn-
drecht, The Netherlands) to determine the maximal contractile re-
sponse of the small artery segments.
Subsequently, concentration-response curves (CRCs) for various
substances (all from Sigma-Aldrich) were acquired using separate, but
in vivo adjacently positioned, segments. Endothelium-dependent va-
sodilation was studied by construction of the CRC for BK (1010–
106 M) upon preconstriction by the thromboxane A2 analog U46619
(106 M) (10). It was previously shown that prostaglandins are not
involved in BK-induced responses in healthy porcine small coronary
arteries (10). To assess the contribution of NO and EDHF to BK-
induced vasodilation, the same BK experiment was performed in
separate small artery segments upon 30 min of preincubation with the
NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME,
104 M), the small- and intermediate-conductance Ca2-activated K
(KCa) channel inhibitors apamin (107 M) and TRAM 34 (105 M),
or apamin  TRAM 34. Endothelium-independent vasodilation was
studied in separate small artery segments by construction of CRCs to
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Fig. 1. Concentration-response curves for bradykinin (BK; A), S-nitroso-N-acetylpenicillamine (SNAP; B), and endothelin-1 (ET-1; C) in small coronary arteries
isolated from male (n  8) and female (n  9) slaughterhouse pigs. No sex differences were observed for any of the vasoactive factors.
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the exogenous NO donor SNAP (1010–3  105 M). In additional
small artery segments, CRCs to ET-1 (1010–106 M) were con-
structed. To test the specific contributions of the ETA and ETB
receptors to this response, the same experiment was performed upon
30 min of incubation with the ETA receptor antagonist BQ123 (106
M), the ETB receptor antagonist BQ788 (107 M), or BQ123 
BQ788.
To examine whether small coronary arteries had undergone
changes in passive tension characteristics, the values of the relaxed
steady-state diameters at each wall tension of the normalization
procedure were fitted by an exponential equation according to Halpern
et al. (27), and the stiffness coefficient was calculated.
Histology
After completion of the vascular function studies, each vascular
segment was fixed in 4% buffered formaldehyde, embedded in
paraffin, and stained with resorcin-fuchsin to assess atherosclerosis
development. Atherosclerotic plaques of different complexity were
described according to the American Heart Association classifica-
tion (63).
Quantitative Real-Time PCR Analysis
Small arteries, dissected simultaneously with vessels isolated for
the vascular function studies, were used to study the expression of
endothelial NO synthase (eNOS), ETA and ETB receptors, and small-,
intermediate-, and big-conductance K channel mRNA. A Qiagen
RNA kit was used to extract RNA from frozen vessel samples. cDNA
was synthesized from 100 ng of total RNA with iScript reverse
transcriptase (Bio-Rad Laboratories, Veenendaal, The Netherlands).
Quantitative real-time PCR (MyIQ, Bio-Rad Laboratories) was per-
formed with SYBR Green (Bio-Rad Laboratories). Target gene
mRNA levels are expressed relative to the housekeeping genes glyc-
eraldehyde-3-phosphate dehydrogenase and cyclophilin as endoge-
nous controls (76). Primer sequences are shown in Table 1.
Microvascular NO Production
Microvascular NO production was evaluated in homogenized seg-
ments of microvessels (snap-frozen directly after excision from the
hearts) of the same size and from the same animals used for the
functional studies. Production of the NO metabolites NO2 and NO3
was measured using the Griess reaction colorimetric assay (Cayman
Chemical, Ann Arbor, MI).
Data Analysis
Values are means SE. Normally distributed model characteristics
were compared by one-way ANOVA followed by Scheffé’s post hoc
test (StatView 5.0, SAS Institute). Vasodilator responses to BK and
SNAP are expressed as percentage of the preconstriction to U46619.
Vasoconstrictor responses to U46619, and ET-1 were normalized to
100 mM KCl. Statistical analysis of CRCs was performed using
two-way ANOVA (with the increasing agonist concentrations and
antagonists as independent variables), followed by Fisher’s PLSD
post hoc correction. Two-tailed P  0.05 was considered statisti-
cally significant.
RESULTS
Hemodynamic Parameters and Plasma Characteristics
At euthanization, body weights of DM  HFD, HFD, and
Normal swine were similar: 93 3, 109 5, and 103 19 kg,
respectively. Furthermore, heart rate (114  3, 111  3, and
87  7 beats/min for DM  HFD, HFD, and Normal, respec-
tively, P  0.05) and mean arterial pressure (103  4, 105 
6, and 121  7 mmHg for DM  HFD, HFD, and Normal,
respectively, P  0.10), as measured under anesthesia, were
similar.
Plasma levels of glucose, insulin, lipids, and inflammation
markers are summarized in Fig. 2. Plasma glucose was signif-
icantly increased in DM  HFD compared with HFD and
Normal swine. Plasma insulin values tended to be increased in
DM  HFD (14.5  4.4 pg/ml), and particularly in HFD
(18.2  1.4 pg/ml), compared with Normal (10.1  1.6 pg/ml)
swine but failed to reach statistical significance (P  0.21).
However, the quantitative insulin sensitivity check index (32)
QUICKI, calculated as 1/[log(I0)  log(G0)], where I0 is
fasting plasma insulin level (in U/ml) and G0 is fasting blood
glucose level (in mg/dl), showed significantly lower values in
DM HFD and HFD than Normal swine, indicative of insulin
resistance in both groups. The high-fat diet resulted in in-
creased plasma total cholesterol and LDL cholesterol in DM
HFD and HFD compared with Normal swine. Plasma trigly-
cerides were higher in both HFD groups, reaching statistical
significance only in DM  HFD swine (P  0.05 vs. Normal).
TNF trended toward increased levels (without reaching sta-
tistical significance, P  0.14) in DM  HFD compared with
HFD and Normal swine. No significant differences between
the three groups were observed in plasma markers of liver and
kidney function (quantitative data not shown). Plasma ET-1
levels were elevated only in DM  HFD swine (Fig. 2).
Small Coronary Artery Structure and Function
Figure 3 shows representative examples of resorcin-fuchsin-
stained small coronary arteries from all three groups. Plaques
with different degrees of complexity (from fatty streaks to
more complex plaques) were observed in small arteries from
HFD (Fig. 3, C and D) and DM HFD (Fig. 3, E and F) swine
to a similar extent, but not Normal swine (Fig. 3, A and B).
Table 1. Primer sequences
Primer
Sequence
Sense Antisense
eNOS CTCTCCTGTTGGCCTGACCA CCGGTTACTCAGACCCAAGG
ETA receptor TTTATCCTGGCCATCCCTGA GCTCTTCGCCCTTGTATTCAA
ETB receptor CCCCTTCATCTCAGCAGGATT GCACCAGCAGCATAAGCATG
Small-conductance K channels TGGTGAAGAAGCCAGACCAC CCGGAGCTTCTGAGCTTGAT
Intermediate-conductance K channels CCATCAACACGTTCCGCCAG AGCTGCAGGTCACACAGGAT
Big-conductance K channels ATTGCTGAGGAGAATGCGCT TAACAACCACCATCCCCCAG
GAPDH TCGGAGTGAACGGATTTG CCTGGAAGATGGTGATGG
Cyclophillin GTCTCCTTCGAGCTGTTTGC AATCCTTTCTCCCCAGTGCT
eNOS, endothelial nitric oxide synthase; ETA and ETB, endothelin receptor types A and B.
H1341CORONARY MICROVASCULAR DYSFUNCTION IN SWINE WITH DM AND CAD
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00458.2015 • www.ajpheart.org
Downloaded from www.physiology.org/journal/ajpheart by ${individualUser.givenNames} ${individualUser.surname} (156.083.001.029) on December 26, 2017.
Copyright © 2016 American Physiological Society. All rights reserved.
Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia
87
7
The constrictor responses to 106 M U46619 (used for
preconstriction) were similar among the three groups (74 
5%, 66  4%, and 67  6% of the response to 100 mM KCl
for DM  HFD, HFD, and Normal, respectively, P  0.56),
indicating equal preconstriction levels. Coronary microvascu-
lar responses to BK, SNAP, and ET-1 are summarized in Fig.
4. Surprisingly, endothelium-dependent vasodilation to BK
was similar among the three groups (Fig. 4A). The response to
the exogenous NO donor SNAP was also similar among all
groups, indicating preserved vascular smooth muscle respon-
siveness to NO (Fig. 4B). In contrast, vasoconstriction to ET-1
was significantly increased in DM  HFD and HFD compared
with Normal swine (Fig. 4C).
Mechanism of BK-induced vasodilation. The specific contri-
butions of NO and EDHF to the endothelium-dependent BK-
mediated vasodilation were studied by blockade of eNOS and
of small- and intermediate-conductance KCa channels, respec-
tively (Fig. 5). In all groups, eNOS blockade with L-NAME
resulted in a significant reduction in the vasodilator response to
BK (all P  0.05; Fig. 5). However, while EDHF blockade
blunted the vasodilation to BK in Normal swine (Fig. 5A), no
effect was observed in the HFD or DM  HFD swine (Fig. 5,
B and C). Yet combined eNOS and EDHF blockade resulted in
larger reductions in vasodilator response to BK than eNOS
alone in all three groups (Fig. 5), suggesting that small arteries
from HFD and DM HFD swine were able to produce EDHF,
but only during inhibition of NO production.
Mechanism of ET-1-induced vasoconstriction. The specific
contributions of ETA and ETB receptors to exogenous ET-1-
induced vasoconstriction are shown in Fig. 6. ETA receptor
blockade blunted ET-1-induced vasoconstriction in all three
groups (all P  0.05), at a magnitude that was similar between
groups (P  0.54). In contrast, while ETB receptor blockade
significantly enhanced the vasoconstrictor response to ET-1 in
Normal swine (P  0.001; Fig. 6A), it had no effect in DM 
HFD swine (Fig. 6C) and significantly blunted vasoconstric-
tion in HFD swine (P  0.05; Fig. 6B). Similarly, compared
with ETA receptor blockade alone, combined ETA  ETB
(ETAB) receptor blockade produced further blunting of the
ET-1-induced vasoconstriction in HFD swine (P  0.05) and
showed a trend toward further blunting in DM  HFD (P 
0.15 at 3  109–107 M), but not Normal, swine.
Quantitative Real-Time PCR Analysis and Microvascular
NO Production
eNOS expression was similar in DM  HFD and Normal
swine and tended to be lower in HFD swine (P  0.13, HFD
vs. DM  HFD and Normal; Fig. 7A). Interestingly, consistent
with eNOS expression, similar levels of the NO metabolites
NO2 and NO3 in small arteries indicated similar basal NO
production in the DM  HFD and Normal swine, while a
significant reduction in microvascular NO production was
observed in HFD compared with Normal swine (Fig. 7B).
Expression of small-conductance K channels in DM 
HFD swine was significantly decreased (P  0.05; Fig. 8A),
and a trend toward a decrease in the HFD group (P  0.07)
was observed compared with Normal swine. Expression of
intermediate-conductance K channels was significantly lower
in HFD than DM HFD swine (P 0.05; Fig. 8B) and tended
to be lower than in Normal swine (P  0.11). Expression of
big-conductance K channels was similar between the three
groups (Fig. 8C).
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Expression profiles of the ET receptors indicated signifi-
cantly increased mRNA expression of both ETA (2-fold) and
ETB receptors (5-fold) in DM  HFD compared with Normal
swine (Fig. 9). In contrast, only ETB receptor mRNA expres-
sion was significantly increased (2-fold) in HFD compared
with Normal swine.
Vascular Stiffness and Wall-to-Lumen Ratio
The stiffness coefficient, as calculated from the relaxed
wall tension-strain relations, was significantly increased in
both DM  HFD (6.45  0.14, n  93 vessels from 5
swine) and HFD (6.65  0.15, n  48 vessels from 5 swine)
compared with Normal (5.48  0.17, n  70 vessels from
15 swine) animals (both P  0.05). These findings indicate
an increased stiffness in HFD and DM  HFD swine, which
occurred in the absence of media hypertrophy; also, wall-
to-lumen ratios measured on histological images were sim-
ilar among DM  HFD, HFD, and Normal swine (0.36 
0.03, 0.27  0.02, and 0.37  0.03, respectively, P 
0.11).
DISCUSSION
We previously showed that 2.5 mo of exposure to DM and
HFD resulted in an impaired BK-induced endothelium-depen-
dent vasodilation due to loss of NO availability, accompanied
by a reduced ET-1-mediated vasoconstriction due to decreased
ETA receptor contribution (71). The present study was under-
taken to characterize the progression of CMD at a later stage of
the disease (i.e., 15 mo) in the same swine model of DM and
HFD (72). The main findings of the present study were as
follows. 1) Coronary microvessels from HFD and DM  HFD
swine showed plaques with different degrees of complexity. 2)
The vasodilator response to BK was not further decreased but,
rather, was maintained in DM  HFD and HFD swine due to
the ability of the NO/EDHF-mediated mechanisms to interact
in synergy. 3) An increased ET-1 responsiveness was present
in DM  HFD and HFD swine that appeared to be principally
due to loss of ETB receptor-mediated vasodilation and in-
creased ETB receptor-mediated constriction, in particular in
HFD swine. 4) Coronary microvessels from HFD and DM 
HFD swine demonstrated increased stiffness, which occurred
A B
C D
E F
Fig. 3. Resorcin-fuchsin-stained small coronary ar-
teries. Note plaques with different degrees of com-
plexity in vessels from HFD (C and D) and DM 
HFD (E and F), but not Normal (A and B), swine.
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in the absence of medial hypertrophy. The implications of
these findings are discussed below.
Model Characteristics
In the present study, DM induction, through partial pancre-
atic -cell destruction, combined with HFD, resulted in mark-
edly elevated plasma glucose and cholesterol levels after 15 mo
of follow-up. Previously we performed similar experiments
using the same experimental model followed for only 2.5 mo
of HFD with or without DM (71). The DM  HFD group
demonstrated increased insulin resistance (reflected in the
QUICKI index) at 2.5 mo (71) and 15 mo (present study),
while increased insulin resistance was observed in the HFD
group at 15 mo (present study), but not at 2.5 mo (71).
Furthermore, in the HFD group, total cholesterol levels were
further elevated at 15 mo compared with 2.5 mo (71). Impor-
tantly, only prolonged exposure to hypercholesterole-
mia  hyperglycemia resulted in hypertriglyceridemia, a form
of dyslipidemia common in diabetic patients and associated
with the onset of CAD (70). In our swine model, atheroscle-
rotic plaques were observed in the large coronary arteries of
DM  HFD and HFD animals after 15 mo and did not appear
to produce flow-limiting obstructions (72). In the present study
we also observed plaques of different complexities in small
(2nd- and 3rd-order) coronary arteries of both groups. Unfor-
tunately, our focus on functional studies (requiring freshly
isolated small arteries) precluded perfusion fixation of hearts
under physiological pressures, which is a prerequisite for
accurate quantification of plaque burden. Consequently, we
limited the description of coronary atherosclerosis to the pres-
ence of plaques of heterogeneous complexity (from small fatty
streaks to more complex fibroatheromatous plaques), which
appeared similar in both groups. Plaques were not observed in
Normal or in HFD or DM  HFD swine studied previously at
2.5 mo (71), underscoring the importance of long-term expo-
sure of the coronary vasculature to pathological stimuli when
developing a large-animal model of coronary atherosclerosis.
Although coronary plaque formation required a longer fol-
low-up time, functional and structural abnormalities of the
small arteries were observed in DM  HFD swine as early as
2.5 mo of follow-up (71). These findings are in accordance
with clinical observations that microvascular alterations pre-
cede obstructive CAD in patients without DM (61), as well as
in patients with DM and increased insulin resistance (52, 59,
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Fig. 5. Concentration-response curves for BK upon blockade of the nitric oxide (NO) system [nitro-L-arginine methyl ester (L-NAME)], endothelium-derived
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60, 66). Furthermore, there is evidence that coronary flow
reserve is impaired not only in DM patients without CAD, but
also in prediabetic subjects, compared with healthy individuals,
indicating the early presence of CMD (20, 55). Microvascular
dysfunction is associated with factors such as oxidative stress,
poor glycemic control, insulin resistance, and hypercholester-
olemia (62), which were present in our DM  HFD swine
model. Since endothelial dysfunction is considered a key factor
in development of DM-associated coronary vascular disease
(62), we investigated coronary endothelial function in more
detail.
Endothelium-Dependent Vasodilation
In patients with DM, the severity of peripheral endothelial
dysfunction correlates with duration of the disease (49). Al-
though coronary microvascular endothelial dysfunction is also
likely related to the duration of DM, most animal studies
(Table 2) have investigated CMD at a single time point only,
usually rather early in the disease (24, 45, 50, 71). One study
in Zucker obese rats assessed multiple time points and showed
that acetylcholine-induced coronary microvascular dilation
was preserved up to 24 wk of age but was almost completely
abolished in older animals as a result of increased oxidative
stress (51), while another study in type 2 DM Goto-Kakizaki
rats showed impaired BK-induced vasodilation from 10 to 20
wk of age (46). However, while overall coronary endothelium-
dependent vasodilation may be preserved early in the disease,
the signaling pathways contributing to this vasodilation may
already be altered. Thus acetylcholine-mediated endothelium-
dependent vasodilation in coronary arterioles of obese rats after
10 wk of HFD was maintained due to enhanced soluble
guanylate cyclase activity that increased coronary vascular
sensitivity to NO (30). Similarly, in aortic rings of female rats
4 wk after induction of streptozotocin-induced diabetes, the
overall vasodilator response to acetylcholine was preserved, as
a reduction in NO bioavailability appeared to be compensated
by a downregulation of phosphodiesterase activity in combi-
nation with an increased vasodilator contribution of prosta-
noids (1). In contrast, 4 wk of high-fructose diet, which
resulted in increased insulin resistance, did not alter the NO-
dependent small coronary artery vasodilator response to ace-
tylcholine but, rather, reduced the contribution of EDHF (45),
while in the coronary arterioles of db/db mice with advanced
type 2 DM, EDHF compensated for diminished NO-dependent
vasodilation to acetylcholine (54). These findings suggest that
compensatory mechanisms may vary, depending on species,
DM model, and possibly the duration of exposure to risk
factors.
In the human coronary circulation (Table 2), DM and CAD
have been proposed to be associated with microvascular dys-
function (43, 75) and a shift in mediators of endothelium-
dependent vasodilation from NO to EDHF (47) and prostacy-
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clin (PGI2) (65), although it is unclear when this shift occurs.
In the present study we did not test the contribution of cyclo-
oxygenase to BK-induced dilation in HFD or DM  HFD
swine. However, data in healthy swine indicate no effect of
cyclooxygenase inhibition on BK-induced dilation (10). In our
swine model, vasodilation to BK was impaired early in the
disease process (after 2.5 mo), but only in DM  HFD
animals, which was due to a reduction in NO bioavailability,
while the contribution of EDHF was preserved (71). In con-
trast, after 15 mo of exposure to DM  HFD, the overall
response to BK was restored to control levels. This restoration
of NO-mediated dilation was consistent with the preserved
basal NO production and eNOS expression in small coronary
arteries of DM  HFD compared with Normal swine. It was
surprising that basal NO production was significantly reduced
in HFD swine, which was paralleled by a similar trend toward
a reduction in eNOS expression. NO and EDHF may influence
each other via intracellular and intercellular mechanisms (58),
as eNOS is capable of producing both NO and superoxide,
which in the presence of adequate antioxidant defense can be
converted to H2O2, which could potentially contribute to BK-
induced vasodilation by acting as an EDHF (16). In the present
study we observed a reduced expression, as well as a reduced
contribution, of KCa channels to the BK-induced vasodilation
in HFD and DM  HFD swine, suggesting that NO remains
the predominant eNOS metabolite contributing to BK-induced
vasodilation and that the interaction between NO and putative
EDHF(s) is altered. Furthermore, the observation that vasodi-
lation in response to the NO donor SNAP was similar in all
groups implies that NO responsiveness was maintained and,
hence, guanylate cyclase and phosphodiesterase activities were
unaltered. Taken together, the results from the present study
show that, even after prolonged exposure to HFD and DM and
despite the presence of CAD, the vasodilator response to BK is
preserved and is largely mediated by NO. In addition, despite
a reduction in small-conductance K channel expression,
EDHF was able to contribute to BK-induced vasodilation, but
only when NO bioavailability was reduced.
In the present study we did not unravel the molecular
mechanisms through which factors such as hyperglycemia,
hypercholesterolemia, and inflammation result in endothelial
dysfunction. However, it has been shown that high glucose
levels can produce endothelial dysfunction by altering EDHF-
dependent mechanisms (69) and can also cause the formation
of extracellular advanced glycation end-products, which may
result in altered cellular signaling, release of proinflammatory
molecules, and oxidative stress (9). Furthermore, inflammatory
cytokines released from perivascular fat in hypercholesterol-
emia may also contribute to increased superoxide production
and eNOS uncoupling, thereby limiting basal NO bioavailabil-
ity (8, 21, 37). This is in agreement with the reduced micro-
vascular NO production and eNOS expression in the HFD
swine, but not with the data obtained in the DM HFD swine,
where both eNOS expression and NO production were essentially
maintained. Furthermore, inflammation and hyperglycemia have
also been suggested to result in inactivation of small- and inter-
mediate-conductance K channels, leading to an impaired EDHF-
mediated vasodilation (17, 41). Our results confirm such reduction
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in the expression of the small- and intermediate-conductance K
channels, which can also partially explain the impaired basal
EDHF-mediated contribution to BK-induced vasodilation.
ET-1-Mediated Vascular Responses
Proper control of vascular tone requires an optimal balance
between vasodilator and vasoconstrictor influences (19). Dia-
betes and insulin resistance are known to alter the production
of, and the response to, endothelium-derived vasoconstrictors
(62). For example, the ET-1 system is activated in diabetes,
resulting in increased ET-1 plasma levels (5, 23), which cor-
relates well with diabetic microangiopathy (2). However, con-
flicting data have been reported regarding ET-1 reactivity, with
reduced responsiveness to exogenous ET-1 in the peripheral
circulation of obese (74) and type 2 DM (15, 44, 59) patients
and increased ET-1 vasoconstriction in animal models of DM
(31, 67, 73). Although this discrepancy is not readily ex-
plained, the present study, in conjunction with our previous
observations (71), demonstrates that disease progression might
be one explanation. Thus a reduced responsiveness to ET-1
was observed in DM  HFD swine at 2.5 mo of follow-up in
the absence of atherosclerotic plaques, while plasma ET-1
levels were still unchanged (71). This is in accordance with
reports in DM patients without evidence of atherosclerotic
disease (15, 44, 59). In addition, short-term exposure to HFD
in a dog model did not alter plasma ET-1 levels and ET-1
responsiveness (34), which was also observed in obese Zucker
rats at 16–18 wk of age (56), similar to our results in HFD
swine at 2.5 mo (71). In contrast, in the present study, 15 mo
of exposure to DM  HFD, but not HFD alone, resulted in
increased plasma ET-1 levels, in accordance with observations
in patients (2, 23), as well as the presence of coronary athero-
sclerotic plaques. At this later time point, both HFD and DM
HFD swine showed an increased responsiveness to exogenous
ET-1. These results are in agreement with rat models of
long-term type 1 DM showing exaggerated coronary ET-1
responsiveness combined with increased ET-1 plasma levels,
although the presence of CAD was not verified (29, 31).
Comparison of ET-1 responsiveness of the coronary circu-
lation in animal models with results obtained in patients with
CAD is difficult, since no data are available regarding the
response to exogenous ET-1 in the coronary circulation of
patients. However, endogenous ET-1 activity has been studied
in the coronary vasculature of patients by using ET-1 receptor
antagonists. The limited data on coronary circulation available
from clinical studies yield conflicting results (Table 3). The
coronary vasoconstrictor influence of ET-1 was increased in
obese compared with healthy humans, which correlated with
the cholesterol levels (42). Furthermore, Kyriakides et al.
reported a reduced effect of endogenous ET-1 on proximal
coronary arterial compliance in patients with type 2 DM (40)
and improved coronary arterial compliance by acute ETA
receptor antagonism in patients with CAD (39), while in
hypertensive patients the effect was not different from that in
controls (38). In the coronary microcirculation of stable CAD
patients with or without DM, endogenous ETA receptor activ-
ity exerts a vasoconstrictor influence, while endogenous ETB
receptor activity exerts a vasodilator influence (14, 26, 53). In
contrast, Feng et al. reported, besides ETA receptor-mediated
vasoconstriction, absence of an ETB receptor-mediated vaso-
dilating response in small coronary arteries of hypertensive,
diabetic patients undergoing coronary bypass grafting, possibly
a more advanced-disease group (22). Therefore, increased
coronary ET-1 activity seems to be present in obese, insulin-
resistant individuals as well as in overt DM patients. In our
swine model, we previously showed that at 2.5 mo the respon-
siveness to exogenous ET-1 was maintained in the HFD group
and actually decreased in the DM  HFD animals due to
reduced ETA receptor-mediated constriction (71). ETA receptor
expression was not significantly altered, suggesting that ETA
Table 2. Studies investigating effects of BK on coronary microvascular function in hypercholesterolemia and/or
metabolic derangement
Study Species Model Tissue FU Time Administration Vasorelaxation Mechanism
Mishra et al. (46) Rat Goto-Kakizaki
(nonobese, type
2 DM)
Isolated full heart
(coronary flow)
10–12 wk,
18–20 wk
Acute
administration
2 KCa ↔, NO?
Given et al. (24) Rat STZ (type 1 DM) Coronary
microvasculature
12 wk Acute
administration
↔ KCa ↔, cGMP ↔
Obrosova et al. (50) Rat STZ (type 1 DM) Isolated coronary
arterioles
6 wk Incubation BK 2 Peroxynitrite 1
Tsai et al. (69) Pig Glucose incubation Isolated healthy coronary
arterioles
1 h Incubation BK 2 EDHF2
Van den Heuvel et al. (71) Pig Type 2 DM  HFD Isolated coronary
arterioles
2.5 mo Incubation BK 2 NO2 EDHF↔
Present study Pig Type 2 DM  HFD Isolated coronary
arterioles
15 mo Incubation BK ↔ NO and EDHF
interact in
synergy
Yoshino et al. (75) Human Types 1 and 2 DM 
dyslipidemia
In vivo CBF ? IC administration 2
Szerafin et al. (65) Human Types 1 and 2 DM Isolated coronary
arterioles
? Incubation BK 1 COX-2 1
Matsumoto et al. (43) Human DM (type not
specified)
In vivo CBF (LAD) ? IC administration 2CBF with
1oxLDL
BK, bradykinin; FU, follow-up; DM, diabetes mellitus; STZ, streptozotocin; HFD, high-fat diet; CBF, coronary blood flow; LAD, left anterior descending 
coronary artery; IC, intracoronary; KCa, Ca2-activated K channel; oxLDL, oxidized low-density lipoprotein; NO, nitric oxide; EDHF, endothelium-derived 
hyperpolarizing factor; COX-2, cyclooxygenase 2; ?, unknown.
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receptor signaling was reduced at this early disease state. In
contrast, at 15 mo, both DM  HFD and HFD swine showed
increased ET-1 responsiveness that was accompanied by in-
creased expression of ETB receptors in both groups and, only
in DM  HFD swine, by a small increase in ETA receptor
expression. Accordingly, the enhanced ET-1 vasoconstrictor
responses appeared to be principally ETB receptor-mediated.
Thus the vasodilator influence of the ETB receptors in Normal
swine was lost in DM  HFD swine and was reversed to a
vasoconstrictor influence in HFD swine. Consequently, we
hypothesize that the increased ETB receptor expression oc-
curred predominantly in coronary vascular smooth muscle
cells, similar to observations in the cerebral vasculature of
diabetic rats (64). Importantly, these results suggest that, with
disease progression, not only is signaling of ETA receptors
restored between 2.5 and 15 mo of exposure to DM HFD but
also, at 15 mo, ETB receptor signaling has shifted from ETB
receptor-mediated vasodilation to ETB receptor-mediated va-
soconstriction. Finally, in all three groups, ETAB receptor
blockade appeared to be slightly greater than the sum of the
individual effects of ETA and ETB receptor blockade, suggest-
ing an interaction between the two receptors. Indeed, the
formation of ETA-ETB receptor dimers has been shown to
enhance the vasoconstrictor response to ET-1 (7, 12, 28).
Whether this ET-1 receptor dimerization plays a role in the in
vivo responsiveness of the coronary microcirculation should be
the subject of future investigations.
Vascular Stiffness
A chronic increase in vascular tone is capable of inducing
inward remodeling due to extracellular matrix restructuring
(7). Hence, the increased circulating levels of ET-1 in the
DM  HFD swine, together with the increased responsiveness
of the small coronary arteries to exogenous ET-1 in vitro, may
have led to a chronic increase in coronary microvascular tone
and, thus, extracellular matrix remodeling. Although we did
not find evidence for microvascular inward remodeling, we did
observe an increase in vascular stiffness, particularly in DM 
HFD swine. These observations contrast with a study by Katz
et al., who reported reduced coronary arteriolar stiffness in type
2 diabetic mice, associated with inward hypertrophic remod-
eling and increased elastin-to-collagen ratio in the vascular
wall (33). Studying Ossabaw swine with metabolic syndrome,
Trask et al. also reported a reduced microvascular coronary
stiffness that was associated with inward remodeling, capill-
ary rarefaction, augmented myogenic tone, and reduced coro-
nary blood flow reserve (68). The divergent observations are
not readily explained but could be due to differences in disease
severity. Indeed, an increased stiffness of resistance, but not
large, arteries due to hyperglycemia was observed in type 1
DM patients (25).
Conclusions
In summary, the present study, in conjunction with our
previous study (71), demonstrates that the balance of vasodi-
Table 3. Studies investigating effects of ET-1 on coronary microvascular function in hypercholesterolemia and/or
metabolic derangement
Study Species Model Tissue FU Time Administration Vasoconstriction Mechanism
Kamata et al. (31) Rat STZ-diabetic (type 1) Isolated heart 9 mo Heart
perfusion
1
Verma et al. (73) Rat STZ-diabetic (type 1) Isolated heart 8 wk Heart
perfusion
1 Reversed by
bosentan
Tickerhoof et al. (67) Rat STZ-diabetic (type 1) Isolated coronary
arterioles
6 wk Incubation
ET-1
1
Prakash et al. (56) Rat Obese Zucker
(pre-DM)
Isolated coronary
arterioles
16–18 wk Incubation
ET-1
2
Van den Heuvel et al. (71) Pig Type 2 DM  HFD Isolated coronary
arterioles
2.5 mo Incubation
ET-1
2 2 ETA
Present study Pig Type 2 DM  HFD Isolated coronary
arterioles
15 mo Incubation
ET-1
1 1 ETA, 1 ETB
Knudson et al. (34) Dog Metabolic syndrome Isolated coronary
arterioles
6 wk Incubation
ET-1
↔
Feng et al. (22) Human Hypertension and DM
(type not specified)
Isolated coronary
arterioles
? Incubation
ET-1
↔ 2 ETB
Altieri et al. (5) Human Type 2 DM and CAD IC levels of circulating
ET-1
1
Bohm et al. (14) Human Hypercholesterolemia
and CAD
Coronary flow ? IC infusion of
BQ123 and
BQ788
1
Halcox et al. (26) Human Hypercholesterolemia
and CAD
Coronary microvascular
vasomotion
? IC infusion of
BQ123 and
BQ788
1ETB 2ET-1 clearance
and NO
bioavailability
Papadogeorgos et al. (53) Human Type 2 DM and CAD Coronary flow ? IC infusion of
BQ123 and
bosentan
1
Mather et al. (42) Human Obesity Myocardial perfusion
(PET)
? IC infusion of
BQ123
↔ 1 Effect with
increased BMI
and cholesterol
DM, diabetes mellitus; STZ, streptozotocin; HFD, high fat diet; CAD, coronary artery disease; IC, intracoronary; BQ123, ETA receptor antagonist; BQ788, 
ETB receptor antagonist; BMI, body mass index; ?, unknown.
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lator and vasoconstrictor mechanisms contributing to CMD
changes markedly during disease progression. Thus, whereas at
2.5 mo after induction of hyperglycemia and hypercholester-
olemia, impaired endothelium-dependent vasodilation was ac-
companied by a reduced ET-1-mediated vasoconstriction (71),
the present study demonstrates that at 15 mo, microvascular
dysfunction was principally characterized by an increased
vasoconstrictor response to ET-1, but with a normal endothe-
lium-dependent vasodilator response to BK. In hypercholester-
olemia only, the progression of microvascular dysfunction is
more subtle, and no significant alterations could be observed at
2.5 mo (71). In contrast, at 15 mo in the present study,
responses were characterized by a normal vasodilator response
to BK and increased vasoconstriction to ET-1 that was princi-
pally due to enhanced ETB receptor-mediated vasoconstrictor
response. These findings indicate that the nature of CMD early
in the disease process can be very different from, and is not
necessarily predictive of, the nature of CMD during later stages
of the disease process. Furthermore, these findings highlight
the importance of performing longitudinal studies of microvas-
cular function in experimental studies of DM and CAD.
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Abstract
Background
Diabetes mellitus (DM) is associated with a range of microvascular complications including 
diabetic nephropathy (DN). Microvascular abnormalities in the kidneys are common histo-
pathologic findings in DN, which represent one manifestation of ongoing systemic microvas-
cular damage. Recently, sidestream dark-field (SDF) imaging has emerged as a 
noninvasive tool that enables one to visualize the microcirculation. In this study, we 
investigated whether changes in the systemic microvasculature induced by DM and an 
atherogenic diet correlated spatiotemporally with renal damage.
Methods
Atherosclerotic lesion development was triggered in streptozotocin-induced DM pigs
(140 mg/kg body weight) by administering an atherogenic diet for approximately 11 
months. Fifteen months following induction of DM, microvascular morphology was visual-
ized in control pigs (n = 7), non-diabetic pigs fed an atherogenic diet (ATH, n = 5), and DM 
pigs fed an atherogenic diet (DM+ATH, n = 5) using SDF imaging of oral mucosal tissue. 
Subsequently, kidneys were harvested from anethesized pigs and the expression levels 
of well-established markers for microvascular integrity, such as Angiopoietin-1 (Angpt1) 
and Angiopoietin-2 (Angpt2) were determined immunohistochemically, while endothelial 
cell (EC) abundance was determined by immunostaining for von Willebrand factor (vWF).
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pathologic findings in DN, which represent one manifestation of ongoing systemic microvas-
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noninvasive tool that enables one to visualize the microcirculation. In this study, we 
investigated whether changes in the systemic microvasculature induced by DM and an 
atherogenic diet correlated spatiotemporally with renal damage.
Methods
Atherosclerotic lesion development was triggered in streptozotocin-induced DM pigs
(140 mg/kg body weight) by administering an atherogenic diet for approximately 11 
months. Fifteen months following induction of DM, microvascular morphology was visual-
ized in control pigs (n = 7), non-diabetic pigs fed an atherogenic diet (ATH, n = 5), and DM 
pigs fed an atherogenic diet (DM+ATH, n = 5) using SDF imaging of oral mucosal tissue. 
Subsequently, kidneys were harvested from anethesized pigs and the expression levels 
of well-established markers for microvascular integrity, such as Angiopoietin-1 (Angpt1) 
and Angiopoietin-2 (Angpt2) were determined immunohistochemically, while endothelial 
cell (EC) abundance was determined by immunostaining for von Willebrand factor (vWF).
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Results
Our study revealed an increase in the capillary tortuosity index in DM+ATH pigs (2.31±0.17)
as compared to the control groups (Controls 0.89±0.08 and ATH 1.55±0.11; p<0.05). Kid-
ney biopsies showed marked glomerular lesions consisting of mesangial expansion and
podocyte lesions. Furthermore, we observed a disturbed Angpt2/ Angpt1balance in the cor-
tex of the kidney, as evidenced by increased expression of Angpt2 in DM+ATH pigs as com-
pared to Control pigs (p<0.05).
Conclusion
In the setting of DM, atherogenesis leads to the augmentation of mucosal capillary tortuosi-
ty, indicative of systemic microvascular damage. Concomitantly, a dysbalance in renal
angiopoietins was correlated with the development of diabetic nephropathy. As such, our
studies strongly suggest that defects in the systemic microvasculature mirror the accumula-
tion of microvascular damage in the kidney.
Introduction
Diabetes mellitus (DM) is associated with macrovascular and microvascular complications that 
lead to retinopathy, neuropathy and nephropathy. Diabetic nephropathy is the leading cause of 
chronic kidney disease (CKD) worldwide [1,2]. In this disease setting, the combination of en-
dothelial dysfunction and an imbalanced angiogenic response play an important role in the de-
velopment of microvascular complications. Recently, the angiopoietins have gained much 
attention as critical regulators of of diverse pathological angiogenic conditions, including vas-
cular complications associated with diabetes. The tight control of Angiopoietin-1 (Angpt1) and 
Angiopoietin- 2 (Angpt2) levels is critical in minimizing microvascular derangements that are 
the direct result of negative interference of Angpt2 with Angpt1-mediated Tie-2 signaling. This 
in turn disturbs the expression levels of key angiogenic factors such as von Willebrand factor 
(vWF) and vascular endothelial growth factor (VEGF). The ensuing loss of EC-pericyte inter-
actions is responsible for destabilization of the capillary network and the loss of microvascular 
integrity. [3,4, 5, 6].
Histopathological findings in patients with diabetic nephropathy (DN) include mesangial 
expansion, mesangial sclerosis and vascular lesions such as hyalinosis [7]. These renal abnor-
malities could potentially be indicative of the systemic microvascular damage [8]. However, the 
detection of such pathophysiologies in DN is complex, as it is asymptomatic in early stages, 
while at later stages the direct demonstration of renal injury requires renal biopsy material, 
which is an unattractive tool for screening purposes due to the invasive nature of the proce-
dure. Therefore, methods geared towards the non-invasive monitoring for early signs of micro-
vascular changes is of clinical importance in patients with DM. However, at present these tools 
do not exist. Sidestream dark-field (SDF) imaging is a relatively new, non-invasive tool that en-
ables one to visualize the microcirculation without the use of fluorescent dyes [9]. Recently, we 
used this apparatus to assess labial mucosal capillary tortuosity and density in diabetic patients 
compared with healthy non-diabetic controls, studies that revealed increased capillary density 
and tortuosity in diabetic patients [10]. These studies focused on the effects of prolonged diabe-
tes in patients (24 ± 14 years). However, at present there is limited data regarding how distur-
bance of the microvasculature in early diabetes correlates with renal damage.
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In light of these considerations, we sought to investigate whether an atherogenic diet in the 
early stages of DM could accelerate microvascular disease, and could serve as a diagnostic tool 
for DM-induced renal damage. Using SDF imaging, we show that an atherogenic diet during 
the early stages of DM leads to microvascular abnormalities, and immunohistochemically con-
firm that these systemic effects are associated with renal endothelial dysfunction, as evidenced 
by a disturbed Angpt2/Angpt1 balance and microalbuminuria.
Materials and Methods
Animal experiments
The experimental protocol was performed in compliance with the ARRIVE guidelines on ani-
mal research [11]. Protocols describing the management, surgical procedures, and animal care 
were reviewed and approved by the ASG-Lelystad Animal Care and Use Committee (Lelystad, 
The Netherlands) and by the Institutional Review Board for animal experimentation of the 
Erasmus University Medical Center (Rotterdam, The Netherlands). Ten neutered male domes-
tic pigs (Landrace x Yorkshire, T-line) with an age ~11 weeks and a body weight of ~30 kg en-
tered the study. After one week of acclimatization, DM was induced in a subgroup of 5 pigs by 
slow intravenous injection of streptozotocin (STZ 140 mg/kg; Enzo Life Sciences, Raams-
donkveer, The Netherlands) as described previously [12–15]. Five non-diabetic pigs received 
placebo treatment. Three weeks after DM induction, all of the pigs were gradually introduced 
to an atherogenic diet (ATH), containing 25% of saturated fats and 1% of cholesterol [16]. The 
5 diabetic pigs (DM+ATH) and 5 non-diabetic pigs (ATH) were subsequently followed for up 
to 15 months, during which similar growth patterns were observed in both groups by adjusting 
individual caloric intake. In the diabetic pigs, glucose and ketone levels in plasma and urine 
were regularly checked in the 15-month follow-up period. Insulin therapy was started only in 
instances where plasma ketones were detected. Following 12 months, 24h urine samples were 
obtained from all pigs, while microcirculatory imaging and plasma samples were obtained from 
anesthetized pigs (20mg/kg ketamine + 1 mg/kg midazolam+ 1 mg atropine, i.m. and 12mg/kg 
thiopental, i.v.) at 14 and 15 months of follow up, respectively. At 15 months, the pigs were 
sacrificed by intravenous injection of an overdose of pentobarbital via the jugular vein catheter 
at 15 months, at which point plasma samples were obtained and the kidneys were har-vested 
for histological examination. Invasive imaging analyses prompted us to choose this time frame 
as after 12 months of follow up more complex atherosclerotic lesions were present in the 
coronary arteries of the studied pigs [23].
In addition, we also studied a separate control group (Controls) of 7 female domestic pigs 
(Landrace) at the age of 5 months with a body weight of ~78 kg, who were fed a standard diet 
for growing pigs.
Microcirculatory imaging and analysis of SDF measurements
SDF microscanning (MicroVision Medical Inc., Wallingford, PA, U.S.A) and analysis of im-
ages was performed as described earlier with minor modifications [10,16]. Anaesthetized pigs 
were imaged at 14 months of study duration. All pigs were studied during standardized condi-
tions of general anesthesia by a trained observer.
Laboratory assessment
Serum Angpt1 and Angpt2 concentrations were measured after 12 months by enzyme-linked 
immunosorbent assay (ELISA) (Bioconnect, Huissen, The Netherlands and Antibodies-online, 
Atlanta, USA).
PLOSONE | DOI:10.1371/journal.pone.0121555 April 24, 2015 3 / 15
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At 12 months, protein and creatinine levels were measured in 24h urine samples. To calcu-
late the urinary albumin-creatinine ratio, we measured albumin excretion by ELISA (ITK diag-
nostics, Uithoorn, The Netherlands), and urinary creatinine concentration was measured by 
standard laboratory methods. Both the plasma and urinary creatinine levels were measured as 
previously described.
Plasma samples collected at 15 months were used to measure concentrations of glucose, 
total cholesterol, triglycerides and low and high-density lipoproteins (LDL and HDL) and cre-
atinine by standardized methods at the clinical chemical laboratory of the Erasmus Medical 
Center (Rotterdam, The Netherlands). In the absence of an established mathematical formula 
to estimate creatinine clearance in pigs, we expressed creatinine levels in μmol/L/kg to adjust 
for body weight. Blood collection tubes were centrifuged for 10 minutes at 3000 rpm after 
which serum was stored in microcentrifuge tubes at -20°C until required for analysis.
Histological analysis of the kidney
Immunohistochemical analyses of snap-frozen porcine kidney cortex sections (4 μm) were air-
dried and acetone fixed as previously described [17]. Monoclonal antibodies utilized were di-
rected against mouse anti-human Angpt1 (clone 171718; R&D Systems, Abingdon, UK), 
mouse anti-human VEGF (sc-7269 Santa Cruz Biotechnology, Huissen, the Netherlands) and 
mouse anti-human plasminogen activator inhibitor-1 (clone HD-PAI-1 14.1) (American Diag-
nostica, Pfungstadt, Germany). Polyclonal antibodies were used directed against goat anti-
mouse Angpt2 (clone F18; sc-7017; Santa Cruz Biotechnology, Huissen, the Netherlands) and 
rabbit anti-human vWF (Codenr A0082; Dako, Glostrum, Germany). Primary antibody bind-
ing was detected using the following isotype-matching secondary horseradish peroxidase
(HRP)-labeled antibodies; goat anti-mouse IgG (Angpt1), rabbit anti-goat IgG (Angpt2), anti-
mouse Envision K4007 (VEGF) or goat anti-rabbit IgG (vWF) (all purchased from Dako, Glos-
trum, Germany). Quantification of immunohistochemistry was performed in a blinded man-
ner by assessing 10 consecutive high power fields (magnification, ×200) using Image J software. 
Glomerular and large vessels were excluded from analysis. For VEGF-A quantifica-tion, 15 
consecutive glomeruli per subject were selected and the percentage of VEGF-A positive area 
was calculated using Image J.
Data are presented in terms of the Angpt2/Angpt1 ratio as previously described[18,19]. 
Immuofluorescent double stainings were performed for desmin (pericyte marker; mouse anti-
pig clone DE-B-5; Millipore, Amsterdam, the Netherlands)/Angpt1 (goat anti-human; clone 
N-18; sc-6319; Santa Cruz Biotechnology, Huissen, the Netherlands) and vWF/Angpt2. Sec-
ondary antibodies were Alexa-488 labeled donkey anti- rabbit (vWF) and alexa-546 labelled 
rabbit anti-mouse (desmin), Furthermore, HRP labelled rabbit anti-goat (Angpt1) and donkey 
anti-goat (Angpt2) were used. Nuclei were visualized using Hoechst (Molecular Probes, Leiden, 
the Netherlands). Photomicrographs were made using a fluorescence microscope (DM5500B; 
Leica, Rijswijk, the Netherlands).
Next, we performed periodic acid-Schiff (PAS) staining on paraffin sections of renal cortex 
for the evaluation of histopathological changes and morphometric analysis of the glomeruli. In 
a blinded fashion, 25 consecutive glomeruli were selected from both superficial and deep cortex 
and the mesangial expansion index was scored. Subsequently, we determined the extent of in-
crease in mesangial matrix (defined as mesangial area) by quantitating PAS-positive and nu-
clei-free areas in the mesangium using Image J [20,21]. Evaluation of histopathological lesions 
was performed by a pathologist who was blinded to the code of the sections.
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Electronmicroscopy
Kidneytissuesforelectronmicroscopywereprocessedasdescribedpreviously[22].Intypical
casesfromtheATHandDM+ATHgroups,theglomerularbasementmembrane(GBM)width
wasmeasured.
RNAisolationandReal-TimePCR
ToanalyzerenalAngpt1andAngpt2mRNAlevels,RT-PCRwasperformedasdescribedpre-
viously[23].Expressionwasnormalizedagainstβ-actinmRNAlevels.RT-PCRanalysisforbi-
ologicalreplicateswasperformedinduplicate.Theprimersequenceswereasfollows:β-actin
(forward5’-ATCGTGCGGGACATCAAGGA-3’andreverse5’-AGGAAGGAGGGCTGG-AA
GAG-3’),Angpt1(forward5’-AGGAGCAAGTTTTGCGAGAG-3’andreverse5’-CTCA-GA
GCGTTTGTGTTGT-3’)andAngpt2(forward5’-AAAGTTGCTGCAGGGAA-AGA-3’and
reverse5’-TCACAGCTCAGAGCGAAGAA-3’).
Statisticalanalysis
Alldataarepresentedasmean±standarderrorofthemean(SEM).Differencesbetweenex-
perimentalgroupswereanalyzedusingoneway-analysisofvariancefollowedbypost-hoctest-
ingwithanunpairedStudent’st-test.AnalyseswereperformedwithGraphPadsoftware
(GraphPadSoftwareInc.,SanDiego,CA,U.S.A.).P-valueslessthan0.05(two-tailed)were
consideredstatisticallysignificant.
Results
Modelcharacteristics
InitialplasmaprofilingofDM+ATHandATHpigsrevealedthatDMsignificantlyinfluenced
glucoselevels(17.64±4.54mmol/Lvs.5.12±0.42mmol/L;p<0.05)(Table1)at15months.
Totalcholesterol,triglycerides,HDLandLDLwerenotsignificantlyaffectedbytheinduction
ofDMinpigs.Twopigswereadministeredinsulinduringthestudyperiodduetoelevated
plasmaketonelevels.Themeanbodyweightatthetimeofmicrovascularimagingwascompa-
rablebetweenDM+ATH(96±2.8kg)andATHgroup(93±0.4kg,p>0.05).Atthetimeofsacri-
fice,substantialcoronarylesionsaswellasgeneralisedatherosclerosisforexampleintheaorta
wereobservedinbothDM+ATHandATHgroups,asdescribedpreviously[24].
Table1.Modelcharacteristicsat15monthsoffollowup.
Controls (N = 7) ATH (N = 5) DM+ATH (N = 5)
Glucose (mmol/l) 4.26±0.29 5.12±0.42 17.64±4.54*#
Triglycerides (mmol/l) 0.18±0.02 0.64±0.2 1.26±0.50*
Total Cholesterol (mmol/l) 1.50±0.05 18.10±2.66* 16.82±1.72*
LDL (mmol/l) 0.76±0.29 14.87±2.45* 13.63±1.3*
HDL (mmol/l) 0.60±0.03 5.70±0.35* 5.12±0.40*
Alldataaremean±SEM.ATH:pigsonatherogenicdiet.DM+ATH:pigswithdiabetesmellituson
atherogenicdiet.Controls:healthycontrolpigsonastandarddiet.LDL:Lowdensitylipoprotein.HDL:High
densitylipoprotein.
* P<0.05 compared with Controls. 
# P<0.05 compared with ATH pigs.
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Early atherogenic diabetes mellitus leads to systemic microvascular 
damage
The microvascular morphology of the oral mucosal tissue in DM+ATH pigs was significantly 
disturbed as compared with the Controls (Fig 1A). Indeed, the capillary tortuosity index was 
sig-nificantly increased in DM+ATH pigs (2.3±0.2) as compared with ATH pigs (1.6±0.1, 
p<0.01; Fig 1B). Furthermore, capillary density was significant lower in the DM+ATH (18.6 
±1.3 capillaries/mm2) pigs as compared with the Controls (24.9 ±0.8 capillaries/mm2, p<0.01; 
Fig 1C).
Renal damage after induction of atherogenic DM in pigs
Plasma creatinine levels were elevated in ATH pigs (2.12±0.03 μmol/L/kg) as compared with 
DM+ATH pigs (1.60±0.13 μmol/L/kg, p<0.01) group. However, urinary albumin/creatinine 
ratio was not found to differ between the DM+ATH group (0.045±0.0182 mg/mmol) and ATH 
pigs (0.002±0.0007 mg/mmol, p>0.05).
Fig 1. Early atherogenic DM leads to increased capillary tortuosity. A. Sidestream darkfield images of the oral mucosa 
visualizing the microvascular capillaries of a representative pig in the Controls, ATH and DM+ATH group. B. Mean tortuosity 
index of microvascular capillaries in the Controls (n = 7), ATH (n = 5) and DM+ATH pigs (n = 5). C. Mean vessel density 
(capillaries/mm2) in Controls (n = 7), ATH (n = 5) and DM+ATH (n = 5) pigs. Data shown are mean±SEM. *P<0.05 compared to 
Controls or ATH pigs. Mean vessel density (capillaries/mm2) was calculated by evaluation of number of vessels per selected 
microcirculatory image. Subsequently, tortuosity of capillary loops was assessed according to a validated scoring system (0: no 
twists to 4: four or more twists) and the average of assessed capillary tortuosity was used to calculate mean tortuosity index per 
patient.
doi:10.1371/journal.pone.0121555.g001
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PAS-stained renal sections revealed marked tubular changes with foamy cytoplasm and hy-
alin droplets in all DM+ATH pigs and there were glomerular lesions consisting of mesangial 
expansion and podocyte lesions, also with foamy cytoplasm and hyaline droplets in four DM
+ATH pigs (Fig 2A). In contrast, but one ATH pig displayed similar lesions (Fig 2A). Some 
glomeruli were found to have dilated capillaries containing numerous red blood cells, a phe-
nomenon that is highly reminiscent of microangiopathic injury lesions that have been de-
scribed to be the result of fibrinolytic/proteolytic activation system in combination with 
increased PAI-1 staining [25]. In keeping with this notion, we observed both co-localization and 
increased PAI-1 staining in the herein described lesions (Fig 2A)  .
Next, we determined the mesangial expansion index in renal cross-sections. These studies 
showed significantly higher scores in the ATH pigs (0.62±0.05, p = 0.03) and a trend towards 
increased scores in the DM+ATH (0.58±0.05,p = 0.066) compared with the Controls (0.49
±0.03; Fig 2B). Interestingly, the width of the GBM increased from 215 nM in a Controls ani-
mal to 252 and 279 nM in cases with mild and severe DN of the DM+ATH group, respectively. 
Moreover, lipid deposits were observed in kidneys of mild and severe DN pigs (Fig 2C).
Diabetes and atherogenic diet induces Angpt2/Angpt1dysbalance in
pigs
Serum Angpt-1 levels in the DM+ATH pigs were increased as compared to control pigs (26035
±1228 pg/ml versus 18061±1228 pg/ml, p<0.01). There were no significant differences in serum 
Ang-1 levels between DM+ATH and ATH pigs (19832±1166 pg/ml, p>0.05). Angpt-2 levels 
were not detectable in the circulation of the different groups.
With regard to Angpt1 staining in the kidneys, we observed positive Angpt1 staining in the 
glomeruli and in a capillary-like pattern between the tubuli of pigs in the Controls group (Fig 
3A). We found no difference in renal Angpt1 protein expression between ATH (78020±12216 
pixels/area) and DM+ATH (46763±12360 pixels/area, p>0.05) pigs, but Angpt1expression was 
significantly higher in the Controls group (91788±9777 pixels/area, p < 0.05; Fig 3A). The 
Angpt1mRNA levels in the kidney were significantly lower in the DM+ATH and ATH group 
compared with the Controls pigs (Fig 3D). Double staining of Angpt1 and the pericyte marker 
desmin revealed predominantly expression of desmin in the glomeruli and Angpt1 expression in 
the same pattern as described above (Fig 3B; left panel). However, no co-localization was ob-
served, suggesting that other cells than pericytes might produce Angpt1 in the glomerulus.
Angpt2 staining was predominantly present in glomeruli and tubuli (Fig 3A) and showed a 
significant increase in DM+ATH (54813±3140 pixels/area) pigs compared to the Controls
(22862±3354 pixels/area, p<0.001) and ATH (31005±5011 pixels/area, p<0.01) pigs (Fig 3C). 
Consequently, a higher Angpt2/ Angpt1ratio was observed in DM+ATH (1.63±0.43) pigs com-
pared with Controls (0.28±0.07, p<0.001) and ATH (0.43±0.07, p<0.01) group (Fig 3C). The 
Angpt2 mRNA levels in the kidney did not significantly differ between groups (Fig 3D). Impor-
tantly, additional staining of vWF and Angpt2 revealed co-expression, suggesting that endothe-
lial cells produce Angpt2 (Fig 3B; middle and right panel).
Staining of the endothelial marker vWF showed expression in the glomeruli and peritubular 
space, in the same pattern as Angpt1 (Fig 4A). No significant differences were observed in vWF 
expression between the Controls (86611±6163 pixels/area), ATH (84547±9000 pixels/area) and 
DM+ATH pigs (102961±13633 pixels/area) (p>0.05).
VEGF-A staining revealed expression in podocytes, parietal epithelial cells and tubuli (most 
extensively) in all groups (Fig 4B). There was no difference in VEGF-A expression between the 
DM+ATH (16.94±0.72), ATH (21.22±2.30) and Controls (20.70±1.24) (p 0.05).
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Fig 2. Early stages of atherogenic DM leads to renal damage. A: Representative illustration of PAS stained 
glomeruli from a DM+ATH pig, showing mesangial proliferation and matrix expansion with capillary loops lying 
around the mesangium as a corona, reminiscent of a beginning Kimmelstiel-Wilson nodule (left panel; thin 
black arrow). Dilated capillary loops with red cell fragments show intense PAI-1 staining on consecutive slides 
(right panel; thick black arrow). B: Mesangial expansion index in Controls (n = 7), ATH (n = 5) and DM+ATH (n 
= 5) pigs. C. Electron microscopy images illustrating a normal GBM architecture (left panel; thick arrow) of the 
Controls pig. In ATH, there is slight effacement of the podocyte pedicles (middle panel; thick arrow). In DM
+ATH, marked lipid deposits were found (right panel). Data are shown as mean ± SEM. *P<0.05 compared to 
Controls or ATH pigs. Original magnification of A: x400 and C: x8000.
doi:10.1371/journal.pone.0121555.g002
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Fig 3. The Angpt2/Angpt1 balance is disturbed in atherogenic DM pigs. A. Representative illustrations of 
kidney sections stained with Angpt1 (upper panels; arrow: glomerulus; arrowhead: peritubular area) or Angpt2 
(lower panels; arrow: glomerulus; arrowhead: tubular staining) in Controls, ATH, and DM+ATH pigs. B. 
Immunofluorescent double staining of representative kidney sections for desmin (green)/Angpt1 (red;left 
panel) and vWF (green/Angpt2 (red; middle/right panel). Insets: double positivity for vWF/Angpt2 staining in 
yellow. C: Quantitative analysis of renal expression of Angpt1, Angpt2 and Angpt2/Angpt1 ratio. D. Relative 
mRNA expression of Angpt1 and Angpt2. Data are shown as mean ± SEM. *P<0.05 compared to Controls or 
ATH pigs. Original magnification of A and B: x400.
doi:10.1371/journal.pone.0121555.g003
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Angpt2/Angpt1 dysbalance and creatinine levels are correlated with 
capillary tortuosity
Correlation analyses were performed between renal Angpt1, Angpt2, Angpt2/Angpt1ratio, creat-
inine levels and albumin/creatinine ratio and oral mucosal capillary tortuosity and density indi-
ces. No correlation was found between capillary density index and renal angiopoietin expression 
or urinary markers for renal function. However, a negative correlation was found between renal 
Angpt1expression and microvascular tortuosity index (r = -0.60, p = 0.0100; Fig 5A). 
Moreover, we demonstrated a positive correlation between capillary tortuosity and Angpt2 
staining (r = 0.70, p = 0.0017; Fig 5B) and Angpt2/Angpt1ratio (r = 0.80, p = 0.0002; Fig 5C).
No significant correlation was found between urinary albumin/creatinine ratio, creatinine 
levels and capillary tortuosity index.
Fig 4. No difference in renal vWf and VEGF-A expression. A. Representative illustrations of kidney 
sections stained with endothelial marker vWF (arrow: glomerulus; arrowhead: peritubular area) in Controls, 
ATH, and DM+ATH pigs. B. Representative images of kidney sections stained with VEGF in Controls, ATH, 
and DM+ATH pigs showing expression in podocytes (arrow head), parietal epithelial cells (thin arrow) and 
tubuli (asterix). Original magnification of A: x 200 and B: x400.
doi:10.1371/journal.pone.0121555.g004
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Fig 5. Correlation between capillary tortuosity and Angpt2/Angpt1balance and creatinine levels. 
Scatter plot showing the correlation of renal protein expression of Angpt1(A), Angpt2 (B), Angpt2/
Angpt1ratio (C).
doi:10.1371/journal.pone.0121555.g005
Discussion
In the present study, we show that the combination of an atherogenic diet and recent onset of 
DM leads to abnormalities in the systemic microvasculature, yielding SDF-detectable increases 
in capillary tortuosity and increased levels of serum Angpt1. Furthermore, we discovered that 
glomerular lesions develop during the early stages of DN and that the tight control of the 
Angpt2/Angpt1balance is perturbed in the kidneys of diabetic atherogenic pigs.
Microvascular dysfunction is one of the most important causes of persistent diabetic com-
plications. This is the result of disturbed hemodynamics and impaired endothelial function in-
duced by metabolic alterations [26,27]. However, the early events involved in the pathogenesis 
of diabetic microvascular complications are not well understood, and are difficult to study in 
humans without the use of invasive techniques. SDF imaging allows for the easy, and rapid as-
sessment of the presence of systemic microvascular derangements that could precede the devel-
opment of diabetic macrovascular complications. In our study, we observed increased capillary 
tortuosity between the DM+ATH and ATH groups, already at ~15 months following DM in-
duction. Using SDF imaging, we recently demonstrated increased capillary tortuosity in diabe-
tes patients, and reversal of microvascular tortuosity after simultaneous pancreas-kidney 
transplantation [16]. Moreover, we have previously shown that increased capillary tortuosity in 
diabetic patients was associated with macrovascular disease [10]. In concordance with our ob-
servations, Sasongko et al demonstrated increased tortuosity in patients with diabetic retinopa-
thy, suggesting that this may be an early sign of microvascular damage in DM [28,29]. 
However, these studies did not include patients with early stage DM and did not focus on the 
role of angiopoietins in microvascular alterations and renal injury in atherogenic DM.
In addition to increased microvascular tortuosity, we also observed increased serum levels of 
Angpt-1 in DM+ATH pigs compared with the control group. These data are in line with 
previous clinical studies in patients with moderate and severe non-proliferative diabetic reti-
nopathy [30] and in patients with hypertension [31] that showed increased Angpt1 serum lev-
els in these patients as well. While serum Angpt1 levels were increased in DM+ATH pigs, we 
found a decrease in Angpt1 protein and mRNA expression in kidneys of diabetic pigs com-
pared to control groups. This observation suggests shedding of Angpt1 from renal vasculature 
into the circulation.
Interestingly, DM+ATH pigs were characterized by higher expression levels of Angpt2 pro-
tein as compared to the ATH group, resulting in a higher Angpt2/ Angpt1 ratio in the DM
+ATH pigs. This is in agreement with Rizkalla and co-workers, who previously have shown
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that both Angpt1 and Angpt2 protein levels are increased in the early phase of STZ-induced 
DM in rats [32]. However, disease progression was found to trigger a decrease in Angpt1ex-
pression while Angpt2 continued to increase, a switch that both markedly alters but also dis-
turbs the Angpt2/Angpt1balance [32]. Although a difference in angiopoietin expression 
between rats and pigs cannot be excluded, these findings suggest that angiopoietins undergo 
time-dependent changes in expression at different stages of DM. Our identification that an in-
creased urinary albumin/creatinine ratio is associated with a higher Angpt2/Angpt1 ratio (in 
DM+ATH pigs) is in keeping with recent studies that demonstrated an inability to express 
Angpt1 leads to extensive glomerular damage and proteinuria, indicating a protective role of 
Angpt1[33]. These data suggest that angiopoietins might play an important role in the patho-
physiology of glomerular disease in DN.
Aside from angiopoietins, numerous other mechanisms have been proposed to be causal for 
microvascular complications in DM, such as VEGF. Under pathological conditions, Angpt2 
acts in concert with VEGF to induce inflammatory angiogenesis. By promoting pericyte drop-
out, Angpt2 will lead to destabilization between ECs and pericytes. In the presence of VEGF, 
Angpt2 can eventually lead to an active, sprouting state of ECs, but when VEGF is absent, 
Angpt2 promotes vessel regression [34–36]. Our immunohistochemical assessment of VEGF 
protein in the different groups revealed high expression levels in podocytes and parietal—and 
tubular epithelial cells, which is in keeping with literature [34,37–40]. However, in contrast to 
previous studies, we did not observe differences between the different groups.
An additional observation we made was the marked increase in PAI-1 expression in regions 
of microvascular injury. PAI-1, a protease and fibrinolysis inhibitor that is poorly expressed in 
healthy kidneys, which is a critical player in angiogenesis and vascular remodeling [41]. Previ-
ous studies in rats and humans by the group of Fogo have shown that the expression level of 
PAI-1 in normal glomeruli is low and increases in pathological conditions, such as diabetic ne-
phropathy [25,42].
Our observation that glomerular and tubular expression of PAI-1 is increased in DM+ATH 
pigs is noteworthy due to the fact that: 1) PAI-1 was found to be prominently expressed in 
Kimmelstiel-Wilson nodules, in particular those with active microvascular damage [25]; 2) 
unilateral ureteral obstruction [43] and glomerulonephritis [44] have also been associated with 
increased expression of tubular PAI-1; and 3) endogenous PAI-1 deficiency protects diabetic 
mice from glomerular injury [45]. Collectively, these data support for a pathogenic role for 
PAI-1 in diabetic renal disease.
In the current study, there was a tendency towards increased mesangial expansion in the 
DM+ATH pigs, and significantly more mesangial expansion in kidneys of ATH pigs. The data 
confirm previous reports on pig studies which revealed that consumption of high-fat diet leads 
to the development of renal injury, characterized by mesangial expansion and increased plasma 
creatinine levels [46,47]. Moreover, rodent studies demonstrated that hyperlipidemia exacer-
bates the development and progression of renal diseases, including DN [48,49]. Furthermore, 
our study also showed higher creatinine levels in the ATH group than the DM+ATH and Con-
trols, which could be explained by the increased mesangial expansion observed in ATH pigs. 
The latter has been associated with obliteration of capillary lumen and decreased capillary per-
fusion in previous studies [50]. Furthermore, our study suggests that the combined hyperglyce-
mia and hyperlipidemia in the DM +ATH pigs, induces a dysbalance in renal angiopoietins 
that results in albuminuria and endothelial damage in the kidney. The potential contribution of 
tubular injury to albuminuria needs to be addressed in additional studies.
Some aspects of our porcine study require further discussion. First, it would have been inter-
esting to study an additional group of pigs with only diabetes (i.e. without ATH) to explore the 
early effects of only hyperglycemia on the microvasculature. However, the clinically most
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relevant group of DN also reflects DM patients with some presence of atherosclerosis as well. 
Secondly, it could be argued that the differences in gender, age and weight between healthy 
control pigs (Controls) versus DM+ATH and ATH pigs may explain part of the difference in 
the observed capillary tortuosity between these groups. This is, however, unlikely as in a human 
study, age did not influence capillary tortuosity [16].
In conclusion, we present SDF imaging as a novel means of documenting capillary tortuosi-
ty, an event that is illustrative of renal injury in the setting of early DM and atherosclerosis. 
This technique enables one to non-invasively detect systemic microvascular damage. Furather-
more, we also identified changes in the Angpt2/Angpt1 balance may represent initiating events 
of renal injury in early DM. We propose that the targeted intervention of angiopoietins signal-
ing could be an effective modality in minimizing microvascular damage that could serve as an 
early initiator of DN.
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Endothelial dysfunction has been implicat­
ed in the pathological process of coronary 
artery disease as weil as an adverse even t after 
coronary drug eluting stent (DES) implanta­
tion. In this review, an overview will be giv­
en of the evidence to date regarding the 
effects of coronary DES on endothelial func­
tion obtained from both clinical and experi­
mental studies. Stenting in general and DES 
seem to impair several aspects of endothe­
lial function: provision of a permeable barrier 
function; modulation of adhesion, thrombo­
sis and inflammation; and regulation of vas­
cular tone. However, new insights show that 
the effects of DES can extend beyond the stent 
and peri-stent area: the vascular bed distal to 
the stent, starting with the distal conduit ves­
sels up to the distal microvasculature, might 
be at risk. In addition, insight into the mech­
anism of DES induced endothelial dysfunc­
tion has been gained. To finalize this review, 
clinical complications and solutions of DES 
associated endothelial dysfunction will be 
discussed. 
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Thrombosis. 
T he endothelium is a continuous cellularmonolayer lining blood vessels through­
out the body and has classically been 
described as a barrier between the blood and 
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tion. In this review, an overview will be giv­
en of the evidence to date regarding the 
effects of coronary DES on endothelial func­
tion obtained from both clinical and experi­
mental studies. Stenting in general and DES 
seem to impair several aspects of endothe­
lial function: provision of a permeable barrier 
function; modulation of adhesion, thrombo­
sis and inflammation; and regulation of vas­
cular tone. However, new insights show that 
the effects of DES can extend beyond the stent 
and peri-stent area: the vascular bed distal to 
the stent, starting with the distal conduit ves­
sels up to the distal microvasculature, might 
be at risk. In addition, insight into the mech­
anism of DES induced endothelial dysfunc­
tion has been gained. To finalize this review, 
clinical complications and solutions of DES 
associated endothelial dysfunction will be 
discussed. 
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T he endothelium is a continuous cellularmonolayer lining blood vessels through­
out the body and has classically been 
described as a barrier between the blood and 
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the vascular wall. lt participates in numer­
ous physiological processes including: for­
mation of a permeable barrier for exchange 
and active transport of (macro) molecules; 
provision of an anti-thrombogenic defence 
and non-adherent surface for inflammatory 
cells; and regulation of vascular tone by 
release of vasoactive molecules (modified 
from 1). Changes in one or more of these 
properties may represent the earliest mani­
festations of endothelial dysfunction charac­
terised for example by: altered permeability 
with invasion of atherogenic substances, 
excessive thrombosis and inflammation and 
exaggerated vasoconstriction. Consequently, 
endothelial dysfunction has been implicated 
in the pathological process of atherosclerosis 
as evidenced early in the process of athero­
genesis, but also later on in the control of 
dynamic plaque burden and eventually in 
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the clinical manifestations of coronary artery 
disease (CAD) .2 Paradoxically, percutaneous 
coronary intervention (PCI) strategies devel­
oped to resolve obstructive CAD have also 
been associated with endothelial dysfunc­
tion. More recently, drug eluting stents (DES) 
have been implicated in impairment of 
endothelial function. In this review, an 
overview will be given of the evidence 
obtained from both clinical and experimen­
tal studies, regarding specific aspects of 
endothelial dysfunction after DES implanta­
tion. 
Endothelial function and coronary 
in terven tions 
By secreting relaxing and contracting fac­
tors the endothelium can induce vasodila­
tion or vasoconstriction in response to shear 
stress and to a variety of endogenous vasoac­
tive substances that are either produced sys­
temically or generated locally by vascular tis­
sues or circulating blood cells. The major 
endothelium-derived relaxing factor is nitric 
oxide (NO), which reduces intracellular cal­
cium within the vascular smooth muscle cells 
(VSMC) resulting in vasodilation.3 The 
endothelium also secretes endothelial hyper­
polarizing factors (EDHFs) 4 and the potent 
vasoconstrictor endothelin-1 (ET-1) .5 Since 
Furchgott et al. have demonstrated that the 
endothelium plays an obligatory role in the 
relaxation of arteries induced by achetyl­
choline (Ach), 6 and the released factor has 
been identified as NO 7 with its key second 
messenger cyclic guanoside monophosphate 
(cGMP) ;8 methods have been developed to 
assess coronary endothelium-dependent 
vasomotor function in the catheterisation lab­
oratory. NO-dependent vasodilator respons­
es to locally infused Ach in coronary con­
duit arteries have shown paradoxical vaso­
constriction in patients with cardiovascular 
risk factors, overt atherosclerosis and ischemic 
manifestations of CAD.2, 9, 10 
In contrast, PCI modalities developed to 
reduce locally obstructive lesions caused by 
CAD, have already for a lang time been asso­
cia ted with extensive arterial wall injury.11 
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Our recent studies in swine have shown that 
even coronary imaging catheters used to 
guide PCI already cause considerable 
amounts of acute endothelial cell damage, 
however this injury tends to heal within a 
few days.12 Although the endothelial barrier 
appears to regenerate, endothelium-depen­
dent vascular function remains impaired lang 
after endothelial regrowth.13 Indeed, early 
clinical studies have demonstrated abnor­
mal endothelium-dependent vasomotion of 
the treated coronary artery several months 
after balloon angioplasty.14, 15 Coronary stent­
ing has appeared to cause even more severe 
arterial injury than balloon angioplasty. 
Earlier work from our group in the pig mod­
el compared the effects of balloon angio­
plasty and stent implantation on certain 
aspects of lang term vascular integrity: 
endothelial permeability and proliferation.16 
Leakage of the endothelium for large mole­
cules such as Evans blue dye bound to albu­
min as well as prolonged endothelial pro­
liferation was seen up to three months after 
the procedure, and was more pronounced 
after stenting than after angioplasty with a 
stent-specific pattern. In the early phase (two 
weeks post-stenting) the lass of the endothe­
lial barrier was characterized by endothelial 
cell retraction and loose intercellular con­
nections (Figure 1), while at three months 
expression of surface folds and adhesion of 
leukocytes was seen.16 In addition, clinical­
ly Caramori et al. showed more severely 
depressed endothelium-dependent vascular 
tone at on average one-and-a-half years after 
stenting in patients as compared to balloon 
angioplasty and directional atherectomy.17 
Therefore, endothelial dysfunction as an 
adverse effect after PCI has already been 
known for a lang time and is not a recently 
discovered phenomenon after DES implan­
tation. However, with DES being the most 
commonly used PCI modality at the moment 
and with new types of DES intended to 
reduce endothelial dysfunction being devel­
oped, evaluation of adverse effects of DES on 
endothelial function seems useful. As the 
endothelium is such a versatile multifunc­
tional vascular layer, several aspects of 
endothelial function can be affected. 
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Figure 1.-Scanning electron microscopy images of the endothelium between the stent struts (A) and on top of the stent 
struts (B, C), two weeks after stenting with a BMS, While the endothelium between the struts has a healthy appearance 
(A), loose cell-cell junctions (B, arrow) and endothelial cell retraction (C, arrow) were seen, contributing to an increased 
permeability of the endothelial layer upon stenting; adapted with permission from van Beusekom et ai.16 
Therefore, below we will discuss the evi­
dence regarding DES and endothelial dys­
function subdivided in separate endothelial 
functions: DES and impaired permeability 
barrier; DES and impaired modulation of 
adhesion, thrombosis and inflammation; DES 
and impaired vascular tone. 
Coronary drug-eluting stents 
Coronary DES, developed to limit in-stent 
restenosis as seen after stenting with bare 
metal stents (BMS), have now been approved 
for use in patients for more than six years. 
DES release high concentrations of immuno­
suppressive, cytostatic, or cytotoxic drugs 
locally at the coronary injury site in order to 
prevent VSMC proliferation.18 The devices 
currently approved by the United States Food 
and Drug Administration are first-generation 
DES sirolimus-eluting stent (SES, 2003) and 
paclitaxel-eluting stent (PES, 2004); and sec­
ond-generation DES zotarolimus-eluting stent 
(ZES, 2008) and everolimus-eluting stent (EES, 
2008). Sirolimus, zotarolimus and everolimus 
belong to the limus family and inhibit VSMC 
proliferation by binding to FKBP12, which 
subsequently binds to the mammalian target 
of rapamycin and blocks the cell cycle in the 
G to S phase.19, 20 Paclitaxel, the active drug 
of PES, stabilizes polymerized microtubules 
and inhibits microtubule disassembly, result­
ing in cell replication arrest in the G0/G1 and 
G/M phases of the cell cycle.21 , 22 In this way, 
DES drugs can inhibit profoundly the devel­
opment of neointima formation after stenting. 
Indeed, DES resulted in a reduction of 
restenosis rates below 10% and significant 
long-term reduction in the number of target 
lesion revascularization procedures as com­
pared to BMS in patients with CAD. However, 
the results vary with the different types of 
DES used and also depend on the studied 
patient population.23-27 
Although most data converge towards a 
sustained reduction of restenosis rates by 
DES as compared to BMS, there is less agree­
ment concerning the suggested association of 
DES with increased risk for late and very late 
stent thrombosis (LSI), an undesirable event 
occurring between 1-12 months after DES 
implantation but also later on. While some 
studies report increased rates of LSI in 
patients who underwent PES and SES implan­
tation, 28-34 other randomized clinical trials 
showed that the incidence of LSI does not 
differ significantly between patients receiving 
DES or BMS.35, 36 Thus studies are not 
unequivocal. A meta-analysis performed by 
Stettler et al. showed no increase in LSI with 
SES and only a small increase with PES.37 
Altogether, it seems clear that more clinical 
data with a longer follow up duration are 
needed to provide more consistent estimates 
of DES and LSI safety. As an underlying 
mechanism of LSI, DES associated impaired 
re-endothelialisation and delayed vascular 
healing 32, 38 as well as inflammation and sec­
ondary stent malapposition 39 have been put 
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Figure 2.-Macroscopic images of the Evans blue dye exclusion test in a non-stented porcine coronary control vessel 
(AJ and a vessel receiving a DES, five days post-implantation. While the control artery shows only occasional blue areas, 
mainly at branching points (A, arrow), extensive blue staining is seen near the stent struts (B, arrow) indicating endothe­
lial leakage of Evans blue; adapted with permission from van der Giessen et al. 12 
forward. Indeed, DES seem to interfere with 
several aspects of endothelial function as 
described below. However, whether these 
specific aspects of endothelial dysfunction 
are due to specific DES implantation or to 
the general stenting procedure remains to be 
solved. 
DES and impaired permeability barrier 
DES alter the endothelial permeable barri­
er as evidenced by loss of cells, usually inter­
preted as delayed in-stent endothelial re­
growth, and leaky cells as shown by an 
increased vascular permeability after stent­
ing. These phenomena together may result in 
the observed delayed healing after DES 
implantation. Most of these data have been 
obtained from experimental studies, with the 
main animal models used being the porcine 
coronary and the rabbit iliac artery model. 
However, delayed vascular healing after DES 
implantation has also been described in clin­
ical autopsy, angioscopy, and atherectomy 
studies. 
With regard to endothelial leakage, unpub­
lished data of our group suggests that fol­
lowing direct stenting of healthy porcine 
coronaries, extensive blue staining near the 
stent struts after the dye-exclusion test 16 is 
observed after five days, regardless of using 
BMS or DES (Figure 2B), as compared to only 
occasional blue areas mainly at branching 
points in the control non-stented artery 
(Figure 2A). This leakage of Evans blue dye 
points towards increased endothelial per­
meability early after stent implantation. 
Regarding impaired endothelialisation and 
delayed vascular healing, the reports vary. 
In our studies of direct stenting in a healthy 
pig model, extensive coverage (> 75%) of the 
stent struts by endothelium can be seen ear­
ly after stent implantation (Figure 3). In this 
study, we showed similar high levels of 
endothelial coverage of the stent struts five 
days post stenting between BMS, SES and 
PES (mean±SD: 96±6% in BMS, 90±14% in 
SES, and 76±27% in PES) _4o Also, Frey et al.
showed in a porcine overstretched coronary 
artery model that high levels of endothelial re­
growth could be seen 3-14 days after implan­
tation of BMS, SES, and a SES with extended 
release.41 The extent of endothelial coverage 
on the stent struts was above 72% at 7 days 
and 85% at 14 days. In addition, Suzuki et al.
reported similar rates of re-endothelialisation 
between SES and BMS at four weeks in over­
stretched porcine coronary arteries. 42 Howe­
ver, in this study more fibrin deposition was 
observed in SES treated arteries, which is 
considered to be a sign of delayed vascular 
healing. Our study of direct stenting in 
porcine coronary arteries with a DES with 
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Figure 3.-Scanning electron microscopy images showing an extensive coverage of the stent struts by endothelium already 
five days after implantation of a BMS (A), and a DES (B) after direct stenting in healthy porcine coronary arteries; 
adapted with permission from van Beusekom et aJ.40
Figure 4.-Details of stent struts surrounded by fibrinoid (arrow) (HE stain). The amount of fibrinoid in Cypher (A) is 
considerably larger than in a SES with an intermediate dose of sirolimus (40 µg) (B), 28 days after stent implantation; 
reproduced with permission from van der Giessen et aJ.43 
sirolimus released from a nonpolymeric 
hydroxyapatite coated stent showed that with 
increasing sirolimus dose, a dose dependent 
increase in fibrinoid deposition could be seen 
(Figure 4) with unaltered neointimal thick­
ness.43 This indicates that by reducing the 
dose of sirolimus, signs of delayed vascular 
healing could be reduced without compro­
mising efficacy. Also in rabbit iliac arteries, 
Klugherz et al. observed a re-endothelialisa-
tion rate above 86% independent of stent 
type (BMS vs. polymer-only stent vs. SES), 
four weeks post implantation.44 
Different results were obtained by Finn et
al. in balloon injured rabbit iliac arteries, four 
weeks after implantation of overlapping 
DES.45 The authors report low levels of 
endothelial coverage together with more local 
inflammation and fibrin deposition only sig­
nificantly so at overlapping sites of PES as 
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compared to SES or BMS suggesting both 
delayed endothelialisation and vascular heal­
ing. The results of this study may be attributed 
to the extent of injury or to higher local drug 
concentrations after overlapping stent implan­
tation. Data obtained more recently by the 
same group in endothelium-denuded iliac 
arteries showed that non-overlapping SES 
had the lowest percentage of re-endothelial­
isation of the stent struts at 14 days, followed 
by PES, ZES, EES versus BMS.46 According 
to the authors, this incomplete endotheliali­
sation could be part of a transitional healing 
surface. At 28 days no significant difference 
in endothelial coverage between the DES 
was seen. In addition, in a porcine model 
with overlapping stents, Lim et al. showed a 
lower endothelial coverage after four weeks 
of overlapping PES implantation as compared 
to overlapping BMS, SES and SES+PES com­
bined.47 The same overlapping DES group 
also showed an increased vascular inflam­
mation score. 
Altogether, an altered endothelial perme­
able barrier is to be expected early after stent­
ing. However, no clear consistency could be 
shown in the effects of DES on in-stent re­
endothelialisation, making the conclusion 
that DES impair endothelial recovery and that 
specific DES have more negative effects dif­
ficult to formulate. In contrast, DES do seem 
to be associated with multifactorial delayed 
vascular healing as evidenced by increased 
amounts of fibrin deposition and inflamma­
tion within the stented vascular wall. This 
delayed healing has also been witnessed in 
clinical studies. 
]oner et aJ.32 examined autopsy data from 
23 patients receiving SES and PES for more 
than 30 days versus 25 patients with BMS. 
DES were associated with incomplete 
endothelialisation and persistent delayed 
healing characterized by more fibrin deposi­
tion as compared to BMS. From the same 
registry of human autopsies, Finn et al.38 con­
cluded that incomplete endothelial coverage 
of the stent struts was the best predictor of 
thrombosis. However, DES lesions with 
thrombus also showed higher amounts of 
vascular fibrin deposition. The drawback of 
small numbered autopsy studies is that the 
DES AND ENDOTHELIAL DYSFUNCTION 
results may not be representative for the 
majority of surviving patients receiving DES. 
Moreover, several angioscopy studies have 
speculated about DES impaired endothelial­
isation based on delayed neointimal coverage 
(NIC) of the stent struts after DES implanta­
tion. Awata et al. showed that serial angio­
scopic findings up to two years after SES 
implantation were markedly different with 
lower grades of NIC as compared to BMS.48, 49 
In addition, different platforms of DES were 
compared using angioscopy. When assess­
ing the effects of SES and PES implantation 
after nine months, more heterogeneous NIC 
was found after PES implantation.50 ZES 
showed greater NIC than SES eight months 
after implantation, and more competent arte­
rial healing was suggested in ZES than SES.51 
However, clear conclusions based on these 
studies with regard to DES and endothelial 
coverage are difficult to draw, since 
angioscopy is a macroscopic technique not 
sensitive enough to discriminate between an 
uncovered stent-strut and a strut covered by 
translucent tissue of only a few cell-layers 
thick. In addition, one can only speculate 
about the cell type covering the struts. 
Histology of in-stent restenosis tissue 
obtained by atherectomy can clarify the 
nature of these cellular contents. Our study 
comparing in-stent restenosis between DES 
and BMS, showed incomplete neointimal 
healing as late as two years after DES implan­
tation.52 PES showed more pronounced signs 
of delayed healing than SES as evidenced by 
a higher amount of fibrinoid. Since this was 
observed in atherectomy specimens, endothe­
lialisation could not be assessed. 
Overall, DES seem to cause delayed vas­
cular healing of the stented vessel segment 
consisting of more factors than impaired 
endothelialisation alone such as neointimal 
organisation, specific tissue constituents such 
as fibrin, specific extracellular matrix build 
up and the presence of inflammation. 
However, only assessing vascular healing 
after DES implantation does not give a com­
plete endothelial health status of the stented 
segment, since a completed vascular healing 
with presence of regenerated endothelium 
does not guarantee normal endothelial func-
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Figure 5.-In-stent immunocytochemic staining for eNOS (A) and vWF (B) in porcine coronary arteries receiving a DES 
for 28 days. While a continuous eNOS staining over the whole vascular circumference was seen, indicating high eNOS 
expression within the stent, the expression of vWF was ver6 weak, with only scarce cells showing vWF staining (arrows); adapted with permission from van Beusekom et al.4 
tion. 53 Therefore, it might be useful to assess 
the influence of DES on endothelial modu­
latory functions within the stented vessel as 
well. 
DES and impaired modulation of 
adhesion, thrombosis and 
inflammation 
The endothelium maintains vascular home­
ostasis by production, release and expres­
sion of modulatory molecules to balance the 
interactions between adhesion, coagulation, 
fibrinolytic and inflammatory regulatory sys­
tems. Expression of these molecules by 
endothelial cells has been used as specific 
markers to evaluate in-stent endothelial func­
tion after DES implantation, mainly ex viva
using immunocytochemistry or Western blot 
analysis on excised stented vessel material. 
However to date, there is no consensus 
regarding a specific expression marker of 
DES associated in-stent endothelial dysfunc­
tion. The following examples have been 
described: 
Endothelial nitric oxide synthase (eNOS), 
plays a key role in vascular homeostasis by 
producing NO from L-arginine in vascular 
endothelial cells. The cofactor tetrahydro­
biopterin (BH4) has emerged as a critical 
determinant of eNOS activity, as in condi-
tions of reduced BH4 bioavailability uncou­
pled eNOS produces superoxide instead of 
NO.54, 55 Ota et al. have shown in cultured 
human endothelial cells that ten days of treat­
ment with 2.Snmol/1 paclitaxel, sirolimus or 
everolimus resulted in reduced expression 
of eNOS, pointing towards endothelial dys­
function induced by the three drugs.56 
However, local NO production by eNOS is 
difficult to quantify in viva. Therefore, most 
data come from NO-metabolite measure­
ments in plasma or from protein assays of 
arterial specimens. But these metabolite data 
do not provide a specific measure of eNOS 
function within the stented segment. In con­
trast to previous assays, we assessed in-stent 
eNOS expression by immunocytochemistry 
(Figure SA) in BMS, SES and PES 28 days 
after stent implantation.40 Our results showed 
a similar high eNOS expression in SES and 
BMS, but a reduced eNOS expression in PES. 
Although these data give an indication of 
endothelial function within the stent and the 
effects of different DES on endothelial expres­
sion, our assay cannot distinguish between 
functional eNOS and its uncoupled form. 
Therefore, eNOS expression might be a valid 
endothelial homeostasis expression marker 
when accompanied by superoxide measure­
ments. 
Platelet endothelial cell adhesion molecule 
(PECAM-1) is a major constituent of endothe-
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lial intercellular junctions; human endothelial 
cells express nearly 106 PECAM-1 molecules 
per cell.57 PECAM-1 has been shown to play 
an important role in endothelial flow sensing 
and NO-production by forming complexes 
with eNOS.ss When endothelial cell contact is 
altered, a loss of PECAM-1 immunostaining at 
the endothelial junctions can be seen. 
Reduced PECAM-1 expression translates in 
a reduced adhesion interaction between adja­
cent endothelial cells with subsequent 
enhanced permeability of the endothelial cell 
layer.SS, 59 Joner et al. assessed in-stent 
endothelial PECAM-1 expression above the 
stent struts in iliac arteries of rabbits receiv­
ing SES, PES, ZES, EES versus BMS for 14 or 
28 days.46 PECAM-1 expression after SES and 
PES implantation was reduced after both 14 
and 28 days, suggesting an inhibition of 
endothelial cell proliferation and migration 
and/or endothelial injury. Therefore, PECAM-
1 might be a valid endothelial adhesion 
expression marker. 
Von Willebrand factor (vWF) is a large gly­
coprotein produced almost exclusively by 
the endothelium. Its primary function is to 
bind to other haemostatic proteins, particu­
larly Factor VIII, and is important in clot for­
mation and platelet adhesion to the endothe­
lium. 60 VWF is regarded as a useful clinical 
marker of risk associated with atherosclero­
sis since systemic plasma levels of vWF are 
elevated in the setting of atherosclerotic car­
diovascular disease in a graded manner pro­
portionate to the risk of cardiovascular dis­
ease events. Pathophysiological evidence 
suggests that vWF is not only a marker but 
also a mediator of cardiovascular disease 
events. VWF is produced and released by 
endothelial cells in response to a variety of 
stimuli, e.g. to inflammatory cytokines in 
response to vascular injury.61 In one of our 
studies in the pig model, we used the 
immunocytochemical detection of expressed 
vWF in the endothelium of coronary arteries 
receiving DES and BMS (Figure SB). Our 
results showed only very low levels of in­
stent endothelial vWF expression (less than 
10% of the total stent endothelial circumfer­
ence was positive for vWF), with no differ­
ences seen between BMS, SES or PES at 28 
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days post stenting.40 Because endothelial 
expression of vWF seems to return to normal 
several days after arterial injury,62 this expres­
sion marker might not be sensitive enough on 
its own to detect chronic endothelial dys­
function. 
Thrombomodulin is an integral membrane 
protein expressed on the surface of endothe­
lial cells, having an anticoagulant function 
by forming high affinity inhibitory binding 
complexes with thrombin. It has been sug­
gested that inflammatory cytokines generat­
ed in the injured vascular wall (as after stent­
ing) may down-regulate thrombomodulin 
promoting a pro-thrombotic state.63 Joner et
al. have measured the expression of throm­
bomodulin 14 and 28 days post-stenting of 
SES, PES, ZES, EES and BMS in denuded, 
overstretched arteries. 46 The authors 
described that overall staining for thrombo­
modulin was moderate in BMS although not 
as high as in non-stented vascular segments; 
while in DES irrespective of type, thrombo­
modulin expression was very weak if not 
absent at both follow-up times. This suggests 
that endothelial dysfunction with an increased 
pro-thrombotic state, as indicated by reduced 
thrombomodulin expression, can be induced 
by stenting itself and be exacerbated by DES. 
Therefore, thrombomodulin might be a sen­
sitive endothelial coagulation-related expres­
sion marker. 
Platelet derived growth factor (PDGF) is 
one of the first identified endothelial-derived, 
paracrine signals required for recruitment 
and communication with surrounding cells in 
the vessel wall. 64 In coronary arteries of 
Yucatan minipigs receiving SES or PES for 
one month, in-stent expression of PDGF was 
higher in PES than in SES. Since the stented 
vascular segments were almost completely 
re-endothelialised with no differences 
between the DES, this suggested a higher 
recruited inflammatory state by PES as com­
pared to SES.65 Therefore, PDGF might be a 
useful endothelial inflammation-related 
expression marker. 
Thus, the markers described above are 
examples used to date to evaluate different 
modulatory aspects of in-stent endothelial 
function early after DES implantation in 
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experimental studies. On their one, they are 
not capable of providing a complete and spe­
cific characterization of an integrated func­
tional endothelium. It has been shown that in 
circumstances of vascular injury, inflammation 
shifts haemostatic mechanisms in favor of 
thrombosis. In addition, dysfunctional anti­
coagulant pathways may play a role in damp­
ening inflammatory responses.63 Therefore, 
one aspect of endothelial function might 
influence other aspects and the task of defin­
ing a single best marker to assess complete 
endothelial functionality seems impossible. 
Thus, we propose that a combination of 
markers covering different endothelial mod­
ulatory functions rather than only one would 
give a more complete overview of endothe­
lial function within the stent. For example, in 
our study comparing different DES, we eval­
uated both eNOS and vWF staining at 28 days 
after stent implantation in pigs (Figure 5). 
While vWF expression was similar for all 
DES, PES showed diminished eNOS expres­
sion.66 In this way, both endothelial home­
ostasis and the thrombotic state within the 
stent were evaluated. An even more com­
plete combination of endothelial expression 
markers could also include PECAM-1, throm­
bomodulin and PDGF to more fully assess 
endothelial permeability, cell-cell adhesion, 
and the thrombotic and inflammatory state. 
However, of notion all above described 
endothelial modulatory expression markers 
have only been used in a limited number of 
experimental animal studies. Whether extrap­
olation to the human situation is valid remains 
to be determined. In addition, evaluation of 
overall endothelial function is not possible 
with use of only in-stent endothelial expres­
sion markers, since modulation of vascular 
tone cannot be fully assessed in a motion­
limited stented vessel segment. 
DES and impaired vascular tone 
DES effects on endothelium-dependent 
vascular tone can only be measured outside 
the motion-limiting stent. Both physiologi­
cal and pharmacological stimuli have been 
used for the evaluation of coronary endothe-
VAN DEN HEUVEL 
lial function after DES implantation in conduit 
arterial segments adjacent to the stent. These 
stimuli act as potent vasodilators in normal 
coronary arteries by promoting the release 
of NO in endothelial cells and via its key sec­
ond messenger cGMP relaxation of VSMC. 
However when endothelial NO release of a 
vessel segment is impaired or insufficient, 
these stimuli can cause paradoxical vaso­
constriction. 
Hofma et al. was the first to report abnor­
mal coronary conduit vasoconstrictive 
responses distal to the stent to the stimulus 
Ach after SES implantation for six months as 
compared to BMS. 67, 68 Constrictive respons­
es of the same vessel segments were pre­
sent, directly after implantation in both BMS 
and SES groups indicating that while in BMS 
endothelial dysfunction was restored in time, 
SES induced prolonged dysfunction. Togni 
et al. evaluated coronary vasodilatory function 
to exercise, six months after SES or BMS 
implantation. In this study, SES was associated 
with exercise-induced paradoxical vasocon­
striction, while BMS did not affect the 
response.69 Fuke et al. performed a compar­
ison of coronary vasomotion function in the 
peri-stent area with intracoronary infusion of 
Ach both before and six months after SES 
implantation. They demonstrated that no 
coronary vasoconstriction was present before 
SES implantation, but Ach induced signifi­
cant vasoconstriction six months after SES 
implantation.YO Togni et al. also showed the 
effects of PES on endothelial vasomotion.71 
PES implantation was associated with exer­
cise-induced coronary vasoconstriction in the 
peri-stent area up to one year as compared to 
BMS. Shin et al. demonstrated that both SES 
and PES implantation were associated with 
endothelial dysfunction at six to nine months 
post intervention, not only in the distal but 
also in the far distal conduit arterial segments 
of the treated vessel.72 Moreover, Kim et al.
compared vascular function of larger patient 
groups of SES and PES with BMS, six months 
after stenting. 73 Again, both SES and PES 
showed peri-stent endothelial dysfunction 
especially in the arterial segments distal to 
DES. 
To summarize, most clinical studies found 
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DES-associated conduit endothelial dysfunc­
tion in the peri-stent area; however the seg­
ment distal to the stent was always most 
severely affected. In addition, even far distal 
conduit arterial segments can be affected. 
These data probably reflect a dose-depen­
dent effect of specific DES on the endotheli­
um distal to the stent. Therefore with the 
advent of new types of DES or DES with dif­
ferent pharmacokinetic drug release charac­
teristics, we may observe other responses. 
Hamilos et al. compared coronary conduit 
vasomotion of a second generation biolimus 
A9-eluting stent (BES) with SES and found 
preserved endothelium-dependent vasomo­
tion adjacent to BES.74 According to Shin et
al. also after ZES implantation for six to nine 
months endothelium-dependent vascular 
function distal to the stent was less altered as 
compared to SES.75 Kim et al. compared 
endothelial function six months after ZES 
implantation with both SES and BMS.76 
Although both DES affected vasomotion in 
the peri-stent area, paradoxical vasocon­
striction was less pronounced after ZES. 
Therefore, in particular first generation DES 
seem to impair endothelial regulation of vas­
cular tone in the peri-stent area as compared 
to BMS in the early time period after stenting. 
However, only these specific DES have been 
most extensively studied as compared to the 
newer generation DES. A limitation of above 
described clinical studies is that testing of in
viva endothelial function in patients is a tech­
nically difficult procedure, irrespective of the 
stimulus used. Thus, sample sizes are usual­
ly small and little comparative data of differ­
ent DES are available. Overall, although stent­
ing on its own has already been associated 
with long term vascular dysfunction, 17 there 
is convincing evidence that first generation 
DES even further impair this endothelium­
dependent vascular function up to almost 
one year after DES implantation. 
New insights in DES induced 
alterations in vascular tone 
Recently, new insights have appeared with 
regard to the extent and the underlying mech-
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anism of DES induced impairments in vas­
cular tone. Especially the coronary vascula­
ture distal to DES seems to be at increased 
risk for endothelium-dependent vasodilatory 
alterations. Li et al. confirmed abnormal coro­
nary vasomotor function distal to SES in a 
porcine model one month after implanta­
tion.77 Besides reduced endothelium-depen­
dent dilation, increased vasoconstriction to 
ET-1 of distal conduit arteries was observed. 
Moreover, Pendyala et al. showed in a pig 
model additionally impaired endothelium­
dependent vascular function of small arteries 
far distally from overlapping PES.78 From our 
own studies of single DES implantation for 
five weeks in a healthy porcine model, we 
also report PES induced vascular alterations 
in endothelial function of distal small arter­
ies.79 Specifically the EDHF component of 
microvascular endothelial function seemed 
to be affected by PES under conditions of 
reduced NO bioavailability (Figure 6). Two 
clinical studies support the concept that DES 
effects can extend far in the distal flow area 
of the stent. Meier et al. reported impaired dis­
tal collateral function six months after both 
SES and PES implantation for de nova CAD.80 
In addition, according to Obata et al. SES 
implantation may also adversely affect dis­
tal endothelium-dependent microvascular 
function after ischemia-reperfusion two 
weeks after an acute myocardial infarction.81 
Altogether, these data converge towards the 
conclusion that DES induced alterations in 
the endothelial regulation of vascular tone 
might be a more generalized distal phenom­
enon than just occurring locally adjacent to 
the stent. 
Experimental studies have provided pre­
liminary insight into the nature of these 
endothelial alterations for both SES and PES. 
Jabs et al. showed that continuous infusion of 
sirolimus for seven days induced a marked 
degree of vascular dysfunction in rats.82 
According to the investigators, increased vas­
cular superoxide production and release might 
contribute to the dysfunctions. In addition, 
Pendyala et al. showed that overlapping PES 
implantation was also associated with 
increased superoxide generation in the peri­
stent area, probably affecting the NO-medi-
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Figure 6.-Effects of five weeks of single implanted BMS, SES, and PES in the three coronary arteries of a pig on in vit­
ro endothelium-depend0ent vasodilation to bradykinin (BK) (control) or to BK after eNOS blockade, in small arteries 
(vessel diameter ~300µm) distal to the stent. While no differences in the BK-induced response were seen under con­
trol conditions, PES resulted in impaired BK-induced dilation after eNOS blockade. This suggests that PES implantation 
affects the EDHF component of BK-induced vasodilation; adapted with permission from van den Heuvel et aJ.79
ated vasodilator response of conduit arteries 
of this area.78 However, direct evidence of 
DES induced effects causing NO impairment 
is scarce, mostly because of the difficulties 
with the direct measurement of NO. 
Nevertheless, it is tempting to speculate that 
impaired endothelial vasomotion mirrors DES 
induced oxidative stress imposed on the vas­
cular wall, impairing profoundly endothelial 
NO bioavailability and perhaps also EDHF 
availability under certain circumstances. 
Conclusions 
Abnormal endothelial function has been 
implicated both in CAD development and as 
an adverse effect after PCI procedures includ­
ing DES implantation. The link between ath­
erosclerosis development and endothelial 
dysfunction induced by DES placement may 
be related to a decreased local bioavailabili­
ty of NO.s3, s4 
In case of DES, evidence indicates that 
overall endothelial dysfunction may be due 
to an altered permeable barrier function after 
stenting in general, delayed vascular healing 
specific to some DES, affected endothelial 
modulatory functions after some DES implan­
tations, and impaired regulation of vascular 
tone after stenting and specific to some DES. 
These aspects might predispose to a pro­
coagulant and pro-inflammatory state within 
the DES and paradoxical vasoconstriction 
outside the DES with the distal circulation 
receiving the highest drug concentrations at 
highest risk. However, it is currently unknown 
whether these impaired aspects of endothe­
lial function remain present after years, long 
after stenting and DES implantation. 
Therefore, the link between enhanced DES 
associated endothelial dysfunction and 
adverse clinical events is speculative and has 
yet to be established. However when persis­
tent, endothelial dysfunction of coronary con­
duit arteries has been associated with long-
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term CAD development, disease progression 
and clinical event rates.85 In addition, 
impaired distal endothelium-dependent 
vasodilation of the coronary microcirculation 
has been associated with exercise-induced 
myocardial ischemia, even in patients with­
out hemodynamically significant obstructive 
coronary lesions.s6 
Finally, if DES-associated endothelial dys­
function proves to be a real harmful phe­
nomenon, then what may provide a solu­
tion? Reduction of DES associated endothe­
lial dysfunction may be provided by optimal 
medical therapy. Besides blood pressure and 
lipid lowering, angiotensin converting 
enzyme inhibitors,87 angiotensin receptor 
blockers,ss selective beta-blockers,89 statins 
90 and fibrates 91 have shown clinical benefi­
cial effects on general endothelial function. 
However, whether additional aggressive ther­
apy translates in improved endothelial out­
come after DES implantation remains to be 
determined. 
Moreover, drug choice, release kinetics, 
polymer-type or non-polymer coatings, and 
stent-type are probably the most important 
components of DES technology determining 
the type of vascular response and the time­
course of healing. Newer, perhaps better DES 
are presently designed and tested that may 
eliminate these adverse effects. Our results 
with a new DES consisting of another limus 
drug, tacrolimus, together with a biodegrad­
able polymer and its own stent-design 
showed promising results with regard to sup­
pression of inflammation and early re­
endothelialisation in the pig model.92 
However, clinically it failed to prevent in­
stent restenosis despite of the theoretical 
advantages of tacrolimus, which has less 
inhibitory effects on endothelial cells than 
VSMC.93 Therefore, modifications in dose and 
release of tacrolimus from this DES seem to 
be mandatory, highlighting the delicate bal­
ance of a DES between wanted restored 
endothelial function and unwanted resteno­
sis. With the development of completely 
bioabsorbable DES, short-term vessel scaf­
folding together with inhibition of cell pro­
liferation can be provided, without the long­
term restrictions of metallic stents. Indeed, 
DES AND ENDOTHELIAL DYSFUNCTION 
Serruys et al. showed promising two year 
results after implantation of a bioabsorbable 
everolimus-eluting coronary stent system with 
regard to prevented restenosis and restored 
vasomotion at both the stented site and the 
peri-stent area.94 However, future experi­
mental and clinical studies are needed to 
evaluate the efficacy and safety of this promis­
ing new approach. 
To conclude, DES associated endothelial 
dysfunction is a fascinating complex phe­
nomenon likely to be related to the funda­
mental mechanisms of CAD development. 
Together the evolution of biotechnology and 
stent design with increased knowledge of 
fundamental disease mechanisms might lead 
to further improvements in future DES with 
the prospect of even better patient outcomes. 
Riassunto 
La disfunzione endoteliale dopa impianto di stent 
medicati 
La disfunzione endoteliale e implicata nei proces­
si patologici della malattia coronarica come evento 
avverso dopa l'impianto di uno stent medicato (drug 
eluting stents, DES). In questa revisione viene offer­
to un quadro generale delle dimostrazioni scientifiche, 
ottenute da studi sia clinici che sperimentali, degli 
effetti dei DES sulle funzioni endoteliali. G!i stent in 
generale e i DES sembrano danneggiare diversi aspet­
ti della funzione endoteliale tra i quali quella di fun­
gere da barriera permeabile, modulare l'adesione, la 
trombosi e l'infiammazione, oltre che regolare ii tono 
vascolare. In ogni caso, nuove ipotesi propongono 
che gli effetti dei DES possono essere estesi oltre !'a­
rea di impianto dello stent che !'area adiacente allo 
stesso: ii letto vascolare distale allo stent, dai vasi 
distali alla microvascolatura distale, possono essere a 
rischio. Inoltre, sono state formulate diverse ipotesi sul 
meccanismo con ii quale i DES inducono la disfun­
zione endoteliale. Concludendo, verranno discussi 
le complicazioni cliniche dei DES associati alla disfun­
zione endoteliale e le relative soluzioni. 
Parole chiave: Stent medicati - Cellule endoteliali -
Vasospasmo coronarico - Stent - Trombosi. 
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Abstract
Aims: Drug eluting stents (DES) are under scrutiny for late stent thrombosis. Impaired re-endothelialisation 
is proposed as an explanation but coronary and peripheral-artery models disagree. We assessed physical 
and functional endothelial restoration within bare (BMS), paclitaxel, sirolimus and tacrolimus eluting stents 
and the distal microvasculature in porcine coronary arteries.
Methods and results: Endothelium within and distal to DES and BMS was assessed for stent-strut 
endothelial-restoration (five days) and endothelial-function (five, 28 days, by eNOS and vWF expression) 
and by in vitro microvascular function. There were no significant differences (P=0.3) in stent strut 
endothelial-restoration at five days between DES (76-90%) and BMS (95%). However, the 
microvasculature distal to PES showed a decreased NO bioavailability at five days, which improved at 28 
days. Within the stent, however, PES still showed a reduced eNOS expression at 28 days (P≤0.002). 
Conclusions: DES in porcine coronary arteries show no significant early differences in re-endothelialisation 
as compared to BMS. However, PES did affect endothelial function both within and distal to stents. These 
results extend the concept of delayed healing in DES to include delayed restoration of function rather than 
endothelial presence as a possible explanation for late unwanted sequelae. Microvascular dysfunction does 
not predict in-stent delayed endothelialisation in this model.
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Introduction
Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) 
have markedly reduced the rate of in-stent restenosis and late 
lumen loss compared to bare-metal stents (BMS), resulting in a 
significantly reduced need for repeat revascularisations.1-3 
Enthusiasm for this technology has been dampened by concerns 
about late thrombosis, an event often with serious clinical 
consequences.4,5 Aside from rarely occurring delayed 
hypersensitivity to DES constituents, impaired re-endothelialisation 
has been suggested as the likely cause of late DES thrombosis 
based on one clinical autopsy study6 and experimental overlapping 
DES implantation in denuded and injured rabbit peripheral 
arteries.7,8 Although data from denudation and overlap models 
cannot be dismissed, they do not represent the full spectrum of the 
clinical arena. Indeed, there is consistent evidence pointing towards 
late endothelial dysfunction as the main derangement after DES. 
This was shown both experimentally and clinically as impaired 
responses to endothelial dependent vasodilators or exercise.9-11 
Combining assessment of in-stent re-endothelialisation with 
endothelial-function of the newly formed neointima and distal 
vasculature has not been reported. This combined assessment is 
important as altered endothelial-function could be the result of both 
dysfunction as well as absence of endothelium. Discriminating 
between these two is, however, difficult to do in patients and 
a correlation between these two parameters might theoretically be 
a diagnostic tool for endothelium within the stent.
Predicting which animal model mimics the human situation the 
closest, is difficult and may well differ between drugs due to species 
differences in sensitivity. Even the choice for healthy, injured or 
atherosclerotic models will affect outcome. While in atherosclerosis 
general endothelial-function may be affected, there is no indication 
it delays endothelial-regrowth.12,13 We therefore studied the effects 
of three distinctively different DES on early endothelial-regrowth 
(five-days follow-up) as well as early and late endothelial-function 
(five and 28 days follow-up) both with the stent and in the distal 
coronary microvasculature (i.e., not the epicardial coronary artery) 
in normal, non-atherosclerotic swine.
Materials and methods
Stents
Four different stent types with a length of 12-13 mm (diameter 3.0 
and 3.5 mm) were studied: 1) 15 bare metal controls (BMS, 
Kaneka corporation, Osaka, Japan), 2) 25 tacrolimus eluting stents 
(TES, 0.9 μg/mm2, Kaneka corporation, Osaka, Japan) 3) 25 
sirolimus eluting stents (SES, 1.4 μg/mm2, Cordis, Johnson & 
Johnson, Warren, NJ, USA) and 4) 25 Paclitaxel eluting stents 
(PES, 1 μg/mm2, Boston Scientific, Natick, MA, USA).
Polymers
The TES coating consists of a fully degradable polylactide-
polyglycolide polymer (PLGA), with a degradation rate ≥90 days.14,15 
SES is coated with biostable poly-ethylene-vinyl-acetate-poly-
butylene-methyl-acetylate (PEVA-PBMA), PES is coated with 
a biostable styrene-b-isobutylene-b-styrene (SIBS).16
Drugs
The intracellular receptors of tacrolimus are the FK binding proteins 
(FKBP, including FKBP12). The tacrolimus-FKBP complex binds to 
the calcineurin-calmodulin complex.17 Tacrolimus effects on 
endothelium includes inhibition of expression of endothelial adhesion 
molecules, and reduction of free radical and inflammatory cytokine 
release.18,19 Sirolimus also binds to FKBP12, but the Sirolimus-FKBP 
complex then inhibits mTOR20, halting cell cycle progression from G1 
to S, as well as vascular cell migration. Paclitaxel inhibits 
depolymerisation of tubulin, thereby arresting cellular replication and 
inhibiting migration of vascular smooth muscle cells.21,22
Animals and preparation
Experiments and animal preparation were performed in farm-bred 
swine (Yorkshire-Landrace, 30-35 kg) as previously described.23,24 
The study was approved by the animal ethics committee of the 
Erasmus University, Rotterdam and complied with the “Guide for 
the care and use of laboratory animals” (NIH publication 85-23). In 
short, animals were pretreated with 300 mg acetyl salicylic acid 
(ASA) and a loading dose of 300 mg of clopidogrel (Plavix; Sanofi 
Aventis, Gouda, The Netherlands) one day prior to the procedure. 
After induction of anaesthesia and connection to the ventilator, 
antibiotic prophylaxis was administered by an intramuscular 
injection of streptomycin, penicillin procaine (0.1 mg/kg). An 
introducer sheath was placed in the carotid artery for arterial 
access. A dose of 250 mg ASA and 10.000 i.u. heparin was 
administered (i.a.).
Stent implantation and angiography
Stent implantation was performed as described before.23,24 Under 
guidance of quantitative angiography (QCA, CAAS II; PIE Medical, 
Maastricht, The Netherlands), arterial segments of 2.5-3.2 mm in 
diameter were selected in each of the coronary arteries. Stents were 
placed with a balloon-artery (B/A) ratio of 1.1 without prior injury. 
Animals received one stent per coronary artery, according to a 
predetermined randomisation scheme for stent type. After the final 
angiogram, animals were allowed to recover from anaesthesia and 
returned to animal care facilities for postoperative recovery. During 
follow-up, 300 mg ASA and 75 mg clopidogrel were administered 
daily. Only in swine followed for 28 days, follow-up angiography was 
planned prior to euthanasia. This was omitted for the five day group 
to prevent catheter induced injury.
Tissue harvesting
Animals were euthanised by an overdose of pentobarbital. Hearts 
were pressure fixed in situ in preparation for histology.24 In case of 
in vitro vasomotor tone experiments, fixation was preceded by 
excision of small myocardial samples from the distal perfusion area 
of the stent for the isolation of the vessels (Table 1).
Endpoints
Completeness of the endothelial layer by scanning electron 
microscopy (SEM) and endothelial function by eNOS- and vWF-
expression were studied at five days. Endothelial presence, 
histology and endothelial eNOS- and vWF-expression were studied
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by light microscopy at 28 days. In a subset of the animals 
(Figure 4), distal vasomotor tone was assessed by in vitro functional 
tests at five and 28 days.
Scanning electron microscopy
After fixation with 2.5% glutaraldehyde in 0.15 mol/l cacodylate 
buffer, the arteries were further processed as previously 
described.25 From photographs, the stent struts were traced, the 
endothelium marked, and the percentage endothelial coverage of 
the stent struts quantified using computer assisted planimetry,
(Clemex vision PE; Clemex Technologies Inc., Longueuil, Canada).
Histology
The arteries were processed for plastic embedding.23,26 Sections 
were collected at three levels (proximal, mid and distal) of the 
stented segments. The sections were stained with haematoxylin-
eosin and resorcin-fuchsin (elastin stain) for quantitative and 
qualitative analysis.
Morphometry
Analysis of neointima and injury was performed as described 
before25. As at 5-days all stents were covered by thrombus and 
granulation tissue containing inflammatory cells, inflammatory 
scores were only determined at 28 days, on HE stained sections, and 
given as the ratio of inflamed over total number of struts at each level 
(proximal, mid and distal) and averaged per stent.
Immunocytochemistry
The complete circumference of the stented vascular segment was 
assessed semi-quantitatively for eNOS (sc-654; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) and von Willebrand 
Factor (vWF) (A0082; DakoCytomation, Copenhagen, Denmark). 
Scores were assigned as: 0=0% positive circumference, 1=0-10%, 
2=10-40%, 3=40-70%, 4=70-90%, 5=90-100%.
In vitro microvascular function
Upon sacrifice, microvascular coronary arteries (~300 μm 
diameter) were dissected free from the myocardial tissue in the 
perfusion territory of the stent. Experiments were performed as 
previously described.27-29
In brief the arteries were cut into segments of ~2 mm length and 
mounted in a Mulvany wire myograph (DMT A/S, Aarhus, 
Denmark). Following 30-minutes stabilisation, the optimal internal 
diameter was set to a tension equivalent of 0.9 times the estimated 
diameter at 100 mmHg effective transmural pressure.30 Vascular 
responses were measured as changes in isometric force. Segments 
from the same vessel were randomly assigned to a different 
experimental protocol, such that in each perfusion territory all 
measurements were performed. After stabilisation, the vessel 
segments were exposed to 100 mM KCl to determine the maximal 
contractile response to KCl. Upon wash-out of KCl, the segments 
were allowed to equilibrate for 30 minutes. The endothelium-
dependent relaxation to bradykinin (10–10-10–6 M) and endothelium-
independent relaxation to the exogenous nitric oxide (NO) donor, 
S-nitroso-N-acetylpenicillamine (SNAP, 10–7-10–6 M) was recorded 
upon preconstriction with the thromboxane analog U46619 (1nM). 
In order to test the contribution of NO-mediated mechanism to the 
bradykinin-induced relaxation, the concentration–response curve 
for bradykinin was constructed after 30 min. incubation with the 
eNOS inhibitor N-Nitro-L-Arginine methyl ester (L-NAME, 10–4 M), 
in a separate set of vessels. Data of six historic control vessels from 
two animals receiving a BMS for 28 days were used for comparison 
in the vascular function study.
Statistical analysis
All data are given as mean ±SD except for in vitro microvascular 
function which is given as mean ±SEM. Histology and QCA were 
analysed with SPSS version 16, (SPSS Inc., Chicago, IL, USA). 
Intergroup differences were assessed using one-way ANOVA 
followed by post-hoc analysis with a Bonferroni correction in case of 
statistical significance. P<0.05 was considered statistically 
significant. In vitro relaxant responses to bradykinin and SNAP are 
expressed as a percentage of the contraction to U46619 and were 
analysed using Stat View (version 5.1). Statistical significance was 
established by a two-way ANOVA followed by post-hoc analysis with 
a Bonferroni correction in case of statistical significance. P<0.05 
was considered statistically significant. Further testing was 
performed using linear regression analysis (SPSS). For QCA the 
main model parameters consisted of follow-up time, balloon-artery
Table 1. Angiographic parameters measured by QCA at implantation and follow-up. No differences were seen in vascular diameters pre- or
post-implantation, balloon/artery ratio or acute gain between groups at either follow-up pointS Late loss was however increased in SES at
28 days as compared to TES and PES (*P=0.02).
BMS TES SES PES
5 days 5 days 28 days 5 days 28 days 5 days 28 days
N=15 N=13 N=12 N=14 N=11 N=13 N=12
I; S; F I; S; F I; F I; S; F I; F I; S; F I; F
Diam. pre. (mm) 2.94±0.25 2.89±0.22 3.00±0.27 2.94±0.25 2.83±0.23 3.00±0.27 2.90±0.14
Diam. post. mm) 3.05±0.27 3.09±0.25 3.11±0.24 3.09±0.23 2.98±0.31 3.20±0.29 2.99±0.20
Acute gain 0.11±0.12 0.18±0.08 0.11±0.08 0.15±0.08 0.16±0.11 0.16±0.07 0.12±0.06
B/A ratio 1.08±0.05 1.12±0.06 1.12±0.04 1.09±0.06 1.14±0.04 1.10±0.02 1.12±0.06
Late Loss n.d. n.d. 0.30±0.22 n.d. 0.45±0.40* n.d. 0.17±0.08
TES: tacrolimus-eluting stent; SES: sirolimus-eluting stent, PES: paclitaxel-eluting stent. S: indicates in which groups SEM was performed for assessment of
re-endothelialisation; I: immunocytochemistry (eNOS and vWF); F: in vitro microvascular function experiments; n.d.: not determined
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ratio and stent type. For morphometry and immunocytochemistry 
the model parameters also included the morphologic injury score 
and inflammation score. For SEM analysis the model parameters 
were procedural characteristics (B/A ratio, acute gain) and stent 
characteristics (drug, design, metal to surface ratio, strut width).
Results
Quantitative angiography showed no differences in diameters 
between pre- or post-implantation or stent/artery at either follow-up 
time (Table 1). Late loss at 28 days was not different between TES 
(0.3±0.2) and PES (0.2±0.1), only SES showed a significant late 
lumen loss (0.5±0.4 mm, p=0.02 versus PES by ANOVA), as a 
result of inflammation. Regression analysis did not yield a significant 
predictive model (ANOVA p=0.6).
Scanning electron microscopy
Data (Table 2), indicate that as early as 5-days the stent struts were 
covered with endothelium to a large extent. There were no 
significant differences in re-endothelialisation between DES and 
BMS (one way ANOVA p=0.3) (Figure 1), indicating that the drugs 
did not inhibit re-endothelialisation. Regression analysis (ANOVA 
p=0.02) confirmed that the drug did not predict re-
endothelialisation. Only stent-artery ratio (p=0.03), stent design 
(p=0.02) and metal to surface ratio (p=0.02) were independent 
predictors of re-endothelialisation. The predictive value of the model 
was, however, rather low (r2=0.4).
Figure 1. Scanning EM of the endothelial layer overlying stent struts in Bare (A), TES (B), SES (C) and PES (D), showing extensive endothelial
(EC) coverage of the struts. Areas devoid of EC (arrow) often show presence of macrophage giant cells (MGC).
Table 2. Quantitative scanning electron microscopy: percentage
endothelium covering the stent struts at five days. ANOVA showed
no significant differences between the groups.
% endothelial coverage ± SD
BMS (n=11) 95.5 ± 6.4
TES (n=10) 82.6 ± 13.2
SES (n=9) 89.7 ± 14.3
PES (n=11) 76.3 ± 26.7
BMS: bare-metal stent; TES: tacrolimus-eluting stent; SES: sirolimus-eluting 
stent; PES: paclitaxel-eluting stent
Histology
At 5-days all stents showed immature granulation tissue in varying 
stages of development (Figure 2). Consistent with SEM, stent struts 
were already endothelialised to a large extent. Lack of endothelium 
often coincided with presence of macrophage giant cells. 
Leukocytes were often found adhering to the endothelium. In 
general, TES showed a response similar to BMS. This granulation 
tissue was more mature in terms of inflammation and colonisation 
with smooth muscle (SMC)-like cells than in PES, while SES 
generally showed the most immature healing response.
At 28 days re-endothelialisation was virtually complete in all groups, 
and in general the neointima showed a mature and organised 
appearance (Figure 3). Each drug, however, had a specific 
appearance: PES showed apoptotic cells and mitotic figures in both 
neointima and media. SES showed luminal and adventitial
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eosinophilic granulocytes and abundant fibrinoid in the intima-
media border zone. TES showed acidic proteins in the intima-media 
border zone, possibly proteoglycans.
Morphometry
Data is summarised in Table 3. At 5-days, all stents tend to show 
thrombus being incorporated and cleared by granulation tissue. 
The damage to the tissue  induced by histological sectioning overlying
the struts was however too great to yield reliable quantitative data
and morphometry of the intima was not performed. At 28-days, SES
induced a considerable inflammatory response in a number of
animals which increased intimal thickening considerably. We
therefore compared the results also in the SES subgroup without
inflammation. This showed that neointima thickness (NIT) was not
Figure 2. Light microscopy images of stent struts covered with immature granulation tissue showing scarce cellular infiltration and loose
endothelium (arrows) at 5-days following implantation of BMS (A), TES (B), SES (C) and PES (D).
Table 3. Morphometric analysis: thickness of neointima, media and adventitia was measured at 28 days on elastin-stained sections taken
from the proximal, medial, and distal region of the stent.
Injury score Inflammation Mitotic NIT NIT without Media Adventitia
score figures (%) (µm) inflamm. (µm) (µm) (µm)
TES (n=12) 0.26±0.17 * 0* 0.01±0.02* 248±43 248±43 122±29 140±30
SES (n=11) 0.95±0.76 0.46±0.47 n.a. 435±216* 259±43 72±38* 327±228
PES (n=12) 0.16±0.18¶ 0.04±0.11¶ 0.12±0.14 258±42 267±38 118±66 159±54
ANOVA *0.005 and *0.001 and *0.03 vs. PES *0.004 and *0.07 vs PES
p-values ¶0.001 vs SES ¶0.003 vs SES 0.003 vs. TES, PES and TES
TES: tacrolimus-eluting stent; SES: sirolimus-eluting stent; PES: paclitaxel-eluting stent; NI: neointima thickness
Figure 3. Three examples of coronary arteries at 28-days following stenting with TES (A), SES (B) and PES (C), showing complete coverage with
an endothelialised fibrocellular neointimal thickening. HE-stain. Bar=1000 µm
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(Regression analysis, ANOVA p=0.4). The NO contribution did 
recover at 28 days (Figure 5C). Endothelial-independent dilation to 
SNAP was similar for all stents and follow-up times (Figure 5D).
Discussion
We set out to assess differences in re-endothelialisation and 
endothelial function after implantation of TES, SES, PES and BMS in 
normal swine coronary arteries. We found that DES demonstrated 
76-95% in-stent endothelialisation at five days after implantation. 
This was not statistically different from BMS. In-stent endothelial 
function as assessed by eNOS expression, was already
demonstrable at 5-days, and almost complete for TES and SES at 
28 days after implantation. PES, however, showed a significantly 
reduced in-stent eNOS expression at 28 days. Consistent with this
significantly different between the groups upon exclusion of stents 
with severe inflammation. Injury and inflammation score, when 
analysed separately as model parameters in regression analysis, 
were both strong predictors of NIT (p<0.0001). However, when 
used simultaneously they were not independent. Endothelial-
function (eNOS, vWF) was not an independent predictor of NIT.
Immunocytochemistry
This data is summarised in Table 4. At 5-days all DES contained 
eNOS positive endothelium (Figure 4). The damage to the tissue 
overlying the struts was however too large to yield reliable 
quantitative data. At 28 days regression analysis of eNOS 
expression (ANOVA p=0.001, R2=0.6) indicated that eNOS 
expression was significantly less in PES as compared to TES and 
SES (See Table 4, p<0.002). Inflammation had no effect on eNOS 
expression (p=0.18), only injury score was an independent negative 
predictor of eNOS expression (p=0.006). In all groups, the number 
of cells expressing vWF was very low (score ~1-1.3), showing no 
significant differences between groups.
Table 4. Semi-quantitative analysis of immunocytochemical 
staining for eNOS and vWF at 28 days. A score of 0 designates 0%, 
1=<10%, 2=10-40%, 3=40-70%, 4=70-90%, 5=90-100%.
eNOS vWF
TES (n=8+6) 4.50±0.5¶ 1.17±0.4
SES (n=8+7) 4.00±0.9‡ 1.29±0.5
PES (n=8+8) 3.25±0.5 1.25±0.5
ANOVA, ¶p=0.00002 and ‡p=0.002 vs PES; TES: tacrolimus-eluting stent; 
SES: sirolimus-eluting stent; PES: paclitaxel-eluting stent; eNOS: endothelial 
nitric oxide synthase; vWF: von Willebrand factor
In vitro vasomotor tone
Data show that bradykinin induced similar levels of endothelium-
dependent vasodilation in the microvasculature, independent of 
stent type and follow-up time. Therefore the five and 28 day data on 
control bradykinin responses were pooled (Figure 5A). Distal to 
BMS, TES and SES, eNOS-blockade resulted in a significant 
impairment in bradykinin-induced dilation both at five and 28 days 
(Figures 5B, C). In the PES area, however, at 5 days L-NAME had 
little effect on the dilation indicating a reduced contribution of NO to 
this response (Figure 5B). This lack of NO-bioavailability was not 
correlated to re-endothelialisation within that stented segment
Figure 4. eNOS staining of porcine coronary arteries at 5-days following stenting with a TES-(A), SES (B), and PES (C) stent. The brown staining,
both on the stent struts and between the stent struts, denotes eNOS positivity (arrows).
Figure 5. Endothelial-dependent dilation to bradykinin and –independemt
to SNAP in small coronary arteries distal to BMS, TES, SES and PES.
No difference was seen between control curves at 5 and 28 days,
therefore, data were pooled (Fig. 5A). eNOS blockade by L-NAME
resulted in a significant reduction in BK-induced dilation. However, at
5 days, the effect of eNOS blockade was impaired distal to PES (Fig.
5B, * P<0.05 vs BMS, # P<0.05 vs TES) as compared to the other
stents. No difference was seen between stents at 28 days (Fig. 5C). No
difference was seen in SNAP responses at 5 or 28 days (5D).
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finding we demonstrated a transient impairment in the NO 
contribution to endothelial-dependent relaxation in the 
microcirculation distal to PES, suggesting abnormal functioning 
eNOS, which was not correlated to re-endothelialisation.
The current study demonstrates that the functional impairment of 
the endothelium can be shown even in presence of apparent 
structural integrity. This finding does not automatically allow to 
dismiss the idea that in atherosclerotic arteries there can be 
instances where the endothelial regrowth is incomplete following 
DES placement. The clinical sequelae of DES are probably resulting 
in individual cases from either structural or functional compromise 
of cellular coverage, or both acting in concert in some other cases.
Re-endothelialisation
The current view is that DES impair re-endothelialisation, supported 
by data from a single institution reporting one human autopsy study 
(coronary), and non-coronary DES implantation in rabbit iliac 
arteries.6-8 Clinical angioscopy and OCT studies imaging DES also 
suggest delayed endothelialisation31-34. But because the resolution of 
angioscopy and OCT are insufficient to detect endothelium on stents, 
we regard those studies as not contributing to the evidence. 
Our results do not support the concept of delayed endothelialisation 
as we show no significant difference in re-endothelialisation between 
DES and BMS as early as five days. This is compatible with previous 
animal studies. In a study by Klugherz et al in a rabbit iliac artery 
model, no evidence of delayed endothelialisation was noted with 28-
day SES compared with polymer-coated stents or BMS.35 In addition, 
in SES and PES a similar degree of re-endothelialisation (>75%) was 
reported in porcine coronary models36-38. Thus, overall, the support 
for the delayed re-endothelialisation concept is equivocal.
Factors influencing endothelialisation
In order to assess the influence of stent and experimental 
conditions on re-endothelialisation, we performed regression 
analysis with stent characteristics (design, drug, strut width, metal 
to surface ratio) and implantation characteristics (balloon-artery 
ratio and acute gain) as model parameters. Design, metal to surface 
ratio, and balloon-artery ratio were independent predictors, while 
drug, strut width and acute gain were not. However, the predictive 
value of the model was rather low (R2=0.4), suggesting that other 
factors, like the kinetics of drug elution and retention in the vascular 
wall should be examined in order to fully explain the data. There 
was no significant correlation between in-stent re-endothelialisation 
and distal microvascular dysfunction.
A recent study indicates that in rabbits, DES do inhibit re-
endothelialisation in previously denuded and injured peripheral 
arteries at “early’ time points (14 days).8 A comparison with 
previous data from the same group indicates that endothelial 
regrowth at 28 days varies considerably for some (but not all) drugs 
and may be subject to experimental conditions.7 In addition, 
a rabbit is much smaller than a swine or a human, and there are 
large species differences of drug stability in plasma and cellular 
sensitivity in culture.39-41 Therefore, predicting which animal model 
mimics closest the human situation is difficult and may well differ 
between drugs.
Endothelial function
While a large percentage of endothelial coverage at early stages is 
considered important by many, it should be clear that this does not 
guarantee full functional integrity of the endothelium.24 In a similar 
regression model as described above, in-stent eNOS expression was 
negatively predicted by morphologic injury score (acute implantation 
damage in combination with chronic irritation by the stent) while 
inflammation was not an independent predictor, nor any angiographic 
parameter, indicating that chronic vascular damage plays an important 
role in the functionality of the endothelial layer after stenting. The 
reduced in-stent eNOS expression observed in our study in PES at 28 
days, when the stent is almost completely re-endothelialised, shows 
that presence of endothelium is not synonymous to endothelial-
function. Indeed, late in-stent endothelial dysfunction may lead to 
increased platelet and leukocyte adhesion which could be one of the 
possible mechanisms responsible for the increased risk for late stent 
thrombosis reported in patients receiving PES.42,43
Microvascular vasomotor function
It has been shown clinically that DES affect vascular function 
immediately distal to stents9,10,44. Our in vitro data indicate that early 
following stent implantation, these effects extend also into the distal 
microvasculature. We used bradykinin, a clinically relevant agent45 
as an alternative to acetylcholine as porcine coronary arteries have 
limited presence of muscarinic receptors and acetylcholine 
therefore does not induce sufficient vasodilation46-48. In the small 
vessels distal to PES we found a significant reduction of the NO 
contribution to the bradykinin-induced dilation at 5-days follow-up. 
This was not due to a reduced smooth muscle cells sensitivity to 
NO, as the response to the exogenous NO donor SNAP remained 
unchanged. In healthy porcine coronary arteries bradykinin-
induced dilation is mediated only by NO or EDHF (endothelium-
derived hyperpolarising factor)28. Our data do indicate that EDHF 
fully compensated for the reduced NO production in PES. 
Interestingly in-stent re-endothelialisation in PES was not correlated 
to distal microvascular dysfunction in PES, nor any other parameter 
studied in regression analysis. It is unclear what is needed to predict 
microvascular dysfunction.
Although PES still showed a reduced in-stent eNOS expression at 
28 days, no overt endothelial dysfunction was seen in the distal 
microvasculature at this time. Thus distal endothelial NO 
production appeared to recover faster than within the stent itself. 
Our in vitro observations are consistent with Togni44 who also 
showed an improvement in endothelial function over time following 
PES implantation in patients.
Conclusion
In this study, all DES and BMS showed similar early re-
endothelialisation. While PES showed a significant effect on 
endothelial function both within the stent as well as in the distal 
microvasculature, we did not find a correlation between the two 
phenomena. These results extend the concept of delayed healing in 
DES to include delayed restoration of function as a possible 
explanation for late unwanted sequelae. Microvascular dysfunction 
does not predict in-stent delayed endothelialisation in this model.
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Objectives The aim of this study was to compare the effects of single drug-eluting stents (DES) on 
porcine coronary function distal to the stent in vivo and in vitro.
Background The mechanism of endothelial dysfunction occurring in human coronary conduit arter-
ies up to 9 months after DES implantation is unknown.
Methods A sirolimus-eluting stent (SES), paclitaxel-eluting stent (PES), and a bare-metal stent (BMS) 
were implanted in the 3 coronary arteries of 11 pigs. After 5 weeks, in vivo responses in distal coro-
nary ﬂow to different doses of bradykinin (BK) and nitrates were measured. In vitro, vasodilation to 
BK and nitrates, as well as vasoconstriction to endothelin (ET)-1 were assessed in both distal coro-
nary conduit and small arteries. In addition, contributions of nitric oxide (NO) and endothelium-
derived hyperpolarizing factors (EDHFs) and cyclic guanosine monophosphate (cGMP) responses to 
BK-stimulation were determined in vitro.
Results Both DES did not alter in vivo distal vasomotion. In vitro distal conduit and small arterial 
responses to BK were also unaltered; DES did not alter the BK-induced increase in cGMP. However, 
after NO synthase blockade, PES showed a reduced BK-response in distal small arteries as compared 
with BMS and SES (p  0.05). The ET-1–induced vasoconstriction and vascular smooth muscle cell 
function were unaltered.
Conclusions In this study of single stenting in healthy porcine coronaries for 5 weeks, SES did not affect 
distal coronary vascular function, whereas PES altered distal endothelial function of small ar-teries under 
conditions of reduced NO bioavailability. Therefore, speciﬁcally the EDH-component of microvascular 
function seems affected by PES. (J Am Coll Cardiol Intv 2010;3:723–30) © 2010 by the American College 
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Percutaneous coronary intervention with stenting is an
established treatment in most patients with obstructive
coronary artery disease. Clinical trials have shown that the 2
ﬁrst-generation drug-eluting stents (DES), the sirolimus-
eluting stent (SES) and paclitaxel-eluting stent (PES),
reduce restenosis and revascularization rates by at least 50%
as compared with bare-metal stents (BMS) (1). Despite
beneﬁcial effects of DES on restenosis, coronary endothelial
dysfunction has been observed in areas adjacent to SES
(2–4) and PES (5) versus BMS, on average 6 months after
implantation. This evidence clearly points toward chronic
coronary endothelial dysfunction in the peri-stent area of
conduit arteries after both types of DES-implantation. In
addition, 9 months after single SES and PES placement,
conduit arterial dysfunction was
shown predominantly in distal
and far distal segments of the
stent (6). This observation sug-
gests that, after single DES, es-
pecially the distal coronary ﬂow
area is at high risk for adverse
effects. However, the exact na-
ture of this distal coronary dys-
function is difﬁcult to study in
clinical settings. Experimental
studies might help to investigate
the underlying mechanism(s) (7).
Overlapping PES implantation
in a porcine model resulted in,
besides distal conduit dysfunction,
abnormal endothelium-dependent
relaxation of distal small arteries
(8). Currently, no data are avail-
able comparing the effects of
single DES on endothelial func-
tion of the coronary microcircu-
lation distal to the stent. In ad-
dition, it is presently unknown
which speciﬁc components of
endothelial function might be
particularly affected. This information is important, be-
cause a functional microvascular endothelium plays a key
role in the regulation of local vascular tone and myocar-
dial perfusion by releasing vasodilating factors, including
nitric oxide (NO) and endothelium derived hyperpolar-
izing factors (EDHFs) (9). The latter is believed to be
more prominent in circumstances of impaired NO-
mediated vasodilatation (10,11).
Consequently, the present study was undertaken to com-
pare the effects of single BMS, SES, and PES on distal
coronary function in healthy pigs (12) with focus on the
microcirculation, in both in vivo and in vitro settings. We
hypothesized that DES implantation would result in distal
endothelium-dependent microvascular dysfunction, evi-
denced by decreased vasodilation and increased vasocon-
striction. Speciﬁcally, we focussed on the NO and EDHF
components of vascular function.
Methods
Coronary intervention. Eleven Yorkshire-Landrace pigs of
either sex (57  4 kg at implantation; 75  7 kg at death)
entered the study. The study was performed in accordance
with the Guide for Care and Use of Laboratory Animals
(National Institutes of Health Publication No. 85-23,
revised 1996), after approval of the local Animal Ethics
Committee.
Animal preparation and stent implantation were per-
formed as described previously (12). In short, 1 day before
surgery animals received 300-mg acetylsalicylic acid and a
loading dose of 300-mg clopidogrel. Under general anes-
thesia, left and right coronary angiography were performed
to select arterial segments of 2.5 to 3.5 mm in diameter in
the left anterior descending, left circumﬂex, and right
coronary arteries. Three types of commercially available
stents were randomly implanted in selected uninjured cor-
onary segments with a balloon/artery ratio of 1:1, such that
each animal received all stents (1 stent/coronary artery) in a
random fashion: a BMS (R-stent Evolution/Prodigy, 316L
stainless steel stent, 15-mm length, 3.0- to 3.5-mm diam-
eter, Orbus MT, Fort Lauderdale, Florida), a SES (Cypher:
DES with 1.4-g/mm2 sirolimus-loading, 316L stainless
steel stent, 13-mm length, 3.0- to 3.5-mm diameter, Cor-
dis, Miami, Florida), and a PES (Taxus: DES with 1.0-g/
mm2 paclitaxel-loading, 316L stainless steel stent, 12-mm
length, 3.0- to 3.5-mm diameter, Boston Scientiﬁc, Natick,
Massachusetts). After repeat angiography, the animals were
allowed to recover and followed for 5 weeks. This period is
believed to result in maximal neointimal thickness after
BMS implantation in animals, comparable to the response
at 6 to 9 months in patients (13). During follow-up, the
animals received 300-mg acetylsalicylic acid and 75-mg
clopidogrel daily.
In vivo coronary function assessment. After 5 weeks,
changes in coronary ﬂow velocities distal to the stent
induced by different agonists were measured with a Doppler
tipped guidewire (FloWire, Volcano Therapeutics, Inc.,
Rancho Cordova, California). Intracoronary ﬂow velocity
measurements were performed continuously, both at stable
baseline hemodynamic status and during intracoronary in-
fusion of the endothelium-dependent vasodilator bradyki-
nin (BK) (0.05 to 1.0 g/kg/min), the endothelium-
independent vasodilating agent sodium nitroprusside (5 to
20 g/kg/min), and at maximal vasodilation to adenosine
(100 g/kg/min) (14,15). The alpha1-adrenoceptor agonist
phenylephrine was co-infused to maintain mean arterial
pressure at approximately 90 mm Hg, while leaving coro-
nary microvascular tone unperturbed (15). Each agonist
Abbreviations
and Acronyms
BK  bradykinin
BMS  bare-metal stent(s)
cGMP  cyclic guanosine
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response curve
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exposed to BK (106 mol/l) with or without pre-incubation
with L-NAME (104 mol/l). The cGMP concentrations
were determined by enzyme-linked immunoadsorbent assay
and expressed as pmol  mg1 protein (17).
Histology. Fixed stented segments were plastic embedded
and stained with hematoxylin-eosin (routine stain) and
resorcin-fuchsin (elastin stain) for quantitative and qualita-
tive analysis. Neointimal thickness at the stent struts and
inﬂammation scores directly adjacent to the struts were
determined (12).
Data analysis. Differences between the stent-types of indi-
vidual outcome variables (procedural, histology data, single
vascular function data, and the like) were assessed with
paired t tests with correction for multiple testing. Statistical
analysis of logarithmic vascular function CRCs was per-
formed with a nonlinear mixed-effects model ﬁt by maxi-
mum likelihood with nested random effects (statistical
program R, version 2.10.1, The R Foundation for Statistical
Computing, Wien, Austria).
In vitro vascular relaxant responses to BK and SNAP
were expressed as percentage of contraction to U46619 and
ET-1, respectively. Constrictor responses were normalized
to 0.1 mol/l potassium chloride. The concentration neces-
sary to produce 50% of its maximal response (pEC50) was
determined for each CRC reaching a maximum, with
logistic function (16,17). Data are given as mean SEM. A
value of p  0.05 was considered statistically signiﬁcant.
Results
Procedural characteristics. Quantitative coronary angiogra-
phy analysis of selected segments revealed no differences in
mean coronary diameter of the 3 stent groups, both before
and immediately after stenting. Also, procedural character-
istics showed no differences in mechanical vessel injury at
stent implantation (Table 1). Furthermore, in a subset of
pigs (n  5), quantitative coronary angiography analysis of
the stented segments was performed 5 weeks after implan-
tation. No signiﬁcant differences in percentage late lumen
loss were observed (BMS vs. SES, PES: 16.8  3.4% vs.
17.7  5.5%, 6.9  1.5%; p  NS).
Effects of DES on distal coronary conduit and small arterial
function. IN VIVO ASSESSMENT. During ﬂow measurements
distal to the stent, no signiﬁcant changes occurred in heart
Table 1. QCA Assessment of Coronary and Procedural Characteristics at the Time of Stent Implantation
Group Pre-Stenting (mm) Post-Stenting (mm) Balloon Size (mm) Max Inﬂation Pressure (atm) BA-Ratio
BMS (n  10) 3.02 0.09 3.15 0.10 3.30 0.09 13.4 1.5 1.09 0.01
SES (n  10) 3.13 0.11 3.29 0.09 3.35 0.10 14.4 1.1 1.07 0.03
PES (n  11) 3.19 0.10 3.37 0.11 3.49 0.11 14.9 1.2 1.09 0.01
Pre- and post-stenting: mean coronary lumen diameter at site of intervention before and directly after stent placement. Balloon size: mean diameter of contrast-ﬁlled balloon during maximal inﬂation. Max
inﬂation pressure: maximal inﬂation pressure used for stent placement.
BA balloon-to-artery; BMS bare-metal stent(s); PES paclitaxel-eluting stent(s); QCA quantitative coronary angiography; SES sirolimus-eluting stent(s).
J A C C :  C A R D I O V A S C U L A R  I N T E R V E N T I O N S ,  V O L .  3 ,  N O .  7 ,  2 0 1 0
J U L Y  2 0 1 0 : 7 2 3 – 3 0
concentration was maintained for 3 min, followed by a 
5-min washout period to allow for restoration of baseline 
ﬂow. The peak-increase in distal coronary ﬂow velocity was 
calculated for each concentration as maximum minus 
baseline.
Tissue collection. All pigs were killed after 5 weeks of 
follow-up. Hearts were immediately excised and collected in 
cold, oxygenated Krebs bicarbonate buffer (16,17). Seg-
ments of epicardial conduit arteries (2 mm diameter), 
starting approximately 0.5 cm distal to the stent and 
segments of epicardial small arteries (approximately 300 m 
diameter) in the speciﬁc distal ﬂow area of the stented 
artery, were isolated and placed in buffer for in vitro 
functional studies. The stented segment was placed in 4%
buffered formaldehyde for histology.
In vitro coronary conduit and small arterial function assessment.
Segments of conduit arteries (approximately 4 mm length) 
were suspended on stainless steel hooks in organ baths. 
Segments of small arteries (approximately 2 mm length) 
were mounted in a Mulvany wire myograph (DMT A/S, 
Aarhus, Denmark). Vascular responses were measured as 
changes in isometric force (16,17).
Both conduit and small arteries were subjected to the 
same experimental protocol. After stabilization, segments 
were exposed to depolarization by 0.1 mol/l potassium 
chloride. Upon wash-out of potassium chloride, after equil-
ibration, in a ﬁrst set of segments, endothelium-dependent 
relaxation to BK (1010 to 106 mol/l) was recorded upon 
pre-constriction with the thromboxane analogue U46619 
(108 to 107 mol/l). To determine NO-dependent and 
-independent contributions to BK-induced relaxation, in a 
second set of pre-constricted segments, the concentration-
response curve (CRC) for BK was constructed after 30 min 
of pre-incubation with 104 mol/l of the NO-synthase 
inhibitor N-nitro-L-arginine methyl ester (L-NAME). 
From a third set, CRCs for endothelin (ET)-1 (1010 to 
107 mol/l) were constructed to study vasoconstriction, 
followed by endothelium-independent but NO-mediated 
vasodilation to S-nitroso-N-acetylpenicillamine (SNAP)
(107 to 106 mol/l).
Cyclic guanosine monophosphate measurements. To study 
BK-induced cyclic guanosine monophosphate (cGMP) pro-
duction, segments of small arteries distal to the stent of a 
subset of pigs (n  5) were nonexposed (control subjects) or
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rate (85  2 beats/min) and mean arterial pressure (92  3
mm Hg) at baseline or during infusion of BK, sodium
nitroprusside, or adenosine. Also, no signiﬁcant differences
in distal vasodilatory responses to BK, sodium nitroprusside,
or adenosine were reported after 5 weeks of BMS, SES, and
PES implantation (Fig. 1).
IN VITRO ASSESSMENT. Contractile responses to potassium
chloride and pre-constriction to U46619 were similar be-
tween stent types, both for conduit and small arteries (data
not shown).
CONDUIT ARTERIES. Segments of coronary conduit arteries
distal to the stent dilated to BK in a dose-dependent
manner (pEC50 BMS vs. SES vs. PES: 8.2  0.2 vs. 8.0 
0.3 vs. 8.0  0.1). Relaxations corresponded with approxi-
mately 70% of the pre-constriction level by U46619, with no
differences between the different stents (Fig. 2A). Pre-
treatment with L-NAME greatly reduced dilation to BK
(p  0.01, L-NAME vs. no L-NAME for all stent-types).
The effect of L-NAME was not different between the stents
(Fig. 2B). The compound ET-1–induced vasoconstriction
in a concentration-dependent manner to 100% of the
response to 0.1 mol/l potassium chloride (pEC50 BMS vs.
SES vs. PES: 7.5  0.1 vs. 7.7  0.1 vs. 7.5  0.1). This
effect was not signiﬁcantly altered by either SES or PES
(Fig. 2C). The exogenous NO-donor SNAP resulted in
vasodilation similar for all stent types (Fig. 2D).
SMALL ARTERIES. Segments of coronary small arteries dis-
tal to the stent dilated to BK in a concentration-dependent
manner (pEC50 BMS vs. SES vs. PES: 8.3  0.2 vs. 8.2 
0.2 vs. 8.0  0.1). Relaxations amounted up to 90% of the
pre-constriction level and were inﬂuenced by stent-type
(Fig. 2E), in that chronic PES implantation caused a
modest rightward shift of the BK-CRC (p  0.01, PES vs.
SES; p  0.1, PES vs. BMS) (Fig. 2E). After pre-
incubation with L-NAME, the BK-CRC was clearly
shifted to the right (p  0.01, L-NAME vs. no L-NAME
for all stent-types) (Fig. 2F). The effect of L-NAME in
small arteries was more modest than in conduit arteries.
This conﬁrms that the NO-independent component of the
BK response in small arteries is more pronounced than in
conduit arteries (16,17). The PES implantation shifted the
BK-CRC in the presence of L-NAME approximately 10
times to the right as compared with BMS and SES (p 
0.02, PES vs. BMS; p  0.02, PES vs. SES) (Fig. 2F).
Thus, small arteries distal of PES showed impaired vasodi-
lation upon incubation with L-NAME (pEC50 BMS vs.
SES vs. PES: 7.6  0.3 vs. 7.9  0.2 vs. 7.0  0.3). The
PES-type of stent speciﬁcally reduced the NO-independent
component of the BK response. The compound ET-1–
induced vasoconstriction in a concentration-dependent
manner up to 150% of the response to 0.1 mol/l potassium
chloride (pEC50 BMS vs. SES vs. PES: 7.7  0.1 vs. 7.6 
0.1 vs. 7.6  0.1), unaffected by stent-type (Fig. 2G). The
exogenous NO-donor SNAP resulted in vasodilation of the
small arteries similar for all stent-types, indicating intact
vascular smooth muscle cell function (Fig. 2H).
Cyclic GMP measurements in distal small arteries. After
BK-stimulation, distal microvascular cGMP levels were 1.95
(0.5 to 11.9) pmol  mg1, 1.01 (0.2 to 2.3) pmol  mg1,
and 1.63 (0.6 to 7.7) pmol  mg1 protein (geometric
mean and range of BMS vs. SES vs. PES; p  NS).
Pre-incubation with L-NAME reduced the microvascular
cGMP content after BK-stimulation by 80.4  7.7% vs.
61.8  22.3% vs. 73.0  6.3%, respectively (p  NS).
Figure 1. In Vivo Coronary Function
Effects of 5 weeks of single stents on baseline (BL), endothelium-dependent (bradykinin [BK]), adenosine (ADO) and endothelium-independent (sodium nitroprus-
side [SNP]) peak increases in coronary ﬂow velocity (CFV) of the distal coronary circulation in vivo (n  5 pigs). BMS  bare-metal stent(s); PES  paclitaxel-elut-
ing stent(s); SES  sirolimus-eluting stent(s).
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These results agree with previously published data on
BK-stimulated porcine coronary small arteries (17).
Histology of stented coronary arteries. Qualitative analysis
showed that the vascular response after stenting followed
patterns typical for BMS (Fig. 3A) and DES (Figs. 3B
and 3C) in pigs (12). The neointima in BMS consisted of
vascular smooth muscle-like cells within a collagenous
matrix largely covered by endothelial cells. The neoin-
tima in DES was similar, including the presence of
endothelial cells in all DES. Typically for DES, the
neointima also contained ﬁbrinoid deposition—a marker
of delayed healing (18)—surrounding the stent struts
(Figs. 3B and 3C). In PES, mitotic ﬁgures characteristic
for paclitaxel were observed (Fig. 3C), whereas SES
showed more inﬂammation resulting in increased neoin-
timal formation on top of the struts (BMS vs. SES vs.
PES: 313  49.3 m vs. 524  82.9 m vs. 268  36.0
m; p  0.01 SES vs. PES). Neointimal thickness was
not signiﬁcantly different among the groups upon exclu-
sion of stents with a high inﬂammation score (BMS vs.
SES vs. PES: 313  49.3 m vs. 355  58.2 m vs.
235  16.6 m; p  NS).
Discussion
In the present study, we compared the effects of ﬁrst-
generation DES on endothelial function of the distal
coronary vasculature with special focus on the microcircu-
lation, in both in vivo and in vitro settings in healthy pigs.
We hypothesized that DES implantation would result in
distal endothelial dysfunction evidenced by decreased vaso-
dilation and increased vasoconstriction. The main ﬁndings
were that after 5 weeks of DES implantation, in vivo
vascular function distal to DES was essentially unaffected.
This was conﬁrmed in vitro, because SES implantation did
not alter BK-mediated vasodilation, whereas PES had only
modest effects. However, under conditions of reduced NO
bioavailability, PES-induced defects in distal microvascular
function in vitro were clearly exposed. These defects were
principally due to impairment of the NO-independent
component of BK-induced vasodilation. Speciﬁcally, endo-
thelial function was affected, because the vasodilation re-
sponse to an exogenous NO donor was unaltered. The
PES-type of stent did not alter the cGMP response upon
BK stimulation in vitro, the key second messenger system of
NO-dependent vasodilation, a ﬁnding in agreement with
the vascular function results.
DES effects on distal coronary function. This study indicates
for the ﬁrst time that the effects of single DES might extend
into the distal coronary microcirculation of healthy pigs.
This conclusion is based on results obtained in vitro in
isolated coronary small arteries. Five weeks after stenting,
microvascular alterations are not primarily induced by cir-
culating concentrations of DES drugs, because 30 days after
DES placement, drug-release from the stent is minimal (1).
Figure 2. In Vitro Coronary Conduit Arterial Function and In Vitro Coronary Small Arterial Function
Effects of 5 weeks of single stents on distal endothelium-dependent (BK, BK after pre-incubation with N-nitro-L-arginine methyl ester [L-NAME]), endothelium-
independent vasodilation (S-nitroso-N-acetylpenicillamine [SNAP]), and vasoconstriction (endothelin [ET]-1) of coronary conduit arteries and small arteries
in vitro (n  11 pigs). Top panels: conduit arteries; bottom panels: small arteries. Concentration-response curves (CRCs) to BK (A, E: p  0.01, PES vs.
SES); CRCs to BK after pre-incubation with L-NAME (B, F: †p  0.02, PES vs. BMS; ‡p  0.02, PES vs. SES); CRCs to ET-1 (C, G); CRCs to SNAP (D, H).
Abbreviations as in Figure 1.
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In addition, in-stent histology showed neointimal healing
for all groups, thereby minimizing ongoing drug release in
the circulation.
A recent pig study already showed abnormal endothelium-
dependent relaxation of distal small arteries after 1 month of
exposure to PES (8). However, in this study overlapping
PES were implanted, creating a more profound local injury
and inﬂammatory reaction contributing to the vasomotor
dysfunction in the peri-stent area as compared with the
present study. Furthermore, with overlapping DES
implantation, additional drug concentrations will be eluted
from the stents, aggravating local side effects. The authors
reported a decreased NO-mediated conduit arterial re-
sponse adjacent to overlapping PES, most likely due to
locally enhanced oxidative stress. However, the mechanisms of
the impaired small arterial responses of the distal perfusion bed
were not examined. Of note, the reported abnormal
endothelium-dependent relaxation of distal small arteries did
not result in enhanced ET-1–induced vasoconstriction (8).
In the present study no clear differences were observed in
distal microvascular functions with BK alone or with
SNAP, either in vivo or in vitro. Only after NO synthase
blockade in vitro, signiﬁcant differences were demonstrated
in microvascular responses of PES-treated coronary arteries.
This suggests that PES speciﬁcally affected the NO-
independent component of BK-induced microvascular en-
dothelial vasodilation (i.e., EDHF) (17). Classically, this
EDHF component can be blocked by applying inhibitors of
small and intermediate conductance calcium-dependent po-
tassium channels (apamin and charybdotoxin) (17). Prelim-
inary data from our laboratory conﬁrm that adding apamin
and charybdotoxin on top of L-NAME fully blocked the
microvascular BK-response after chronic DES-implantation
(data not shown). The EDHFs are known to be of partic-
ular importance in small arteries, although their exact
molecular mechanisms and pathways remain to be unrav-
elled (16,17,19,20). In agreement with an alteration in
EDHF and not in NO, the cGMP-response—the key
second messenger system of NO—was unaltered by PES
in vitro. The PES did not affect ET-1–induced micro-
vascular constriction, possibly because NO and ET-1 are
balanced (21).
The exact molecular mechanisms by which 5 weeks of
single PES resulted in alterations of distal EDHF-mediated
microvascular function cannot be derived from the present
study. However, it is of interest to note that, although both
DES reduce restenosis rates effectively (1), they have dif-
ferent mechanisms of action (18). Accumulation of extra-
cellular reactive oxygen species is a crucial step for
paclitaxel-induced cancer cell death (22). In addition, over-
lapping PES implantation was associated with enhanced
local oxidative stress affecting NO-mediated vasodilation of,
in particular, conduit arteries in the peri-stent area (8).
However, reactive oxygen species increase—in particular, a
rise in hydrogen peroxide—also has been reported to in-
hibit EDHF-synthesis by cytochrome P450 epoxygenases
(17,23,24). Therefore, local vascular accumulation of pacli-
taxel might give rise to local oxidative stress, modifying
Figure 3. In Stent Histology
Representative in-stent histological sections. The BMS shows a well-healed
neointima with vascular smooth muscle cells in a collagenous matrix (A);
SES shows less cellularity and moderate amounts of ﬁbrinoid (red) (B); PES
also shows ﬁbrinoid surrounding the stent struts as well as mitotic spindles
(C, magniﬁcations). All stents were largely covered by endothelium (hema-
toxylin-eosin stain; bar  100 m; magniﬁcation inserts: 2 original
image; white squares: areas of magniﬁcation). Abbreviations as in Figure 1.
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L-NAME.
Study limitations. In the present study, part of the experi-
ments were performed in an in vitro setting. Although in
vitro not all the inﬂuencing factors of in vivo are present,
this speciﬁcally allowed us to examine vascular responses
with and without NO bioavailability in the DES-exposed
coronary vessels of each animal. In the in vivo setting, such
an extensive vasoactive protocol would be hampered both by
the potential systemic effects of NO blockade as well as
BK-induced tachyphylaxis, which needs to be taken into
account when studying vasomotion with and without NO
blockade.
Additionally, the present study reports the in vitro results
of PES in a relatively limited number of pigs that was large
enough to show clear changes like the microvascular re-
sponse to BK after pre-incubation with L-NAME but
might have been too low to draw conclusions on the basis of
a small difference such as the microvascular response to BK.
Conclusions
We compared the functional effects of ﬁrst-generation
single DES on the distal coronary circulation. Particularly
PES might show distal endothelium-dependent microvas-
cular dysfunction, because the loss of local EDHF-mediated
vasodilation eventually might alter the vasomotor balance
and therefore local myocardial perfusion in the in vivo
setting. Our results might be relevant for vulnerable coro-
nary artery disease patients with severe microvascular endo-
thelial dysfunction, given their already existing reduced
microvascular NO-bioavailability. However, the in vitro
observations of the present study warrant further studies to
examine distal vascular alterations caused by PES over time
in more detail as well as at longer follow-up.
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Abstract
Background
DM remains a risk factor for poor outcome after stent-implantation, but little is known if and
how DM affects the vascular response to BVS.
Aim
The aim of our study was to examine coronary responses to bioresorbable vascular scaf-
folds (BVS) in swine with and without diabetes mellitus fed a ‘fast-food’ diet (FF-DM and FF-
NDM, respectively) by sequential optical coherence tomography (OCT)-imaging and
histology.
Methods
Fifteen male swine were evaluated. Eight received streptozotocin-injection to induce DM.
After 9 months (M), 32 single BVS were implanted in epicardial arteries with a stent to artery
(S/A)-ratio of 1.1:1 under quantitative coronary angiography (QCA) and OCT guidance.
Lumen, scaffold, neointimal coverage and composition were assessed by QCA, OCT and
near-infrared spectroscopy (NIRS) pre- and/or post-procedure, at 3M and 6M. Additionally,
polarization-sensitive (PS)-OCT was performed in 7 swine at 6M. After sacrifice at 3M and
6M, histology and polymer degradation analysis were performed.
Results
Late lumen loss was high (~60%) within the first 3M after BVS-implantation (P0.01 FF-DM
vs. FF-NDM) and stabilized between 3M and 6M (5% change in FF-DM, ~10% in FF-NDM;
Neoatherosclerosis development following
bioresorbable vascular scaffold implantation
in diabetic and non-diabetic swine
Nienke S. van Ditzhuijzen¹, Mie Kurata¹, Mieke van den Heuvel¹, Oana Sorop¹, Richard 
W.B. van Duin¹, Ilona Krabbendam-Peters¹, Jurgen Ligthart¹, Karen Witberg¹,
Magdalena Murawska², Brett Bouma³, Martin Villiger³, Hector M. Garcia-Garcia⁴, 
Patrick W. Serruys⁴, Felix Zijlstra¹, Gijs van Soest¹, Dirk-Jan Duncker¹, Evelyn Regar¹,⁵, 
Heleen M.M. van Beusekom¹*
¹ Department of Cardiology, Thoraxcenter, Cardiovascular Research school COEUR, Erasmus 
University edical Center, Rotterdam, The Netherlands; ² Department of Biostatistics, Erasmus 
University Medical Center, Rotterdam, The Netherlands; ³ Wellman Center for Photomedicine, 
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States 
of America; ⁴ Cardialysis B.V., Rotterdam, The Netherlands; ⁵ Dept. of Cardiovascular Surgery, 
University Hospital Zurich, Zurich, Switzerland
* h.vanbeusekom@erasmusmc.nl
Neoatherosclerosis development following BVS implantation in diabetic and non-diabetic swine
161
12
P!0.20). Neointimal coverage was highly heterogeneous in all swine (DM vs. NDM P!0.05),
with focal lipid accumulation, irregular collagen distribution and neointimal calcification. Like-
wise, polymer mass loss was low (~2% at 3M, ~5% at 6M;P!0.20) and not associated with
DM or inflammation.
Conclusion
Scaffold coverage showed signs of neo-atherosclerosis in all FF-DM and FF-NDM swine,
scaffold polymer was preserved and the vascular response to BVS was not influenced by
diabetes.
Introduction
Patients with diabetes mellitus (DM) are generally at risk for worse outcome after stent-
implantation than patients without DM.[1] Due to the complex and multifactorial nature of 
the disease process, including metabolic abnormalities and vascular dysfunction, the vascular 
response to stent-implantation is generally impaired, complicating current stenting strategies.
[2–4]
The everolimus-eluting bioresorbable vascular scaffold (BVS) may offer advantages. It elutes 
everolimus in the first 3 to 6 months after implantation, inhibiting excessive neointimal growth 
[5] and starts losing structural integrity 3 months after implantation,[5] potentially enabling 
vascular function restoration.[6]
Histology in healthy swine demonstrated that struts are covered at 28 days and resorbed 
around 3 years with minimal calcification and inflammation.[7, 8] In selected patients from the 
ABSORB Cohort A (BVS 1.0) and B (BVS 1.1) trials, excellent results for treatment of coro-
nary artery lesions were observed.[9, 10] However, only 3%-20% of the study population suf-
fered DM and no studies were performed in diabetic animals. Thus, little is known about the 
effect of DM on the vascular response to BVS. DM may cause inflammation, which could 
influence scaffold degradation by disregulated acid-base balance or body-temperature.[11]
Animal models reflecting the impact of atherosclerosis and DM can be useful, as they allow 
us to study vascular responses and scaffold degradation in a more complex setting.[12] More-
over, swine can be rendered diabetic and in combination with an atherogenic diet they develop 
atherosclerosis comparable to humans.[13] Scaffolds can be placed in coronary arteries and 
in-vivo sequential intracoronary imaging can be performed by optical coherence tomography
(OCT), polarization-sensitive (PS)-OCT and near-infrared spectroscopy (NIRS). After sacri-
fice, histology and gel permeation chromatography (GPC) can be performed to assess scaffold 
coverage and degradation of the polymer.
We examined the mechanistic and morphological aspects of the coronary response to 
BVS1.1 in DM and non-DM swine fed a fast-food diet (FF-DM, FF-NDM respectively) using 
longitudinal intracoronary imaging and histology.
Materials and methods
Experimental design
The Erasmus MC Animal Ethics committee approved the study, performed in accordance 
with the Guide for Care and Use of Laboratory Animals.[14] Fifteen male [Yorkshire x Land-
race] swine with an age of ~11 weeks and a body weight of ~30kg were included (see S1 File
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for a detailed description). DM was induced by streptozotocin (140mg/kg iv, single dose) in 8 
randomly selected male crossbred swine.[15] During streptozotocin injection, the swine were 
anesthetized with intramuscular azaperone (2 mg/kg, Stressnil, Janssen, Tilburg, The Nether-
lands), followed by intravenous thiopental (15 mg/kg, Nesdonal, Rhone Merieux, Lyon, 
France). The swine were housed in metabolic cages and were fed two fast-food (FF) meals a 
day during which they had access to food for one hour. The FF-diet is a diet containing 10%
sucrose, 15% fructose, 25% (swine) lard, 1% cholesterol and 0.7% sodiumcholate (bile salts). 
The food intake was monitored for each animal separately and titrated to maintain growth at 
~1.5 kg/week.
After 9 months, all 8 FF-DM and 5 FF-NDM received single 3.0x18.0mm Absorb BVS1.1 
implants in 2, and 2 FF-NDM received single Absorb BVS1.1 implants in all 3 coronary arter-
ies to ensure an even amount of scaffolds in FF-DM (N = 16) and FF-NDM (N = 16) (see S1 
File for details about the BVS1.1). One day prior to BVS1.1-implantation the swine received 
300 mg acetylsalicylic acid and a loading dose of 300 mg clopidogrel (Plavix, Sanofi). After an 
overnight fast, the swine were sedated using ketamine/ midazolam (20 mg/kg / 1 mg/kg i.m.) 
and atropine (1mg/30kg i.m.). After induction of anesthesia with thiopental (15 mg /kg i.v.; 
Nesdonal, Aventis), the swine were connected to a ventilator that administered a mixture of 
oxygen and nitrous oxide (1:2 [vol/vol]). Vascular access was obtained with an 8F vascular 
sheath in the carotid artery, 10.000 IU heparin was administered initially and thereafter 5000 
IU of heparin was administered every hour. Anesthesia was maintained using 0.5–2.5 vol% iso-
flurane (Florence, Abbott Laboratories) as guided by hemodynamics and pain reflexes to 
ensure adequate analgesia and sedation. Antibiotic prophylaxis was administered by an intra-
muscular injection of 8 mL 200 mg/mL procaine-benzylpenicillin and 250 mg/mL streptomy-
cin. After BVS-implantation, all swine were treated with clopidogrel (75mg) and acetylsalicylic 
acid (300mg) daily, until the end of the study. The latter also functions as analgesia during the 
post-operative recovery.
Sequential coronary imaging included QCA and OCT pre-, immediately, 3 and 6 months 
(M) post-implantation and NIRS pre-, 3M and 6M post-implantation. PS-OCT was performed 
in N = 3 FF-DM and N = 4 FF-NDM BVS at 6M. 3M imaging was included when pre and/or 
post-implantation imaging were available and 6M imaging was included when pre- and/or 
post—and 3M imaging were available. After the 3M imaging assessment, 3 FF-DM and 2
FF-NDM were sacrificed and after the 6M imaging assessment the remaining swine were sacri-
ficed. After sacrifice, hearts were removed, the coronary tree dissected free and coronary arter-
ies containing BVS randomized to histological (3M N = 5/10, 6M N = 12/22) or GPC analysis 
(3M N = 5/10, 6M N = 10/22) (Fig 1).
Fasting blood samples were obtained at baseline, 3M and 6M to measure glucose, total, 
low- and high-density lipoprotein cholesterol (TC, LDL, HDL) and triglyceride levels. Further-
more, in the FF-DM swine, glucose levels were assessed weekly by 24-hour urine samples. 
When glucose appeared in undiluted urine samples, venous glucose and ketone levels were 
checked via ear vein puncture and a handheld reader. When glucose levels were high (>20 
mmol/L), in combination with ketone production, subcutaneous insulin (approx. 5–15 units 
once daily) was given to eliminate detectable ketone production while maintaining hyperglyce-
mic state.
In-vivo QCA, (PS)-OCT and NIRS analysis
See S1 File for a detailed description of the imaging analyses. Coronary angiograms were 
obtained in two orthogonal views and QCA-analysis was performed (CAAS, version 5.9.2 Pie 
Medical Imaging BV). Mean (LD) and minimal lumen diameter (MLD), scaffold to artery
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12(S/A) ratio, acute gain and late lumen loss (LL) were documented. Longitudinal matching ofOCT pullbacks (C7XR Fourier-Domain, St. Jude Medical) was performed as described previ-
ously using dedicated CURAD analysis software (CURAD BV).[16]
OCT parameters for vascular reaction, including lumen and scaffold dimensions and scaf-
fold strut appearance, apposition, neointimal coverage and coverage morphology were
assessed in 1-mm intervals using off-line OCT analysis software according to previously pub-
lished methodology.[17] In pre-implantation lesions not exceeding the penetration depth of
OCT, plaque burden (PB) was determined. Mean number of discernible struts were docu-
mented immediately post-implantation and at follow-up. Changes in strut appearances were
categorised as preserved, open, dissolved bright, and dissolved black box.[18] Struts were
scored as covered or uncovered and the morphology of the coverage—defined as [SA—LA]
[16]–was described as homogeneous or heterogeneous. Heterogeneous coverage was further-
more described as lipid-laden, calcified, surrounding the struts or subluminal, or mixed
(S1 Fig).[19]
PS-OCT was performed using a prototype imaging system. PS-OCT provides a measure of
tissue birefringence, an optical tissue property that describes the interaction with polarized
light. It grossly relates to microscopic tissue organization, and enables characterization of col-
lagen content and smooth muscle cell (SMC) density in atherosclerotic plaques.[20]
Fig 1. Study design. BVS = bioresorbable vascular scaffold, FUP = follow-up, QCA = quantitative coronary angiography, PS = Polarization
Sensitive, OCT = optical coherence tomography, NIRS = near-infrared spectroscopy, GPC = gel permeation chromatography.
https://doi.org/10.1371/journal.pone.0183419.g001
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NIRS analysis (LipiScan, InfraReDx) was used for lipid core plaque (LCP) characterization.
[21] Lipid-core burden index (LCBI) was documented, indicating high probability that LCP is 
present. To evaluate the agreement between OCT and NIRS for detection of lipid, we com-
pared—per scaffold—the LCBI score to the percentage of OCT cross-sections with lipid-con-
taining morphology.
Ex-vivo degradation analysis
GPC was performed as described previously (see S1 File).[7] Degradation in our model was 
studied in relation to DM, time, inflammation, scaffold recoil, OCT-derived strut appearance 
and pre-implantation plaque burden.
Ex-vivo histological analysis
See S1 File for a detailed analysis. Proximal, middle and distal sections within each BVS were 
obtained. Tissue sections were stained by Hematoxylin-Eosin (HE) as an overview stain, Res-
orcin-Fuchsin for elastin, Alcian-Blue for proteoglycans, Oil-red-O (ORO) for lipids, Picrosir-
ius Red (PSR) for collagen, von Kossa for calcium, and immunohistochemistry for smooth 
muscle cells (aSMA, clone 1A4, Dako, the Netherlands) and leukocytes (CD45, clone MCA 
1447, AbD Serotec, UK). Polarization microscopy was performed to assess scaffold struts.
Histological analysis included neointimal healing and organization, collagen distribution, 
injury and inflammation score, lipid accumulation and presence of calcium classified as sub-
luminal or surrounding struts (S2 Fig).
Statistical analysis
Statistical analysis (SPSS 20.0) entailed the Kolmogorov-Smirnov test for normality of the data. 
Normal distribution was expressed as mean ± standard deviation. Non-normally distrib-uted 
data were presented as median with interquartile range. Comparison of in-vivo imaging 
between FF-DM and FF-NDM was performed by generalized estimating equations (GEE) 
modeling. GEE is a statistical method that accounts for the clustered nature of >1 scaffold ana-
lyzed from one swine, which might result in unknown correlations among measurements 
within these scaffold clusters. A linear response model was applied with an exchangeable struc-
ture for the within-cluster correlation matrix. For repeated measures, GEE modeling was per-
formed using a linear response model with an autoregressive (AR(1)) structure for the within-
cluster correlation matrix. Comparison of ex-vivo GPC between FF-DM and FF-NDM swine 
was performed by independent samples t-test. To assess variable relations, the Spearman cor-
relation coefficient was computed. All statistical tests were 2 tailed, and P<0.05 was considered 
statistically significant.
Results
Plasma measurements
Average TC, LDL and HDL were similar between FF-DM and FF-NDM (TC 18.7±5.0mmol/l 
and 19.0±5.8mmol/l (P = 0.86); LDL 15.1±5.1mmol/l and 15.6±5.1mmol/l (P = 0.75); HDL 5.4
±0.8mmol/l and 5.7±0.7mmol/l (P = 0.13) in FF-DM and FF-NDM respectively). In the
8 swine that received a steptozotocin-injection, DM was successfully induced. Average plasma 
glucose and triglyceride levels were elevated in FF-DM compared to FF-NDM (15.0±7.8mmol/
l vs. 4.5±1.0 mmol/l (P<0.01), 1.1±0.8mmol/l vs. 0.6±0.5mmol/l (P = 0.02), respectively). All
FF-DM swine received insulin in the first 10 weeks after streptozotocin injection and 2 FF-DM
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swine received insulin throughout the entire study based on detectable venous ketone body 
production.”
In-vivo QCA, (PS)-OCT and NIRS
All 32 BVS were successfully implanted with a mean S/A-ratio of 1.1±0.1 in FF-DM and
FF-NDM (P = 0.20).
QCA findings are presented in Fig 2A + 2B and S1 Table. Pre-implantation lesions were 
mild and similar between FF-DM and FF-NDM (P = 0.33). In all swine, mean LD decreased 
from post-implantation to 3M (P<0.01) and remained fairly stable from 3M to 6M (P = 0.34 
and P = 0.54, respectively).
Quantitative OCT findings are presented in Fig 2C–2F and S1 Table. Pre-implantation 
lumen dimensions (LD, LA and MLA) were similar between FF-DM and FF-NDM (P = 0.46,
P = 0.46 and P = 0.74) and pre-implantation %PB was mild (9±2% FF-DM, 10±1% FF-NDM; 
P = 0.58). Scaffolds were implanted according to protocol with an S/A ratio 1.1. Thus, LD 
increased in all swine from pre- to post-implantation (P>0.10). No signs of scaffold damage 
nor procedure-related injury were documented. No edge dissection or thrombus was observed 
and minor tissue prolapse was documented. Mild acute ISA was observed in 2 FF-DM BVS
(mean ISA area 0.26±0.11mm2) and 1 FF-NDM BVS (mean ISA area 0.03mm2; P<0.01). 
From post-implantation to 3M, mean LD, LA and MLA decreased (~60%). At 3M, all ISA 
resolved, no late acquired ISA developed and all struts were covered. Restenosis, however, 
hampered OCT imaging at 3M in one FF-NDM. At 6M, OCT demonstrated a substantial 
neointima with a highly heterogeneous morphology, which was confirmed by histology
(S3 Fig). From 3M to 6M, mean LD, LA, MLA, SD and SA remained fairly stable in all swine 
(Fig 2C–2E; S1 Table)
Changes in coverage morphology. See Table 1 for OCT findings. A heterogeneous mor-
phology predominated in all swine at 3M, with a relatively high prevalence of calcium (25%
(16%; 43%) in FF-DM and 16% (5%; 36%) in FF-NDM; P = 0.49). At 6M, the heterogeneous 
pattern predominated and was mainly characterized by calcium (41% (33%; 66%) in FF-DM 
and 59% (37%; 85%) in FF-NDM) (P = 0.82) (S1 and S2 Videos). Moreover, the accumulation 
of calcium increased (P<0.05), whereas the accumulation of lipid remained moderate (FF-DM 
P = 0.67, FF-NDM P = 0.97).
PS-OCT was only qualitatively analyzed and showed a heterogeneous neointima with 
spots of elevated birefringence (Fig 3E and 3K). Rapid depolarization of the signal was often 
observed, focally (Fig 3F2) and in areas with the appearance of lipid-rich plaque and inflamma-
tion (Fig 3F and 3L).
See S2 Table for NIRS findings. Similar to OCT, the prevalence of lipid was relatively low in 
FF-DM (9/15 BVS) and FF-NDM (3/11 BVS) at 3M with relatively low LCBI scores (3.00
(0.00; 22.50) in FF-DM, 0.00 (0.00; 3.00) in FF-NDM; P = 0.69). From 3M to 6M, the preva-
lence of lipid increased numerically, in FF-DM (6/6 BVS) and FF-NDM (5/8 BVS). Subse-
quently, LCBI scores slightly increased (17.50 (9.75; 26.00) in FF-DM, 6.50 (0.00; 47.25) in 
FF-NDM; P = 0.49).
The association of LCBI-score and percentage of OCT cross-sections with a lipid-laden or 
mixed appearance was modest at 3M (Spearman’s rho 0.397; P = 0.05) but became stronger at 
6M (Spearman’s rho 0.666; P<0.01).
Changes in strut appearance. See S3 Table. The number of discernible struts per OCT 
cross-section was similar post-implantation (8±2 in FF-DM, 8±1 in FF-NDM) and at 3M (8±1 
in FF-DM, FF-NDM) and decreased to 6M (7±1 in FF-DM, 6±2 in FF-NDM). The majority 
kept a preserved box appearance from 3M (79% in FF-DM, 81% in FF-NDM) to 6M (77% in
Chapter 12
166
Fig 2. QCA and OCT analysis results. A+B) Mean lumen diameter (LD) slightly increased from pre-to post-implantation, decreased
from post-implantation to 3M and remained stable from 3M to 6M. Grey: FF-DM, black: FF-NDM.C-E) Mean lumen area (LA), lumen
diameter (LD) and minimal lumen diameter (MLD) increased slightly from pre- to post-implantation. Mean LA, LD and MLD and mean
scaffold area (SA) and scaffold diameter (SD) decreased from post-implantation to 3M and mean LA, LD, MLD, SA, SD and coverage
area (CA) remained stable from 3M to 6M. F) Proximal and distal reference LA slightly decrease from pre- to post-implantation and
stabilized from post-implantation to 3M and 6M.
https://doi.org/10.1371/journal.pone.0183419.g002
Neoatherosclerosis development following BVS implantation in diabetic and non-diabetic swine
167
12
FF-DM, 68% in FF-NDM). Interestingly, a substantial amount of struts appeared as dissolved 
black box at 3M (20% in FF-DM, 18% in FF-NDM) and 6M (22% in FF-DM, 31% in FF-
NDM).[22]
Ex-vivo GPC
See Table 2. The initial Mn, Mw and PDI were 109.55 KDa, 229.68 KDa and 2.10 respectively. 
The initial mass was 8.53±0.08mg in FF-DM and 8.50±0.07mg in FF-NDM. Up to 6M, Mn, 
Mw and PDI decreased and mass loss was low: 5.5±1.9% in FF-DM and 4.3±1.4% in FF-NDM 
(P = 0.28).
There was no relationship between scaffold degradation and DM (P>0.10), or with OCT-
derived pre-implantation %PB (P = 0.22), scaffold recoil (P = 0.59), preserved (P = 0.92), open 
(P = 0.45) or dissolved black box appearance (P = 0.99) at 3M, or at 6M (P = 0.29, P = 0.73
P = 0.27, P = 0.36 and P = 0.64 respectively).
Ex-vivo histology
See Table 2. All struts were covered by neointima 3M post-implantation (FF-DM 0.76
±0.1mm, FF-NDM 0.62±0.1mm; P>0.10). Neointimal organization score was higher at 3M 
than 6M (P<0.01) in FF-DM and FF-NDM (P = 0.14). Injury was moderate. Injury scores 
were 1.30±0.42 and 1.10±0.14 (P = 0.58) at 3M and 1.10±0.13 and 1.04±0.33 (P = 0.74) at 6M 
in FF-DM and FF-NDM, respectively.
Collagen poor regions were observed within the neointima. They contained leukocytes, 
were evident at sites with extracellular lipids and often coincided with calcifications (Fig 4). 
Collagen poor but SMC positive tissue generally contained lipid accumulation (P>0.10 for FF-
DM vs. FF-NDM) (Fig 4G–4I). Mainly intra- and extracellular lipid deposits with few cho-
lesterol crystals were observed and advanced necrotic cores were absent.
Neointimal and peristrut calcifications were observed in FF-DM and FF-NDM (P = 0.04) 
at 3M and 6M (Fig 3, Table 2), with varying size, shape and location between animals, suggest-
ing an inter-animal difference. From 3M to 6M, lipid-accumulation remained (Fig 5) and
Table 1. OCT coverage analysis.
3M 6M P‡
FF-DM FF-NDM P FF-DM FF-NDM P FF-DM FF-NDM
Coverage thickness, mm 0.420.08 0.390.11 0.50 0.390.06 0.410.11 0.59 0.05 0.38
Coverage area, mm2 4.380.48 4.030.67 0.19 4.090.42 4.200.59 0.65 0.03 0.10
Coverage appearance
Homogeneous, % 0 (0;6) 0 (0;4) 0.17 0 (0;0) 0 (0;4) 0.51 0.05 0.09
Heterogeneous, % 100 (94;100) 100 (96;100) 0.17 100 (100;100) 100 (96;100) 0.51 0.05 0.09
Lipid-laden, % 0 (0;12) 0 (0;14) 0.57 6 (6;11) 6 (0;15) 0.97 0.54 0.79
Calcified, % 25 (16;43) 16 (5;40) 0.49 41 (33; 66) 72 (37;87) 0.64 0.01 0.01
Strut area,% 19 (10;31) 13 (0;34) 0.70 29 (13;63) 15 (5;47) 0.49 0.14 0.05
Subluminal,% 3 (0;7) 0 (0;4) 0.51 5 (0;6) 3 (0;29) 0.29 0.49 0.07
Strut area + subluminal,% 0 (0;0) 0 (0;0) 0.55 5 (0;8) 19 (3;29) 0.11 0.09 0.01
Mixed, % 0 (0;7) 0 (0;9) 0.99 22 (12;48) 13 (1;40) 0.71 0.01 0.04
Normally distributed data are presented as meanSD, non-normally distributed data as median (interquartile range). FF-DM = fast-food fed diabetic swine,
FF-NDM = fast-food fed non-diabetic swine, OCT = optical coherence tomography, 3M = 3 months follow-up, 6M = 6 months follow-up.
*P-value for the comparison between FF-DM and FF-NDM swine,
‡P-value for the difference between 3M and 6M.
https://doi.org/10.1371/journal.pone.0183419.t001
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calcifications were observed more frequently subluminally (in 3/5 FF-DM BVS, 6/7 FF-NDM
BVS).
At 6M, signs of myxoid degeneration with lipid accumulation were present (S4 Fig). In 3
BVS (N = 1 FF-DM, N = 2 FF-NDM) thrombus remnants were observed at 6M but not at 3M.
Furthermore, the polymeric scaffold struts demonstrated birefringence with polarized light,
confirming preservation of scaffold struts in all swine.
Discussion
The present study describes the coronary artery response to BVS1.1 in FF-DM and FF-
NDM swine. A remarkable neotintima burden with a highly heterogeneous appearance was
observed in all swine, with lipid accumulation and calcification, indicative for the formation of
Fig 3. (PS)-OCT and corresponding histology at 6M.OCT demonstrated the development of a highly heterogeneous neointima with lipid and calcium
accumulation in FF-DM and FF-NDM swine at 6 months (A, L), which was confirmed by histology (D, I, O, S; Oil-red-O). Phase retardation corresponding
to tissue birefringence (B, M) and depolarization (G, Q) imaged by PS-OCT, demonstrated enhanced birefringence and depolarization (C) in an SMC-poor
area (E; aSMA) with inflammation (F; CD45). Furthermore, PS-OCT demonstrated focal depolarization (H) in a collagen-poor area with loss of structure
and evidence of early necrosis (J, K; HE, PSR).N shows coarse-grained high birefringence in an area with strongly circumferentially organized intimal
SMCs (P; RF); lipid-rich, SMC-poor tissue (T; SMA) exhibits a more finely speckled heterogeneity, associated with a rapid loss of polarization degree (R).
Asterisk (*) indicates guidewire artefact, arrowheads lipid, white lines calcium.
https://doi.org/10.1371/journal.pone.0183419.g003
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neoatherosclerosis. The scaffold polymer was preserved up to 6M, independent of inflamma-
tion or the presence of DM in FF-swine.
Neoatherosclerosis development following BVS-implantation
Interestingly, considerable neointima formation with complete strut coverage was observed in
all swine, independent of the presence of DM. This is relevant, as uncovered struts have been
associated with adverse events like stent thrombosis.[23] However, the neointima was highly
heterogeneous in all swine, with substantial lipid- and calcium accumulation and lack of inti-
mal organization at 6M, consistent with neoatherosclerosis formation. This is of note, as previ-
ously published experimental studies in healthy swine and clinical studies in selected patients
demonstrated a favorable vascular response with rather homogeneous coverage following
BVS-implantation.[7, 10, 24] There are three main differences between our study and the pre-
viously published experimental study by Onuma et al., namely 1: the version of the BVS; 2: the
species in which the majority of the study was performed (miniswine) and 3: the presence of
diabetes and hypercholesterolemia; In addition, we expect that, given the size of the animals in
our study, our stents were implanted more distally.
First, in the histological evaluation of the first-generation BVS, revision 1.0, implanted in
the coronary arteries of healthy Yorkshire x Landrace or Yucatan miniswine of unspecified
age, minor calcifications were observed around the scaffold struts in the majority of BVS as
early as 28 days post-implantation.[7] After an initial increase, the presence of calcifications
decreased to 17.2% between two and four years post-implantation. In our study, implantation
Table 2. GPC and histology results.
3M 6M
FF-DM FF-NDM P FF-DM FF-NDM P
GPC results
BVS evaluated, n 3 2 5 5
Mn, KDa 82.764.36 80.130.85 0.41 67.173.11 65.553.40 0.46
Mw, KDa 159.317.07 160.394.03 0.84 134.552.47 132.238.03 0.56
PDI 1.930.02 2.000.03 0.10 2.010.09 2.020.04 0.84
%Mass loss 2.60.6 2.06.6 0.86 5.51.9 4.31.4 0.28
Histological results
BVS evaluated, n 3 2 5 7
Neointimal thickness, mm 0.760.08 0.620.07 0.13 0.600.06 0.650.11 0.38
Medial thickness, mm 0.060.01 0.060.03 1.00 0.070.02 0.090.03 0.17
Adventitial thickness, mm 0.130.02 0.140.09 0.95 0.100.02 0.110.03 0.32
Scaffold area, mm2 7.200.36 6.530.97 0.50 5.610.73 5.650.63 0.92
Injury sore 1.300.42 1.100.14 0.58 1.100.13 1.040.33 0.74
Inflammation score 0.950.32 0.320.08 0.08 0.220.18 0.300.47 0.71
Lipid accumulation, % 7.2 (5.4;17.3) 3.72.8;5.3) 15.8 (9.5;20.0) (9.0;(0.9;1.4) 0.83 19.5 (15.8;19.8) 9.4 (6.1;24.6) 0.76
Calcium
Surrounding strut,% 88.038.21 94.058.41 0.48 72.5411.63 74.2119.63 0.87
Score per-strut 1.230.24 1.200.14 0.87 0.860.38 0.940.26 0.67
Subluminal, n 2 1 0.79 3 6 0.36
GPC = gel permeation chromatography, Mn = number average molecular weight, Mw = weight average molecular weight, PDI = polydispersity index [Mn/
Mw]. Percentage (%) mass loss = [(Initial mass prior to scaffold implantation [T = 0] (mg)–Found mass (mg)) / Initial mass [T = 0] (mg) x 100].
*P-value for the comparison between FF-DM and FF-NDM swine. Footnotes and the remaining abbreviations are as listed in Table 1.
https://doi.org/10.1371/journal.pone.0183419.t002
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of BVS 1.1 demonstrated calcifications around the majority of scaffold struts at 3M, which
included calcifications of the luminal border at 6M in both FF-DM and FF-NDM swine. Sec-
ond, the majority of swine coronary arteries studied by Onuma et al. were from Yucatan min-
iswine, whereas we studied the coronary arteries of Yorkshire x Landrace swine with a similar
race as the 28-day Onuma data, showing calcifications as early as 28 days. Although strain dif-
ferences have not been described before as cause of a different vascular response to the poly-
mer, this cannot be excluded as a cause for the different vascular response observed between
the study by Onuma et al. and our study. The final main difference between the study by
Onuma et al. and our study is the presence of hypercholesterolemia in all animals, and of DM
in a subgroup, where especially the former seems to drive the response for the vascular
response. Hypercholesterolemia is indeed detrimental to the endothelium, diminishing the
Fig 4. Irregular collagen distribution in the neointima.Collagen poor areas in peri-strut regions and neointima (A, D; Picrosirius Red) often
demonstrated lipid accumulation (B, E; Oil-red-O), and leucocytes (C, F; CD45). Additionally,G (Picrosirius Red) demonstrates a patchy collagen poor
lesion with lipid accumulation (H; Oil-red-O) and smooth muscle cells (I; aSMA). *: strut void, L: lumen.
https://doi.org/10.1371/journal.pone.0183419.g004
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vascular wall barrier-function against excessive uptake of circulating lipids, resulting in 
neoatherosclerosis formation.[25, 26] In humans, calcification is accelerated by young age and 
mechanical stress and this might explain why we found such a high incidence in our swine 
model.[27] While it is not completely clear to what extent our observations can be extrapolated 
to the clinical setting, our observation of considerable neoatherosclerosis formation under diet 
induced dyslipidemia might point at neoatherosclerosis as an important contributor to BVS 
failure at long term, similar to that described for DES and BMS.[28, 29, 30] It might also be in 
line with individual observations of asyptomatic neoplaque rupture after BVS-implantation 
and recently reported cases of BVS thrombosis.[10, 17, 24, 31]
Furthermore interesting is the fact that neoatherosclerosis development was observed in all 
swine, independent of the presence of DM. Kereiakes et al. demonstrated that diabetic patients 
who were receiving insulin treatment had a worse outcome after stent-implantation compared
Fig 5. Corresponding QCA, OCT, NIRS and histology at 6M.QCA (A) demonstrates the scaffolded region (white block), with the yellow line
indicating the region corresponding to the NIRS, (PS)-OCT and histology images (B-G). The NIRS chemogram demonstrates presence of lipid (B),
also observed by OCT (D; arrowheads) that additionally demonstrates the presence of calcium (white circles). The PS-OCT phase retardation image
demonstrates a finely grained pattern (E) consistent with lipid-rich neointima (F; Oil-Red-O) and active inflammation (G; CD45).
https://doi.org/10.1371/journal.pone.0183419.g005
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to those who were not receiving insulin.[32] In our study we did not observe a correlation 
between the amount of insulin given and the development of neoatherosclerosis. Of note, the 
swine receiving the most insulin, were not the swine that developed the worst neoatherosclero-
sis. Even in the two swine that received insulin throughout the entire study, who also received 
the greatest amount of food to ensure a similar growth pattern in all swine, neoatherosclerosis 
development was similar compared to all other FF-DM and FF-NDM swine. Factors such as 
duration of DM and hypertension may attribute to the severity of atherosclerotic disease and 
may therefore attribute to a more human-like evaluation of the coronary vascular healing 
response after BVS-implantation. Moreover, hypertension, not present in the current study, 
has been associated with adverse atherosclerosis-related events in DM patients.[33] Future 
studies assessing the coronary healing response after stent or scaffold-implantation in swine 
should consider using mature swine, and include risk factors such as hypertension to accu-
rately evaluate the coronary vascular healing response to stent-implantation in a model that 
mimics human coronary atherosclerotic disease.
This study presents the first data of neoatheroasclerotic tissue organization characterized 
with PS-OCT. We observed enhanced tissue birefringence in areas with SMC alignment in 
the neointima, as well as in areas with inflammation. Macrophage recruitment in atherosclero-
sis has been associated with formation of cholesterol crystals [34], which are highly birefrin-
gent [35]. The contrast provided by PS-OCT, consisting of birefringence and depolarization, 
reflects tissue organization, which has an impact on structural plaque stability. A fuller under-
standing of the features highlighted by PS-OCT may complete our comprehension of 
neoatherogenesis and its impact on clinical sequelae.
Preserved scaffold integrity
GPC and histology demonstrated preserved scaffold integrity up to 6M after BVS1.1-implanta-
tion in all swine, which was not affected by DM or inflammation. This is expected as the 
scaffold starts losing structural integrity at 3–6 months, and scaffold resorption is driven by 
hydration, rather than inflammation. Although, theoretically, other factors associated with 
inflammation such as deregulated acid-base balance or body-temperature could influence scaf-
fold degradation, this was not seen in the present study.[11]
Interestingly, OCT did demonstrate morphological changes at individual strut levels despite 
preserved scaffold integrity. The OCT classification of strut appearances was developed in the 
ABSORB Cohort A trial to characterize the optical changes of the struts during the process of 
bioresorption.[9] However, preclinical evaluation of BVS1.0 demonstrated full degradation of 
the scaffold struts by GPC, while OCT demonstrated the presence of so-called ‘preserved black 
boxes’ within the vascular wall.[7] As the OCT signal is arising from the interface of structures 
with different optical indices, OCT reflects changes of tissue surrounding the struts, rather 
than changes in strut morphology. This should be kept in mind when interpreting in-vivo clin-
ical and preclinical OCT observations in BVS.
Methodological considerations
Sacrifice was planned for 1/3 of the swine at 3M, and thus the serial BL, 3M and 6M sample 
size was relatively small. The aim of our study, however, was to longitudinally examine mecha-
nistic and morphological aspects of the coronary response to BVS1.1 in FF-DM and FF-NDM 
swine. To accurately assess the mechanistic aspects—e.g. scaffold resorption—at various time 
points, additional planned sacrifice at 3M was beneficial. Furthermore, atherosclerotic lesions 
that developed in FF-DM and FF-NDM swine before scaffold-implantation were relatively 
small. However, distribution and size of the lesions were similar in both groups, allowing for
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adequate comparison of vascular responses following BVS-implantation between FF-DM and
FF-NDM swine.
Conclusions
Scaffold coverage showed signs of neo-atherosclerosis in all FF-DM and FF-NDM swine, scaf-
fold polymer was preserved and the vascular response to BVS was not influenced by diabetes.
Supporting information
S1 Fig. Qualitative OCT analysis of the scaffold coverage. In the top OCT cross-sections of a
homogeneous, heterogeneous, lipid-laden, calcified and mixed appearance of the coverage are
depicted and on the bottom the magnifications. The ‘open’ stars indicate the black boxes of the
scaffold struts at follow-up. The asterix () indicates the guide wire artifact. The arrowheads
indicate the region containing lipid and the drawn white lines indicate calcified regions.
(TIF)
S2 Fig. Schematic representation of histological regions of interest.Within the neointima, 2
specific regions were discerned: para-strut neointima, defined as in contact with the struts,
and subluminal: located near the lumen.
(TIF)
S3 Fig. Restenosis at 3M. Restenosis of a BVS implanted in an FF-NDM swine at 3M. Coro-
nary angiography post-implantation (A) and at 3M (B) demonstrates a significant lumen loss,
with a percentage diameter stenosis (%DS) of 70% which persisted at 6M, (C). At 3M OCT
was not performed as the lesion was considered too tight to allow passage of an OCT catheter
without risk of causing ischemia and all the potential sequelae thereof. Therefore OCT was
restricted to 6M follow-up, the scheduled sacrifice time point. OCT demonstrated a highly
heterogeneous neointima (D), which is confirmed by histology demonstrating a large neointi-
mal burden with calcification subluminal and surrounding the struts (E H&E + F, ORO).
D Lesion = Diameter of the lesion, Ref D Lesion = Reference diameter.
(TIF)
S4 Fig. Organized and non-organized luminal layers in the neointima. The vessels with
well-organized neointimal layers (two arrows in A-D) showed dense elastic fibers (B) with 3
or more layers of ċSMA positive cells (C) without lipid accumulation (D). The unorganized
neointima showed myxoid degeneration (double arrow in E-H) with disarray and low density
of ċSMA positive cells (G). In the same area, lipid accumulation was clearly seen (H). ċSMA:
alpha smooth muscle cell actin, L: lumen, A-D: 3 months DM, E-H: 6 months non-DM, A and
E: H&E, B and F: Resorcin-Fuchsin, C andG: ċSMA, E andH: Oil red O, Scale bar in A -H:
100 μm, insert bar of A and E: 1000 μm.
(TIF)
S1 Table. Quantitative QCA and OCT analysis results.Normally distributed data are pre-
sented as mean ± SD, non-normally distributed data as median (interquartile range).
FF-DM = fast-food fed diabetic swine, FF-NDM = fast-food fed non-diabetic swine,
QCA = Quantitative coronary angiography, OCT = optical coherence tomography,
BVS = bioresorbable vascular scaffold, post = post-implantation, 3M = 3 months follow-up,
6M = 6 months follow-up. P-value for the comparison between FF-DM and FF-NDM swine,
†P-value for the difference between post-procedure and 3M, ‡P-value for the difference
between 3M and 6M.
(DOCX)
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S2 Table. NIRS analysis results. NIRS = Near-infrared spectroscopy, LCBI = lipid core bur-
den index. §P-value for the difference between pre-procedure and 3M. Remaining footnotes 
and abbreviations are as listed in Table 1.
(DOCX)
S3 Table. OCT strut appearance. Percentages are calculated as mean from the total (100%). 
Footnotes and abbreviations are as listed in Table 1.
(DOCX)
S1 Video. 6M OCT pullback of a BVS implanted in a FF-DM swine. OCT imaging at 6M in 
a FF-DM swine demonstrates a highly heterogeneous appearance of the coverage. The red line 
in the longitudinal view of the OCT pullback (middle panel) corresponds to the location of the 
OCT catheter in the 2D pullback (left panel) and 3D pullback (right panel). The asterisk () 
indicates the guidewire artefact, the green line delineates the contour of the lumen area, the 
stars indicate scaffold struts, the arrowheads lipid, the white circles calcium and the red circle 
indicates the marker of the scaffold. Word did not find any entries for your table of contents.
(MP4)
S2 Video. 6M OCT pullback of BVS in an FF-NDM swine. OCT imaging at 6M in an
FF-NDM swine demonstrates a highly heterogeneous appearance of the coverage. The red line 
in the longitudinal view of the OCT pullback (middle panel) corresponds to the location of the 
OCT catheter in the 2D pullback (left panel) and 3D pullback (right panel). The green line 
delineates the contour of the lumen area, the stars indicate scaffold struts, the arrowheads lipid 
and the white circles indicate calcium.
(MP4)
S1 File. Supporting material and methods. Supporting information accompanying the man-
uscript titled: “Neoatherosclerosis development following bioresorbable vascular scaffold 
implantation in diabetic and non-diabetic swine coronary arteries”.
(DOC)
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Background:Westudied the effect of bioresorbable vascular scaffold (BVS) implantation on distal coronary endo-
thelial function, in swine on a high fat diet without (HFD) or with diabetes (DM + HFD).
Methods: Five DM+HFD and ﬁveHFD swine underwent BVS implantation on top of coronary plaques, andwere
studied six months later. Conduit artery segments N5 mm proximal and distal to the scaffold and corresponding
control segments of non-scaffolded coronary arteries, as well as segments of small arteries within the ﬂow-
territories of scaffolded and non-scaffolded arteries were harvested for in vitro vasoreactivity studies.
Results: Conduit segments proximal and distal to the BVS edges showed reduced endothelium-dependent
vasodilation as compared to control vessels (p b 0.01), with distal segments being most prominently affected
(p b 0.01). Endothelial dysfunction was only observed in DM+ HFD swine and was principally due to a loss of
NO. Endothelium-independent vasodilation and vasoconstriction were unaffected. Surprisingly, segments from
themicrocirculation distal to the BVS showed enhanced endothelium-dependent vasodilation (p b 0.01), where-
as endothelium-independent vasodilation and vasoconstriction were unaltered. This enhanced vasorelaxation
was only observed in DM+ HFD swine, and did not appear to be either NO- or EDHF-mediated.
Conclusions: Sixmonths of BVS implantation inDM+HFD swine causes NO-mediated endothelial dysfunction in
nearby coronary segments, which is accompanied by a, possibly compensatory, increase in endothelial function
of the distal microcirculation. Endothelial dysfunction extending into coronary conduit segments beyond the
implantation-site, is in agreement with recent reports expressing concern for late scaffold thrombosis and of
early BVS failure in diabetic patients.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Drug-eluting stents (DES) are widely used for the treatment of ob-
structive coronary artery disease (CAD), including in patients with 
dia-betes mellitus (DM) [1]. However, the use of, in particular ﬁrst 
generation, DES has raised concern regarding long-term endothelial
dysfunction adjacent to the stent including the distal microcirculation
[2,3], which could be related to adverse events including late stent
thrombosis [4]. Second generation DES have partially succeeded in re-
ducing thrombosis, however paradoxical vasoconstriction adjacent to
the stent has still been reported [4–6].
The everolimus-eluting bioresorbable vascular scaffold (BVS) has
been introduced with the aim to provide temporary vessel scaffolding
and to be subsequently resorbed over time with restoration of
vasomotion. Indeed, the ABSORB trials have demonstrated efﬁcacy for
the treatment of simple CAD in selected DM and non-DM patients up
to ﬁve years with some restoration of vasomotion [7–10]. Conversely,
paradoxical vasoconstriction has also been observed within the scaffold
and adjacent segments even at ﬁve years after implantation [7,8],
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indicating persisting impairment of endothelial function. Of concern,
higher rates of BVS thrombosis have recently been reported in unselected
populations and in meta-analyses of all randomized trials up to
24 months after BVS implantation as compared to a speciﬁc second gen-
eration DES [11–13], as well as lack of superior vasomotor reactivity after
36 months [14] and still incomplete vasomotion after 5 years [9]. There-
fore, endothelial dysfunction with its subsequent associated adverse
events still remains an issue, also after BVS implantation. Moreover,
whether BVS affects endothelial function in the distal perfusion territory
of the scaffold is presently unknown. This is of importance since a healthy
microcirculation plays a key role in the regulation of optimal myocardial
perfusion [15], also after percutaneous coronary intervention (PCI).
A signiﬁcant proportion of PCIs involves DMpatients that experience
a higher incidence of treatment failure, including stent thrombosis [1].
Indeed, DM has been shown to be an independent predictor of
revascularisation failure six months after BVS implantation [11]. DM
and endothelial dysfunction are closely related [16]. However, in the
setting of DM, detailed studies of endothelial function of both coronary
macro- and micro-circulation in the restoration phase of the BVS are
currently lacking.
Swine are an excellent model for the evaluation of coronary scaffolds
because of the anatomical similarities between porcine and human cor-
onary arteries [17,18]. In addition, DM-induction in combination with a
high fat diet (HFD) is known to generate atherosclerosis, and speciﬁc
components of endothelial function can be studied to unravel underlying
mechanisms [19,20]. Although the effects of BVS implantation have been
studied in healthy swine, showing resemblance to the human situation
including lack of vasomotion of the scaffold six months after implanta-
tion [17,18], details regarding endothelial function in the restoration
phase in an atherosclerosis model with and without DM are currently
lacking. Consequently, the present study was undertaken to evaluate
in vitro the effect of BVS on adjacent endothelial function, as well as of
thedistalmicrocirculation, sixmonths after implantation in dyslipidemic
swine with or without DM.
1. Methods
1.1. Study device
The ABSORB™ BVS (Abbott Vascular, USA) is a balloon-expandable, fully bioresorba-
ble scaffold that consists of a poly (L-lactide) backbonewith a poly (D,L-lactide) coating in a
1:1 ratio with everolimus.
1.2. Experimental design
The protocol was approved by the local animal ethics committee and the study was
performed according to the National Institutes of Health guide for the care and use of Lab-
oratory animals. The protocol has been described in detail elsewhere [19–21]. In short, ten
male crossbred (Yorkshire × Landrace) swine were fed a cholesterol-rich diet (HFD). Five
animalswere renderedDM(DM+HFD) by a single-dose injection of streptozotocin. After
nine months of atherogenesis, quantitative coronary angiography (QCA) was performed.
All anesthetized swine (isoﬂurane, 1–2.5% v/v) received randomly assigned single 3.0
× 18.0 mm BVS implants in two epicardial coronary arteries with a scaffold to artery
ratio of 1.1 on top of an atherosclerotic lesion, based on the angiogram, with follow up
(FU) of six months. The untreated coronary artery served as a control. After stent implan-
tation, all swine received acetylsalicylic acid (300mg) and clopidogrel (75mg) once daily.
Blood samples were obtained, as published previously [19,20]. Also, plasma von
Willebrand factor (vWf) levels were determined as described previously [22].
At six months FU, QCA was repeated in anesthetized swine (pentobarbital sodium
20 mg ∙kg−1 ∙h−1) and afterwards they were euthanized. The hearts were excised and
placed in Krebs buffer [3,19]. Of each animal, one coronary artery treated with a BVS and
oneuntreated arterywere used. Segments of epicardial conduit arteries (N2mmdiameter)
of a BVS treated artery, located N5 mm proximal or distal to the scaffold's edges, were iso-
lated. Also, segments of the untreated artery at approximately similar locations were ob-
tained. In addition, segments of epicardial small arteries (~300 μm diameter) in the
distal ﬂow area of the scaffold and of a similar location of the untreated control artery
were dissected out for subsequent functional studies. The scaffold, including immediately
adjacent ~5 mm proximal and distal vessel segments, was used in a separate study [21].
1.3. Quantitative coronary angiography
QCA analysis was performed by the Coronary Angiographic Analysis System (CAAS,
version 5.9.2 Pie Medical Imaging BV, The Netherlands). After maximal vasodilation
with isosorbide dinitrate (1 mg/artery i.c.), minimal and maximal lumen diameter were
measured both proximal and distal to the BVS and in corresponding segments of
unscaffolded reference coronary arteries.
1.4. In vitro coronary conduit and small arterial function assessment
Segments of conduit arteries (~4 mm length) were suspended in organ baths. Seg-
ments of small arteries (~2 mm length) were mounted in Mulvany wire-myographs
(DMT, Denmark). Vascular responses were measured as changes in isometric force. Both
conduit and small arteries were subjected to the same experimental protocol as described
previously [3,19]. In short, after determination of the maximal contractile response to
0.1 mol/l potassium chloride (KCl), concentration-response curves (CRCs) were acquired
using separate, in vivo adjacently positioned, segments. Endothelium-dependent relaxa-
tion to bradykinin (BK, 10−10–10−6 mol/l) was recorded upon pre-constriction by the
thromboxane analogue U46619 (10−6 mol/l) in a ﬁrst set of segments. In order to deter-
mine nitric oxide (NO) dependent and NO-independent contributions, in a second set,
theCRC for BKwas constructed after 30minof pre-incubationwith theNO-synthase inhib-
itor N-nitro-L-arginine methyl ester (L-NAME, 10−4 mol/l) to block endogenous NO-
production. From a third set, endothelium-independent but NO-mediated vasodilation to
S-nitroso-N-acetylpenicillamine (SNAP, 10−9–10−5 mol/l) was measured. Finally, CRCs
for endothelin-1 (ET-1, 10−10–10−7 mol/l) were constructed to study vasoconstriction in
a fourth set of vessel segments.
In addition, small arteries were subjected to an extended protocol, due to availability of
more vessel-segments and experimental set-ups, to study endothelial function inmore de-
tail. Additional sets of segmentswere incubatedwith the small conductance Ca2+-activated
K+-channel inhibitor apamin (APA,10−7 mol/l), together with the intermediate conduc-
tance Ca2+-activated K+-channel inhibitor TRAM34 (10−5 mol/l) to block the
endothelium-derived hyperpolarizing factor (EDHF) component of BK-induced relaxation
[23] alone or in combination with L-NAME. This combination of blockers has previously
been shown to almost completely abolish BK-induced vasodilation [19]. All reagents used
were obtained from Sigma-Aldrich, The Netherlands.
1.5. Histology
Finally, conduit arterial segments were formaldehyde-ﬁxed and stained en face with
Oil-red-O (Sigma, The Netherlands) as a macroscopic stain of fat accumulation or stained
with resorcin-fuchsin as a microscopic overview stain. Morphometry of the Oil-red-O
staining was performed by measuring total area and stained area with an image analysis
system (Clemex Technologies Inc., Canada) and data are presented as percentage lipid
area.
1.6. Data analysis
Values are presented as mean ± SEM. Differences between outcome variables were
analysed using paired t-testing, after normal distribution of data was conﬁrmed with
Komolgorov-Smirnov normality test. Vasodilator responses to BK and SNAPwere expressed
as percentage of pre-constriction to U46619. Vasoconstriction to ET-1was normalized to the
response to 0.1mol/l KCl. Statistical analysis of CRCswas performed using two-way ANOVA,
followed by Bonferroni's post hoc correction (StatView). P b 0.05 (two-tailed) was consid-
ered statistically signiﬁcant.
2. Results
2.1. Model characteristics
Both DM+HFD and HFD swine showed elevated cholesterol levels,
and only DM+HFD swine showed high glucose levels [19–21]. Plasma
vWf-levels increased over time in both DM+HFD (0.28±0.02 IU/ml at
implantation; 0.34 ± 0.01 IU/ml at 6 months FU, p b 0.05) and
HFD swine (0.30 ± 0.04 IU/ml at implantation, 0.37 ± 0.02 IU/ml
at 6 months FU, p b 0.05), without a difference between the groups
(p N 0.1).
2.2. QCA analysis
At 6 months FU, calculated mean lumen diameters both proximal
and distal to the BVS were similar between BVS-treated coronaries
and corresponding segments in non-scaffolded coronaries in DM
+HFD and HFD animals (example shown in Fig. 1A). Mean lumen di-
ameters of vessels used in the functional experiments were similar
between groups (DM+HFD proximal to BVS: 4.06± 0.25 vs. Control
proximal: 3.38 ± 0.46 mm; DM + HFD distal to BVS: 2.66 ± 0.26 vs.
Control distal: 2.37± 0.34mm; HFD proximal to BVS: 3.53± 0.42 vs.
Control proximal 3.50 ± 0.04 mm; HFD distal to BVS: 2.09 ± 0.18 vs.
Control distal 2.74 ± 0.41 mm; all, p N 0.1).
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Fig. 1.Representative angiogramwith depicted vessel segments located N5mmproximal (delineated by the dashedwhite lines A–A) and distal (delineated by the dashed red lines C–C) to
the BVS edges (delineated by the dashed yellow lines B–B), or corresponding segments of the reference (control) artery fromwhich themean lumen diameters were calculated (panel A).
Representative segments (opened longitudinally), showing macroscopic fatty streaks, as visualized by en face Oil-red-O staining (panel B), and representative cross-sections (resorcin-
fuchsin staining) showing plaques with different degrees of complexity from DM+ HFD (panels C–J) and HFD (panels K–S) swine. ⁎Indicates plaque. Arrows indicate endothelial
lining.
The effect of BVS implantation on distal coronary endothelial function in diabetic and non-diabetic swine
183
13
2.3. In vitro vascular function
Contractile responses to KCl and U46619 were not signiﬁcantly dif-
ferent between vessel segments of BVS-treated and control coronaries
of DM + HFD and HFD swine, both for conduit and small arteries
(data not shown).
2.3.1. Conduit arteries
DM on top of HFD slightly enhanced BK-induced dilation in con-
trol arteries (Fig. 2). BVS markedly blunted BK-induced vasodilation
in DM+ HFD swine, without altering the BK-response in HFD swine
(Fig. 2). In accordance with previous studies from our laboratory [3],
the BVS-induced attenuation of BK-mediated vasodilation was more
pronounced in distal conduit artery segments as compared to prox-
imal segments (Suppl. Fig. 1). Consequently, Fig. 2 only shows the
responses in conduit artery segments located distal to the BVS, and
vascular function was studied in more detail in these segments.
Responses to SNAP and ET-1 were unaffected by either DM or BVS
as compared to control vessels, indicating a BK-speciﬁc effect
(Fig. 2).
L-NAME reduced BK-induced vasodilation under all conditions
(Fig. 3). However, BVS signiﬁcantly attenuated the surface area
encompassed by the BK-response curves in the presence and absence
of L-NAME in DM + HFD swine, so that the smallest NO-dependent
area under the curve was observed in BVS treated vessels (25 ± 9), as
compared to control vessels (101 ± 18) in DM + HFD swine and
compared to BVS-treated vessels in HFD swine (56 ± 8; both p b
0.05). These observations indicate that loss of NO contributed to the
blunted BK-induced vasodilation in conduit artery segments located
N5 mm distal to the BVS in DM+ HFD swine (Fig. 3).
2.3.2. Small arteries
In HFD swine, BVS did not alter the response to BK in small arter-
ies of the microcirculation distal to the BVS (Fig. 4). However, in HFD
+ DM swine, BVS signiﬁcantly enhanced the response to BK, both
versus its own control and versus the BVS group of HFD swine
(Fig. 4A, E). This difference remained apparent during L-NAME,
TRAM34 and apamin, and the combination of these inhibitors. Inhi-
bition of eNOS, with or without concomitant EDHF blockade, re-
duced the responses to BK, the largest reductions being observed in
the presence of all inhibitors. However, this reduction appeared
smaller in the BVS group of DM+HFD swine, indicating a remaining
non-NO/non-EDHF mediated component of the BK-response, al-
though this failed to reach statistical signiﬁcance (Fig. 4A–H). Re-
sponses to SNAP (Fig. 4I, J) and ET-1 (Fig. 4K, L) were unaltered by
either DM or BVS.
2.4. Histology
The Oil-red-O area was similar in conduit arterial segments
located N5 mm distal to the BVS implant as compared to control coro-
nary conduit arteries in both DM + HFD and HFD swine respectively
Fig. 2. Detailed coronary conduit artery function located N5 mm distal to the BVS and in control arteries, in dyslipidemic swine with or without DM. Figure highlighting the effects of six
months of BVS implantation on BK-mediated vasodilation (A, D), SNAP-mediated vasodilation (B, E), and ET-1 mediated vasoconstriction (C, F) of distal conduit segments of DM+HFD
(A-C) and HFD swine (D-F). Figure also highlighting the effect of DM+HFD on conduit arterial function of control segments (A–C) vs. HFD control segments (D–F). ⁎p b 0.01 DM+HFD
BVS vs. DM+HFDControl; †p=0.051DM+HFDControl vs. HFDControl. BK=bradykinin, BVS=bioresorbable vascular scaffold, DM=diabetesmellitus, ET-1=endothelin-1, HFD=
high fat diet, n = number of animals, SNAP = S-nitroso-N-acetylpenicillamine.
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(DM+HFD: BVS vs. Control: 30±7% vs. 27±8%, HFD: BVS vs. Control:
30± 6% vs. 26± 9%; all p N 0.1). Representative segments are shown in
Fig. 1B.
As published previously [20], plaques with different degrees of
complexity were observed to a similar extent in the coronary conduit
arteries from DM + HFD and HFD swine, with presence of intact
endothelium in both the lesion area as well as in the structurally un-
altered vessel wall. Representative examples are shown in Fig. 1C–J,
K–S. Also, as reported previously [19], coronary small arteries of both
groups showed fatty streak lesions. The effect of BVS implantation on
the atherosclerosis process distal to the BVS was not studied in detail
in the present study.
3. Discussion
In the present study, we evaluated the effects of BVS implantation
on endothelial function in vitro, of the vasculature located in the
proximity (N5 mm from the edges) of the implanted BVS in a dyslipid-
emic swine model with or without DM. We hypothesized that the
coronary circulation distal to the BVS would be at increased risk
for endothelial dysfunction, especially in DM. The main ﬁndings
were that: (i) only in the presence of DM, coronary conduit arteries
showed decreased endothelium-dependent vasodilation, particularly
distal to the BVS. This was principally due to loss of NO-mediated
dilation; (ii) interestingly, the microcirculation within the distal perfu-
sion territory showed slightly enhanced endothelium-dependent vaso-
dilation that appeared to be independent of NO- or EDHF-mediated
mechanisms.
In the present animal model, the high fat diet resulted in a similar
degree of non-obstructive coronary atherosclerosis in DM+ HFD com-
pared to HFD swine [19,20], aswell as increased plasma vWf-levels over
time, indicating systemic endothelial dysfunction associated with CAD
development [24]. In contrast, speciﬁc components of both systemic
and coronary microvascular function were altered only in the presence
of DM, similar to diabetic patients [19,25], making it a relevant model
for the study of coronary interventions in the context of CAD and DM.
BVS implantation within this model resulted in a similar vascular
healing response with or without DM, with a heterogeneous coverage
of the scaffold and a low polymer mass loss of the BVS at six months
[21]. Therefore, the scaffold is likely to be immobile at this time-point
according to prior results [8,18], although we did not perform
vasomotion experiments to conﬁrm this. For the present study, we fo-
cused on coronary vascular function in the segments located N5 mm
from the scaffold's edges.
Fig. 3.NO- and non NO-mediated endothelial function located N5mmdistal to the BVS and in control arteries, in dyslipidemic swinewith or without DM. Figure highlighting the effects of
sixmonths of BVS implantation onNO-mediated endothelium-dependent vasodilation of distal conduit segments of DM+HFD (A, B) and HFD swine (C, D). The grey area in between the
BK and L-NAME curves depicts the speciﬁc contribution of the NO-mediated component of the BK-response. ⁎p b 0.05 area DM+HFD BVS vs. area DM+HFD Control; †p b 0.05 area DM
+ HFD BVS vs. area HFD BVS; ‡p b 0.05 BK vs. BK + L-NAME. Abbreviations as in Fig. 2. In addition: L-NAME = N-nitro-L-arginine methyl ester, NO = nitric oxide.
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Only in swine with DM, we observed impaired coronary conduit
endothelium-dependent vasodilation distal to the BVS. This impairment
is in accordance with previous DES-studies, which also showed
endothelial dysfunction in the peri-stent area, particularly in the distal
segment, 6–16months after implantation, in particular for ﬁrst genera-
tion [2], and less extensively also for second generation [4–6] DES. In ad-
dition, endothelial dysfunction has also been demonstrated adjacent to
the BVS, with signs of improvement up to ﬁve years after implantation
[7–9,14]. Overall, these clinical studies demonstrated impaired adjacent
vasomotion in small groups of both DM and non-DM patients, which
were too limited to examine the subgroup of DM speciﬁcally. However,
a relation between DM and early BVS failure has been observed [11]. In
addition, none of these studies addressed vascular responsiveness of the
untreated vessel as a control. This is relevant since atherosclerosis can
also result in endothelial dysfunction,whichmakes it difﬁcult to directly
relate the observed vascular effects to the intervention per se. In the
present study, six months of BVS implantation without DM did not af-
fect adjacent endothelial function, which is in accordance with the
results found by Gogas et al., one and two years after scaffold implanta-
tion in a healthy porcine model [17]. These observations suggest that
our ﬁndings are speciﬁc to BVS combined with DM. Indeed, DM is
known to complicate PCI success as shown by a reduced clinical
outcome after two years in a large DES-study [26], as well as being an
independent predictor of treatment failure up to one year after BVS im-
plantation [11], highlighting again the interaction of DES, including BVS,
with DM.
Speciﬁcally, in the present study, we showed that the endothelial im-
pairment was caused by a reduced NO-mediated vasodilation. Impair-
ment of NO bioavailability adjacent to DES has been described before
[27]. Increased inﬂammation and oxidative stress due to vascular injury
caused by the procedure, drug or other components of the BVS, have
been proposed as possible mechanisms [27–29]. While everolimus has
been shown to reduce NO-release [30], it is unlikely that the drug is re-
sponsible for this effect six months after implantation, as most of it has
been released from the scaffold after threemonths [31]. Other scaffold re-
lated processes, including a change in regional wall shear stress and the
consequent alterations in local gene expression [32], could also have con-
tributed to the loss of NO synthase activity, although this does not readily
explain why this was observed only in the DM+ HFD-group. Recently,
the AIDA trial was halted after two years due to safety concerns of the
BVS with a higher incidence of scaffold thrombosis as compared to the
metallic everolimus-coated DES [12]. A recent meta-analysis of all
randomized BVS trials to date reported a similar concern for BVS as com-
pared to its DES counterpart in clinical practice [13]. This further indicates
Fig. 4.Detailed coronary small arterial function in the distal perfusion area of the BVS and in control segments, in dyslipidemic swinewith or without DM. Figure highlighting the effects of
BVS on endothelium-dependent BK-induced vasodilation (A, E) after speciﬁc blockers (B, C, D, F, G, H), as well as endothelium-independent SNAP-induced vasodilation (I, J) and ET-1-
induced vasoconstriction (K, L) of segments from the distal coronary microcirculation of DM+ HFD (A, B, C, D, I, K) and HFD swine (E, F, G, H, J, L). Figure also highlighting the effect
of DM+ HFD on BK-mediated small arterial function distal to BVS (A) vs. BVS-treated vessels of HFD swine (E). L-NAME: blockage of endogenous NO (B, F). TRAM+ APA: blockage of
speciﬁc EDHFs (C, G). L-NAME + TRAM+ APA: blockage of both endogenous NO and of speciﬁc EDHFs (D, H). ⁎p b 0.01 DM+ HFD BVS vs. DM + HFD Control; †p b 0.05 DM+ HFD
BVS vs. DM + HFD Control; ‡p b 0.01 DM + HFD BVS vs. HFD BVS. Abbreviations as in Fig. 2. In addition: EDHF = endothelium-derived hyperpolarizing factor, TRAM + APA =
TRAM34 and apamin.
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that not the drug everolimus, but the scaffold and its degradation
products or the resulting pathology may be responsible for the observed
endothelial dysfunction. These effects are thought to extend downstream
through accumulation and diffusionwithin the vasa vasorum, explaining
the more pronounced distal effects. Furthermore, DM is known to be
strongly associated with NO-mediated endothelial dysfunction [16],
although we did not ﬁnd any evidence of DM-induced altered NO-
mediated coronary function within the present model [19,20]. However,
combined effects of both BVS and DM might explain the observed re-
duced NO-availability.
To study the extent of the endothelial dysfunction, we examined
small arterial function in the distal perfusion area of the BVS. Previously,
we and others have reported distal microvascular dysfunction after ﬁrst
generation DES implantation [3,27]. Therefore, the distal microcircula-
tion is considered at increased risk of dysfunction. Surprisingly, we
found an enhanced microvascular endothelium-dependent response,
however only in the presence of reduced NO-mediated conduit endo-
thelial function. This effect can be explained by the assumption that
the distal microcirculation is reacting to the endothelial dysfunction oc-
curring more proximally. Indeed, the coronary microcirculation is
known to enable substantial variations in coronary ﬂow due to several
endothelium-dependent regulatory mechanisms including NO, EDHF,
and prostacyclins [15]. This heterogeneity supports the concept of
compensatorymechanisms that allow substitution of one dilator for an-
other in the presence of disease [33], as shown in the coronary circula-
tion of DM-patients [34]. Therefore, also within the present study, we
propose amechanismof local autoregulation of endothelial function be-
tween coronary conduit and small arteries in which a loss of NO-
mediated component in the conduit artery is compensated for by NO-,
EDHF-, and non-NO/non-EDHF-mediated components in the distal
microcirculation.
3.1. Study limitations
Although the present large animal model with cardiovascular risk
factors and early atherosclerosis does not completely mimic human ob-
structive CAD, it allows extensive functional analysis of early alterations
in coronary vascular function. However, vascular function was only
assessed in vitro. Although it is clear that in vitro several modulators
of vascular tone are altered compared to the in vivo situation, including
autonomic inﬂuences, myocardial metabolism, and blood ﬂow, the
in vitro approach allowed us to examine vascular function in parallel
and in great detail. In an in vivo setting, such extensive vascular function
studieswould be hampered both by the potential systemic effects of the
various compounds as well as by the long half-life of some of the sub-
stances and thus by the interaction of different substances within each
animal. Nevertheless, the results from the present studywarrant further
studies to examine the alterations in endothelial function produced by
the BVS inDM in vivo over an extended period of time, in order to assess
the longitudinal pattern of coronary vascular impairment following BVS
implantation.
A second limitation is that the functional measurements in isolated
coronary vessels did not allowpressureﬁxation of the coronary vascular
bed in situ, precluding detailed quantitative investigation of BVS-
induced alterations in coronary microvascular structure.
3.2. Conclusions
This is the ﬁrst study evaluating the effect of six months of BVS-
implantation on coronary endothelial function in segments proximal
and distal to the BVS. Speciﬁcally, in the presence of DM, coronary conduit
artery segments located N5mmdistal to the BVS, showed decreased NO-
mediated vasodilation. In contrast, the coronary microcirculation in the
distalﬂowarea of the BVS showedenhanced endothelium-dependent va-
sodilation, possibly acting as a compensatory mechanism.
3.3. Perspectives
The present study demonstrates that signiﬁcant endothelial dys-
function is present in epicardial coronary artery segments located
N5 mm proximal or distal to the BVS in diabetic swine on a high fat
diet, as late as 6 months after BVS implantation. These observations
may explain, at least in part, recent clinical studies reporting late scaf-
fold thrombosis after BVS implantation aswell as early treatment failure
up to one year after BVS implantation, particularly in diabetic patients.
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Morbidity andmortality of diabetesmellitus are strongly associatedwith cardiovascular disease including
nephropathy. A discordant tissue renin–angiotensin system (RAS) might be a mediator of the endothelial
dysfunction leading to both micro- and macrovascular complications of diabetes. The elevated plasma
levels of prorenin in diabetic subjects with microvascular complications might be part of this discor-
dant RAS, especially since the plasma renin levels in diabetes are low. Prorenin, previously thought of
as an inactive precursor of renin, is now known to bind to a (pro)renin receptor, thus activating locally
angiotensin-dependent and -independent pathways. In particular, the stimulation of the transforming
growth factor- (TGF-) system by prorenin could be an important contributor to diabetic disease com-
plications. This reviewdiscusses the concept of the prorenin–(pro)renin receptor–TGF-1 axis, concluding
that interferencewith this pathwaymight be anext logical step in the search for new therapeutic regimens
to reduce diabetes-related morbidity and mortality.
© 2008 Elsevier Ireland Ltd. All rights reserved.
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1. Diabetes mellitus and the renin–angiotensin system
Cardiovascular disease, including nephropathy, accounts for 
most of the morbidity and mortality in patients with diabetes mel-
litus (Grundy et al., 1999). Both macrovascular and microvascular 
injury, with endothelial dysfunction as the main initiating event, 
are thought to underlie diabetic disease complications (de Jager
∗ Corresponding author at: Division of Pharmacology, Vascular and Metabolic
Diseases, Room EE1418b, Department of Internal Medicine, Erasmus MC, Dr. Mole-
waterplein 50, 3015 GE Rotterdam, The Netherlands. Tel.: +31 10 7043540;
fax: +31 10 7044733.
E-mail address: a.danser@erasmusmc.nl (A.H.J. Danser).
et al., 2006; Ladeia et al., 2005). Prospective studies have demon-
strated that endothelial dysfunction is highly predictive of future
cardiovascular disease (Schachinger et al., 2000).
The renin–angiotensin system(RAS) is amajor contributor to the
cardiovascular and renal complicationsofdiabetesmellitus (Gilbert
et al., 2003; Hollenberg et al., 2004). While the systemic RAS is
undoubtedly of importance in the regulation of blood pressure and
volume homeostasis, a ‘local’ RAS has been linked to tissue damage
(Danser, 2003). Inhibition of the RAS, by blocking the generation
or action of its end-product angiotensin (Ang) II, with angiotensin-
converting enzyme (ACE) inhibitors andAng II type 1 (AT1) receptor
blockers, respectively, not only improves blood pressure control
but also ameliorates endothelial function and cardiovascular/renal
outcomes in patients with diabetes and nephropathy (Lewis et al.,
0303-7207/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
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2001; Yusuf et al., 2000; Zuanetti et al., 1997). In addition, RAS inhi-
bition is capable of reducing the incidence of new-onset diabetes
(Perkins and Davis, 2008).
Remarkably, the circulating renin levels in diabetic subjects are
low to normal (Danser et al., 1998; Stankovic et al., 2006). The
additional, blood pressure-independent effect of RAS inhibition in
diabetes may therefore point to increased tissue RAS activity in
diabetic patients, e.g. in the vascular wall and kidney. This would
imply that the systemic and tissue RAS are discordant in diabetes
mellitus (Gilbert et al., 2003). The underlying mechanism of this
phenomenon is unknown.
2. Prorenin–(pro)renin receptor–TGF-1 axis
2.1. Prorenin
The components required to synthesize Ang II in multiple tis-
sues are generated at speciﬁc sites in the body: renin in the kidney,
angiotensinogen in the liver, andACEon the cell surface of endothe-
lial and various other cells. With the cloning of the renin gene in
1984, prorenin was proven to be the precursor of renin (Hobart
et al., 1984). A 43-amino acid N-terminal propeptide explains the
absence of enzymatic activity of prorenin as compared to renin.
This propeptide covers the enzymatic cleft and obstructs access
of angiotensinogen to the active site of renin to generate Ang I.
Circulating prorenin is mainly derived from the juxtaglomerular
epithelioid cells of the kidney, although the reproductive organs,
together with the adrenal, eye, and submandibular gland also gen-
erate and release prorenin (Krop and Danser, 2008; Krop et al.,
2008). Prorenin release occurs constitutively, and the prorenin lev-
els in human blood plasma are ≈10-fold higher than those of renin
(Danser et al., 1998). Renin and prorenin levels are highly corre-
lated but do not always alter in parallel (Danser et al., 1998). This
is due, at least in part, to the fact that renin, unlike prorenin, is not
synthesized extrarenally. Consequently, following a nephrectomy,
only prorenin is detectable in blood plasma (Krop et al., 2008).
For unknown reasons, prorenin is elevated in patients with dia-
betes mellitus with microvascular complications (Luetscher et al.,
1985). In fact, this elevation appears to precede the occurrence
of these complications (Deinum et al., 1999). A recent study sug-
gests that the source of the elevated prorenin in diabetesmellitus is
the collecting duct. Unexpectedly, at this site Ang II stimulates the
synthesis of prorenin (Kang et al., 2008), as opposed to its inhibit-
ing effects in the juxtaglomerular apparatus. Furthermore, plasma
prorenin in diabetic subjects was found to correlate with the ren-
ovascular response to captopril (Stankovic et al., 2006). This would
imply a direct effect of prorenin in the renal vascular bed. Taken
together, these ﬁndings suggest that circulating prorenin, in con-
trast to what was originally thought (i.e., that it has no function),
may have some function after all.
An attractivepostulate is that the elevatedprorenin levels india-
betic subjects are responsible for the increased tissue RAS activity
in this disease, thus causing the above-mentioned disease com-
plications (Danser and Deinum, 2005). Supporting evidence for a
local role of prorenin comes fromstudies in transgenic rodentswith
(inducible) prorenin expression in the liver. These animals display
increased tissue angiotensin levels, and cardiac and renal pathology
independently of hypertension (Prescott et al., 2002; Véniant et al.,
1996). However, no clear evidence exists for local prorenin–renin
conversion (Saris et al., 2001a), and infusing prorenin does not
result in the appearance of renin (Lenz et al., 1991). In the absence
of extrarenal renin generation, the question then remains how
proreninmight exert a local effect. The recent discovery of a recep-
tor for both renin and prorenin offers an explanation.
2.2. (Pro)renin receptor
Theheart andvascularwall donot express the reningene. There-
fore, renal renin and/or prorenin need to be taken up from the
circulation to allow Ang I generation in these organs. Simple diffu-
sion cannot explain the renin levels at cardiac tissue sites (Danser
et al., 1994; Katz et al., 1997; van Kesteren et al., 1999), and thus
receptor-mediated uptake mechanisms might be involved (Danser
et al., 1999). Indeed, endothelial cells, cardiomyocytes and car-
diac ﬁbroblasts are all capable of binding and internalizing renin
and prorenin (Admiraal et al., 1999; van Kesteren et al., 1997). At
least two candidate receptors have been proposed: themannose 6-
phosphate/insulin-like growth factor II receptor (M6P/IGF2R) (Saris
et al., 2001a,b; vandenEijndenet al., 2001; vanKesterenet al., 1997)
and the (pro)renin receptor (Nguyen et al., 2002). The M6P/IGF2R
non-selectively binds M6P-containing proteins like prorenin and
renin. However, such binding did not result in Ang II generation,
and it is now believed that the M6P/IGF2R actually is a clearance
receptor for prorenin and renin (Saris et al., 2002).
This leaves the (pro)renin receptor as themost promising candi-
date for speciﬁc tissueuptakeof circulatingprorenin and renin. This
receptor binds prorenin with higher afﬁnity than renin and, unlike
theM6P/IGF2R, it does not internalize these proteins (Batenburg et
al., 2007, 2008). Prorenin binding to the (pro)renin receptor allows
the renin precursor to become catalytically active without prote-
olytic cleavage of the prosegment (Batenburg et al., 2007; Nguyen
et al., 2002;Nurunet al., 2007) (Fig. 1). Such ‘non-proteolytic activa-
tion’ (involving a conformational change of the prorenin molecule)
is also known to occur at low temperature (‘cryo-activation’) and
low pH (‘acid-activation’) (Schalekamp et al., 2008). Apparently,
Fig. 1. Schematic overview of the prorenin–(pro)renin receptor–TGF-1 axis. A 43-
amino acid N-terminal propeptide normally covers the enzymatic cleft of prorenin,
thus obstructing access of angiotensinogen (Aog). (Pro)renin receptor-binding how-
ever induces a conformational change in the prorenin molecule, now allowing
prorenin, like renin, to generate angiotensin (Ang) I from Aog, despite the fact
that the prosegment is still present. In addition, prorenin binding per se (i.e.,
independently of angiotensin generation) activates intracellular signaling path-
ways. Theoretically, a (pro)renin receptor blocker will block both the (pro)renin
receptor-mediated prorenin activation (resulting in angiotensin-dependent effects)
and the direct (pro)renin receptor-induced intracellular signaling (resulting in
angiotensin-independent effects), whereas a renin inhibitor will only block the
angiotensin-mediated effects. ACE, Angiotensin-converting enzyme; AT1R, Ang II
type 1 receptor; (P)RR, (pro)renin receptor, PAI-1 plasminogen-activator inhibitor-1;
TGF-1, transforming growth factor 1.
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binding to the receptor allows the prorenin molecule to undergo
the same conformational change as exposure to low temperature or
low pH. Receptor-mediated, non-proteolytic activation of prorenin
solves the problem related to the absence of prorenin–renin con-
verting enzymes at extrarenal tissue sites: binding of prorenin to
its receptor is apparently sufﬁcient to allow the inactive precursor
to gain full enzymatic activity.
The (pro)renin receptor is a 350-amino acid proteinwith a single
transmembrane domain. Although it was ﬁrst described on cul-
tured human mesangial cells (Nguyen et al., 2002), the C-terminal
part of the receptor had been described earlier as an 8.9 kDa frag-
ment being associated with a vacuolar H+-ATPase (Ludwig et al.,
1998). This part is highly homologous in both mammalian and
non-mammalian species, suggesting that it has an important con-
served function (Burcklé and Bader, 2006). Indeed, inactivation
of the (pro)renin receptor gene before the end of embryogenesis
is lethal in zebraﬁsh (Amsterdam et al., 2004). The extracellular,
prorenin- and renin-binding part of the receptor, retains high simi-
larity between mammals only (Burcklé and Bader, 2006). This part
of the (pro)renin receptor might therefore have developed later in
evolution, for instance because there are advantages upon its bind-
ing with prorenin or renin (Bader, 2007). Interestingly, (pro)renin
receptor expression appears to be upregulated under pathological
conditions, e.g. at cardiac tissue sitesof stroke-prone spontaneously
hypertensive rats on a high salt diet (Ichihara et al., 2006a), and in
the clipped kidneys of Goldblatt rats (Krebs et al., 2007).
After the discovery of the (pro)renin receptor, peptidic antag-
onists were designed based on the idea that the prosegment of
prorenin contains a ‘handle region’ which binds to the receptor,
allowing prorenin to become catalytically active (Ichihara et al.,
2004; Nurun et al., 2007). These antagonists, known as ‘handle
region peptides’ (HRPs), mimic the handle region and thus will
bind competitively to the receptor, thereby preventing receptor-
mediated prorenin activation and reducing tissue RAS activity. In
support of this, HRP infusion normalized the elevated renal Ang
II content in diabetic rats (Ichihara et al., 2004), as well as the
cardiac Ang II content in stroke-prone spontaneously hyperten-
sive rats, without affecting blood pressure (Ichihara et al., 2006a).
Concomitantly, the development of diabetic nephropathy and car-
diac ﬁbrosis were prevented, suggesting that these phenomena
depended on prorenin-induced tissue Ang II generation. Surpris-
ingly however, identical renal effects of HRP occurred in diabetic
AT1a receptor deﬁcient mice (Ichihara et al., 2006b), despite the
fact that in these animals Ang II is no longer able to exert its nor-
mal effects (van Esch et al., 2006). This raises the possibility that
(pro)renin receptor activation also results in Ang II-independent
effects, in other words, that prorenin and renin act as agonists of
the (pro)renin receptor, in addition to their capacity to generate
Ang I when bound to the receptor.
2.3. Angiotensin-independent effects of (pro)renin receptor
stimulation
Experiments with cells expressing the (pro)renin receptor have
conﬁrmed the concept of Ang II-independent effects mediated
via this receptor. Both prorenin and renin were found to acti-
vate mitogen-activated protein kinases (MAPK) in the presence of
RAS blockers (Huang et al., 2006, 2007b; Ichihara et al., 2006b;
Nguyen et al., 2002; Saris et al., 2006). In neonatal rat cardiomy-
ocytes, prorenin-induced MAPK p38 activation resulted in heat
shock protein 27 phosphorylation and an alteration in actin ﬁl-
ament dynamics, potentially affecting cardiac hypertrophy (Saris
et al., 2006). In addition, in mesangial cells renin stimulated
transforming growth factor 1 (TGF-1) production via MAPK
p42/p44, which subsequently resulted in an upregulation of proﬁ-
brotic and prothrombotic molecules like ﬁbronectin, collagen-1,
and plasminogen-activator inhibitor-1 (PAI-1) (Huang et al., 2006,
2007b; Nguyen et al., 2002). Increased expression of TGF-1 is
of particular interest in relation to the disease complications of
diabetes mellitus (Fig. 1). The RAS and TGF- system have been
suggested to act together, providing an ‘emergency response’ to tis-
sue injury (Border and Noble, 1998). However, when this response
is inappropriate, as in diabetes, continued activation of the RAS
and TGF- system leads to progressive tissue injury with ﬁbrosis
and ultimately organ failure (Border and Noble, 1998; Gilbert et
al., 2003). The TGF- system regulates tissue remodeling by stim-
ulation of matrix synthesis and inhibition of matrix degradation
(Border and Noble, 1998). Indeed, overexpression of the TGF- axis
induces hyperplasia, apoptosis and ﬁbrosis (Schulick et al., 1998),
potentially leading to vascular and cardiac dysfunction (Chen et al.,
2007). Furthermore, via upregulation of PAI-1 (Huang et al., 2007a),
thrombotic cardiovascular eventsmay occur, especially in the pres-
ence of a dysfunctional endothelium. TGF-1 also plays a pivotal
role in the pathogenesis of diabetic nephropathy (Sharma et al.,
1997; Yamamoto et al., 1993).
Results from in vivo studies in transgenic rats overexpressing
the human (pro)renin receptor are in agreement with the concept
of (pro)renin-induced, angiotensin-independent effects (Burcklé et
al., 2006; Kaneshiro et al., 2007). The human (pro)renin receptor
binds, but does not activate rat prorenin (Kaneshiro et al., 2007),
and thus rat prorenin will only induce signaling via the human
(pro)renin receptor. Indeed, the plasma and tissue angiotensin
levels of transgenic rats overexpressing the human (pro)renin
receptorwereunaltered.Yet, theseanimalsdisplayed increased lev-
els of aldosterone in blood plasma and of cyclooxygenase-2 in the
renal cortex. Moreover, from the age of 7 months, they developed
hypertension, proteinuria and/or glomerulosclerosis. The latterwas
accompanied by increased MAPK p42/p44 phosphorylation and
TGF-1 expression. HRP prevented the development of glomeru-
losclerosis in human (pro)renin transgenic rats (Kaneshiro et al.,
2007). Moreover, it even reversed the glomerulosclerosis that had
developed in diabetic rats (Takahashi et al., 2007).
In contrast with these observations, glomerulosclerosis did not
occur in transgenic ratswith inducible prorenin expression, despite
the fact that such rats, following induction, displayed a 200-fold
rise in plasma prorenin andwere hypertensive (Peters et al., 2008).
Moreover, HRP blocked neither prorenin binding to cells overex-
pressing the human (pro)renin receptor (Batenburg et al., 2007),
nor prorenin-induced signaling in U937 monocytes (Feldt et al.,
2008a). It was also ineffective in double transgenic rats expressing
both human renin andhuman angiotensinogen (Feldt et al., 2008b),
and in spontaneously hypertensive rats on a normal salt diet (Susic
et al., 2008). Remarkably, in the latter model, it did decrease car-
diac hypertrophy and ﬁbrosis during high-salt conditions (Susic
et al., 2008). Furthermore, HRP bound to cells which expressed a
(pro)renin receptor variant lacking the transmembrane region, so
that binding should actually not have occurred (Feldt et al., 2008a).
Thus, at present it is uncertain to what degree the beneﬁcial in vivo
effects of HRP are solely due to prorenin blockade. Possibly, HRPhas
an alternative, as yet unknown mechanism of action, unrelated to
the (pro)renin receptor, and/or its effectiveness is limited to animal
models with a high prorenin/renin ratio (like in diabetes).
3. Prorenin inhibition
The beneﬁcial effects of ACE inhibitors and AT1 receptor antago-
nists involve interference with the generation or effects of Ang II at
tissue sites (van Kats et al., 1998, 2000). Thus if, as discussed above,
prorenin is a major determinant of tissue angiotensin production,
prorenin is anobviousdrug target. There arepotentially twoways to
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inhibitprorenin:renin inhibitorswill block theenzymatic activityof
prorenin (as present after ‘unfolding’ of the prosegment (Batenburg
et al., 2008; Feldman et al., 2008)), and (pro)renin receptor blockers
will block both the receptor-induced prorenin activation and any
receptor-mediated, angiotensin-independent effects of prorenin
(Fig. 1).
The current RAS blockers (i.e., the ACE inhibitors and AT1
receptor blockers) act downstream of any prorenin-induced Ang
I generation. Since Ang II, like prorenin, stimulates TGF-1, their
beneﬁcial effects in diabetesmight involve, at least in part, a reduc-
tion of TGF-1. Indeed, the ACE inhibitor-induced reduction in
the serum levels of TGF-1 correlated with long-term renopro-
tection in diabetic patients (Sharma et al., 1999). Recently renin
inhibitors have been introduced into the clinical arena. These drugs
act directly at the start of the angiotensin generation cascade, and
the question is whether they will do better than the existing RAS
blockers. The ﬁrst clinical results with the only renin inhibitor
that is currently available, aliskiren, suggest they do. Aliskiren
reduced albuminuria on top of optimal antihypertensive therapy
(including AT1 receptor blockade) in type 2 diabetic subjects with
nephropathy (Parving et al., 2008), and increased renal plasma
ﬂow far greater than any other RAS blocker (Fisher et al., 2008).
To explain these beneﬁcial ﬁndings, one has to assume that renin
inhibitors either block the RAS more effectively or that they exert
additional, unexpected effects, e.g. related to the (pro)renin recep-
tor.
So far, in vitro studies do not reveal any blocking effects of
aliskiren towards the direct effects of renin/prorenin via their
receptor. Aliskiren neither affected the binding of renin/prorenin
to the receptor, nor their signaling cascade following receptor acti-
vation (Batenburg et al., 2008; Feldman et al., 2008; Feldt et al.,
2008a). Aliskiren however did block angiotensin generation by
receptor-bound prorenin (Batenburg et al., 2008). In addition, renin
inhibitors will suppress the consequences of the renin rise that
occurs in response to every type of RAS blocker. During both ACE
inhibition and AT1 receptor blockade this renin rise will result in
the generation of substantial amounts of Ang I, allowing an Ang
II ‘escape’ during ACE inhibition and the stimulation of non-AT1
receptors during AT1 receptor blockade (Danser, 2007). During
renin inhibition however, the continuous presence of the renin
inhibitor prevents such Ang I generation (Danser et al., 2008),
and thus the angiotensin levels will remain low (Fisher et al.,
2008). Therefore, the most important reason for the effectiveness
of aliskiren, particularly on top of maximum doses of other RAS
blockers, appears to be that renin inhibitors offer superior RAS
blockade.
RAS blockers not only cause a rise in renin, but also (although
to a lesser degree) a rise in prorenin (Schalekamp et al., 2008).
One might argue that this would result in increased (pro)renin
receptor activation, thus potentially causing detrimental effects.
However, no such detrimental effects have been observed during
any of the many clinical trials with RAS blockers. A possible expla-
nation for the lack of such effects comes from the work of Schefe
et al. (2006, 2008), who showed that, on activation of the receptor,
the transcription factor promyelocytic zinc ﬁnger is translocated to
the nucleus and represses transcription of the (pro)renin receptor
itself, thus creating a short negative feedback loop. In other words:
high (pro)renin levels, as occurring during RAS blockade, will sup-
press (pro)renin receptor expression, thereby preventing excessive
receptor activation. In fact, diabetic rats treated with aliskiren, dis-
played a decrease in (pro)renin receptor expression (Feldman et
al., 2008), possibly due to the above described feedback mech-
anism. Such downregulation might also explain, at least in part,
the absence of glomerulosclerosis in transgenic rats with inducible
prorenin expression (Peters et al., 2008).
Given the lack of effect of aliskiren versus direct prorenin/renin-
induced effects, (pro)renin receptor blockers would be expected to
exert additional effects on top of renin inhibitors, e.g. they might
induce a (further) reduction in TGF-1 levels. Although the ﬁrst
results with such blockers, particularly in diabetic animals, indeed
look promising (Ichihara et al., 2004, 2006a; Kaneshiro et al., 2007),
the lack of effect ofHRPobserved in animalswith high-renin hyper-
tension (Feldt et al., 2008a,b) suggests thatmorework and/or better
blockers are needed. No clinical data are currently available with
these drugs.
4. Conclusions
The prorenin–(pro)renin receptor–TGF-1 axis is an exciting
new pathway that ﬁnally provides a role for the ‘inactive’ precur-
sor of renin. This is of particular relevance in diabetes accompanied
by microvascular complications given the high prorenin (and low
renin) levels observed in this condition. Why prorenin is elevated
in the ﬁrst place and whether in humans, as in rats (Kang et al.,
2008), it originates in the collecting duct remains to be determined.
Prorenin might be the ‘missing link’ explaining the high tissue RAS
activity and low plasma RAS activity in diabetes. Its local activation
does not require a prorenin–renin converting enzyme (for which
there is no evidence (Saris et al., 2001a)), but simple binding to
a receptor. Renin inhibitors will efﬁciently block any Ang I gen-
eration by receptor-bound prorenin (Batenburg et al., 2008), thus
potentially explaining why they exert effects on top of optimal
therapy with ‘classical’ RAS blockers like the ACE inhibitors and
AT1 receptor antagonists. Renin inhibitors do not interfere with
the direct, angiotensin-independent effects of prorenin mediated
via the (pro)renin receptor. Since the latter involve, among oth-
ers, TGF-1 production (Huang et al., 2007b), a (pro)renin receptor
blocker might theoretically reduce TGF-1 on top of maximal RAS
blockade. This is attractive since combined RAS blockade and TGF-
 inhibition already resulted in enhanced antiﬁbrotic effects (Yu et
al., 2004).
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Urinary renin, but not angiotensinogen or aldosterone,
reflects the renal renin–angiotensin–aldosterone system
activity and the efficacy of renin–angiotensin–aldosterone
system blockade in the kidney
Mieke van den Heuvela,c, Wendy W. Batenburga, Sjaam Jainandunsinga,
Ingrid M. Garreldsa, Jeanette M.G. van Goola, Richard A. Feeldersb,
Anton H. van den Meirackera and A.H. Jan Dansera
Objective To study which renin–angiotensin–aldosterone
system (RAAS) component best reflects renal RAAS activity.
Methods and results We measured urinary and plasma
renin, prorenin, angiotensinogen, aldosterone, albumin and
creatinine in 101 diabetic and nondiabetic patients with or
without hypertension. Plasma prorenin was elevated in
diabetic patients. Urinary prorenin was undetectable.
Urinary albumin and renin were higher in diabetic patients.
Men had higher plasma renin/prorenin levels, and lower
plasma angiotensinogen levels than women. Plasma
creatinine and albumin were also higher in men. Urinary
RAAS components showed no sexual dimorphism, whereas
urinary creatinine and albumin were higher in men.
Angiotensin-converting enzyme inhibitors and angiotensin
II type 1 receptor blockers increased plasma renin and
decreased plasma angiotensinogen, without altering
plasma aldosterone. In contrast, in urine, these drugs
decreased renin and aldosterone without affecting
angiotensinogen. When analyzing all patients together,
urinary angiotensinogen excretion closely mimicked that of
albumin, whereas urinary angiotensinogen and albumin
levels both were 0.05% or less of their concomitant plasma
levels. Thismay reflect the identical glomerular filtration and
tubular handling of both proteins, which have a comparable
molecular weight. In contrast, urinary renin excretion did not
correlate with urinary albumin excretion, and the urinary/
plasma concentration ratio of renin was more than 200
times the ratio of albumin, despite its comparablemolecular
weight. Urinary aldosterone excretion closely followed
urinary creatinine excretion.
Conclusion The increased urinary renin levels in diabetes
and the decreased urinary renin levels following RAAS
blockade, occurring independently of changes in plasma
renin, reflect the activated renal RAAS in diabetes and the
success of RAAS blockade in the kidney, respectively.
Urinary renin, therefore, more closely reflects renal RAAS
activity than urinary angiotensinogen or aldosterone.
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Lippincott Williams & Wilkins.
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Introduction
Urinary angiotensinogen has been suggested to reflect
intrarenal angiotensin (Ang) production, that is, to
provide an indication of the Ang generation at renal
tissue sites [1–6]. A putative site of angiotensinogen
synthesis in the kidney is the proximal tubulus [7].
Urinary angiotensinogen levels are elevated in patients
with chronic kidney disease [1–4], and studies infusing
100mg human angiotensinogen in rats followed by a 5-h
collection of urine did not result in the appearance of
human angiotensinogen in urine [4]. This implies that
urinary angiotensinogen might originate at the proximal
tubulus rather than the circulation. Indeed, given its
molecular weight (65 kD), at most only very modest
amounts of angiotensinogen will be filtered across the
glomerular membrane. Yet, the same applies to albumin
(molecular weight 67 kD), and urinary albumin and
angiotensinogen levels correlated significantly according
to several studies [3,8]. Thus, a careful analysis involving
the simultaneous measurement of both proteins in urine
and plasma, in order to allow a correction for the filtration
of albumin, is warranted.
Alternative markers of intrarenal renin–Ang–aldosterone
system (RAAS) activity might be renin, its precursor
prorenin and/or aldosterone. Diabetic patients display
low-to-normal plasma renin levels [9–10]. Yet their
renal plasma flow response to Ang-converting enzyme
0263-6352  2011 Wolters Kluwer Health | Lippincott Williams & Wilkins DOI:10.1097/HJH.0b013e32834bbcbf
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inhibitors (ACEi) or Ang II type 1 receptor blockers
(ARBs) is greatly enhanced [11–13], so that it has been
postulated that there is an activated RAAS in the diabetic
kidney. Even more intriguing, diabetic patients suffering
from the microvascular complications of this disease have
elevated plasma prorenin levels and the higher these
levels, the worse their retinopathy and/or nephropathy
[9–10,14–15]. Prorenin might even serve as an early
marker of these complications [16]. In rats, the collecting
duct has been reported to be the source of this prorenin
[17] and, unexpectedly, Ang II stimulates prorenin
release in the collecting duct in contrast to its negative
feedback effect on juxtaglomerular renin release. Finally,
aldosterone synthesis is believed to occur in the kidney,
independently of the adrenals, and this renal aldosterone
synthesis is increased in diabetic animals [18].
In the present study, we set out to measure urinary
renin, prorenin, angiotensinogen and aldosterone in non-
diabetic and diabetic patients in order to determine
which of these RAAS components best reflects intrarenal
RAAS activity. We simultaneously measured these com-
ponents in plasma, and we measured creatinine, albumin
and total protein in plasma and urine, to allow a correction
for filtration from blood. Finally, given the well known
sexual dimorphism of renin, prorenin and angiotensino-
gen [19], as well as data indicating that ACEi and/or ARBs
may affect the release of angiotensinogen in urine [1–2],
we evaluated the role of sex and the consequences of
RAAS blockade in our analysis.
Patients and methods
Patients
The experimental protocol of this study was approved
by the Medical Ethical Review Board of the Erasmus
MC. All patients willing to participate and visiting
the outpatient hypertension clinic of the Department
of Internal Medicine of the Erasmus MC between
November 2008 and September 2010 were included.
They were diagnosed with (type 1, n¼ 3 and type 2,
n¼ 40) or without (n¼ 58) diabetes mellitus, and of the
type 2 diabetic patients, 19 were insulin-dependent.
Most patients were hypertensive according to the
European Society of Hypertension/European Society
of Cardiology 2007 guidelines. After written informed
consent had been obtained, body weight, height, BMI,
present medication use, disease duration and disease
complications were recorded. SBP and DBP were mea-
sured with an automatic oscillometric device (Datascope
Accutorr Plus Inc., Montvale, New Jersey, USA) after at
least a 5-min rest in the sitting position. A peripheral
venous blood sample was taken in tubes containing
EDTA (final concentration 6.25mmol/l) and patients
were asked to collect and to hand in a urine portion on
the same day. Plasma was obtained after centrifugation at
3000g for 10min, and both plasma and urine were stored
at �208C until analysis.
Biochemical measurements
Plasma and urine concentrations of sodium, total protein,
albumin and creatinine were measured at the clinical
chemical laboratory of the Erasmus MC using standard
protocols.
Plasma renin was measured with a commercial immuno-
radiometric kit (Renin III; Cisbio,Gif-sur-Yvette, France).
Total plasma renin was determined simultaneously with
the same kit after the induction of a conformational
change in the prorenin molecule with aliskiren
(10mmol/l for 48 h at 48C), which enabled its recognition
by the active site-directed radiolabeled antibodies
applied in the Cisbio kit [20]. Subtraction of the renin
concentration from the total renin concentration yielded
the prorenin concentration. The detection limit of this
assay is 1 pg/ml. The urinary renin concentrations were
often below this detection limit. Therefore, urinary renin
was measured with the more sensitive enzyme-kinetic
assay (EKA), that is, by quantifying Ang I generation
in the presence of excess sheep angiotensinogen [21].
Urinary total renin was determined after incubation with
trypsin coupled to Sepharose [22]. The detection limit of
the EKA is 0.05 ng Ang I/ml per hour, and the Ang I-
generating activities were converted to renin concen-
trations based on the fact that 1 ng Ang I/ml per hour
correspondswith 2.6 pghuman renin/ml [23]. In a selected
set of urine samples, prorenin was also measured with
a direct prorenin assay (Molecular Innovations, Novi,
Michigan, USA), making use of an antibody that
recognizes an epitope near prorenin’s cleavage site.
Urine was concentrated five-fold with Amicon Ultra-10
centrifugal filter devices (Millipore, Cork, Ireland) before
applying the samples in the assay. The detection limit
of the direct prorenin assay under these conditions was
2 pg/ml.
Angiotensinogen in plasma and urine was measured
as the maximum quantity of Ang I that was generated
during incubation with excess recombinant renin [24].
The detection limit of this assay is 0.50 pmol/ml.
Aldosterone was measured by solid-phase radioimmuno-
assay (Diagnostic Products Corporation, Los Angeles,
California, USA), with detection limit of 25 pg/ml [25].
Statistical analysis
Datasets were complete for virtually all parameters.
Only in a few cases, due to technical reasons, one or
two measurements were missing. Data are expressed
as mean�SD or geometric mean and range. In case of
nonnormal distribution, data were logarithmically trans-
formed before analysis. Levels that were below the
detection limit were taken to be equal to the detection
limit to allow statistical evaluation. The estimated
glomerular filtration rate (eGFR) was calculated using
creatinine clearance according to the simplified
Modification of Diet in Renal Disease formula [26].
Univariate linear associations between the urine/plasma
2148 Journal of Hypertension 2011, Vol 29 No 11
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concentration ratios of the various parameters were
assessed by calculating Pearson’s coefficient of corre-
lation. Differences between groups were evaluated
by Student’s t-test. A P value less than 0.05 was
considered significant. Statistical analysis was performed
with the SPSS 7.0 package (SPSS Inc., Chicago, Illinois,
USA).
Results
Patient characteristics, markers of renal function and
RAAS components in plasma and urine are presented
in Tables 1 and 2. On average, patients were middle-
aged, and approximately 60% had secondary cardio-
vascular complications such as nephropathy, retinopathy,
neuropathy, coronary artery disease and peripheral
vascular disease. Almost 90% of the patients used anti-
hypertensive medication consisting of (combinations of)
renin–Ang system (RAS) blockers (71%), diuretics
(52%), calcium antagonists (51%), b-blockers (30%),
mineralocorticoid receptor antagonists (13%), a-adreno-
ceptor blockers (11%) and other antihypertensives
(centrally acting antihypertensives or direct vasodilators,
2%) (Table 3).
In urine, the EKA results before and after trypsin
activation of prorenin were identical. This suggests that
urine does not contain prorenin. Measurements with
a direct prorenin assay in five-fold concentrated urine
samples (n¼ 10) confirmed this view. To rule out the
possibility that urinary prorenin had been converted to
renin, either in vivo or during storage and handling of
the samples, recombinant human prorenin was added
to urine (approximately 50 pg/ml) and incubated at 4,
22 or 378C for 22 h maximally (n¼ 3 for each condition).
At 4 and 228C, maximally approximately 5% of prorenin
was found to become recognizable as renin (Fig. 1, left
andmiddle panel), whereas at 378Cprorenin was found to
disappear without becoming recognizable as renin (Fig. 1,
right panel). Importantly, at 4 and 228C, the sum of renin
and prorenin (i.e. total renin) remained unaltered over the
entire 22-h period, whereas at 378C total renin decreased
with a half-life of 102� 24 h. These data support the
concept that at lower temperatures, the prorenin proseg-
ment unfolds from the enzymatic cleft, allowing prorenin
to become recognizable in a renin assay, although the
prosegment is still present. This conformational change is
reversible and, at higher temperatures, the equilibrium
shifts into the direction of the closed conformation.
Clearly, therefore, at 378C, when there is no rise in renin,
the prorenin disappearance is due to metabolism. Such
metabolism also occurred when studying the fate of
renin at 378C (n¼ 3, data not shown). Taken together,
these data suggest that the absence of prorenin in urine is
not due to its rapid conversion to renin, either in vivo
or in vitro. Consequently, Table 2 only shows urinary
renin levels. Ta
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Diabetes mellitus
Diabetic patients were older (P< 0.01), more obese
(P< 0.05) and displayed a lower DBP (P< 0.01)
and eGFR (P< 0.05) than nondiabetic individuals (Tables
1 and 2). In addition, urinary albumin levels were higher in
diabetic patients (P< 0.01). PlasmaRAAScomponents did
not differ between diabetic and nondiabetic individuals,
with the exception of prorenin that was almost doubled in
diabetic patients (P< 0.01). In urine, renin was twice as
high in diabetic patients (P< 0.01), whereas all other
RAAS components were identical in the two groups.
Importantly, the use of antihypertensive medication
was identical in both groups (Table 3).
Sex
Men and women displayed the well known differences
with regard to height, weight and creatinine (P< 0.01 for
all, Table 1). In agreement with previously published
data [19], men had higher plasma renin and prorenin
levels and lower plasma angiotensinogen levels (P< 0.05
for all). Remarkably, despite these differences in plasma
levels, urinary RAAS component levels in men and
women were identical (Table 2). Men had higher urinary
levels of total protein, albumin and creatinine (P< 0.05
for all). They also used more antihypertensive medi-
cation (P< 0.05, Table 3).
Use of angiotensin-converting enzyme inhibitors and/or
angiotensin II type 1 receptor blockers
Weight (P< 0.05), plasma creatinine (P< 0.01), SBP
(P< 0.05) and DBP (P< 0.01) were higher in patients
using ACEi and/or ARBs, whereas eGFR was lower
(P< 0.01, Tables 1 and 2). On top of these two blockers,
these patients used significantly more antihypertensive
medication (P< 0.01) than patients not using ACEi or
ARBs (Table 3). As expected, the use of ACEi and/or
ARBs was accompanied by higher plasma renin levels
(P¼ 0.08) and lower levels of plasma angiotensinogen
and urinary aldosterone (P< 0.05 for both). Plasma
aldosterone levels tended to be decreased. Remarkably,
urinary renin was lower during the application of ACEi
and/or ARBs (P< 0.05).
Correction for urinary creatinine levels
Previous studies expressed their urinary RAAS com-
ponent, albumin and total protein levels as per gram
creatinine. In the present cohort, this resulted in angio-
tensinogen [geometric mean (range) 0.9nmol/g (0.2–10)];
albumin [14.2mg/g (1.5–1586)]; total protein [118mg/g
(9–2170)] and aldosterone [55ng/g (1–1256)] levels that
were in the same range as those reported earlier [1,3,8].
Urinary renin levels ranged from 0.06 to 433ng/g (geo-
metric mean 1.12). The results of subdividing the creati-
nine-correcteddata according to thepresenceor absence of
diabetes mellitus, sex or RAS blocker treatment were
identical to those of the subdivisions described above
without the correction for creatinine (data not shown).Ta
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Origin of urinary renin–angiotensin–aldosterone
system components
Given their comparable molecular weight, we first com-
pared the urine/plasma concentration ratios (�100%) of
albumin (geometric mean 0.026, range 0.004–2.6), angio-
tensinogen (geometric mean 0.050, range 0.014–0.246)
and renin (geometric mean 6.2, range 0.13–4300), and
second those of aldosterone (geometric mean 78, range
12–868) and creatinine (geometric mean 9.3, range 1.4–
46). This was done based on the assumptions that, first,
urinary albumin and creatinine are plasma-derived and,
second, the urine/plasma concentration ratio provides an
indication of urinary excretion. Figure 2 (panels a and c)
and Table 4 show that the ratios of albumin and angio-
tensinogen were correlated (r¼ 0.28, P< 0.01) in contrast
to those of albumin and renin (r¼�0.10, P¼NS).
When replacing albumin by total protein (geometric
mean urine/plasma concentration ratio� 100% 0.14,
range 0.02–2), the findings were identical (r¼ 0.35,
P< 0.01 for angiotensinogen; r¼�0.14, P¼NS for
renin) (Table 4 and Fig. 2b and d).
Moreover, the urine/plasma concentration ratios of
aldosterone and creatinine correlated highly significantly
(r¼ 0.55, P< 0.01) (Fig. 3). The urine/plasma concen-
tration ratio of aldosterone did not correlate with that of
Table 3 Antihypertensive medication use in patient (sub)groups
Antihypertensive
treatment
All
(n¼101)
No diabetes
(n¼58)
Diabetes
(n¼43)
Men
(n¼55)
Women
(n¼46)
ACEi/ARB yes
(n¼72)
ACEi/ARB no
(n¼29)
RAS-blocker 72 44 28 43 29 72 0
Diuretic 53 33 20 30 23 46 7
Calcium antagonist 52 34 18 32 20 31 11
b-Blocker 30 13 17 20 10 22 8
Mineralocorticoid receptor antagonist 13 9 4 10 3 12 1
a-Adrenoceptor blocker 11 8 3 7 4 8 3
Other 2 2 0 1 1 2 0
Number of different antihypertensive drugs (n)
0 12 4 8 3 9 0 12
1 19 9 10 9 10 13 6
2 24 17 7 13 11 15 9
3 25 17 8 16 9 23 2
4 15 7 8 10 5 15 0
5 6 4 2 4 2 6 0
Mean�SD 2.3�1.4 2.4�1.3 2.1�1.5 2.6�1.3 1.9�1.4M 2.8�1.2 1.0�1.0#
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; RAS, renin–angiotensin system. MP<0.05 vs. comparator group. #P<0.01
vs. comparator group.
Fig. 1
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albumin (r¼�0.08, P¼NS) or total protein (r¼ 0.09,
P¼NS), whereas the urine/plasma concentration ratio of
creatinine did not correlate with that of angiotensinogen
(r¼ 0.01, P¼NS) or renin (r¼ 0.05, P¼NS). Finally,
eGFR correlated negatively with the urine/plasma con-
centration ratios of both albumin (r¼�0.44, P< 0.01)
and angiotensinogen (r¼�0.32, P< 0.01), but not that
of renin (r¼ 0.13, P¼NS) (Fig. 4).
Taken together, these data indicate that urinary angio-
tensinogen excretion closely mimics urinary albumin
(and total protein) excretion, and that urinary aldosterone
excretion mimics urinary creatinine excretion. Urinary
renin excretion does not resemble the excretion of any of
these components.
Discussion
This article is the first to show that urinary renin levels
in humans do not parallel plasma renin levels nor follow
the urinary albumin excretion pattern. Urinary renin
levels are elevated in diabetic patients, in parallel with
the putative activation of the renal RAAS in diabetes,
and treatment with ACEi and/or ARBs decreased urinary
renin levels, as opposed to the well known increase
in plasma renin that occurs during such treatment. The
latter is the consequence of interference with the nega-
tive feedback loop between Ang II and juxtaglomerular
Fig. 2
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Correlations between the urine/plasma concentration ratios of albumin [a (r¼0.28, P<0.01); c (r¼�0.10, P¼NS)] or total protein [b (r¼0.35,
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Table 4 Pearson’s coefficient of correlation
Urine/plasma
concentration ratios
Albumin Total protein Creatinine
r P r P r P
Renin �0.10 0.35 �0.14 0.17 0.05 0.65
Angiotensinogen 0.28 <0.01 0.35 <0.01 0.01 0.93
Aldosterone �0.08 0.46 0.09 0.42 0.55 <0.01
Correlation describing the relationship between the urine/plasma concentration
ratios of renin–angiotensin–aldosterone system components and those of albu-
min, total protein and creatinine.
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renin release. As the opposite occurs at the site of the
collecting duct [17,27], the decrease in urinary renin
during treatment with ACEi and/or ARBs might reflect
the consequence of Ang II blockade at the site of
the collecting duct. Possibly, therefore, urinary renin
originates at this location and as such reflects renal RAAS
activity.
In agreement with previous studies [3,8], urinary
angiotensinogen excretion paralleled urinary albumin
excretion. Not only did their urine/plasma concentration
ratios mimic each other but their levels in urine,
expressed as a percentage of their levels in plasma,
were also identical. Moreover, their fractional excretion
(100%�urinary/plasma concentration ratio of albumin
or angiotensinogen divided by the urine/plasma con-
centration ratio of creatinine) was identical: 0.0003%
(0.00003–0.08) for albumin vs. 0.0005% (0.0001–0.007)
for angiotensinogen. Our data, thus, support the concept
that only very modest amounts of large molecular weight
proteins such as angiotensinogen and albumin will be
filtered across the glomerular membrane (or, more likely,
that angiotensinogen and albumin, once filtered, are
largely reabsorbed in the tubules [28]): the urinary angio-
tensinogen and albumin levels were more than 2000-fold
lower than those in plasma. A previous study in rats,
infusing human angiotensinogen, did not detect human
angiotensinogen in urine [4]. However, the authors
performed a western blot analysis with 0.1ml plasma
vs. 1.5ml urine. Given the concentration difference of
more than three orders of magnitude between plasma and
urine, the application of a 15-fold larger urine sample will
Fig. 3
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have been insufficient to accurately measure human
angiotensinogen in urine. Consequently, the lack of
human angiotensinogen in urine under those conditions
cannot be taken as evidence that there is no filtration of
circulating angiotensinogen. Obviously, given its close
correlation with albumin, urinary angiotensinogen will
reflect both renal dysfunction and the beneficial effects of
RAS blockade – hence, also its negative correlation with
eGFR in this and a previous study [1]. In other words,
urinary angiotensinogen levels are likely to provide the
same information as urinary albumin levels and, as such,
are a valid biomarker of renal dysfunction. In our study,
nondiabetic individuals, women and patients not using
ACEi or ARBs had higher plasma angiotensinogen
levels, which is in full agreement with previous reports
[19,25]. However, these three groups also displayed the
lowest urinary albumin levels and, as a consequence, their
urinary angiotensinogen levels were not different from
the levels in their comparator groups (diabetic patients,
men and users of ACEi and/or ARBs).
Unexpectedly, urine did not contain detectable amounts
of prorenin. This was not due to prorenin–renin con-
version in urine, either in vivo (at 378C) or ex vivo (at 4
or 228C). As plasma prorenin levels are much higher
than plasma renin levels, this finding, combined with
the comparable molecular weights of renin (48 kD),
prorenin (54 kD), angiotensinogen and albumin, strongly
argues against the appearance of renin in urine as the
mere consequence of glomerular filtration. Such filtration
does occur, as has been previously reported in mice
[29–30], but is accompanied by virtually complete tubular
reabsorption, both for renin and prorenin. The same
applies to albumin and angiotensinogen [28]. From
this point of view, the urinary renin and prorenin
levels (relative to plasma) should have been of the same
magnitude as those of albumin and angiotensinogen, that
is, more than 2000-fold below their plasma levels.
Such low levels would have been beyond the detection
limit of our assay. Consequently, it seems reasonable to
assume that prorenin was in fact present in urine at
such levels. Urinary renin levels were, however, more
than 200-fold higher than expected, and the sexual
dimorphism of renin in plasma did not apply to renin in
urine. Moreover, urinary renin decreased during treat-
ment with ACEi and/or ARBs, whereas the opposite
occurred in plasma. Most likely, therefore, urinary renin
does not originate in blood, but is rather released from
renal tissue sites. Given the predominant release of
prorenin from the collecting duct [17], at least in rats, it
appears that either this prorenin is retained in the tubular
cells (e.g. due to its binding to the (pro)renin receptor),
allowing selective secretion of renin in urine, and/or that
collecting duct prorenin is converted to renin before its
release into urine.
Xue and Siragy [18] recently reported that in rats the renal
aldosterone levels, as opposed to plasma aldosterone
levels, did not disappear following adrenalectomy.
Remarkably, in their study, renal aldosterone levels were
approximately 15000 pg/g vs. aldosterone levels in blood
plasma and renal interstitial fluid of approximately
700 and approximately 15 pg/ml, respectively. As renal
tissue contains approximately 5% blood plasma, and
approximately 10% interstitial fluid, this implies that
more than 99% of renal aldosterone is located intra-
cellularly. The half-life of such intracellular aldosterone
is unknown and, thus, future studies should exclude that
this represents internalized, adrenal-derived aldosterone.
Indeed, the heart is another location where, despite
initial reports on local aldosterone synthesis, eventually
it was concluded that this does not occur [31–32].
Remarkably in this regard, Xue and Siragy localized
aldosterone synthase in glomerular nucleoli, that is,
outside its usual site of action, the mitochondria. Our data
now reveal that urinary aldosterone levels are almost
identical to plasma aldosterone levels, and that the
urine/plasma concentration ratio of aldosterone (mole-
cular weight 0.4 kD) mimics that of creatinine (molecular
weight 0.1 kD). This strongly suggests that urinary
aldosterone is entirely blood-derived. Had the kidney
been an important site of aldosterone production,
resulting in the overflow of renal aldosterone in urine,
no correlation between the urine/plasma concentration
ratios of aldosterone and creatinine should have been
present. In fact, when analyzing urinary samples of
four bilaterally adrenalectomized patients (two men
and two women, age 60 10 years, adrenalectomized
because of Cushing’s syndrome 1, 9, 17 and 32 years
ago, respectively), aldosterone levels were found to be
undetectable (R.A. Feelders, unpublished observations).
Moreover, we are not aware of data showing release of
aldosterone into blood from renal tissue sites.
In summary, the current study reveals that urinary
renin, and not urinary prorenin, angiotensinogen or
aldosterone, is an important marker of renal RAAS
activity. Our data are the first to demonstrate directly
renal RAAS activation in diabetic patients (and not
indirectly by quantifying the renal effect of RAAS
blockers). This might explain why such patients, despite
low-to-normal plasma renin levels, respond strongly
to RAAS blockers. The data also show that the con-
sequences of RAAS blockade in plasma and kidney are
not necessarily the same. A limitation of our study is the
large diversity of the patients, particularly with regard to
treatment. For instance, 30% received a b-blocker, 51% a
calcium antagonist and 13% a mineralocorticoid receptor
antagonist, that is, drugs that may also (modestly) affect
RAAS component levels. Future studies should now
carefully address the effect of such drugs on urinary renin
in a prospective manner, as well as that of ACEi, ARBs
and renin inhibitors. Renin inhibitors are of particular
interest, given the large rise in plasma renin that occurs
during renin inhibition [12,33–34].
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The (pro)renin receptor blocker handle region peptide
upregulates endothelium-derived contractile factors in
aliskiren-treated diabetic transgenic (mREN2)27 rats
Wendy W. Batenburg*, Mieke van den Heuvel*, Joep H.M. van Esch, Richard van Veghel,
Ingrid M. Garrelds, Frank Leijten, Alexander H.J. Danser
The (pro)renin receptor blocker handle region peptide
upregulates endothelium-derived contractile factors in
aliskiren-treated diabetic transgenic (mREN2)27 rats
 . Batenburg�, ie e van den Heuvel�, Joep H.M. van Esch, Richard van Veghel, 
Ingrid M. Garrelds, Frank Leijten, and Alexander H.J. Danser
Background: Elevated prorenin levels associate with
microvascular complications in patients with diabetes
mellitus, possibly because prorenin affects vascular
function in diabetes mellitus, for example by generating
angiotensins following its binding to the (pro)renin
receptor [(P)RR]. Here we evaluated whether the renin
inhibitor aliskiren, with or without the putative (P)RR
antagonist handle region peptide (HRP) improved the
disturbed vascular function in diabetic TGR(mREN2)27
rats, a high-prorenin, high-(P)RR hypertensive model.
Methods: Telemetry transmitters were implanted to
monitor blood pressure. After 3 weeks of treatment,
rats were sacrificed, and iliac and mesenteric arteries
were removed to evaluate vascular reactivity.
Results: Diabetes mellitus enhanced the contractile
response to nitric oxide synthase (NOS) blockade,
potentiated the response to phenylephrine, diminished the
effectiveness of endothelin type A (ETA) receptor blockade
and allowed acetylcholine to display constrictor, cyclo-
oxygenase-2 mediated, endothelium-dependent responses
in the presence of NOS inhibition and blockers of
endothelium-derived hyperpolarizing factors. Aliskiren
normalized blood pressure, suppressed renin activity, and
reversed the above vascular effects, with the exception of
the altered effectiveness of ETA receptor blockade.
Remarkably, when adding HRP on top of aliskiren, its
beneficial vascular effects either disappeared or were
greatly diminished, although HRP did not alter the effect
of aliskiren on blood pressure and renin activity.
Conclusions: Renin inhibition improves vascular
dysfunction in diabetic hypertensive rats, and HRP
counteracts this effect independently of blood pressure
and angiotensin. (P)RR blockade therefore is unlikely to be
a new tool to further suppress the renin–angiotensin
system (RAS) on top of existing RAS blockers.
Keywords: (pro)renin receptor blockade, diabetes,
endothelium-derived contracting factor, nitric oxide,
prorenin, renin inhibition
Abbreviations: (P)RR, (pro)renin receptor; ACh,
acetylcholine; Ang, angiotensin; COX, cyclo-oxygenase;
CRC, concentration–response curve; EDCF, endothelium-
derived contractile factor; EDHF, endothelium-derived
hyperpolarizing factor; EKA, enzyme-kinetic assay; ETA/ETB
receptor, endothelin receptor type A or B; HPRT1,
hypoxanthine phosphoribosyl transferase-1; HRP, handle
region peptide; MAP, mean arterial pressure; MAPK,
mitogen-activated protein kinases; NOS, NO synthase; PRA,
plasma renin activity; RAS, renin–angiotensin system;
Ren2, TGR(mREN2)27; SKCa/IKCa channels, small/
intermediate conductance Ca2þ-activated Kþ-channel;
SNAP, S-nitroso-N-penicillamine; STZ, streptozotocin;
U46619, 9,11-dideoxy-11a,9a-epoxy-methano-
prostaglandin F2a
INTRODUCTION
T
he renin–angiotensin (Ang) system (RAS) contrib-
utes to the pathogenesis of diabetic nephropathy,
since RAS blockers prevent the deterioration of renal
function in patients with diabetes mellitus [1,2]. Remarkably
however, diabetic patients tend to have low renin levels,
whereas their levels of prorenin, the inactive precursor
of renin, are greatly elevated [3]. In fact, these high
prorenin levels are an early predictor of the microvascular
complications of diabetes, including retinopathy and
nephropathy [4,5]. The protective effect of RAS blockade,
particularly in the diabetic kidney, has therefore been
attributed to interference with prorenin-dependent RAS
activation. This may occur through binding of prorenin
to the so-called (pro)renin receptor [(P)RR]. This receptor
binds both renin and prorenin, and binding of the
latter induces a conformational change in the prorenin
molecule, allowing it to display full enzymatic activity
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laboratory rat chow and water ad libitum. Radiotelemetry
transmitters were implanted as described before [33]
for continuous measurement of heart rate, blood pressure,
and activity. Two weeks later, to induce diabetes mellitus,
rats were fasted overnight and administered streptozotocin
(STZ; 55mg/kg i.p.; Sigma–Aldrich, Zwijndrecht, The
Netherlands). Rats were checked regularly for blood
glucose and b-ketone levels by tail incision (Precision
Xceed; Abbott, Zwolle, The Netherlands). Only rats with
a glucose level more than 15mmol/l were considered
diabetic, and they subsequently received 2–4U insulin
per day (Levemir; Novo Nordisk, Denmark). After 2 weeks
of diabetic status osmotic minipumps (2ML4; ALZET,
Cupertino, California, USA) were implanted subcu-
taneously under isoflurane anesthesia to infuse vehicle
(saline; n¼ 8) or aliskiren (a gift of Novartis, 10mg/kg
per day) with (n¼ 8) or without (n¼ 7) rat HRP (NH2-
RILLKKMPSV-COOH, 1mg/kg per day; Biosynthan, Berlin,
Germany). In the animals receiving two drugs, two separate
minipumps were implanted at both sides of the body.
Three weeks later, animals were anaesthetized by
pentobarbital injection i.p., and the hepatic portal vein
was cannulated to collect blood for the measurement of
renin, prorenin and plasma renin activity (PRA). Mesenteric
arteries and iliac arteries were isolated and transported to
ice-cold oxygenated Krebs bicarbonate solution (inmmol/l:
NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25 and glucose 8.3; pH 7.4) until the start of the
experiment the same day. Blood and vessels were also
obtained from six diabetic Ren2 rats treated with saline
for 3 weeks, eight untreated nondiabetic Ren2 rats, and
eight age-matched untreated Sprague–Dawley rats. None
of these rats underwent haemodynamic measurements.
Myograph studies
Following isolation, mesenteric arteries and iliac arteries
were cut into segments of approximately 2mm length and
mounted in a Mulvany myograph (Danish Myo Techno-
logy, Aarhus, Denmark) with separated 6-ml organ baths
containing Krebs bicarbonate solution, aeratedwith 95%O2
and 5% CO2, and maintained at 378C. Tissue responses
were measured as changes in isometric force, using
Powerlab with Labchart software. To remove the endo-
thelium, a human hair was gently rubbed through
the lumen of the mesenteric artery. Following a 30-min
stabilization period, the optimal internal diameter was set to
a tension equivalent to 0.9 times the estimated diameter at
100mmHg effective transmural pressure as described by
Mulvany andHalpern [34]. Endothelial removal was verified
by observing no relaxation to 1mmol/l acetylcholine (ACh)
after preconstrictionwith 100 nmol/l of the thromboxane A2
analogue U46619 (9,11-dideoxy-11a,9a-epoxy-methano-
prostaglandin F2a). Subsequently, to determine the
maximum contractile response, the tissue was exposed
to 100mmol/l KCl. The segments were then allowed
to equilibrate in fresh organ bath fluid for 30min. Next,
segments were preincubated for 30min with the NO
synthase (NOS) inhibitor L-NAME (100mmol/l), the small
conductance Ca2þ-activated Kþ-channel (SKCa) inhibitor
apamin (100 nmol/l), the intermediate conductance Ca2þ-
activated Kþ-channel (IKCa) inhibitor TRAM34 (10mmol/l),
without cleavage of the prosegment (i.e. without being 
converted to renin).
In support of a role for the (P)RR in the diabetic 
kidney and eye, the (P)RR inhibitor handle region peptide 
(HRP) exerted renoprotective and oculoprotective 
effects in diabetic rodents [6–9]. HRP represents the part 
of the prosegment that determines prorenin binding to 
its receptor. Unexpectedly, (P)RR-bound prorenin not 
only displayed Ang I-generating activity [10,11], but also 
stimulated cellular signal transduction in an angiotensin-
independent manner [10,12]. This signaling resulted in 
the upregulation of fibrotic pathways, involving mitogen-
activated protein kinases (MAPK p42/44, p38) activation, 
transforming growth factor-b1 synthesis and plasminogen 
activator-inhibitor 1 release [10,12,13]. In addition, a posi-
tive feedback loop exists between the (P)RR and cyclo-
oxygenase 2 (COX-2), which is regulated by the level of 
glucose [14–17]. It is therefore feasible that (P)RR blockade 
with HRP also exerts effects beyond RAS suppression.
However, not all studies with HRP were positive, and 
its capacity to block the (P)RR is not uniformly accepted 
[12,18–21]. Moreover, there is some doubt whether 
prorenin truly interacts with the (P)RR in vivo, given its 
picomolar levels and the nanomolar affinity of the receptor 
[10,11,22].
A suitable animal model to study prorenin–(P)RR inter-
action is the TGR(mREN2)27 rat (Ren2 rat). These rats, 
which overexpress the mouse Ren2 gene, not only have 
greatly elevated prorenin and Ang II levels, but also display 
increased (P)RR expression and are severely hypertensive 
[23–26]. After streptozotocin injection, they develop a 
diabetic phenotype that closely mimics that in human 
diabetic patients, characterized by high prorenin levels, 
retinal pathology, vascular dysfunction and nephropathy 
[27–30]. We and others have already demonstrated that 
the renin inhibitor aliskiren lowers blood pressure and 
improves albuminuria in this model [24,31]. In the present 
study, we focused on the effects of aliskiren on vascular 
dysfunction in diabetic Ren2 rats, evaluating in particular 
the altered endothelium-dependent and endothelin-1 
(ET-1)-mediated responses that have been noted before 
in diabetic animals [32]. We also determined to what 
degree HRP exerts vascular effects on top of renin inhi-
bition. We reasoned that, if anywhere, the beneficial 
effects of this putative (P)RR blocker should be observed 
in this high-prorenin, high-(P)RR model.
METHODS
Animal studies
Homozygous Ren2 rats (400–500 g; a kind gift of Dr 
M. Bader, Berlin, Germany), were crossed with Sprague–
Dawley rats (Harlan, Boxmeer, The Netherlands) to 
generate heterozygous Ren2 rats. Heterozygous rats were 
subsequently used in all studies, as these rats, in contrast 
to homozygous Ren2 rats, did not require lisinopril treat-
ment (10 mg/ml in drinking water) to decrease mortality. 
All studies were performed under the regulation and 
permission of the Animal Care Committee of the Erasmus 
MC. Rats were housed in individual cages and maintained 
on a 12-h light/dark cycle, having access to standard
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CCAGAAAGCAAAGGACACCC-30; rat COX-2 forward 50-
ATTGCTGGCCGGGTTGCTGG-30, reverse 50-TCAATGGA
GGCCTTTGCCACTGC-30.
Statistical analysis
Data are given as mean� SEM. Relaxant responses to
either acetylcholine or SNAP are expressed as a percentage
of the contraction to U46619 or phenylephrine where
appropriate. Contractile responses to Ang II, phenylephrine
or ET-1 are expressed as a percentage of the contraction
to 100mmol/l KCl. CRCs were analyzed as described [36] to
obtain pEC50 (�10logEC50) values. In experiments wherein
no clear maximum effect (Emax) was reached, Emax was
defined as the effect obtained at the highest concentration
tested. pEC50 values were not calculated when Emax was
less than 20%, and in such cases statistical analysis was
performed under the assumption that pEC50 equalled the
highest concentration tested. Haemodynamic parameters
were compared by two-way ANOVA. All other data were
analyzed by Student’s t-test or one-way ANOVA, followed
by posthoc evaluation according to Dunnet or Tukey (for
comparisons within and between groups, respectively).
P< 0.05 was considered significant.
RESULTS
Induction of diabetes mellitus and
hemodynamic parameters
Diabetes mellitus induction increased blood glucose
from 5.8� 0.2 before STZ injection to maximally 25.8�
0.9mmol/l at 2 weeks after STZ injection (n¼ 11;
P< 0.001), and the 3-week treatment period did not alter
this further in any of the three groups (data not shown).
Plasma b-ketone levels remained unaltered after STZ
injection (0.3� 0.1mmol/l before STZ vs. 0.5� 0.1mmol/
l at 2 weeks after STZ), and were also not affected by
treatment. The levels of blood glucose (4.7� 0.6mmol/l)
and plasma b-ketone (0.3� 0.1mmol/l) in Sprague–
Dawley rats were identical to those in nondiabetic Ren2
rats.
The renin inhibitor aliskiren, either alone or combined
with the (P)RR blocker HRP lowered mean arterial pressure
(MAP) versus saline, with no effect on heart rate or activity
(Fig. 1). Significance for the effect on MAP vs. saline was
reached by day 7 (P< 0.05), and on day 21 MAP in the rats
treated with aliskiren or aliskirenþHRP was 104� 5
and 103� 3mmHg, respectively (vs. 123� 4mmHg in
saline-treated diabetic Ren2 rats; P< 0.05 for both). MAP
in the presence of aliskirenþHRP did not differ from
MAP with aliskiren alone.
Prorenin, renin and plasma renin activity
Nondiabetic Ren2 rats (n¼ 12) displayed higher prorenin
and lower renin levels than Sprague–Dawley rats (n¼ 6;
Fig. 2, P< 0.05 for both). PRA was also lower in nondiabetic
Ren2 rats. Diabetes increased prorenin two-fold to three-
fold (P< 0.05 vs. nondiabetic Ren2 rats), without affecting
renin or PRA. Renin and prorenin could not be measured
in the aliskiren-treated animals, due to the interference
of aliskiren with the enzyme-kinetic assay [33]. Aliskiren
Batenburg et al.
the endothelin type A (ETA) receptor antagonist BQ123 
(1 and 10 mmol/l), the endothelin type B (ETB) receptor 
antagonist BQ788 (10 nmol/l), the nonselective cyclo-
oxygenase (COX) inhibitor indomethacin (10 mmol/l), 
the COX-2-selective inhibitor NS398 (10 mmol/l), the throm-
boxane/endoperoxide receptor antagonist GR32191B 
(1 mmol/l) and/or the superoxide scavenger tempol 
(1 mmol/l). Thereafter, concentration–response curves 
(CRCs) were constructed to Ang II and phenylephrine 
(iliac arteries) or ET-1 (mesenteric arteries). To construct 
CRCs to ACh or S-nitroso-N-penicillamine (SNAP), 
mesenteric arteries were preconstricted with U46619 
(0.1–0.3 mmol/l) or phenylephrine (in the studies with 
GR32191B; 1 mmol/l). All drugs were from Sigma–Aldrich. 
To mimic the diabetic in-vivo conditions in the organ bath, 
parallel experiments in six mesenteric arteries of diabetic 
rats were performed with 25 instead of 8.3 mmol/l glucose. 
ACh-induced relaxations (pEC50 7.7 � 0.1 vs. 7.5 � 0.1 
and Emax 97 � 2 vs. 97 � 2%) were identical under both 
conditions, and all studies were therefore performed in 
regular Krebs buffer.
Biochemical measurements
PRA was measured by quantifying Ang I generation during 
incubation of plasma for 60 min at pH 7.4 and 378C in  
the presence of a mixture of inhibitors to block Ang I 
degradation, Ang I–II conversion, and prorenin–renin 
conversion, and to prevent bacterial growth [33]. Plasma 
renin and prorenin concentration were measured by 
enzyme-kinetic assay (EKA) in the presence of excess 
sheep angiotensinogen. Total renin was measured after 
prorenin had been converted to renin by incubation of 
the sample for 48 h at 48C with trypsin coupled to Sepharose 
[35]. Subtraction of the renin concentration from the 
total renin concentration yielded the prorenin concen-
tration. In all assays, the generated Ang I was measured 
by radioimmunoassay.
Cyclo-oxygenase-2 and endothelin type A 
receptor expression
Total RNA was isolated from snap-frozen rat aortas using 
Trizol (Life Technologies, Grand Island, Nebraska, USA) and 
reverse transcribed into cDNA using the QuantiTect Reverse 
Transcription Kit (Qiagen, Venlo, The Netherlands). The 
resulting cDNA was amplified in 40 cycles (denaturation at 
958C for 10 min; thermal cycling at 958C for 15 s, annealing/
extension at 608C for 1 min) with a Step-One cycler (NYSE, 
Life Technologies) using the SYBR Green PCR Master Mix 
(Life Technologies). The intron-spanning oligonucleotide 
primers for qPCR were designed with NCBI (Primer-BLAST). 
The comparative cycle time method (DDCT) was used 
for relative quantification of gene expression, using the 
geometric mean of the housekeeping genes hypoxanthine 
phosphoribosyl transferase-1 (HPRT1) and b-actin for 
normalization. The following primers were used: rat 
HPRT1 forward 50-GGACAGGACTGAAAGACTTGCTCG-
30, reverse 50-TTCAGCACACAGAGGGCCACA-30; rat b-actin 
forward 50-GGGAAATCGTGCGTGACATT-30, reverse 
50-GCGGCAGTGGCCATCTC-30; rat ETA receptor forward 
50-CGTCCGAGGAGCTCTAAGGGGAA-30, reverse 50-ACG
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Iliac artery
Ang II constricted iliac arteries of Sprague–Dawley rats
to maximally 47� 14% of the response to Kþ (Fig. 3,
Table 1). The NOS inhibitor L-NAME greatly increased
the response to Ang II (P< 0.05), without altering its
potency. L-NAME did not affect baseline contractility
in Sprague–Dawley rats. In contrast, in nondiabetic
Ren2 rats, L-NAME marginally increased baseline
contractility (P¼ 0.06 vs. Sprague–Dawley), whereas in
vehicle-treated diabetic Ren2 rats it increased baseline
contractility to �65% of the response to Kþ (P< 0.01
vs. Sprague–Dawley and nondiabetic Ren2). Aliskiren
reduced the effect of L-NAME in diabetic Ren2 rats
to the levels in nondiabetic Ren2 rats (P< 0.05 vs.
vehicle-treated diabetic Ren2 rats), and HRP reversed this
effect of aliskiren. The Ang II Emax doubled in nondiabetic
and diabetic-vehicle Ren2 rats compared with Sprague–
Dawley rats, and aliskiren alone, but not aliskirenþHRP,
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FIGURE 1 Top, mean arterial pressure (MAP) during a 3-week infusion of vehicle, aliskiren or aliskiren þ HRP in diabetic Ren2 rats. Data are mean� SEM of 7–8 rats.
� P<0.05 vs. vehicle. Bottom, heart rate (HR), SBP DBP and activity level in the above rats. Data are means of 7–8 rats.
reduced PRA by more than 60%, both with and without HRP 
(P < 0.05 for both).
Vascular reactivity
To determine the diabetes mellitus-induced changes in 
vascular function, as well as the possible reversal of these 
changes by treatment, iliac arteries of Sprague–Dawley rats, 
nondiabetic Ren2 rats and diabetic Ren2 rats treated with 
vehicle, aliskiren, or aliskiren þ HRP, were exposed to the 
vasoconstrictors Ang II and phenylephrine, and mesenteric 
arteries of these animals were exposed to the vasoconstric-
tor ET-1 and the vasodilators SNAP and ACh. Experiments 
were repeated in the presence of endothelin receptor 
blockers (BQ123, BQ788) and inhibitors of the NO 
(L-NAME) and endothelium-derived hyperpolarizing factor 
(TRAM34 þ apamin) pathways [32], to determine potential 
causes of the changes in vascular function.
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tended to normalize this response. However, none of the
changes in Emax were significant, and no changes in pEC50
were observed. The Ang II Emax in the presence of L-NAME
was identical in all groups, and its pEC50 with L-NAME was
also not affected by treatment.
Phenylephrine constricted iliac arteries in Sprague–
Dawley rats to maximally 348� 62% (Fig. 3, Table 1). L-
NAME shifted the phenylephrine CRC in Sprague–Dawley
rats �10-fold to the left (P< 0.01), without altering its Emax.
Results in nondiabetic Ren2 rats were identical to those in
Sprague–Dawley rats. Diabetes mellitus potentiated the
effect of phenylephrine in Ren2 rats, and reduced its Emax
(P< 0.05 for both), while eliminating the leftward shift
induced by L-NAME. Aliskiren normalized phenylephrine’s
potency, increased its Emax, and re-introduced the leftward
shift by L-NAME (Table 1). HRP, when given on top of
aliskiren, counteracted the effect of aliskiren alone on the
phenylephrine Emax.
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SNAP relaxed preconstricted mesenteric arteries of
Sprague–Dawley and nondiabetic Ren2 rats to the same
degree (Fig. 5 and Table 1). Diabetes mellitus induction
shifted the SNAP CRC �10-fold to the right (P< 0.05) and
reduced Emax (P< 0.05). Treatment did not alter this.
ACh fully relaxed preconstricted mesenteric arteries
of Sprague–Dawley rats, and L-NAME combined with
TRAM34 (IKCa inhibitor) þ apamin (SKCa inhibitor), but
not L-NAME alone or TRAM34þ apamin alone, blocked this
effect (Fig. 5, Table 1). ACh also fully relaxed mesenteric
arteries of nondiabetic Ren2 rats. L-NAME, with or without
TRAM34 þ apamin (but not TRAM34 þ apamin alone),
partially prevented this effect (P< 0.05). ACh identically
relaxed mesenteric arteries of diabetic Ren2 rats. However,
L-NAME now not only reduced its Emax, but also diminished
its potency (P< 0.05 for both). Moreover, the combined
application of L-NAME and TRAM34þ apamin uncovered a
constrictor action of ACh (P< 0.01 vs. nondiabetic Ren2
rat). Aliskiren annihilated these diabetes mellitus-induced
alterations, whereas HRP reversed this effect of aliskiren.
To further investigate the contractile effect induced by
ACh in the presence of L-NAME and TRAM34þ apamin,
CRCs to ACh were constructed in preconstricted mesenteric
arteries of a second set of untreated diabetic Ren2 rats. COX
TABLE 1. pEC50 and Emax values (mean�SEM of n¼5–8) for angiotensin (Ang) II, phenylephrine (PE), endothelin-1 (ET-1), SNAP,
acetylcholine (ACh) and L-NAME in iliac (Ang II, PE, L-NAME) or mesenteric (ET-1, SNAP, ACh) arteries of Sprague–Dawley
rats, nondiabetic Ren2 rats, and diabetic Ren2 rats treated for 3 weeks with vehicle, aliskiren (10mg/kg per day) or aliskiren þ
HRP (10 and 1mg/kg per day, respectively), in the absence or presence of L-NAME (100mmol/l), BQ123 (1mmol/l), BQ788
(10nmol/l), TRAM34 (T; 10mmol/l) and/or apamin (A; 100nmol/l)
pEC50 Sprague–Dawley Non-DM DM-vehicle DM-aliskiren DM-aliskirenþHRP
Ang II 7.7�0.4 8.3�0.3 7.9�0.4 7.2�0.4 7.5�0.5
Ang IIþL-NAME 7.8�0.4 8.5�0.2 8.7�0.2 8.6�0.2 8.3�0.4
PE 6.3�0.1 6.6�0.1 7.8�0.2�# 7.0�0.4 7.4�0.2
PEþL-NAME 7.2�0.1z 7.4�0.2$ 8.0�0.3 8.3�0.3þ 8.2�0.2$
ET1 8.2�0.2 8.3�0.1 7.8�0.1# 7.5�0.1# 7.8�0.1#
ET1þBQ123 7.6�0.2$ 7.7�0.1$ 7.5�0.1 7.4�0.1 7.4�0.1z
ET1þBQ788 8.3�0.2 8.4�0.1 7.8�0.2 7.5�0.1 8.0�0.2
SNAP 8.0�0.3 8.0�0.3 7.4�0.2# 6.9�0.1# 6.9�0.1#
ACh 7.3�0.2 8.0�0.1� 8.1�0.1� 7.9�0.1 7.9�0.1
AChþL-NAME 7.3�0.3 7.5�0.3 7.3�0.3$ 7.4�0.1$ 7.3�0.2$
AChþTþA 7.4�0.2 8.0�0.1� 8.1�0.1� 7.9�0.1 8.0�0.1
AChþL-NAMEþTþA 6.7�0.2 7.0�0.4 – – –
Emax Sprague–Dawley Non-DM DM-vehicle DM-aliskiren DM-aliskirenþHRP
Ang II 47�14 87�17 96�29 70�24 92�38
Ang IIþL-NAME 185�59$ 139�27$ 168�30$ 144�30$ 145�34$
PE 348�62 291�24 217�17� 245�40y 232�21
PEþL-NAME 334�37 311�23 299�31 311�32 245�31
ET1 244�37 156�18� 153�14� 181�13 152�5
ET1þBQ123 199�18 185�18 168�8 171�9 140�16
ET1þBQ788 274�52 166�14 165�6 177�7 141�16
SNAP 103�4 103�6 77�5�# 71�5# 75�5#
ACh 88�7 90�3 87�2 89�1 91�2
AChþL-NAME 76�13 67�8$ 65�9$ 76�7 75�5$
AChþTþA 84�8 84�6 76�5 79�5 81�5
AChþL-NAMEþTþA 47�16$ 34�8$ �29�17$D 11�9$y �6.7�9$#
L-NAME 3�2 13�4 66�19�# 15�7y 25�12
ACh, acetylcholine; Ang, angiotensin; DM, diabetes mellitus; ET-1, endothelin type 1; HRP, handle region peptide; PE, phenylephrine; SNAP, S-nitroso-N-penicillamine.
�P<0.05 vs. SD.
D P<0.01 vs. non-DM.
# P< 0.05 vs. non-DM.
y P<0.05 vs. vehicle.
z P<0.01 vs. no inhibitor.
$P<0.05 vs. no inhibitor.
þP¼0.06 vs. no inhibitor.
Mesenteric artery
ET-1 constricted mesenteric arteries in Sprague–Dawley 
rats to maximally 244 � 37% (Fig. 4, Table 1). The ET-1 Emax 
was greatly diminished in nondiabetic Ren2 rats (P < 0.05), 
although its potency was unchanged. The induction 
of diabetes mellitus diminished the potency of ET-1 in 
Ren2 rats, without affecting its Emax. Aliskiren increased 
the latter to Sprague–Dawley values, and HRP prevented 
this. The ETA receptor antagonist BQ123 (1 mmol/l), 
but not the ETB receptor antagonist BQ788, shifted 
the ET-1 CRC in Sprague–Dawley rats and nondiabetic 
Ren2 rats four-fold to five-fold to the right (P < 0.05), and 
the effect of BQ123 (1 mmol/l) þ BQ788 was identical 
to that of BQ123 alone (data not shown). Remarkably, 
following the induction of diabetes mellitus, the effect 
of 1 mmol/l BQ123 disappeared, and returned only by 
increasing its concentration 10-fold. Aliskiren alone 
did not alter the effect of diabetes mellitus, whereas the 
addition of HRP allowed the return of the blocking effect 
of 1 mmol/l BQ123 (P < 0.01 vs. no BQ123). With HRP, 
10 mmol/l BQ123 fully blocked the effect of ET-1. These 
data indicate a diminished sensitivity of ETA receptors to 
BQ123 in diabetes mellitus, which is restored to normal by 
HRP but not aliskiren.
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inhibition with the nonselective COX inhibitor indo-
methacin or the COX-2-selective inhibitor NS398, as
well as endothelium removal, but not the thromboxane/
endoperoxide receptor antagonist GR32191B or the
superoxide scavenger tempol, prevented this effect
(Fig. 6).
Vascular cyclo-oxygenase 2 and endothelin
type A receptor expression
Since the vascular reactivity studies revealed potential
changes in COX-2 and ETA receptor reactivity, we quanti-
fied the vascular COX-2 and ETA receptor expression.
These studies were performed in aortic tissue since
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FIGURE 4 Contractions of mesenteric arteries, obtained from Sprague–Dawley rats, nondiabetic Ren2 rats, and diabetic Ren2 rats treated for 3 weeks with vehicle,
aliskiren or aliskirenþHRP, to endothelin-1 in the absence or presence of BQ123 (1mmol/l, closed squares, or 10mmol/l, open triangles) or 10 nmol/l BQ788. Contractions
(mean� SEM, n¼5–8) have been expressed as a percentage of the response to 100mmol/l Kþ. Please note that the 10mmol/l BQ123 data in the middle panel represent
1 experiment. See Table for statistical information. DM, diabetes mellitus.
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FIGURE 5 Relaxations/constrictions of mesenteric arteries, obtained from Sprague–Dawley rats, nondiabetic Ren2 rats, and diabetic Ren2 rats treated for 3 weeks with
vehicle, aliskiren or aliskirenþHRP, to S-nitroso-N-penicillamine (SNAP) or acetylcholine in the absence or presence of 100mmol/l L-NAME, 10mmol/l TRAM34 þ 100nmol/l
apamin, or L-NAME þ TRAM34 þ apamin. Effects (mean� SEM, n¼4–8) have been expressed as a percentage of the response to U46619 (0.1–0.3mmol/l). See Table for
statistical information. DM, diabetes mellitus.
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insufficient mesenteric arterial material was left for such
measurements after performing the above organ bath
studies. Aortic ETA receptor mRNA expression was
decreased in nondiabetic Ren2 rats compared with
Sprague–Dawley rats. Induction of diabetes mellitus
increased ETA receptor mRNA expression, and this was
prevented (P< 0.05) by aliskirenþHRP only (Fig. 7). Aortic
COX-2 mRNA expression was unaltered in nondiabetic rats
vs. Sprague–Dawley rats, and was also unaffected by
the induction of diabetes mellitus. Neither aliskiren nor
aliskirenþHRP altered the aortic COX-2 mRNA expression.
DISCUSSION
This study shows that HRP unexpectedly counteracted the
beneficial vascular effects of aliskiren in diabetic Ren2
rats in a blood pressure-independent manner. Ren2 rats
did not display a greatly altered vascular responsiveness vs.
Sprague–Dawley rats, in full agreement with previous
studies [37,38]: Ang II and phenylephrine responses were
identical in both strains, and ET-1 displayed a reduced
efficacy in Ren2 rats. Furthermore, ACh-induced, endo-
thelium-dependent responses, as well as the direct vascular
smooth muscle cell responsiveness to NO were fully intact
in Ren2 rats. Yet, their sensitivity to NOS inhibition was
increased, as evidenced by the large rightward shift of the
ACh CRC in the presence of L-NAME. This rightward shift
was also present in diabetic animals. Moreover, following
the induction of diabetes, L-NAME increased contractility
per se, suggesting an enhanced baseline NO exposure in
diabetic animals, for example, due to eNOS upregulation
[39]. Indeed, in accordance with such NO upregulation, the
potency of the NO donor SNAP diminished �10-fold in
diabetic animals, confirming that the continuous exposure
to elevated NO levels had decreased the sensitivity of the
soluble guanylyl cyclase-cGMP pathway to NO [40,41].
Moreover, the phenylephrine response decreased by one
third, returning to its prediabetic Emax only in the presence
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FIGURE 6 Constrictions of mesenteric arteries, obtained from diabetic Ren2 rats, to acetylcholine in the presence of 100mmol/l L-NAME þ 10mmol/l TRAM34 þ 100nmol/l
apamin with or without 10mmol/l indomethacin, 10mmol/l NS398, 1mmol/l tempol, 1mmol/l GR32191B or after removal of the endothelium (no endothelium). Effects
(mean� SEM, n¼6) have been expressed as a percentage of the response to U46619 (0.1–0.3mmol/l) or phenylephrine (1mmol/l in the case of GR32191B). See Table for
statistical information.
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of L-NAME. The latter emphasizes the possibility that high
endogenous NO levels in diabetic rats counteracted the
constrictor effects of phenylephrine.
In addition to NO, diabetes also upregulated endo-
thelium-derived contractile factor(s) (EDCFs) and vascular
ETA receptor expression in Ren2 rats. As a consequence,
ACh induced vasoconstriction during combined blockade
of the NO and endothelium-derived hyperpolarizing
factor pathways, and 10-fold higher BQ123 concentrations
were required to block ET-1-induced constriction. Towhat
degree the upregulation of the constrictor pathways are
the consequence of the NO upregulation, or vice versa,
cannot be concluded from our data. COX-2 inhibition,
as well as nonselective COX inhibition, prevented the
ACh-induced vasoconstriction. Yet, we did not observe a
significant increase in vascular COX-2 mRNA expression
following the induction of diabetes when studying the
aorta. This does not exclude that increased COX-2 protein
levels contributed to EDCF production in mesenteric
arteries, but rather suggests that the increased EDCF
synthesis may also involve the upregulation of one or
more of the enzymes that metabolise the COX-2 product
prostaglandin H2 (PGH2), for example thromboxane
synthase, prostacyclin synthase, prostaglandin D synthase,
prostaglandin E2 synthase or prostaglandin F2 synthase.
Our data with the thromboxane/endoperoxide receptor
antagonist GR32191B exclude a role for thromboxane A2,
and raise the possibility that either PGH2 itself, and/or
its metabolites PGI2, PGD2, PGE2 and PGF2a acted as
COX-derived EDCF(s) [42]. Altered COX metabolism has
been noted before in diabetes [43], as have ET-1 and ETA
receptor abundance [44,45]. The latter are believed to be
the consequence of increased reactive oxygen species
(ROS) generation and protein kinase C activation in dia-
betes [46,47]. Increased ROS were not responsible for the
acute ACh-induced vasoconstrictor effects in the present
study, as these effects could not be prevented by the ROS
scavenger tempol.
Aliskiren normalized most diabetes-induced vascular
alterations: it annihilated the upregulated effect of L-NAME
on baseline contractility, and normalized the phenyl-
ephrine and ACh responses. After aliskiren, ACh no longer
caused constriction. Aliskiren did not alter the diminished
SNAP responsiveness, possibly because a 3-week treatment
period is not long enough to reverse the consequences
of increased NO exposure. It also did not affect the absent
ETA receptor blocker response, and at most showed a
tendency to downregulate the increased vascular ETA
receptor expression.
Remarkably, and contrary to our expectation, HRP on
top of renin inhibition, reversed the above effects of alis-
kiren. In addition, it fully normalized the ET-1 responsive-
ness, that is, it allowed the return of the BQ123-dependent
rightward shift, which was observed only in the nondiabetic
state (Fig. 4). Since HRP did not significantly affect the
blood pressure-lowering effects of aliskiren, it can be
concluded that the vascular reactivity alterations in the
present study were not the consequence of changes in
blood pressure. Rather, they represent the interference
of aliskiren with local, vascular Ang II generation. Similar
observations have been made before in the coronary
vascular bed of the spontaneously hypertensive rat [21,33],
and in the forearm vascular bed of hypertensive patients [48].
The lack of effect of HRP on blood pressure is in agree-
ment with previous studies [6,18,21,49], and seems to
suggest that the (P)RR does not contribute to the generation
of Ang II that determines blood pressure, but at most to the
generation of Ang II that determines blood pressure-
independent effects, for example at tissue sites. Indeed,
HRP counteracted retinopathy and nephropathy in diabetic
rodents [6,9,50], and suppressed fibrosis in the hypertensive
rat heart [51]. As its beneficial effects in diabetes were also
observed in animals lacking the most important angiotensin
receptor (i.e., the AT1a receptor) [7], they may even
represent blockade of the direct (angiotensin-independent)
effects of prorenin–(P)RR interaction. In support of an
angiotensin-independent effect of HRP, our current data
show no interference of HRP with the aliskiren-induced
suppression of PRA. Similarly, in a previous study in
spontaneously hypertensive rats, HRP did not affect the
aliskiren-induced changes in angiotensin levels [21].
Yet, whether prorenin–(P)RR interaction truly occurs
in vivo, given the nanomolar affinity of the receptor for
prorenin (which occurs in blood at picomolar levels)
[11,22], is still a matter of debate. We have chosen the
Ren2 rat because of its high endogenous prorenin levels,
which are further elevated (up to 55-fold vs. Sprague–
Dawley rats) following the induction of diabetes (Fig. 2).
Nevertheless, even under those conditions, no beneficial
add-on effect of HRP was observed. Importantly, recent
studies in (P)RR knockout animals point to the possibility
that the (P)RR may exert functions that are entirely un-
related to the RAS. For instance, cardiomyocyte-specific
(P)RR knockout in mice results in the development of heart
failure due to defective autophagy and ultimately cell death
[52]. Moreover, the (P)RR functions as an adaptor between
vacuolar Hþ-ATPase and receptors for members of the
Wnt family of signaling molecules [53]. In addition, (P)RR
overexpressing rats display increased COX-2 levels, and
COX-2 overexpression in podocytes exacerbates diabetic
nephropathy by increasing (P)RR expression [15]. Thus, a
positive feedback loop appears to exist between the (P)RR
and COX-2 [16]. Interference of HRP with this feedback
loop (instead of blocking direct prorenin–(P)RR inter-
action) may underlie its upregulation of the EDCF pathway.
In fact, its role as a (P)RR antagonist in general might
be sufficient to explain some of the controversial, RAS-
independent observations made on this drug [12,18–21].
To address this possibility, additional studies are required
investigating the effects of HRP alone.
In conclusion, renin inhibition normalizes vascular
dysfunction in diabetic hypertensive rats, and (P)RR block-
ade counteracts this effect independently of blood pressure
and angiotensin. Although (P)RR blockade did reduce
vascular ETA receptor expression, its antagonizing effects
towards renin inhibition do not warrant its application as
add-on drug on top of RAS blockade.
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Diabetic patients have high prorenin levels and vascular
complications. The paper shows the effect of a renin
blocker, aliskiren, and a prorenin receptor antagonist,
handle region peptide (HRP), in vascular dysfunction from
a diabetic hypertensive animal model. The main finding
is that aliskiren diminished endothelium-dependent
contractile responses in diabetic hypertensive rats, however
aliskirenþHRP did not affect the responses. These data
are interesting and open up new clinical importance.
A week point is lack of evidence of the molecular-based
mechanism.


Deterioration of kidney function by the (pro)
renin receptor blocker handle region peptide 
in aliskiren-treated diabetic transgenic 
(mRen2)27 rats
te Riet L., van den Heuvel M., Peutz-Kootstra C.J., van Esch J.H., van Veghel R., Garrelds I.M., 
Musterd-Bhaggoe U., Bouhuizen A.M., Leijten F.P., Danser A.H. and Batenburg W.W.
Am J. Physiol Renal Physiol. 2014 May 15;306(10)
17
Chapter 17
226
Deterioration of kidney function by the (pro)renin receptor blocker handle
region peptide in aliskiren-treated diabetic transgenic (mRen2)27 rats
Luuk te Riet,1 Mieke van den Heuvel,1 Carine J. Peutz-Kootstra,2 Joep H. M. van Esch,1
Richard van Veghel,1 Ingrid M. Garrelds,1 Usha Musterd-Bhaggoe,1 Angelique M. Bouhuizen,1
Frank P. J. Leijten,1 A. H. Jan Danser,1 and Wendy W. Batenburg1
1Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The 
Netherlands; and 2Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands
Submitted 7 January 2014; accepted in final form 25 March 2014
te Riet L, van den Heuvel M, Peutz-Kootstra CJ, van Esch JH, 
van Veghel R, Garrelds IM, Musterd-Bhaggoe U, Bouhuizen AM, 
Leijten FP, Danser AH, Batenburg WW. Deterioration of kidney 
function by the (pro)renin receptor blocker handle region peptide 
in aliskiren-treated diabetic transgenic (mRen2)27 rats. Am J
Physiol Renal Physiol 306: F1179–F1189, 2014. First published 
April 2, 2014; doi:10.1152/ajprenal.00010.2014.—Dual renin-an-
giotensin system (RAS) blockade in diabetic nephropathy is no longer 
feasible because of the profit/side effect imbalance. (Pro)renin recep-
tor [(P)RR] blockade with handle region peptide (HRP) has been 
reported to exert beneficial effects in various diabetic models in a 
RAS-independent manner. To what degree (P)RR blockade adds 
benefits on top of RAS blockade is still unknown. In the present study,
we treated diabetic TGR(mREN2)27 rats, a well-established nephrop-
athy model with high prorenin levels [allowing continuous (P)RR 
stimulation in vivo], with HRP on top of renin inhibition with 
aliskiren. Aliskiren alone lowered blood pressure and exerted reno-
protective effects, as evidenced by reduced glomerulosclerosis, diure-
sis, proteinuria, albuminuria, and urinary aldosterone levels as well as
diminished renal (P)RR and ANG II type 1 receptor expression. It also 
suppressed plasma and tissue RAS activity and suppressed cardiac 
atrial natriuretic peptide and brain natriuretic peptide expression. 
HRP, when given on top of aliskiren, did not alter the effects of renin 
inhibition on blood pressure, RAS activity, or aldosterone. However, 
it counteracted the beneficial effects of aliskiren in the kidney, 
induced hyperkalemia, and increased plasma plasminogen activator-
inhibitor 1, renal cyclooxygenase-2, and cardiac collagen content. All 
these effects have been linked to (P)RR stimulation, suggesting that 
HRP might, in fact, act as a partial agonist. Therefore, the use of HRP
on top of RAS blockade in diabetic nephropathy is not advisable.
prorenin; diabetes; renin inhibition; (pro)renin receptor blockade; 
kidney
HYPERTENSIVE PATIENTS WITH DIABETES exhibit an increased risk
for cardiovascular complications such as nephropathy, stroke,
and heart failure. The renin-angiotensin system (RAS) is be-
lieved to modulate the underlying structural and functional
changes in the kidney and heart (29, 33), thereby explaining the
beneficial effects of RAS blockers in this condition. Elevated
levels of prorenin, the precursor of renin, are an early indicator
of nephropathy in diabetes (9, 32). Prorenin has been specu-
lated to contribute to ANG generation in the kidney via binding
to the so-called (pro)renin receptor [(P)RR]. Indeed, (P)RR-
bound prorenin displays ANG I-generating activity (1, 37).
However, it also stimulates (P)RR-mediated signal transduc-
tion in an ANG-independent manner, resulting in the activation
of ERK1/2, cyclooxygenase (COX)-2, and fibrotic pathways
(2, 37). The latter includes enhanced transforming growth
factor (TGF)-1 synthesis, plasminogen activator inhibitor
(PAI)-1 release, and the upregulation of fibronectin and colla-
gens (2, 18, 19, 37). In agreement with this concept, ubiquitous
expression of the human (P)RR in rats leads to proteinuria,
glomerulosclerosis, and nephropathy, which could be re-
versed by the putative (P)RR blocker handle region peptide
(HRP) (25). Beneficial renal effects of HRP were also
observed in ANG II type 1a receptor (AT1aR)-deficient
mice, suggesting that they are not solely due to interference
with the RAS. However, the capacity of HRP to block
(P)RR is controversial (34), and recent studies (28, 38, 40)
in knockout animals have suggested that (P)RR deletion in
cardiomyocytes or podocytes is actually lethal. Thus, a
relevant question is to what degree HRP should still be used,
e.g., on top of RAS blockade in diabetic patients with
nephropathy and heart failure. This is of particular impor-
tance now that the combination of two or more RAS
blockers is no longer advocated in diabetic patients, since
the side effect profile (hypotension and hyperkalemia) of
this approach outweighs the beneficial effects (7, 39).
In the present study, we therefore set out to study the effects
of HRP on top of renin inhibition (with aliskiren) in a well-
established high-prorenin model, the TGR(mRen2)27 (Ren2)
rat, which overexpresses the mouse Ren2 gene (36) and also
displays elevated (P)RR levels (5). Aliskiren is renoprotective
in this model, and its effects are comparable with those ob-
served during AT1R blockade or ANG-converting enzyme
inhibition, despite the nonequivalent blood pressure-lowering
effects of these three types of RAS blockers (27, 45). Cardio-
protective effects of aliskiren have also been observed in
diabetic rodents (10, 47).
Rats were made diabetic with streptozotocin (STZ) and
treated for 3 wk with aliskiren and/or HRP. We used a dose
of HRP that has been applied before in several rodent
studies (12, 22, 23, 25). We reasoned that, if anywhere, the
beneficial effects of this putative (P)RR blocker on the
kidney and heart should be observed in this high-prorenin,
high-(P)RR model.
METHODS
Animal Experiments
Homozygous Ren2 rats (400–500 g, a kind gift from Dr. M. Bader,
Berlin, Germany) were crossed with Sprague-Dawley rats (Harlan,
Boxmeer, The Netherlands) to generate heterozygous Ren2 rats.
Heterozygous rats were subsequently used in all experiments, since
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these rats, in contrast to homozygous Ren2 rats, did not require
lisinopril treatment (10 g/ml in drinking water) to decrease mortal-
ity. All experiments were performed under the regulation and permis-
sion of the Animal Care Committee of the Erasmus MC. Rats were
housed in individual cages and maintained on a 12:12-h light-dark
cycle with access to standard laboratory rat chow and water ad
libitum. Radiotelemetry transmitters were implanted as previously
described (42) for continuous measurements of heart rate, blood
pressure, and activity. Two weeks later, to induce diabetes mellitus
(DM), rats were fasted overnight and administered STZ (1 injection of
55 mg/kg STZ ip, Sigma-Aldrich, Zwijndrecht, The Netherlands).
Rats were checked for nonfasting blood glucose and -ketone levels
by tail incision daily during the first 3 days after STZ injection and
once weekly thereafter (Precision Xceed, Abbott, Zwolle, The Neth-
erlands). Only rats with glucose levels of 15 mM were considered
diabetic, and they subsequently received 2–4 U insulin/day (Levemir,
Novo Nordisk, Denmark). Diabetic Ren2 rats had an average blood
glucose level of 25.8 0.9 mmol/l. After 2 wk of DM status, osmotic
minipumps (2ML4, Alzet) were implanted subcutaneously under
isoflurane anesthesia to infuse vehicle (saline, n  8), aliskiren (a gift
from Novartis, 10 mg·kg1·day1, n  8), or aliskiren  rat HRP
(NH2-RILLKKMPSV-COOH, 1 mg·kg1·day1, Biosynthan, Berlin,
Germany, n  7). In animals that received aliskiren  HRP, two
separate minipumps were implanted in both sides of the body. During
the study, rats were placed in metabolic cages on day 14 (non-DM),
day 0 (DM), and day 21 (DM treatment) to collect 24-h urine. Each
rat served as its own control for the non-DM state. Urine was frozen
and stored until analysis of total protein, albumin, creatinine, Na,
endothelin (ET)-1, and aldosterone. After three weeks of treatment,
animals were anesthetized by an intraperitoneal pentobarbital injec-
tion, and the hepatic portal vein was cannulated to collect blood for
measurements of ANG I, ANG II, aldosterone, ET-1, TGF-1, PAI-1,
K, cystatin C (a marker of glomerular filtration that is less dependent
on muscle mass compared with creatinine), and creatinine (day 21).
The kidney and heart were excised, weighed, divided into transverse
segments, and fixed in 4% paraformaldhyde for histological analysis
or frozen in liquid nitrogen for gene expression analysis. Blood and
organs were also obtained from six DM Ren2 rats treated with saline
for 3 wk and eight untreated non-DM Ren2 rats, which did not
undergo hemodynamic measurements.
Table 1. Real-time RT-PCR primers
Gene Forward Primer Reverse Primer
HPRT-1 5=-TGGACAGGACTGAAAGACTTGCTCG-3= 5=-CTTCAGCACACAGAGGGCCACA-3=
-Actin 5=-AGCCATGTACGTAGCCATCCA-3= 5=-TCTCCGGAGTCCATCACAATG-3=
2-Microglobulin 5=-ATGGCTCGCTCGGTGACCG-3= 5=-TGGGGAGTTTTCTGAATGGCAAGCA-3=
Rat renin 5=-CGGGAGGAGGATGCCTCTCTGG-3= 5=-CAAGATTCGTCCAAAGCTGGCTGT-3=
Collagen-1 5=-TCTGGCGCAAGAGGCGAGAGA-3= 5=-GTTGCCGGGGGCACCATTGT-3=
TGF-1 5=-AGTGGCTGAACCAAGGAGACGGA-3= 5=-TGCCCAGGTCACCTCGACGT-3=
(P)RR 5=-TGAAGGAAGACCTGTCTTGGCCAGG-3= 5=-ATAATGGTAGCCCGGGGCCGG-3=
AT1R 5=-ACTGCCTGAACCCTCTGTTC-3= 5=-TCGTAGACAGGCTTGAGTGG-3=
COX-2 5=-ATTGCTGGCCGGGTTGCTGG-3= 5=-TCAATGGAGGCCTTTGCCACTGC-3=
TNF- 5=-GACCCTCACACTCAGATCATCTTCT-3= 5=-TGCTACGACGTGGGCTACG-3=
NF-B 5=-TCTGATTGGCCAGAGGCTCCC-3= 5=-GGGCGTGGCCATAGTTCAAGGG-3=
ANP 5=-ATGGGCTCCTTCTCCATCAC-3= 5=-TCTACCGGCATCTTCTCCTC-3=
BNP 5=-ACAATCCACGATGCAGAAGCT-3= 5=-GGGCCTTGGTCCTTTGAGA-3=
-MHC 5=-ATGGACCTGGAGCGAGCAAA-3= 5=-GTCCTTCTTTTTGAGTCGCTCATCC-3=
Ngal 5=-GGGCTGTCCGATGAACTGAA-3= 5=-CATTGGTCGGTGGGAACAGA-3=
HPRT-1, hypoxanthine phosphoribosyltransferase 1; TGF-1, transforming growth factor-1; (P)RR, (pro)renin receptor; AT1R, angiotensin II type 1 receptor;
COX-2, cyclooxygenase 2; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; -MHC, -myosin heavy chain; Ngal, neutrophil gelatinase-associated 
lipocalin.
Table 2. Main characteristics as well as urine and plasma analysis in non-DM Ren2 rats and DM rats treated with vehicle,
aliskiren, or aliskiren  HRP
Non-DM Rats
DM Rats
Vehicle Aliskiren Aliskiren  HRP
Mean arterial pressure on day 21, mmHg‡ ND 123  7 104  9† 103  4†
Body weight, kg 0.562  0.02 0.409  0.01* 0.419  0.01* 0.422  0.01*
Heart weight, g 2.15  0.06 1.55  0.07* 1.51  0.04* 1.60  0.05*
Heart weight/body weight, g/kg 3.9  0.10 3.7  0.11 3.6  0.12 3.7  0.09
Kidney weight, g 1.48  0.06 1.58  0.07 1.69  0.04* 1.63  0.05
Kidney weight/body weight, g/kg 2.7  0.12 4.1  0.15* 4.0  0.10* 3.9  0.12*
Blood glucose, mM‡ 6.0  0.5 24.5  0.8* 26.1  1.0* 24.8  1.0*
Urine
Creatinine, mol/day 128  4 114  9 116  13 109  5
Endothelin-1, pg/day 3.6  0.7 7  3 0.5  0.5 3.8  2
Creatinine clearance, ml/min ND 3.4  0.3 3.3  0.3 2.8  0.2
Plasma
Creatinine, nmol/ml 32.6  1.6 23.9  0.9* 23.9  0.7* 27.8  1.8
Endothelin-1, pg/ml 9.1  4 12.4  9 19.6  8 18.4  14
Plasminogen activator inhibitor-1, ng/ml 3.2  0.5 7.7  1.2 7.6  1.9 11.8  3.9*
TGF-1, pg/ml 423  99 266  78 408  124 268  80
Data are means  SE; n  7–8 rats/group. Non-DM, nondiabetic; DM, diabetic; HRP, handle region peptide; ND, not determined. Creatinine clearance in
non-DM rats could not be calculated since plasma and urine creatinine levels in this group were determined on day 21 and day 14, respectively, i.e., not on
the same day. *P  0.05 vs. non-DM rats; †P  0.05 vs. vehicle. ‡Data are from Batenburg et al. (3).
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Biochemical Measurements
ET-1 was assessed by chemiluminescent ELISA (QuantiGlo, R&D
Systems), albumin by enzyme immunoassay (Spi-Bio, Montigny-Le-
Bretonneux, France), and aldosterone by radioimmunoassay (Coat-
a-Count, Siemens Medical Solutions Diagnostics, Los Angeles,
CA). TGF-1, cystatin C (Quantikine, R&D systems), and PAI-1
(Zymutest, Tebu-Bio, Le Perray-en-Yvelines, France) were mea-
sured by ELISA. Creatinine, K, Na, and total protein were
measured at the clinical chemical laboratory of the Erasmus MC.
ANG I and ANG II were measured by radioimmunoassay, after
SepPak extraction and reverse-phase HPLC separation as previ-
ously described (6, 8).
Histology
After fixation, kidney and heart sections were dehydrated and
paraffin embedded. Gomori silver staining was applied to sections
(5 m) of the left ventricle of the heart to visualize individual
cardiomyocytes. Sirius red staining was applied to visualize col-
lagen as a measure of cardiac fibrosis. Cardiomyocyte size and the
amount of collagen were measured using Qwin (Leica).
Transversely sliced kidney sections (deparaffinized, 2 m) were
stained with periodic acid-Schiff to localize kidney damage and
-smooth muscle actin to identify interlobar arteries. The glomerular
volume, arterial wall thickness, and lumen diameter of interlobar
arteries were blindly assessed in the sections. To measure glomerular
volume, 50 individual glomeruli from each kidney section were traced
along Bowman’s capsule to measure glomerular circumference using
the system of NanoZoomer Digital Pathology. Glomerular volume
was calculated from the glomerular circumference and radius accord-
ing the method of van Damme et al. (41) using the following formula:
4/3r2, where r is the radius. To measure the arterial wall thickness-
to-lumen diameter ratio, the arterial and lumen circumference of 6
interlobar arteries/kidney section was measured using the system
of NanoZoomer Digital Pathology. Arterial wall thickness was
calculated by deduction of the lumen radius from the arterial outer
radius. Data were also expressed as arterial wall thickness divided
by the lumen diameter ratio to correct for the size of the arteries
measured.
The presence of focal segmental glomerulosclerosis was assessed
in all glomeruli of one kidney section per animal with a mean of
181  4 glomeruli per section. All sections were semiquantitatively
scored by a renal pathologist in a blinded manner. Renal scarring of
all glomeruli was scored on an arbitrary scale from 0 to 4, where
grade 0 (n0) indicates no glomerulosclerosis, grade 1 (n1) indicates
25% of sclerosis, grade 2 (n2) indicates 25–50% of sclerosis, grade
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3 (n3) indicates 50–75% of sclerosis, and grade 4 (n4) indicates
75% of sclerosis per glomerulus. Hereafter, the individual glomer-
ulosclerosis index (GSI) was calculated for each rat with the following
formula: [(1n1)  (2n2)  (3n3)  (4n4)]/(n0  n1  n2 
n3  n4). Furthermore, 10 images of each kidney section (100
magnification) were analyzed for arterial hyalinosis, intima fibrosis,
and mediahypertrophy as well as tubular atrophy, interstitial fibrosis,
and renal inflammation according to the Banff classification (35).
Each parameter was graded in 10 fields with a score of 0–3, in which
0 indicates no changes in pathology, grade 1 indicates 25% of
change, grade 2 indicates 25–50% of change, and grade 3 indicates
50% of change in affected tissue. From these data, the tubulo-
interstitial score was calculated by dividing the combined score of
tubular atrophy, interstitial fibrosis, and renal inflammation with
the number of parameters.
Quantitative Real-Time RT-PCR
Total RNA was isolated from snap-frozen rat kidneys and hearts
using TRIzol (Life Technologies) and reverse transcribed into cDNA
using the QuantiTect Reverse Transcription Kit (Qiagen, Venlo, The
Netherlands). The resulting cDNA was amplified for 40 cycles (de-
naturation at 95°C for 10 min, thermal cycling at 95°C for 15 s, and
annealing/extension at 60°C for 1 min) with a Step-One cycler
(NYSE, Life Technologies) using SYBR Green PCR Master Mix
(Life Technologies). The intron-spanning oligonucleotide primers for
quantitative PCR were designed with Primer-BLAST (National Cen-
ter for Biotechnology Information; Table 1). The comparative cycle
time method (CT, where CT is threshold cycle) was used for the
relative quantification of gene expression using the geometric mean of
the housekeeping genes hypoxanthine phosphoribosyl transferase-1,
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2-microglobulin, and -actin for normalization. In cardiac left ven-
tricular tissue, gene expression of atrial natriuretic peptide (ANP),
brain natriuretic peptide (BNP), -myosin heavy chain (-MHC),
(P)RR, and AT1R was determined. Gene expression of rat renin,
(P)RR, AT1R, collagen-1, TGF-1, TNF-, NF-B, COX-2, and
neutrophil gelatinase-associated lipocalin (Ngal; a marker of tubular
damage) was measured in the kidney medulla and cortex.
Statistical Analysis
Statistical analysis was performed using an unpaired t-test after
one-way ANOVA with a Bonferroni posttest confirmed differences
between groups. Data are given as means  SE. P values of 0.05
were considered significant.
RESULTS
Animal Characteristics
Hemodynamic data have been previously reported (3). In
brief, diabetic Ren2 rats were severely hypertensive, and a
3-wk treatment with aliskiren (but not vehicle) lowered blood
pressure (Table 2). The effect on blood pressure was unaltered
by HRP. Diabetic Ren2 rats displayed reduced body weight
and heart weight and an increased kidney weight; as a result,
the heart weight-to-body weight ratio was unaltered in diabetic
animals, whereas their kidney weight-to-body weight ratio was
increased (Table 2). Treatment with aliskiren with or without
HRP did not affect these parameters.
Biochemical Measurements
STZ-induced DM increased blood glucose in Ren2 rats
approximately fourfold, and this was unaffected by treatment
(Table 2). DM increased urinary volume time dependently. It
was up4-fold after 2 wk and after an additional 3 wk (during
treatment with vehicle) 13-fold (Fig. 1). Aliskiren prevented
this rise in diuresis, most likely due to its effects on blood
pressure, whereas HRP negated the protective effects of al-
iskiren. Changes in urinary protein and albumin ran in parallel
with the changes in urinary volume, although HRP did not
prevent the effect of aliskiren on albumin (Fig. 1).
DM decreased plasma creatinine, and this was unaffected by
aliskiren treatment. HRP, when given on top of aliskiren, normalized
plasma creatinine. No significant changes in urinary creatinine or
creatinine clearance were observed after DM induction with or
without treatment (Table 2). Likewise, there was no change in plasma
cystatin C, indicating no change in the glomerular filtration rate due
to 5 wk of DM with or without treatment (Fig. 3).
DM marginally decreased plasma renin activity [P  not
significant (NS)], and this was accompanied by a significant
decrease in ANG levels in the heart and kidney (Fig. 2).
Aliskiren further reduced these levels in the kidney, both with
and without HRP. Plasma aldosterone levels were also de-
creased in diabetic Ren2 rats, and this resulted in increased
natriuresis and a (nonsignificant) increase in plasma K levels
(Fig. 3). Remarkably, despite the reduction in plasma aldoste-
rone, urinary aldosterone excretion rose eightfold. Aliskiren
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(TGF)-1 (E), cyclooxygenase (COX)-2 (F), and neutrophil gelatinase-associated lipocalin (Ngal; G) in the kidney medulla and cortex from non-DM and DM
Ren2 rats, with the latter treated for 3 wk with vehicle, aliskiren, or aliskiren  HRP. Data are means  SE; n  5–9. Values are expressed as fold changes
versus non-DM. *P  0.05 vs. non-DM; $P  0.05 vs. vehicle.
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with or without HRP greatly reduced the latter and yet non-
significantly increased plasma aldosterone. As a result, natri-
uresis tended to diminish (P NS). Of interest, HRP on top of
aliskiren further increased plasma K.
Plasma levels of TGF-1 and PAI-1 were not affected by
diabetes or treatment with aliskiren. However, HRP on top of
aliskiren increased plasma PAI-1 by 50% compared with
vehicle- or aliskiren-treated rats without affecting TGF-1
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Fig. 5. Top: representative images of periodic acid-Schiff-stained kidney sections (a and b) and -smooth muscle actin-stained interlobar arteries (c). Bottom:
glomerular volume (A), glomerulosclerosis index (GSI; B), tubulointerstitial score (TIS; C), interlobar arterial lumen diameter (D), wall thickness (E), and
wall-to-lumen ratio (F) in kidney sections from non-DM and DM Ren2 rats, with the latter treated for 3 wk with vehicle, aliskiren, or aliskiren  HRP. Data
are means  SE; n  7–8. *P  0.05 vs. non-DM.
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(Table 2). Plasma and urinary ET-1 levels were unaffected by
DM or treatment (Table 2).
The Kidney
Gene expression. DM did not alter rat renin, AT1R, COX-2,
or Ngal expression in the medulla or cortex (Fig. 4). It
increased (P)RR and collagen-1 expression in the medulla and,
to a lesser degree (P  NS), in the cortex. DM decreased
TGF-1 expression in the cortex, whereas it induced a nonsig-
nificant increase in TGF-1 expression in the medulla. Similar
changes were observed for TNF- and NF-B, but these were
not significant (data not shown). Aliskiren did not alter DM-
induced changes in TGF-1 and collagen-1 and increased
cortical rat renin expression. A similar increase in renin ex-
pression, albeit nonsignificant, was observed in the medulla.
Aliskiren diminished cortical (P)RR and AT1R expression
without affecting these parameters in the medulla. Aliskiren
tended to increase cortical COX-2 expression (P  NS).
Changes by aliskiren were unaltered in the presence of HRP
except for the increase in COX-2, which became significant
after the addition of HRP.
Histology. DM did not alter tubulointerstitial score, glomer-
ular volume, interlobar arterial lumen diameter, and wall thick-
ness (nor the ratio of the latter two) and nonsignificantly
decreased GSI (Fig. 5). Arterial hyalinose, intima fibrosis, and
media hypertrophy were not observed. Aliskiren reduced GSI
without affecting any of the other parameters. HRP, when
given on top of aliskiren, did not alter its effects on GSI but
tended to increase glomerular volume and lumen diameter,
with the latter resulting in a decrease in the lumen diameter-
to-wall thickness ratio. However, none of these changes were
significant.
The Heart
Gene expression. DM did not affect cardiac ANP, BNP, and
(P)RR expression and increased -MHC and AT1R expression
(Fig. 6). Aliskiren with HRP, but not aliskiren alone, normal-
ized the latter. Drug treatment did not affect (P)RR or -MHC
expression. Aliskiren, with or without HRP, reduced cardiac
BNP expression, and similar trends were observed for cardiac
ANP expression, although the changes were significant only
during combination treatment.
Histology. DM increased cardiac collagen content without
altering myocyte size. Aliskiren did not affect these changes,
whereas aliskiren with HRP further increased collagen content
and marginally diminished myocyte size (Fig. 7).
DISCUSSION
This study shows that HRP counteracts the favorable effects
of aliskiren on early renal damage in diabetic Ren2 rats. In
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Fig. 6. Gene expression analysis of atrial natriuretic peptide (ANP; A), brain natriuretic peptide (BNP; B), -myosin heavy chain (-MHC; C), (P)RR (D), and
AT1 receptor (E) in hearts from non-DM and DM Ren2 rats, with the latter treated for 3 wk with vehicle, aliskiren, or aliskiren  HRP. Data are means  SE;
n  7–10. Values are expressed as fold changes versus non-DM. *P  0.05 vs. non-DM; $P  0.05 vs. vehicle.
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agreement with previous studies (3, 26), the hypertensive Ren2
rat, when made diabetic with STZ, displayed mild glomerulo-
sclerosis, accompanied by albuminuria, proteinuria, and diure-
sis. A 3-wk treatment with aliskiren improved these parame-
ters, whereas the addition of HRP on top of aliskiren negated
the protective effects of aliskiren on the latter two. HRP also
induced hyperkalemia and increased plasma PAI-1, renal
COX-2, and cardiac collagen content. This argues against the
application of HRP in combination with aliskiren in diabetic
patients.
Plasma creatinine decreased after the induction of DM, most
likely reflecting the weight (and muscle) loss occurring in these
animals. There were no changes in cystatin C or renal Ngal
expression, suggesting that indeed the renal damage in our DM
animals was at an early stage, not yet resulting in alterations in
glomerular filtration or tubular damage. Of interest, aliskiren
alone did not alter these parameters, whereas HRP on top of
aliskiren increased plasma creatinine and tended to increase
(P NS) cortical Ngal expression, again suggesting that HRP,
if anything, worsened renal function when combined with
aliskiren.
DM reduced plasma, cardiac, and renal RAS activity in the
Ren2 rat, although only the reduction in tissue was significant.
The reduction in plasma renin activity was modest, in full
agreement with the consequence of diabetes in humans (15).
Along with this RAS suppression, plasma aldosterone de-
creased by almost 50%. Not surprisingly, this resulted in
natriuresis and a (nonsignificant) rise in plasma K. Yet,
urinary aldosterone excretion increased eightfold. This is sug-
gestive for a net rise in adrenal aldosterone production, most
likely to compensate the loss of aldosterone via urine (1.5
ng/day). Of interest, aliskiren greatly diminished the urinary
aldosterone loss, reflecting a reduction in aldosterone produc-
tion, although plasma aldosterone, if anything, tended to go up,
thereby counteracting the above effects on natriuresis and
hyperkalemia. The effects of aliskiren on aldosterone and
natriuresis were unaltered by HRP. However, it greatly ele-
vated plasma K. Since this occurred independently of
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Fig. 7. Top: representative images of Gomori-stained cardiomyocytes (a) and of Sirius red-stained left ventricular tissue. Bottom: cardiomyocyte size (A) and
fibrotic area (B) in left ventricular tissue of hearts from non-DM and DM Ren2 rats, with the latter treated for 3 wk with vehicle, aliskiren, or aliskiren  HRP.
Data are means 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changes in aldosterone, it might be the consequence of direct
effects of HRP, e.g., via (P)RR (31).
The aliskiren-induced reduction in renal ANG content, to-
gether with the reduction of cortical AT1R expression, proba-
bly underlies the beneficial effect of renin inhibition in the
kidney. Aliskiren-induced AT1R suppression has been previ-
ously reported, both in the kidney and other organs (11, 30,
43). At 5 wk after STZ injection, we observed modest regional
changes in renal TGF-1, TNF-, NF-B, and collagen-1
expression, although no fibrosis or inflammation could be
detected. It is therefore not surprising that aliskiren did not
significantly affect these parameters in the kidney. Such effects
have been observed before, but this required a longer duration
of DM (10 wk) and aliskiren treatment starting at the moment
of STZ injection (11). HRP did not alter the effect of aliskiren
on TGF-1 but unexpectedly increased the levels of PAI-1.
These observations contrast with the idea that HRP prevents
(pro)renin-(P)RR interactions, thereby blocking the rise in
PAI-1 that result from such (P)RR stimulation, at least in vitro
(19, 48). Possibly, the increase in renal (rat) renin expression
after aliskiren was too modest to increase PAI-1. In addition,
aliskiren suppressed (P)RR expression. Recently, HRP has
been reported to act as a partial agonist of (P)RR (31, 46).
Thus, its stimulatory effects on PAI-1 on top of aliskiren might
also be the consequence of direct (P)RR stimulation.
Hyperglycemia elevates (P)RR expression in rat mesangial
cells via PKC, ERK1/2, and JNK (17), and this has been
suggested to facilitate ANG II generation and AT1R-dependent
COX-2 induction (13). Ubiquitous overexpression of human
(P)RR in the rat also resulted in COX-2 upregulation (25).
Simultaneously, COX-2 inhibition reduced the glucose-in-
duced (P)RR upregulation, suggesting that COX-2 itself up-
regulates (P)RR (16). Our study confirms renal (P)RR upregu-
lation in diabetic Ren2 rats. However, significant COX-2
upregulation was only seen after concomitant HRP adminis-
tration, even in the face of aliskiren-induced (P)RR suppres-
sion. This suggest that (P)RR upregulation per se is insufficient
to increase COX-2 and requires additional (P)RR stimulation,
either by renin, HRP, or their combination. COX-2 elevation
has been previously reported in the macula densa after renin
upregulation due to salt restriction (14). Such COX-2 upregu-
lation has detrimental effects, for instance, COX-2 generated
endothelium-derived contractile factors in diabetic Ren2 rats,
thereby inducing vascular dysfunction (3), and the COX-2
upregulation in human (P)RR-overexpressing rats was accom-
panied by proteinuria and glomerulosclerosis (25).
Natriuretic peptides are released by the hypertrophied heart,
and their levels are elevated in patients with heart failure (4)
and in homozygous Ren2 rats (44). Aliskiren reduced cardiac
ANP and BNP expression in the diabetic, heterozygous Ren2
rats of the present study, most likely due to its blood pressure-
lowering effect. Yet, aliskiren did not affect cardiac hypertro-
phy, -MHC expression, or myocyte size. These effects were
unaltered by HRP. Moreover, no changes occurred in cardiac
(P)RR expression, suggesting that (P)RR upregulation by hy-
perglycemia is not a uniform phenomenon. Although aliskiren
with or without HRP did not significantly reduce cardiac ANG
content, HRP combined with aliskiren did suppress cardiac
AT1R expression, suggesting that this combination may have
reduced the consequences of ANG II-AT1R interactions. How-
ever, this did not result in a reduction of cardiac fibrosis,
possibly because the degree of fibrosis in our model was still
modest. Remarkably, however, cardiac fibrosis increased sig-
nificantly after cotreatment of aliskiren with HRP. This con-
trasts with a previous study (21) showing antifibrotic effects of
HRP in stroke-prone spontaneously hypertensive rats and once
again illustrates the partial agonistic capacities of HRP.
In conclusion, renin inhibition improves renal function in
diabetic Ren2 rats with early kidney damage, and (P)RR
blockade with HRP not only counteracted this effect in a
RAS-independent manner but also increased K, PAI-1, renal
COX-2, and cardiac fibrosis. This contrasts with the beneficial
cardiac and renal effects of HRP observed in various models
(20, 22, 24) but agrees with the deleterious effects of (P)RR
knockout in the heart and kidney (28, 40). A uniform expla-
nation might be that HRP acts as a partial agonist (43, 46).
Nevertheless, given these controversial findings, it seems that,
at this stage, HRP should not be considered as add-on drug in
diabetics treated with a RAS inhibitor. Furthermore, given the
uncertainty whether HRP is a (P)RR blocker or not, future
studies should carefully examine the exact function of (P)RR in
diabetes, e.g., making use of (inducible) renal cell-specific
knockout models, to define its role as a treatment target.
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Abstract
Dysfunction of renin-angiotensin system (RAS) contributes to the pathogenesis of diabetic retinopathy (DR). Prorenin, the
precursor of renin is highly elevated in ocular fluid of diabetic patients with proliferative retinopathy. Prorenin may exert
local effects in the eye by binding to the so-called (pro)renin receptor ((P)RR). Here we investigated the combined effects of
the renin inhibitor aliskiren and the putative (P)RR blocker handle-region peptide (HRP) on diabetic retinopathy in
streptozotocin (STZ)-induced diabetic transgenic (mRen2)27 rats (a model with high plasma prorenin levels) as well as
prorenin stimulated cytokine expression in cultured Mu¨ller cells. Adult (mRen2)27 rats were randomly divided into the
following groups: (1) non-diabetic; (2) diabetic treated with vehicle; (3) diabetic treated with aliskiren (10 mg/kg per day);
and (4) diabetic treated with aliskiren+HRP (1 mg/kg per day). Age-matched non-diabetic wildtype Sprague-Dawley rats
were used as control. Drugs were administered by osmotic minipumps for three weeks. Transgenic (mRen2)27 rat retinas
showed increased apoptotic cell death of both inner retinal neurons and photoreceptors, increased loss of capillaries, as
well as increased expression of inflammatory cytokines. These pathological changes were further exacerbated by diabetes.
Aliskiren treatment of diabetic (mRen2)27 rats prevented retinal gliosis, and reduced retinal apoptotic cell death, acellular
capillaries and the expression of inflammatory cytokines. HRP on top of aliskiren did not provide additional protection. In
cultured Mu¨ller cells, prorenin significantly increased the expression levels of IL-1a and TNF-a, and this was completely
blocked by aliskiren or HRP, their combination, (P)RR siRNA and the AT1R blocker losartan, suggesting that these effects
entirely depended on Ang II generation by (P)RR-bound prorenin. In conclusion, the lack of effect of HRP on top of aliskiren,
and the Ang II-dependency of the ocular effects of prorenin in vitro, argue against the combined application of (P)RR
blockade and renin inhibition in diabetic retinopathy.
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and diabetes. Although the RAS was classically considered a
circulating system having general systemic effects, it is now
recognized that there are also local tissue RASs, for instance in the
retina [7]. Activation of such local RASs may contribute to end-
organ damage in diabetes and associated complications [7,8].
It has long been recognized that diabetes with microvascular
complications is associated with increased plasma prorenin [9,10].
Relative to albumin, ocular fluids contain higher concentrations of
prorenin than plasma, and ocular prorenin increases even further
in diabetic patients with proliferative retinopathy [10–12]. This
has led to the suggestion that prorenin may be a marker of diabetic
complications [10]. Elevated prorenin may contribute to diabetic
complications by binding to its putative receptor, the so-called
(pro)renin receptor ((P)RR). Such binding activates prorenin,
leading to increased angiotensin generation in target tissue and
subsequent signaling by the classic RAS pathway [13]. In addition,
binding of (pro)renin to the (P)RR also directly initiates a cascade
Introduction
Diabetic retinopathy (DR) is the most common diabetic
microvascular complication and the leading cause of severe vision 
loss in people under the age of sixty [1]. The prevalence of DR 
increases with the duration of diabetes, and nearly all individuals 
with type 1 diabetes and more than 60% of those with type 2 
diabetes have some form of retinopathy after 20 years [2,3].
Several molecular, biochemical and hemodynamic pathways 
have been identified to contribute to the pathogenesis of DR [4]. 
Hyperactivity of the renin-angiotensin system (RAS), resulting in 
elevated concentrations of its principal effector peptide, angioten-
sin (Ang) II, plays a key role in activating pathways leading to 
increased vascular inflammation, oxidative stress, endothelial 
dysfunction and tissue remodeling in variety of conditions, 
including diabetes and its associated complications [5,6]. As a 
result, RAS inhibitors are first-line therapeutic agents for treating 
patients with cardiovascular diseases, cardiometabolic syndrome
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Retinal histology and immunofluorescence
Eyes were fixed in 4% paraformaldehyde freshly made in
phosphate-buffered saline (PBS) at 4uC overnight. Eyecups were
cryoprotected in 30% sucrose/PBS for several hours or overnight
prior to quick freezing in optical cutting temperature (OCT)
compound. Then 12 mm thick sections were cut at –20 to –22uC.
A rabbit polyclonal antibody against glial fibrillary acidic protein
(GFAP, 1:1000, Sigma, St. Louis, MO), was used. The secondary
antibody (conjugated with Alexa594) was from Molecular Probes
(Invitrogen, Carlsbad, CA) and used according to the manufac-
turer’s instruction. Sections were coverslipped using VECTA-
SHIELD (Vector Laboratories, Burlingame, CA), and examined
with a Zeiss (AxionVision, Carl Zeiss MicroImaging, Inc, NY)
microscope equipped with epifluorescence illumination and a high
resolution digital camera. For morphological analysis, eyes were
fixed in 10% formalin solution, processed for paraffin embedding,
sectioned at a thickness of 4 mm, and stained with hematoxylin
and eosin (H&E). For quantitative measurement of retinal
ganglion cell (RGC) density, the number of nuclei in the RGC
layer was counted from at least 10 sections from each eye, 4 eyes
from each group.
In situ cell death detection
To detect apoptotic cells, an In Situ Cell Death Detection Kit
based on TUNEL technology (In Situ Cell Death Detection Kit,
TMR red, Roche Applied Science, Indianapolis, IN, USA) was
used according to the instructions supplied by the manufacturer.
Retinal vascular preparation and H&E staining
Retinal vasculature was prepared using method as described
previously [44]. Briefly, eyes were fixed in 4% paraformaldehyde
freshly made in PBS overnight. Retinas were dissected out from
the eyecups and digested in 3% trypsin (GIBCO-BRL) for 2–3
hours at 37uC. Retinal vessels were separated from other retinal
neuronal cells by gentle shaking and manipulation under a
dissection microscope. The vessels were then mounted on a clean
slide, allowed to dry, and stained with PAS-H&E (Periodic Acid
Solution- Hematoxylin, Gill No.3, Sigma, St. Louis, MO)
according to the instruction manual. After staining and washing
in water, the tissue was dehydrated and mounted in permount
mounting media. The prepared retinal vessels were photographed
using a Zeiss microscope equipped with a high resolution digital
camera (AxioCam MRC5, Zeiss Axionvert 200). Six to eight
representative, non-overlapping fields from each quadrant of the
retina were imaged. Acellular capillaries were counted from
images for each retina, and expressed as number of acellular
vessels per mm2.
RT-PCR of inflammatory cytokines
Total RNA was isolated from freshly dissected retinas using
Trizol Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instruction. Reverse transcription was performed
using Enhanced Avian HS RT-PCR kit (Sigma, St. Louis, MO)
following the manufacturer’s instructions. Real time PCR was
carried out on a real time thermal cycler (iCycler, Bio-Rad Life
Sciences) using iQTM Syber Green Supermix (Bio-Rad Life
Sciences). The threshold cycle number (Ct) for real-time PCR was
set by the cycler software. Optimal primer concentration for PCR
was determined separately for each primer pair. The primer
sequences used in this study are shown in Table 1. Each reaction
was run in duplicate or in triplicate, and reaction tubes with target
primers and those with GAPDH/actin primers were always
included in the same PCR run. To test the primer efficiencies, the
of signaling events involving mitogen-activated protein kinases 
such as ERK1/2 and p38, that are known to be associated with 
profibrotic and proliferative actions independent of Ang II [13,14]. 
The role of (P)RR in end-organ damage and diabetic complica-
tions is supported by several studies demonstrating that an 
inhibitor of (P)RR, a peptide derived from the prosegment of 
prorenin, the so-called handle-region peptide (HRP), afforded 
renal and cardiovascular protection [15,16], presumably by 
inhibiting the binding of prorenin to the (P)RR [17]. HRP has 
also been shown to be beneficial in ocular pathologies [18–21].
Aliskiren is the first renin inhibitor that blocks the activity of 
renin, a key rate-limiting enzyme in the first step of the RAS 
cascade [22]. It has shown high efficacy not only in controlling 
blood pressure [23], but also in renal and cardiovascular 
protection [24,25]. It is also effective in patients with metabolic 
syndrome, obesity and diabetes [26,27], as well as in experimental 
atherosclerosis [28,29]. Although aliskiren is able to bind to (P)RR-
bound renin and prorenin [30–32], its role in (P)RR-mediated 
Ang II-independent signaling remains controversial with conflict-
ing reports [33,34]. We have previously shown that HRP 
unexpectedly counteracted some of the beneficial effects of 
aliskiren [35,36]. In the present study, we investigated the effects 
of aliskiren on diabetes-induced retinopathy in a transgenic rat 
model overexpressing the mouse renin gene, i.e., the (mRen2)27 
rat (Ren2 rat). This rat exhibits significantly elevated prorenin and 
Ang II levels, and displays increased PRR expression and severe 
hypertension [37–40]. After streptozotocin injection, these animals 
develop a diabetic phenotype that closely mimics that in diabetic 
patients, characterized by high prorenin levels, retinal pathology, 
vascular dysfunction and nephropathy [41,42]. We also examined 
the effects of HRP on top of renin inhibition with aliskiren. Our 
data show that renin inhibition with aliskiren reduced both 
neuronal and vascular pathologies in the diabetic Ren2 rat retina, 
and that HRP on top of aliskiren did not provide additional 
protection, nor counteracted the beneficial effects of aliskiren.
Materials and Methods
Animals and treatment groups
Adult heterozygous Ren2 rats (400–500 g) with a Sprague–
Dawley (SD) background [36] were used in this study. Rats were 
housed in individual cages and maintained on a 12-h light/dark 
cycle, having access to standard laboratory rat chow and water ad 
libitum. All procedures were performed under the regulation and 
approval of the Animal Care Committee of the Erasmus MC. 
Blood pressure was measured by radiotelemetry transmitters that 
were implanted as described before [43] two weeks prior to 
diabetes induction. To induce diabetes, rats were fasted overnight 
and administered streptozotocin (STZ; 55 mg/kg i.p., Sigma–
Aldrich, Zwijndrecht, The Netherlands). Blood glucose levels were 
checked by tail incision (Precision Xceed, Abbott, Zwolle, The 
Netherlands). Only rats with a glucose level .15 mmol/L were 
considered diabetic, and they subsequently received 2–4 U insulin 
per day (Levemir, Novo Nordisk, Denmark). Aliskiren (a gift of 
Novartis, 10 mg/kg per day) with (n = 8) or without (n = 7) rat 
HRP (NH2- RILLKKMPSV-COOH, 1 mg/kg per day, Bio-
synthan, Berlin, Germany), or vehicle (saline, n = 8) were 
administered for 3 weeks by osmotic minipumps (2ML4 ALZET, 
Cupertino, USA) implanted subcutaneously two weeks after 
diabetes induction. In the animals receiving two drugs, two 
separate minipumps were implanted at both sides of the body. 
Eyes were collected at the end of the treatment period. For 
comparison, eyes were also collected from 9 untreated nondiabetic 
Ren2 rats, and 5 age-matched untreated SD rats.
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one-step RT-PCR was run with each target primer. Relative
quantification was achieved by the comparative 2-DDCt method1.
The relative increase/decrease (fold-induction/repression) of
mRNA of target X in the experimental group (EG) was calculated
using the control group as the calibrator: 2-DDCt, where DD Ct is
{Ct.x [EG] -Ct. GAPDH [EG]} - {Ct.x [control] - Ct. GAPDH
[control]}.
Cell culture and treatment
Mu¨ller cells (a kind gift of Dr. G. Astrid Limb, UCL Institute of
Ophthalmology, London, United Kingdom) [45] were cultured in
24-well plates with Dulbecco’s Modified Eagle Medium (DMEM)
(Thermo Fisher Scientific, Waltham, MA) containing 10% fetal
bovine serum (FBS) (Thermo Fisher Scientific, Waltham, MA).
The ON-Target plus (P)RR siRNA and scrambled control siRNA
were from (Thermo Fisher Scientific, Waltham, MA). Different
concentrations and incubation times of (P)RR-siRNA were pre-
tested to determine the optimal concentration and incubation time
according to the manufacturer’s recommendation. Cells grown to
70% confluence in the serum medium were replaced by Opti-
MEM I-reduced serum medium (Life Technologies, Carlsbad,
CA), and the ON-Target plus (P)RR siRNA or control siRNA, or
vehicle only was added into the medium at a final concentration of
30 nmol/L. After 24-hour incubation with the siRNA, the cells
were replaced with serum-free DMEM medium (Thermo Fisher
Scientific, Waltham, MA) for 2 hours. Following the serum
starvation, the cells were either untreated (control) or treated with
prorenin (100 nmol/L) alone, prorenin (100 nmol/L) + HRP
(10 mmol/L, GenScript), prorenin + aliskiren (10 mmol/L), prore-
nin + HRP (10 mmol/L) + aliskiren (10 mmol/L), and prorenin
(100 nmol/L) + losartan (10 mmol/L, according to previous
studies [46]). After the 6 hour incubation, cells were harvested
and total RNA was extracted, real time RT-PCR was performed
and analyzed using the methods described previously.
Statistics
All values are presented as mean 6 SD. Paired Student’s t-test
was used to assess significance between two groups. One-way
ANOVA followed by the post hoc Tukey (Fisher’s protected least
significant difference) test was used to assess statistical significance
between multiple groups. Differences were considered significant
at p,0.05.
Results
Induction of diabetes mellitus and blood pressure
Blood glucose levels and mean arterial pressure (MAP) have
been reported before [36]. In short, Ren2 rats had a normal blood
glucose level, identical to that in Sprague–Dawley (SD) rats. STZ-
induced diabetes mellitus increased blood glucose levels ,5-fold,
and treatment with aliskiren or aliskiren+HRP did not alter this.
Aliskiren lowered MAP in Ren2 rats from 12364 mmHg to
10465 mm Hg, and this effect was unaltered by simultaneous
administration of HRP [47].
Retinal gliosis
Retinal gliosis, a salient feature of the retina under stress or
injury including diabetic retinopathy, is characterized by elevated
expression of the intermediate filament, glial fibrillary acidic
protein (GFAP) in Mu¨ller cells and astrocytes. GFAP is normally
predominantly expressed in astrocytes in the inner retinal fiber
layer (Figure 1a, b). A slight increase of GFAP expression was
observed in astrocytes of the retina of non-diabetic Ren2 rats, but
this was not different from the wildtype SD rat retina (Figure 1c,
d). GFAP expression was elevated in the diabetic Ren2 rat retina
(Figure 1e, f), and aliskiren prevented this elevation, both without
(Figure 1g, h) and with HRP (Figure 1i, j).
Apoptosis and RGC loss
In the SD rat retina, very few apoptotic cells could be detected
(data not shown). The Ren2 rat retina showed a significant
increase of TUNEL positive apoptotic cells in both inner retina
Table 1. Primers used for Real-Time RT-PCR analysis.
Gene name Accession # Sequences
Rat VEGF NM_031836 Forward: 59 -TGCACCCACGACAGAAGGGGA-39
Reverse: 59-TCACCGCCTTGGCTTGTCACAT-39
Rat MCP1 NM_031530 Forward: 59 -GCAGCAGGTGTCCCAAAGAAGCT-39
Reverse: 59-AGAAGTGCTTGAGGTGGTTGTGGAA-39
Rat ICAM1 NM_012967 Forward: 59 -CCCCACCTACATACATTCCTAC-39
Reverse: 59-ACATTTTCTCCCAGGCATTC-39
Rat TNFa NM_012675 Forward: 59 -CCTTATCTACTCCCAGGTTCTC-39
Reverse: 59-TTTCTCCTGGTATGAAATGGC-39
Rat GAPDH AF106860 Forward: 59 -TGCTGGGGCTGGCATTGCTC-39
Reverse: 59- CCCCAGGCCCCTCCTGTTGT-39
Human IL-1a NM_000575 Forward: 59-ATCAGTACCTCACGGCTGCT-39
Reverse: 59-TGGGTATCTCAGGCATCTCC-39
Human TNFa NM_000594 Forward: 59-ATCTACTCCCAGGTCCTCTTCAA-39
Reverse: 59-GCAATGATCCCAAAGTAGACCT-39
Human b actin NM_001101 Forward: 59-GCAGGAGTATGACGAGTCCG-39
Reverse: 59-AGGGACTTCCTGTAACAATGC-39
doi:10.1371/journal.pone.0100954.t001
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Figure 1. Immunofluorescence detection of GFAP expression in the retinas of wildtype (WT) Sprague–Dawley rats, non-diabetic
(NDM) Ren2, diabetic (DM) Ren2 rats treated with vehicle, aliskiren or aliskiren+HRP. ONL: outer nuclear layer; OPL: outer plexiform layer;
INL: inner nuclear layer; IPL: inner plexiform layer; RGC: retinal ganglion cell layer.
doi:10.1371/journal.pone.0100954.g001
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Moreover, Mu¨ller cells express several RAS components [7,51],
including (pro)renin [52] and its receptor (P)RR, so that Mu¨ller
cell dysfunction might contribute to ocular dysregulation in
diabetes [18,21,53,54]. In fact, ocular prorenin upregulation is
known to occur in patients with proliferative [10–12]. Prorenin
was previously shown to increase proinflammatory cytokine
expression in cultured neurons [55], To determine whether
prorenin is also able to increase the expression of proinflammatory
cytokines in Mu¨ller cells, cultured Mu¨ller cells were treated with
prorenin, with and without HRP, aliskiren and/or the AT1R
blocker losartan. The expression levels of IL-1a and TNF-a at 6
hours after the prorenin treatment were examined. Our results
showed that the prorenin treatment significantly increased the
expression of IL-1a (by ,12-fold) TNF-a (by ,3-fold) (Figure 6).
Both aliskiren and HRP when given separately completely blocked
these increases, and the results were identical when given in
combination. Losartan treatment also completely blocked prore-
nin stimulated increased expression of IL-1a and TNF-a (Figure 6),
suggesting that the increased expression of these cytokines is Ang
II- dependent. (P)RR-siRNA completely blocked the prorenin
stimulated increase of these cytokines, whereas the control
scrambled siRNA had no effect (Figure 6), suggesting that the
prorenin stimulated, Ang II-dependent increase in cytokine
expression in Mu¨ller cells involves (P)RR binding.
Discussion
The present study demonstrates that the Ren2 rat retina
exhibited increased capillary loss and inflammatory cytokine
expressions, and neuronal apoptotic cells. Diabetes mellitus further
exacerbated these changes and enhanced gliosis. Renin inhibition
counterbalanced these phenomena, whereas (P)RR blockade on
top of renin inhibition did not offer additional advantages. The
protective effect of aliskiren on retinal vasculopathy and inflam-
mation in diabetic Ren2 rats is consistent with a previous report
[56]. Diabetic retinopathy is not only associated with vascular
dysfunction, but also with a loss of retinal neurons [57]. Our study
further showed that aliskiren treatment normalized both photo-
receptor and RGC loss in Ren2 rats to wildtype (SD rat) level.
Elevated plasma prorenin levels associate with microvascular
complications in patients with diabetes mellitus. Prorenin is also
highly elevated in ocular fluid in patients with diabetic retinopathy
and its level correlates with the severity of DR in diabetic patients
[10,11]. Prorenin may contribute to diabetic complication and
end-organ damage by binding to the (P)RR, resulting in increased
generation of Ang II by the classic RAS pathway at the cell/tissue
level [13]. Alternatively, such binding may initiate a cascade of
signaling events that are associated with profibrotic and prolifer-
ative actions, independent of Ang II [13]. To what degree
prorenin-(P)RR interaction is physiologically relevant, given the
nanomolar prorenin levels (i.e., several orders above its normal
plasma levels) that are required for such interaction, is still a matter
of debate [58]. Nevertheless, since the eye is a prorenin-producing
organ, with Mu¨ller cells releasing prorenin in the retina [52], if
anywhere, such interaction might occur at ocular sites.
The importance of the (P)RR in the pathogenesis of end-stage
organ damage in diabetes and hypertension has been demonstrat-
ed by in vitro and in vivo animal studies using HRP, the only
(P)RR blocker that is currently available [15]. The possible
Figure 1. Immunofluorescence detection of GFAP expression in the retinas of wildtype (WT) Sprague–Dawley rats, non-diabetic
(NDM) Ren2, diabetic (DM) Ren2 rats treated with vehicle, aliskiren or aliskiren+HRP. ONL: outer nuclear layer; OPL: outer plexiform layer;
INL: inner nuclear layer; IPL: inner plexiform layer; RGC: retinal ganglion cell layer.
doi:10.1371/journal.pone.0100954.g001
and photoreceptor layer (Figure 2a, b), and this increase was more 
prominent in the peripheral retina (Figure 2b) compared with the 
central retina (Figure 2a). This increase in apoptotic cells was 
dramatically further exacerbated in the diabetic Ren2 rat retina 
(Figure 2c, d). Treatment with either aliskiren alone or aliskiren+ 
HRP significantly reduced apoptotic cell death to levels in the SD 
rat retina (Figure 2e, f, g). Morphologically the central retina of 
non-diabetic Ren2 rat is indistinguishable from wild type rat 
retina, however there is significant cell loss in the retinal ganglion 
cell (RGC) layer in peripheral retina (Figure 3). The diabetic Ren2 
rat retina showed significantly increased cell loss in the RGC layer, 
which was more profound in the peripheral retina. The cell loss 
was normalized by either aliskiren or aliskiren+HRP treatment 
(Figure 3).
Retinal capillaries
The Ren2 rat retina showed an increased loss of capillaries 
compared to age-matched SD rat retinas (Figure 4A and B), and 
this loss was further exacerbated in diabetic Ren2 rat retinas 
(Figure 4C). Aliskiren reduced the acellular capillaries to the level 
seen in non-diabetic Ren2 rat retina (Figure 4D), but the number 
of acellular capillaries was still significantly higher compared to 
that of the SD retina. HRP treatment in combination with 
aliskiren did not add additional protection against capillary loss 
(Figure 4E). Figure 4F displays these results in a quantitative 
manner.
Retinal inflammatory cytokines
Inflammatory cytokine expression in the retina was evaluated by 
real-time RT-PCT. VEGF expression was increased .2-fold in 
the Ren2 rat retina compared to age-matched SD rat retinas, and 
this increase was even larger in diabetic Ren2 rat retinas. 
Treatment with either aliskiren alone or combined with HRP 
reduced VEGF to non-diabetic Ren2 rat levels (Figure 5). MCP-1 
expression was also significantly increased in Ren2 rat retinas with 
or without diabetes mellitus and aliskiren alone or in combination 
with HRP normalized this (Figure 5). A significant increase of 
ICAM1 was only seen in diabetic Ren2 rat retinas, and both 
aliskiren and aliskiren+HRP normalized this (Figure 5). TNFa 
expression was also highly increased in the Ren2 rat retina, and 
diabetes mellitus further upregulated this. Aliskiren significantly 
reduced TNFa to non-diabetic Ren2 rat levels. Aliskiren+HRP 
tended to reduce this even further, but the difference versus 
aliskiren was not statistically significant.
Increased cytokine expression stimulated by 
recombinant prorenin in cultured human Mu¨ ller glial 
cells and blockade by HRP and aliskiren
Mu¨ller cells, which span the entire neural retina, are the 
primary glial cell of the retina. They not only provide architectural 
support of the neural layers, but also have multiple functions such 
as providing metabolic support to energy-demanding retinal 
neurons, regulation of retinal synaptic activity by neurotransmitter 
recycling, and regulation of retinal water and ion homeostasis 
[48,49]. Mu¨ller cells are intimately connected with retinal 
endothelial cells, pericytes, and astrocytes and play a crucial role 
to establish and maintain the blood–retinal barrier (BRB) [48,49]. 
In addition, Mu¨ller cells modulate retinal immunity [50].
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blockade of both the Ang II-dependent pathway (by aliskiren) and
the (P)RR-mediated, Ang II-independent pathway (by HRP)
would provide better protection against diabetes-induced retinal
pathophysiology. However, the present study showed that HPR
Figure 2. In situ cell death detection in the retina. A, Apoptotic cells were detected in situ by TUNEL assay in the retinas from non-diabetic
(NDM) Ren2 rats (a & b), diabetic (DM) Ren2 rats treated with vehicle (c & d), and aliskiren (e & f). ONL: outer nuclear layer; INL: inner nuclear layer;
RGC: retinal ganglion cell layer. B, Quantitative measurement of apoptotic cells detected by TUNEL assay. #p,0.01 (vs. wildtype (WT) Sprague–
Dawley rats); $p,0.01 (vs. NDM Ren2 and WT); *p,0.01 (vs. NDM Ren2 and DM Ren2+ vehicle).
doi:10.1371/journal.pone.0100954.g002
pathological role of the PRR in the retina has been established by 
several reports in which HRP was shown to prevent pathological 
angiogenesis [18,21], and ocular inflammation induced by 
endotoxin [20] and diabetes [19]. It was thus expected that
blockade of both the Ang II-dependent pathway (by aliskiren) and
the (P)RR-mediated, Ang II-independent pathway (by HRP)
would provide better protection against diabetes-induced retinal
pathophysiology. However, the present study showed that HPR
Figure 2. In situ cell death detection in the retina. A, Apoptotic cells were detected in situ by TUNEL assay in the retinas from non-diabetic
(NDM) Ren2 rats (a & b), diabetic (DM) Ren2 rats treated with vehicle (c & d), and aliskiren (e & f). ONL: outer nuclear layer; INL: inner nuclear layer;
RGC: retinal ganglion cell layer. B, Quantitative measurement of apoptotic cells detected by TUNEL assay. #p,0.01 (vs. wildtype (WT) Sprague–
Dawley rats); $p,0.01 (vs. NDM Ren2 and WT); *p,0.01 (vs. NDM Ren2 and DM Ren2+ vehicle).
doi:10.1371/journal.pone.0100954.g002
pathological role of the PRR in the retina has been established by 
several reports in which HRP was shown to prevent pathological 
angiogenesis [18,21], and ocular inflammation induced by 
endotoxin [20] and diabetes [19]. It was thus expected that
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Figure 3. Representative retinal micrographs of wildtype (WT) Sprague–Dawley rats, non-diabetic (NDM) Ren2 rats, and diabetic
(DM) Ren2 rats treated with vehicle, aliskiren or aliskiren+HRP (A). INL: inner nuclear layer; IPL: inner plexiform layer; RGC: retinal ganglion
cell layer. Quantitative measurement of cell density in RGC layer in the central (B) and peripheral (C) retinas of wildtype (WT) Sprague–Dawley rats,
non-diabetic (NDM) Ren2 rats, and diabetic (DM) Ren2 rats treated with vehicle, aliskiren or aliskiren+HRP. N= 4. *p,0.01 (vs. WT).
doi:10.1371/journal.pone.0100954.g003
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and angiotensin-independent manner [35,36]. This may be
explained on the basis of partial agonism of HRP towards the
(P)RR [21,60]. Intriguingly, although HRP did not exert beneficial
effects on top of aliskiren in the diabetic Ren2 rat retina, it also did
not counteract the protective ocular effects of aliskiren. Thus,
possibly the retinal levels of HRP (when administered systemically)
were not sufficiently high to generate similar counteracting effects.
Yet, when infused at similar doses alone, HRP did exert beneficial
effects in the diabetic eye [21]. It cannot be excluded that such
effects are (P)RR-independent, but if so, they can apparently no
longer be seen on top of RAS blockade.
Hypertension plays an important role in retinal pathophysiology
and is one of the major risk factors that exacerbates the initiation
and progression of DR [1]. As shown in our previous report [36],
diabetic Ren2 rats displayed severely elevated blood pressure;
aliskiren normalized blood pressure, suppressed renin activity, and
Figure 4. Representative capillary images of wildtype (WT) Sprague–Dawley rats (A), non-diabetic (NDM) Ren2 rats (B), and diabetic
(DM) Ren2 rats treated with vehicle (C), aliskiren (D) or aliskiren+HRP (E). Diabetic Ren2 rat retinas showed further increased acellular
capillaries (arrow) and both aliskiren and aliskiren+HRP reduced this. F: Quantitative measurements of acellular capillaries. *P,0.01 (vs. DM Ren2+
vehicle group).
doi:10.1371/journal.pone.0100954.g004
did not provide additional beneficial effects on top of aliskiren. In 
part, this is due to the fact that, with regard to at least some 
parameters, aliskiren already provided maximal benefit. This 
would suggest that prorenin-dependent effects, if present, might be 
largely due to activation of the Ang II-AT1 receptor axis. 
Obviously, aliskiren will block angiotensin generation by recep-
tor-bound prorenin (or renin) [31,32]. In addition, renin inhibition 
may lower (P)RR expression [33], thus potentially diminishing the 
capacity of HRP to exert an effect at all. It is unlikely that aliskiren 
blocked renin/prorenin-(P)RR interaction, since renin/prorenin 
binding to the (P)RR was unaltered in the presence of aliskiren, 
while aliskiren also did not affect (pro)renin-induced signaling 
[58,59].
We previously reported that aliskiren normalized vascular 
dysfunction in diabetic hypertensive rats, while HRP unexpectedly 
counteracted these beneficial vascular effects in a blood pressure-
and angiotensin-independent manner [35,36]. This may be
explained on the basis of partial agonism of HRP towards the
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capillaries (arrow) and both aliskiren and aliskiren+HRP reduced this. F: Quantitative measurements of acellular capillaries. *P,0.01 (vs. DM Ren2+
vehicle group).
doi:10.1371/journal.pone.0100954.g004
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reversed vascular dysfunction, whereas HRP did not affect the
blood pressure-lowering effects of aliskiren [15,35,61]. The
beneficial effects of aliskiren in the diabetic Ren2 rat retina may
be due to its blood pressure-lowering effect and associated
improvement of renal and other systemic cardiovascular function.
However, in a previous study in the same model, ACE inhibition
resulted in better blood pressure control, while aliskiren provided
greater retinal protection [56]. This strongly suggests that the
beneficial effects of renin inhibition extend beyond the blood
pressure-lowering effects of aliskiren. Clearly, this needs to be
tested in normotensive animal models of diabetic retinopathy in
future studies.
In cultured Mu¨ller cells, prorenin significantly increased the
expression levels of IL-1a and TNF-a, consistent with previous
observations [55]. Both aliskiren and HRP completely blocked
these effects as did treatment with (P)RR siRNA and the AT1R
blocker losartan. This suggests that these prorenin-induced effects
are entirely (P)RR- and Ang II-dependent, i.e., involve Ang II
generation by (P)RR-bound prorenin, identical to the prorenin-
dependent Ang II generation described earlier in vascular smooth
muscle cells [58]. Possibly, such generation also contributes to the
elevated ocular Ang II levels under many pathological conditions
[10–12,51,62–64].
Recent evidence clearly indicates the (P)RR as multi-functional
receptor, affecting a wide range of signaling pathways, many of
which are not necessarily related to prorenin and Ang II/AT1R
signaling. In fact, a truncated form of (P)RR at the C-terminal
region was previously described as a vacuolar H+ -ATPase (V-
Figure 5. Real-time RT-PCR analysis of retinal expression of inflammatory cytokines: VEGF, MCP1, ICAM1 and TNFa. Values on y-axis
represent fold change in mRNA levels compared to WT (normalized as 1). *P,0.01 (vs. DM Ren2+vehicle group). WT, wildtype, DM/NDM, diabetic/
nondiabetic. N = 5.
doi:10.1371/journal.pone.0100954.g005
Figure 6. Real-time RT-PCR analysis of the expression of inflammatory cytokines IL-1a and TNF-a in cultured Mu¨ller cells. Values on y-
axis represent fold change in mRNA levels compared to control (non-treated, normalized as 1). *P,0.01 (vs. control); # P,0.01 (vs. prorenin treated
group). N = 4.
doi:10.1371/journal.pone.0100954.g006
reversed vascular dysfunction, whereas HRP did not affect the
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Combined renin inhibition/(pro)renin receptor blockade in diabetic retinopathy
249
18
ATPase) associated protein (Atp6ap2), and the (P)RR may thus
also affect V-ATPase activity [65]. Such activity determines the
intracellular pH homeostasis that is critical in diverse physiological
cellular functions including endocytosis, processing of proteins and
signaling molecules, membrane sorting and trafficking, activation
of lysosomal and autophagosomal enzymes, and patterning during
development [66,67]. Consequently, it is conceivable that the
(P)RR contributes not only to tissue RAS activation but also to
multiple molecular and cellular processes via its V-ATPase
connection. Further studies are required to further elucidate
whether prorenin affects these functions.
In conclusion, the renin inhibitor aliskiren reduced both
neuronal and vascular pathologies, including retinal gliosis,
apoptotic cell death of retinal neurons, acellular capillaries and
expression of inflammatory cytokines in diabetic mRen2 rats. The
putative (P)RR blocker HRP did not provide add-on beneficial
effects when combined with aliskiren, nor counteracted the effects
of aliskiren in the retina of diabetic mRen2 rats. The latter
contrasts with earlier observations in the kidney of diabetic mRen2
rats, where HRP counteracted the beneficial effects of aliskiren
[47]. The former agrees with our in-vitro studies in Mu¨ller cells,
showing prorenin-induced effects that are entirely Ang II-
dependent. Taken together, these results suggest that aliskiren is
a promising treatment option for patients with diabetic retinop-
athy, and that its combination with HRP in this condition is not
advisable.
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Summary
Part I Endothelial dysfunction in the development of coronary artery disease 
It is clear that endothelial dysfunction precedes and propagates the atherosclerotic disease 
process and subsequently the development of CAD.1 Therefore, the measurement of endothelial 
function might predict the presence of CAD in patients.2 In chapter 2, we tested the applicability 
of peripheral endothelial dysfunction as a measurement for the presence of CAD in symptomatic 
patients in a hospital outpatient setting. We showed that endothelial function measurement 
with peripheral arterial tonometry (PAT) at the fingertip is a heterogeneous measurement with 
poor correlation with traditional noninvasive CAD diagnostic measurements. Moreover, the 
PAT measurement failed to predict revascularization within one year. Therefore, in spite of the 
pathophysiological basis of endothelial dysfunction in CAD, no evidence was found for peripheral 
endothelial function measurement as a diagnostic tool to detect clinically relevant CAD. 
 Since patient studies to unravel underlying disease processes are usually hampered by 
limited measurements because of ethical concerns; experimental disease models in animals can 
enhance our understanding of the pathogenesis of CAD. In chapter 3, an overview of relevant 
animal models for atherosclerosis research was presented. We concluded that for the study of 
CAD and related diagnostic and therapeutic interventions, a porcine disease model is the most 
suitable since it has almost the same anatomy and physiology of the cardiovascular system as 
humans.3 Pig models, with DM induction and with use of specific diets, have been proposed 
for the study of atherosclerosis.4 The study presented in chapter 4 demonstrated that in a 
diabetic porcine model, a diet high of saturated fats and cholesterol rich can induce a systemic 
inflammatory response related to aortic atherosclerosis development. This corresponds to how 
human atherosclerosis is thought to develop,5 making it likely to be a relevant model for the study 
of human CAD. In the study presented in chapter 5, we demonstrated that only small coronary 
arteries (as a reflection of the coronary microcirculation), and not coronary conduit arteries, 
showed functional alterations in vitro with regard to NO and ET-1 systems in the process of early 
systemic atherosclerosis in diabetic pigs on a saturated fat and cholesterol rich diet. Specifically, 
in coronary conduit arteries, both endothelium-dependent as well as endothelium-independent 
vasodilation and vasoconstriction were unaltered. In contrast, coronary small arteries showed 
decreased endothelium-dependent vasodilation due to loss of endogenous NO, and reduced 
vasoconstriction to exogenous ET-1, possibly because of decreased endothelin type A (ETA) 
receptor dominance. The changes in NO and ET-1 systems were associated. This could reflect an 
altered coronary microvascular balance.6 
 The diabetic, atherosclerotic pig model was also used to study more advanced CAD 
development. We showed in the study of chapter 6, that both diabetic and non-diabetic 
pigs on a high saturated fat and cholesterol rich diet gradually developed CAD after 12 to 
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15 months of study duration. This coronary atherosclerosis was too small to visualize with 
coronary computed tomography angiography, but could be demonstrated by intracoronary 
optical coherence tomography (OCT) and near-infrared spectroscopy (NIRS). Therefore, this 
study showed very elegantly, with clinically used coronary imaging techniques, that this animal 
model develops spontaneous coronary atherosclerosis over time, highly resembling the human 
disease process. We examined in the study of chapter 7, whether the CAD progress resulted 
in further impairment of coronary microvascular balance of NO and ET-1. CAD progress was 
demonstrated by the presence of early atherosclerotic plaques, also in the small coronary 
arteries of both diabetic and non-diabetic atherosclerotic pigs. Surprisingly, endothelium-
dependent vasodilation was maintained due to an increase in endogenous NO availability 
relative to EDHF. However, exogenous ET-1 mediated vasoconstriction was increased in both 
diabetic and non-diabetic atherosclerotic animals, resulting mainly from endothelin type B (ETB) 
receptor mediated vasoconstriction. In addition, the coronary small arteries of both groups of 
pigs showed characteristics of increased vascular stiffness. Taken together, this study clearly 
showed that in vitro the balance of vasodilator and vasoconstrictor mechanisms of the coronary 
microcirculation changed markedly during the CAD progress. This altered endothelial balance 
is a systemic process contributing to cardiovascular disease, which we demonstrated in the 
study of chapter 8. Again, in the diabetic, atherosclerotic pig model with presence of CAD, 
we showed that systemic microvascular damage is present in the form of augmented mucosal 
capillary tortuosity, as well as a dysbalance of renal angiopoietins which correlated to diabetic 
nephropathy. 
Part II Endothelial dysfunction after percutaneous coronary interventions
In chapter 9, we presented an overview of the available literature on endothelial dysfunction 
after DES implantation. Stenting in general impairs several aspects of endothelial function. 
First generation DES even further impair endothelium-dependent vascular function of the 
peri-stent area up to one year after implantation. As an explanation, it has been postulated 
that DES imposes oxidative stress on the vascular wall, causing impaired endothelial NO-
bioavailability and perhaps also EDHF-availability under certain circumstances. In addition, even 
the microcirculation in the distal perfusion area of specific DES might be at risk for endothelium-
dependent vasodilatory alterations. We described in the study of chapter 10, coronary 
endothelial dysfunction early after certain types of DES implantation and compared it to BMS 
implantation in a healthy porcine model. DES did not impair endothelial coverage of the stent 
struts five days after implantation, nor neointimal formation 28 days after implantation. However, 
each drug type of DES demonstrated a specific cellular appearance within this neointima. 
PES specifically, showed the least endothelial nitric oxide synthase (eNOS) expression within 
the stent 28 days after implantation. However, this did not affect endothelial function of the 
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microcirculation distal to the stent, although a reduced NO-contribution was observed five days 
after implantation. This suggested that PES induces at least a temporary abnormal functioning 
of eNOS and therefore shows evidence of endothelial dysfunction. In addition, microvascular 
dysfunction distal to the DES did not correlate with in-stent delayed endothelialisation. We 
studied in chapter 11, also in a healthy porcine model, coronary conduit and microvascular 
endothelial function distal to the stent in relation to different DES as well as to BMS, both in vivo 
and in vitro. No differences in endothelial vasodilatory response distal to the stent were noted in 
vivo five weeks after implantation. In addition, distal coronary conduit function was unaffected 
in vitro. However, distal small artery function in vitro was affected by PES implantation, showing 
a reduced endothelium dependent vasodilation mediated by a NO-independent component, 
possibly EDHF. This study clearly demonstrated that the effect of PES can extend into the distal 
microcirculation.
 In response to the possible disadvantages of DES, the BVS has been developed in an attempt 
to overcome these disadvantages by providing only a temporary scaffold. In chapter 12, the BVS 
was implanted in a porcine model with CAD with or without DM, and the coronary response 
to BVS implantation was examined by in vivo coronary imaging (OCT and NIRS), as well as with 
ex vivo histology. The coronary response of the scaffold showed a high percentage of lumen 
loss at three months after implantation with complete BVS strut coverage, which remained 
stable at six months after implantation. This late lumen loss consisted of a heterogeneous 
neointimal burden in both diabetic and non-diabetic pigs, with focal lipid accumulation, 
irregular collagen distribution and calcification. The absolute percentages of these neointimal 
substances changed over time, indicative for the formation of neoatherosclerosis.  In addition, 
the number of discernible struts of the BVS decreased only slightly over time and also the 
polymer of the scaffold was shown to be preserved at six months after implantation. DM or the 
presence of inflammation did not influence the coronary response or the process of scaffold 
degradation. The response of neoatherosclerosis formation within the BVS might be caused 
by a dysfunctional barrier function of the endothelium, indicating the presence of endothelial 
dysfunction. We continued to study coronary endothelial function adjacent to the BVS and of 
the distal microcirculation in chapter 13. Again, in the porcine model of CAD with or without 
DM, the effect six months after BVS implantation on distal coronary endothelial function was 
studied in vitro. Only in DM pigs, coronary conduit segments proximal and distal to the BVS 
edges showed reduced endothelium-dependent vasodilation, with the distal segments being 
most prominently affected. This endothelial dysfunction was principally due to a loss of NO. 
Surprisingly, segments from the microcirculation distal to the BVS showed slightly enhanced 
endothelium-dependent vasodilation. This enhanced vasodilation was again only observed in 
DM pigs and did not appear to be either NO- or EDHF-mediated. It was striking that specifically 
the DM animals showed an altered endothelial response. 
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Part III Endothelial dysfunction related to diabetes mellitus and the renin-angiotensin-
aldosterone system
In chapter 14, we gave an overview of the role of an overactive RAAS in cardiovascular 
complications of DM. It was postulated that a discordant tissue RAAS might be a mediator 
of endothelial dysfunction leading to both micro- and macrovascular complications of DM 
resulting in cardiovascular disease. The elevated plasma levels of prorenin in DM might be part 
of this overactive RAAS. Prorenin is thought to bind to a (pro)renin receptor, thus activating 
locally Ang II-dependent and -independent pathways. Inducing inflammation and fibrosis 
by (pro)renin receptor stimulation could be an important contributor to the cardiovascular 
disease complications of DM. Therefore, blocking this receptor would be a next logical step 
in the search for new therapeutics to reduce DM-related cardiovascular disease. To examine 
which RAAS components are activated in DM, we studied in chapter 15 these components in 
both plasma and urine samples of both diabetic and non-diabetic patients with hypertension. 
We demonstrated that diabetic patients show besides elevated plasma prorenin levels, also 
elevated urinary renin levels. In addition, we proved that urinary renin more closely reflects 
renal RAAS activity than urinary angiotensinogen or aldosterone. 
 The relation between an overactive RAAS, DM and endothelial dysfunction was further 
studied in chapter 16 with use of diabetic, hypertensive, transgenic rats with high prorenin, 
renin and (pro)renin receptor levels, resulting in continuous (pro)renin receptor activation in 
vivo. We evaluated whether the renin inhibitor aliskiren, with or without the putative (pro)renin 
receptor antagonist HRP, improved the disturbed vascular function of diabetic transgenic rats. 
Both diabetic and non-diabetic animals showed slightly enhanced Ang II mediated contractile 
responses of peripheral conduit arteries; only DM animals showed a marked increase after eNOS 
blockade, suggesting an NO upregulation in DM. The DM rats showed reduced responsiveness 
to phenylephrine, possibly because of this NO-upregulation. Again, both diabetic and non-
diabetic rats showed a reduced response to exogenous ET-1, however only DM animals 
showed a diminished effectiveness of ETA receptor blockade besides increased ETA receptor 
expression. Moreover, peripheral small arteries of DM rats showed in vitro a COX-2 dependent 
vasoconstrictive response to acetylcholine, only when eNOS and EDHF were inhibited. This 
indicates an upregulation of EDCF. Therefore endothelial dysfunction with an altered vasomotor 
balance seems to be present within this animal model, involving upregulation of NO and 
EDCF, possibly resulting in reduced responsiveness to exogenous phenylephrine and ET-1. In 
this study we also demonstrated that treatment of the diabetic, transgenic rats with the renin 
inhibitor aliskiren reversed the above mentioned vascular effects, with the exception of the 
altered effectiveness of ETA receptor blockade and the diminished endothelium independent 
vasodilation. This indicates that renin inhibition can at least partially reverse the altered 
endothelial balance of DM and an overactive RAAS, possibly via affecting NO, ET-1 and EDCF 
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mechanisms. Remarkably, when blocking the (pro)renin receptor on top of renin inhibition, the 
beneficial vascular effects either disappeared or were greatly diminished, although ETA receptor 
responsiveness normalized and also the effects on blood pressure and plasma renin activity 
were maintained. 
 We also studied the effect of (pro)renin receptor blockade on cardiovascular end organ 
disease. In chapter 17, we tested whether (pro)renin receptor blockade adds benefits on top of 
renin inhibition with regard to DM nephropathy. Within the same animals, it was demonstrated 
that aliskiren treatment lowered blood pressure and exerted reno-protective effects. It also 
suppressed plasma and tissue RAAS activity. (Pro)renin receptor blockade with HRP, when 
given on top of renin blockade, did not alter the effects on blood pressure or RAAS activity. 
However, it counteracted the beneficial effects of aliskiren in the kidney. In chapter 18, we 
tested whether (pro)renin receptor blockade adds benefits on top of renin blockade with regard 
to DM retinopathy. The same DM animals as used in chapters 16 and 17, showed increased 
loss of capillaries, as well as increased expression of inflammatory cytokines within the retina. 
Aliskiren treatment reduced these effects, and HRP on top of aliskiren treatment did not provide 
additional protection. 
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Nederlandse samenvatting
Hart- en vaatziekten zijn een van de hoofdoorzaken van morbiditeit en mortaliteit in Nederland. 
Het begrijpen van de onderliggende pathofysiologie is belangrijk om de morbiditeit en mortaliteit 
te verminderen en ook om de meest optimale behandeling te vinden. Endotheel disfunctie 
is betrokken in het gehele pathologische proces van atherosclerose: vroeg in het proces van 
atherogenese, later in de beheersing van dynamische plaques, in de klinische manifestaties 
van hart- en vaatziekten zoals coronairlijden, en het beïnvloedt zelfs het behandelresultaat van 
PCI. Diabetes is een onafhankelijke en sterke voorspeller van hart- en vaatziekten, gekenmerkt 
door atherosclerose van de slagaders en disfunctie van de microcirculatie. Endotheel disfunctie 
speelt een belangrijke rol bij het ontstaan van diabetes gerelateerde macro- en microvasculaire 
complicaties. Een overactief renine-angiotensine-aldosteron systeem is geïdentificeerd als een 
belangrijke bijdragend systeem aan de cardiovasculaire complicaties van diabetes. Echter, de 
exacte onderliggende mechanismen en de relatie met endotheel disfunctie zijn op dit moment 
nog onbekend. Voorafgaande studies hebben al laten zien dat endotheel disfunctie zeer 
voorspellend is voor toekomstige cardiovasculaire aandoeningen. Daarom is gedetailleerde 
studie van endotheel disfunctie van het grootste belang.
Het doel van dit proefschrift was om veranderingen in endotheel functie in verschillende 
stadia van het cardiovasculaire ziekteproces te bestuderen, met speciale aandacht voor de 
microcirculatie. Dit proefschrift richtte zich specifiek op endotheel disfunctie in de ontwikkeling 
van coronairlijden in deel I; op endotheel disfunctie na percutane coronaire interventies in deel 
II; en op endotheel disfunctie in relatie tot diabetes en het renine-angiotensine-aldosteron 
systeem in deel III.
Deel I Endotheel disfunctie in de ontwikkeling van coronairlijden
Het is duidelijk dat endotheel disfunctie voorafgaat en bijdraagt aan het atherosclerotische 
ziekteproces en vervolgens aan de ontwikkeling van coronairlijden. Daarom kan de meting van 
endotheel functie mogelijk de aanwezigheid van coronairlijden bij patiënten voorspellen. In 
hoofdstuk 2 hebben we de toepasbaarheid van perifere endotheel disfunctie getest als een 
maat voor de aanwezigheid van coronairlijden bij symptomatische patiënten op de polikliniek. 
We hebben aangetoond dat de meting van endotheel functie met perifere arteriële tonometrie 
(PAT) aan de vingertop een heterogene meting is, met een slechte correlatie met traditionele 
niet-invasieve diagnostische metingen van coronairlijden. Bovendien kon de PAT-meting 
revascularisatie, wegens obstructief coronairlijden, binnen een jaar niet voorspellen. Daarom 
werd er, ondanks de pathofysiologische basis van endotheel disfunctie in coronairlijden, geen 
bewijs gevonden voor de perifere meting van endotheel functie als een diagnostisch hulpmiddel 
om klinisch relevant coronairlijden te detecteren.
Chapter 19
260
 Omdat patiënten-studies, om onderliggende ziekteprocessen te kunnen ontrafelen, meestal 
worden belemmerd door beperkte metingen vanwege ethische bezwaren, kunnen experimentele 
ziektemodellen met gebruik van dieren ons begrip van de pathogenese van coronairlijden 
vergroten. In hoofdstuk 3 werd een overzicht gegeven van relevante diermodellen voor 
onderzoek naar coronairlijden en gerelateerde diagnostische en therapeutische interventies. 
Wij concludeerden dat voor de studie van coronairlijden en gerelateerde diagnostische 
en therapeutische interventies, een varkensmodel met ziekte het meest geschikt is omdat 
een varken bijna dezelfde anatomie en fysiologie van het cardiovasculaire systeem heeft als 
de mens. Varkensmodellen, met diabetes-inductie en met gebruik van specifieke diëten, 
zijn voorgesteld voor de studie van atherosclerose. De studie gepresenteerd in hoofdstuk 4 
toonde aan dat binnen een diabetisch varkensmodel, een dieet met veel verzadigde vetten en 
cholesterolrijk, een systemische inflammatoire respons kan veroorzaken die gerelateerd is aan 
de ontwikkeling van atherosclerose in de aorta. Dit komt overeen met hoe atherosclerose zich 
in de mens ontwikkelt, waardoor dit waarschijnlijk een relevant model is voor de studie van 
coronairlijden in mensen. In de studie van hoofdstuk 5 hebben we aangetoond dat alleen de 
kleine kransslagadertjes (als een reflectie van de coronaire microcirculatie) en niet de grote 
kransslagaders, functionele veranderingen toonden in vitro met betrekking tot de vasoactieve 
stikstof monoxide en endotheline systemen in het proces van vroege atherosclerose vorming 
in diabetische varkens op een verzadigd vet- en cholesterolrijk dieet. Specifiek in de grote 
kransslagaders waren zowel endotheel-afhankelijke als endotheel-onafhankelijke vasodilatatie 
en vasoconstrictie onveranderd. Terwijl de kleine kransslagadertjes verminderde endotheel-
afhankelijke vasodilatatie lieten zien, wat te wijten was aan verlies van endogeen stikstof 
monoxide, als ook aan verminderde vasoconstrictie door exogeen endotheline, mogelijk als 
gevolg van verminderde endotheline type A-receptor dominantie. De veranderingen in stikstof 
monoxide en endotheline systemen waren geassocieerd. Dit zou een gewijzigde coronaire 
microvasculaire balans kunnen weerspiegelen.
 Het diabetische, atherosclerotische varkensmodel werd ook gebruikt om de ontwikkeling 
van meer gevorderd coronairlijden te bestuderen. We hebben in de studie van hoofdstuk 
6 aangetoond dat zowel diabetische als niet-diabetische varkens op een verzadigd vet en 
cholesterolrijk dieet geleidelijk coronairlijden ontwikkelden na 12 tot 15 maanden studieduur. 
Deze atherosclerose was te weinig om met coronaire computer tomografie-angiografie in 
beeld te brengen, maar kon wel worden aangetoond door intra-coronaire optische coherentie 
tomografie (OCT) en door nabij-infrarood spectroscopie (NIRS). Deze studie toonde daarom 
zeer elegant aan dat met klinisch toegepaste coronaire beeldvormingstechnieken dit diermodel 
na verloop van tijd spontane coronaire atherosclerose ontwikkelt, die zeer sterk lijkt op het 
menselijke ziekteproces. We onderzochten in de studie van hoofdstuk 7 of de ontwikkeling 
van coronairlijden in het diermodel resulteerde in verdere verslechtering van de coronaire 
microvasculaire balans van stikstof monoxide en endotheline. De ontwikkeling van coronairlijden 
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werd aangetoond door de aanwezigheid van vroege atherosclerotische plaques, ook in de kleine 
kransslagadertjes van zowel diabetische als niet-diabetische varkens. Verrassend genoeg, bleef 
de endotheel-afhankelijke vasodilatatie gehandhaafd als gevolg van een toename in endogene 
stikstof monoxide beschikbaarheid ten opzichte van endotheel afkomstige hyperpolariserende 
factoren (EDHF). Echter, exogene endotheline gemedieerde vasoconstrictie was versterkt bij 
zowel diabetische als niet-diabetische atherosclerotische dieren, voornamelijk als gevolg van 
endotheline type B receptor gemedieerde vasoconstrictie. Bovendien vertoonden de kleine 
kransslagadertjes van beide groepen varkens kenmerken van toegenomen vaatstijfheid. Daarom 
toonde deze studie duidelijk aan dat in vitro de balans van vaatverwijdende en vaatvernauwende 
mechanismes van de coronaire microcirculatie aanzienlijk veranderde tijdens de progressie 
van coronairlijden. Deze veranderde endotheel balans is een systemisch proces dat bijdraagt 
aan cardiovasculaire ziekte vorming, zoals aangetoond in de studie van hoofdstuk 8. In het 
diabetische, atherosclerotische varkensmodel met coronairlijden, hebben we aangetoond 
dat er systemische microvasculaire schade aanwezig is in de vorm van verhoogde mucosale 
capillaire tortuositeit, evenals een disbalans van renale angioproteïnen die gecorreleerd zijn aan 
diabetische nefropathie. 
Deel II Endotheel disfunctie na percutane coronaire interventies
In hoofdstuk 9 gaven we een overzicht van de beschikbare literatuur over endotheel disfunctie 
na drug eluting stent (DES) implantatie. Stent implantatie in het algemeen, beschadigt 
verschillende aspecten van endotheel functie. Eerste generatie DES beschadigen echter de 
endotheel-afhankelijke vaatfunctie van het peri-stent gebied nog meer, tot één jaar na DES-
implantatie. Als een verklaring wordt er verondersteld dat DES oxidatieve stress induceerde 
op de vaatwand, dat de stikstof monoxide beschikbaarheid van het endotheel verminderde 
en dat mogelijk ook de EDHF-beschikbaarheid onder bepaalde omstandigheden verminderde. 
Bovendien kan zelfs de microcirculatie in het distale perfusiegebied van specifieke DES bedreigd 
worden door veranderingen in endotheel-afhankelijke vaatverwijding. We beschreven in de 
studie van hoofdstuk 10, coronaire endotheel disfunctie vroeg na de implantatie van specifieke 
DES en vergeleken deze met bare metal stent (BMS) implantatie in een gezond varkensmodel. 
DES had geen nadelige invloed op de endotheel bedekking van de stent vijf dagen na implantatie, 
en ook niet op neo-intima vorming 28 dagen na implantatie. Echter, ieder medicijn van de 
verschillende DES liet een specifieke samenstelling van cellen zien in deze neo-intima. Specifiek 
vertoonde paclitaxel eluting stent (PES) de minste endotheliale stikstofmonoxide synthase 
(eNOS) expressie binnen in de stent, 28 dagen na implantatie. Dit had echter geen invloed op de 
endotheel functie van de microcirculatie distaal van de stent, hoewel er wel een verminderde 
stikstof monoxide bijdrage vijf dagen na implantatie werd waargenomen. Dit suggereert dat 
PES op zijn minst een tijdelijk abnormaal functioneren van eNOS en daarmee van de endotheel 
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disfunctie induceert. Bovendien correleerde microvasculaire disfunctie distaal van de DES niet 
met vertraagde endothelialisatie binnen in de stent. We bestudeerden in hoofdstuk 11, ook 
in een gezond varkensmodel, kransslagader functie en microvasculaire functie distaal van de 
stent van verschillende DES en van BMS, zowel in vivo als in vitro. Er werden geen verschillen 
in de endotheel afhankelijke vaatverwijdende respons distaal van de stent opgemerkt in vivo, 
vijf weken na implantatie. Bovendien werd de kransslagaderfunctie distaal van de stent niet 
beïnvloed in vitro. De functie van kleine kransslagadertjes werd echter wel beïnvloed door PES-
implantatie in vitro, die een verminderde endotheel-afhankelijke vaatverwijding vertoonden, die 
werd gemedieerd door een component die niet van stikstof monoxide afhankelijk is, mogelijk is 
dit EDHF. Deze studie toonde duidelijk aan dat het effect van specifieke DES zich kan uitstrekken 
tot in de distale microcirculatie van de stent.
Als reactie op de mogelijke nadelen van DES, is de bioresorbeerbare vasculaire scaffold 
(BVS) ontwikkeld in een poging om deze nadelen te overwinnen door slechts een tijdelijke 
ondersteuning te bieden. In de studie van hoofdstuk 12 werd de BVS geïmplanteerd in een 
varkensmodel met coronairlijden met of zonder de aanwezigheid van diabetes, en werd de 
coronaire respons op de BVS implantatie onderzocht door coronaire beeldvorming in vivo met 
OCT en NIRS en ex vivo met histologie. De coronaire respons van de scaffold vertoonde een 
hoog percentage lumen verlies op drie maanden na de implantatie met volledige bedekking 
van de BVS, een proces wat stabiel bleef tot zes maanden na de implantatie. Dit late lumen 
verlies bestond uit een heterogene neo-intima bij zowel de diabetische als de niet-diabetische 
varkens, met lokale lipiden accumulatie, onregelmatige collageenverdeling en verkalking. De 
absolute percentages van deze neo-intima substanties veranderden in de tijd, wat indicatief is 
voor de vorming van neo-atherosclerose. Bovendien nam het aantal waarneembare stutten van 
de BVS slechts weinig af in de loop van de tijd en bleek ook dat het polymeer van de scaffold zes 
maanden na implantatie nog niet was verdwenen. Diabetes of de aanwezigheid van ontsteking 
had geen invloed op de coronaire respons of op het afbraakproces van de scaffold. De reactie van 
neo-atherosclerose-vorming binnenin de BVS kan worden veroorzaakt door een disfunctionele 
barrière functie van het endotheel, wat wijst op de aanwezigheid van endotheel disfunctie. 
Vervolgens onderzochten we de coronaire endotheel functie direct naast de BVS en van de 
distale microcirculatie in hoofdstuk 13. Wederom in het varkensmodel met coronairlijden met 
of zonder diabetes, werd het effect van zes maanden BVS-implantatie op de distale coronaire 
endotheel functie in vitro bestudeerd. Alleen in DM-varkens vertoonden de kransslagader 
segmenten proximaal en distaal ten opzichte van de BVS-randen, een verminderde endotheel-
afhankelijk vaatverwijding, waarbij het effect op de distale segmenten het grootst was. Deze 
endotheel disfunctie was voornamelijk te wijten aan een verlies van stikstof monoxide. 
Verrassend genoeg, vertoonden segmenten van de microcirculatie distaal van de BVS een 
iets verbeterde endotheel-afhankelijke vaatverwijding. Deze verhoogde vasodilatatie werd 
opnieuw alleen waargenomen bij diabetische varkens en leek niet stikstof monoxide- of EDHF-
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gemedieerd te zijn. Het is opvallend dat alleen de diabetische dieren een veranderde endotheel 
respons vertoonden. 
Deel III Endotheel disfunctie gerelateerd aan diabetes mellitus en het renine-angiotensine-
aldosteron systeem
In hoofdstuk 14 gaven we een overzicht van de rol van het overactieve renine-angiotensine-
aldosteron systeem in de cardiovasculaire complicaties van diabetes. Er werd verondersteld dat 
een disharmonisch weefsel specifiek renine-angiotensine-aldosteron systeem een mediator 
zou kunnen zijn voor endotheel disfunctie wat zou kunnen leiden tot zowel de micro- als de 
macrovasculaire complicaties van diabetes, wat uiteindelijk resulteert in cardiovasculaire 
ziekte. De verhoogde plasmaspiegels van prorenine, de voorloper van renine, bij diabetische 
patiënten met microvasculaire complicaties kunnen deel uitmaken van dit disharmonische 
renine-angiotensine-aldosteron systeem. Prorenine wordt verondersteld te binden aan de (pro)
renine receptor, waardoor lokale angiotensine-afhankelijke en angiotensine-onafhankelijke 
processen worden geactiveerd. Door (pro)renine receptor stimulatie zouden ontsteking en 
fibrose geïnduceerd kunnen worden, wat daarmee zou bijdragen aan de cardiovasculaire 
complicaties van diabetes. Daarom is blokkering van deze receptor de volgende logische stap 
in de zoektocht naar nieuwe therapeutische regimes om diabetes gerelateerde cardiovasculaire 
aandoeningen te verminderen. Om te onderzoeken welke specifieke componenten van het 
renine-angiotensine-aldosteron systeem in diabetes worden geactiveerd, bestudeerden we in 
hoofdstuk 15 deze componenten in zowel plasma- als urinemonsters van zowel diabetische 
als niet-diabetische patiënten met hypertensie. We toonden aan dat diabetici naast verhoogde 
plasma prorenine, ook verhoogde urine renine spiegels hebben. Bovendien hebben we 
aangetoond dat urine renine beter de activiteit van het renine-angiotensine-aldosteron systeem 
in de nieren weerspiegelt dan urine angiotensinogeen of aldosteron. 
De relatie tussen het over geactiveerde renine-angiotensine-aldosteron systeem van 
diabetes met endotheel disfunctie werd verder bestudeerd in hoofdstuk 16 door gebruik te 
maken van diabetische, hypertensieve transgene ratten met hoge prorenine, renine en (pro)
renine-receptor concentraties, wat zou kunnen resulteren in continue (pro)renine receptor 
activatie in vivo. We evalueerden of de renine remmer aliskiren, met of zonder de vermeende 
(pro)renine receptor antagonist HRP, de gestoorde vaatfunctie van de diabetische transgene 
ratten verbeterde. Zowel diabetische als niet-diabetische dieren vertoonden enigszins 
versterkte contractiele responsen van perifere slagaders, wat angiotensine gemedieerd was, 
met een duidelijke toename na eNOS blokkade bij alleen de diabetische dieren, hetgeen een 
opregulering van stikstof monoxide in diabetes suggereert. De diabetische ratten vertoonden 
een verminderde respons op fenylefrine, mogelijk vanwege deze stikstof monoxide opregulatie. 
Opnieuw vertoonden zowel niet-diabetische als diabetische ratten een verminderde respons 
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op exogeen endotheline, maar alleen de diabetische dieren vertoonden een verminderde 
effectiviteit van endotheline receptor type A blokkade naast verhoogde endotheline receptor 
type A expressie. Bovendien vertoonden de perifere kleine slagadertjes van alleen de 
diabetische ratten een acetylcholine geïnduceerde endotheel afhankelijke constrictie, die COX-
2 gemedieerd bleek, in de aanwezigheid van eNOS-remming en blokkers van EDHF in vitro. 
Dit duidt op een opregulatie vanuit het endotheel afkomstige contractiele factoren. Daarom 
lijkt er endotheel disfunctie met een veranderde vasomotorische balans aanwezig te zijn ook 
in dit diabetische diermodel, met opregulatie van stikstof monoxide en uit het endotheel 
afkomstige contractiele factoren, wat mogelijk resulteerde in een verminderde respons op 
exogeen fenylefrine en endotheline. In deze studie hebben we ook aangetoond dat behandeling 
van de diabetische, transgene ratten met de renine-remmer aliskiren de bovengenoemde 
vasculaire effecten omkeerde, met uitzondering van de veranderde effectiviteit van endotheline 
type A receptor blokkade en de verminderde endotheel-onafhankelijke vasodilatatie. Dit geeft 
aan dat renine inhibitie de veranderde endotheel balans van diabetes en van een overactief 
renine-angiotensine-aldosteron systeem ten minste gedeeltelijk kan omkeren, mogelijk door 
mechanismen van stikstof monoxide, endotheline en uit het endotheel afkomstige contractiele 
factoren te beïnvloeden. Opmerkelijk genoeg verdwenen de gunstige vasculaire effecten na het 
blokkeren van de (pro)renine receptor bovenop renine blokkade of waren deze sterk verminderd, 
hoewel de responsiviteit van de endotheline type A receptor normaliseerde en de effecten op 
de bloeddruk en de plasma renine activiteit gehandhaafd bleven. Het effect van (pro)renine 
receptor blokkade op eind orgaan schade werd verder bestudeerd in de hoofdstukken 17 en 
18. In hoofdstuk 17 testten we of (pro)renine receptor blokkade extra voordelen geeft bovenop 
renine blokkade met betrekking tot diabetes gerelateerde nefropathie. Door gebruik te maken 
van dezelfde dieren, werd aangetoond dat renine blokkade met aliskiren bloeddruk verlagende 
en nier beschermende effecten uitoefende. Het onderdrukte ook plasma- en weefsel renine-
angiotensine-aldosteron systeem activiteit. (Pro)renine-receptor blokkering met HRP, indien 
toegediend bovenop de renine blokkade, had geen invloed op de bloeddruk of op renine-
angiotensine-aldosteron systeem activiteit. Het ging echter ten koste van de gunstige effecten 
van aliskiren op de nier. In hoofdstuk 18 testten we of (pro)renine receptor blokkade extra 
voordelen geeft bovenop renine blokkade ten aanzien van diabetische retinopathie. Wederom 
in dezelfde dieren, werd aangetoond dat de diabetische dieren een verhoogd verlies van 
retinale capillairen vertoonden, evenals een verhoogde expressie van ontstekingscytokinen in 
het netvlies. Renine remming met aliskiren verminderde deze effecten en HRP bovenop aliskiren 
gaf geen extra bescherming. 
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General discussion and clinical perspectives
The experiments described in this thesis were performed both in patients and in animal models 
and their results can be translated into clinical practice and provide a basis for future research. 
However, the intriguing question is: which results obtained in which model are useful? This was 
already answered in 1983 by Prof. W.J. van der Giessen and still remains valuable today: “The 
apparent discrepancies in results obtained from different models tend to be confusing. However, 
one often forgets that these models may have different features, and that these differences 
are responsible for the spread in results. With this in mind, one might be able to select data 
from relevant models to direct a human validation study, finally resulting in therapy which is of 
benefit to patients, as no single animal model can provide a situation which completely mimics 
the derangements of the human”.1 An animal model mimicking the human disease process as 
close as possible, which can be followed over time and is accessible for human diagnostics and 
therapeutics, is probably the most ideal,2-4 but that should be verified in future experiments.
Part I clinical considerations of coronary artery disease development
In part I of this thesis, we demonstrated a nonlinear relationship between obstructive CAD and 
microvascular endothelial dysfunction. This can partially be explained by the fact that clinically 
relevant CAD results from an underlying complex disease process that is likely to be present 
for many years and is influenced by multiple factors over time, which cannot be expressed in 
a single measurement of endothelial function at one vascular location and at one time point. 
We showed that coronary microvascular endothelial dysfunction alters in the process of CAD, 
highlighting the importance of assessment of endothelial dysfunction over time and to separate 
the evaluation of coronary conduit arteries from the evaluation of the microcirculation. Indeed, 
in clinical practice, the relation between symptoms, the presence of obstructive CAD and 
microvascular dysfunction is not always straightforward, as has been demonstrated with patients 
with microvascular angina.5 These patients, who previously all belonged to cardiac syndrome X, 
are now considered to represent a spectrum of diseases: (i) coronary microvascular dysfunction 
in the absence of myocardial disease and obstructive CAD; (ii) coronary microvascular dysfunction 
in the presence of myocardial diseases; (iii) coronary microvascular dysfunction in the presence 
of obstructive CAD; and (iv) iatrogenic coronary microvascular dysfunction (e.g. related to 
PCI). In all of them microvascular endothelial dysfunction is thought to play a role.6 Therefore, 
endothelial function studies in these subgroups of patients will be of particular interest to assess 
the relation between peripheral and coronary microvascular dysfunction, as well as the relation 
between microvascular dysfunction and obstructive CAD. In addition, future studies have to 
resolve whether the assessment of microvascular dysfunction will result in a specific treatment 
strategy and whether this strategy will improve microvascular function, and finally if it will yield 
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an improved clinical outcome. Finally, the development of direct and quantitative methods to 
detect coronary microvascular disease is essential to diagnose patients with non-obstructive 
CAD, as well as to guide therapy.7-9
We also aimed to unravel the mechanisms of endothelial dysfunction related to cardiovascular 
disease. Traditionally, NO has been considered to be the key endothelium-derived vasodilating 
factor that plays a prominent role in the maintenance of vascular tone.10 Indeed, many studies 
have reported endothelial dysfunction as a loss of NO-mediated vasodilator capacity. However, 
endothelial function not only depends on NO.  For example, vessel size influences the relative 
contribution of NO: with a large role in conduit arteries but a small role in resistance arteries, 
where EDHF has a dominant role.11-13 As the studies of chapters 5, 7 and 16 showed, the term 
endothelial dysfunction should rather describe a defect in the homeostatic mechanism of 
endothelial function. These studies clearly indicate that disturbances in the balance between 
vasodilation and vasoconstriction are modulated during the progression of cardiovascular 
disease, rather than pathology of a single molecule. Indeed, striking functional interactions seem 
to exist between NO and ET-1 in the regulation of coronary tone via not completely understood 
mechanisms influenced by cardiovascular risk factors.14 The clinical relevance of a dysfunctional 
endothelial balance has already been demonstrated in the pathology of vasospastic angina.5 
Over time this dysbalance will probably become more irreversible and will finally result in 
pathological sequelae. Future studies are necessary to unravel this irreversibility and the following 
pathological events. We also demonstrated an altered endothelial balance of NO and ET-1 in 
the mesenteric circulation with a role for EDCF. Indeed, in the presence of hypertension, the 
endothelium can become a source of EDCF, contributing to endothelial dysbalance.15 However, 
the mechanisms regulating the balance between NO, EDCF and ET-1 need to be elucidated 
further. Finally, one has to realize that endothelial control mechanisms can vary between organs 
and that the impact of cardiovascular risk factors on the microcirculation can also differ between 
organs hampering the translation of the findings in one organ to another.16 
Besides an altered endothelial balance over time, we also demonstrated structural remodeling 
of the coronary microcirculation, in combination with coronary atherosclerosis formation (see 
chapters 5, 6 and 7). Therefore, this model is a representative model for a subgroup of patients 
with microvascular angina, in whom the presence of both coronary microvascular dysfunction 
and obstructive CAD plays a role.6 In addition, coronary endothelial dysbalance and structural 
remodeling have an impact on the surrounding cardiomyocytes, which could finally result 
in the development of heart failure.16 However, more studies are necessary to unravel the 
underlying processes and the development of myocardial dysfunction over time, but animal 
models with cardiovascular disease hold great promise for the study of heart failure3,4. The 
studies of chapters 8, 17 and 18 already demonstrated that the vascular alterations at least 
coincide with specific organ pathology, making these animal models interesting candidates 
also because of the presence of comorbidity, e.g. renal dysfunction. However, translation to 
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the clinical situation with more heterogeneous disease is still needed. Finally, measurement of 
endothelial dysfunction over time, for example with use of a multimarker strategy that would 
include a broad set of endothelial biomarkers could help in the assessment of patients at risk of 
cardiovascular disease or to guide therapy.17-19
Part II clinical considerations of percutaneous coronary interventions
In clinical practice, more stent thrombosis has been observed after first generation DES.20 
Indeed, clinical studies have demonstrated coronary endothelial dysfunction in the peri-stent 
area after coronary intervention with PES, a first generation of DES.21 The studies of chapters 10 
and 11 also clearly demonstrated different endothelial alterations after PES implantation. Our 
results suggest including delayed restoration of endothelial function rather than only endothelial 
absence, thereby extending the concept of delayed healing after PES, as a possible explanation 
for unwanted clinical sequelae. In diabetic patients, a worse clinical outcome one year after 
implantation has been reported for first generation DES as compared to second generation 
DES.22 This observation can partly be explained by our results that the adverse effects of PES can 
extend into the distal microcirculation. The loss of microvascular EDHF-mediated vasodilation 
might be of particular importance in diabetic patients given their already reduced microvascular 
NO-availability,23 which could result in a clinically relevant endothelial dysbalance. Therefore, 
further studies are necessary focusing on subpopulations at risk of endothelial dysfunction after 
DES implantation. 
With the development of the fourth generation of DES, a first generation of BVS has 
appeared aiming at restoration of vascular function. However, chapters 12 and 13 demonstrated 
convincingly the presence of endothelial dysfunction after BVS implantation, although distal 
microvascular function was preserved in DM because of a non-NO or non-EDHF mediated 
upregulation. Again, this demonstrates the intricate balance of different vascular mechanisms 
interacting and determining overall coronary microvascular endothelial function. Clinical 
studies confirm the presence of endothelial dysfunction after BVS implantation,24 and clinical 
practice has demonstrated an increased risk of scaffold thrombosis.25 In addition, the BVS has 
been associated with the formation of neoatherosclerosis.26 Also, our study demonstrated the 
presence of this process. Finally, BVS failure has been reported more often in DM patients,27 
again in accordance with our study results. These observations confirm the consistency between 
our experimental results and clinical observations with the BVS. Endothelial dysfunction 
might predispose to a pro-coagulant and pro-inflammatory state within the scaffold, and to 
paradoxical vasoconstriction outside the scaffold. This may result in clinically relevant symptoms 
of thrombosis and restenosis. However, future studies are still warranted to prove this causality.
These findings indicate that with the BVS, the optimal balance in endothelial function 
has not been reached. Therefore, it is clear that the BVS needs to be optimized further and 
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future studies should focus on the degradation process, endothelial dysfunction over time and 
neoatherosclerosis formation, with special attention for the increased risk in DM. For now, 
the BVS has been removed from routine clinical practice and second or third generation DES 
remain the first choice of treatment. As stated by prof. W.J. van der Giessen, already in 1989: 
“The intracoronary stent, (in this case the BVS), seems to be following the well-worn path of 
initially elated euphoria where enthusiasm holds sway over scientific evidence, followed by 
critical skepticism with little optimism for the future.” “A period of critical scientific evaluation 
is now needed, in which the lessons learned from the past are implemented”.28 Indeed, next 
generations of new PCI devices should be tested extensively in experimental settings, preferably 
with use of human-like disease models, as well as in clinical settings before being adopted in 
daily clinical practice. Polymer-free DES and second generation bioresorbable scaffolds, e.g. with 
a magnesium backbone, hold promise with regard to stent or scaffold thrombosis.29
Part III clinical considerations of diabetes and the renin-angiotensin-aldosterone system
We demonstrated in the study of chapter 15 that diabetic patients showed elevated urinary 
renin levels, indicating an overactive renal RAAS in DM, thereby possibly reflecting a discordant 
tissue RAAS in these patients. Whether elevated urinary renin levels correlate with endothelial 
dysfunction and future cardiovascular disease is a topic of further studies. If such a relation would 
exist, this could reinforce the need of RAAS blockade treatment in these patients. However, 
more studies are needed to detect the exact source of the elevated urinary renin: probably a 
part will originate from the plasma filtration, a part will originate from the collecting duct of the 
kidney and a part will originate from the intrarenal conversion of prorenin to renin.30 It is well 
known that as a consequence of RAAS blockade, plasma renin levels increase. In addition to this 
increase, we demonstrated that treatment with RAAS blockers decreased urinary renin levels. 
An explanation for this decrease could be the inhibition of a discordant tissue RAAS. Therefore, 
measurement of urinary renin might also be a useful marker to assess the success of RAAS 
blockade. Future studies are needed to address the effects of specific RAAS blockers on urinary 
renin amount, as well as the correlation with clinical outcome.
In chapters 16, 17 and 18 we studied the concept of an overactive RAAS in DM further and 
demonstrated that it resulted in systemic endothelial dysfunction, nephropathy and retinopathy, 
since renin inhibition reversed these effects. However, blockade of the (pro)renin receptor with 
HRP on top of traditional RAAS blockade did not result in additional disease modifying effects. 
On the contrary, when administered in a high dose, it resulted in a reversal of the beneficial 
effects of traditional RAAS blockade apart from the blood pressure lowering effect. This suggests 
that HRP interferes with traditional RAAS blockade in a manner that does not affect blood 
pressure, possibly via activation of tissue RAAS. Indeed, HRP has now been reported to act as a 
partial agonist of the (pro)renin receptor instead of an antagonist.31 Importantly, recent studies 
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have pointed to the possibility that the (pro)renin receptor may also exert functions that are 
entirely unrelated to the RAAS.32 The (pro)renin receptor is now thought to be a multi-functional 
receptor, which has been linked to generalized cellular processes related to vacuolar H+-ATPase 
integrity.33 In addition, it may have a role in the regulation of lipid and glucose metabolism and 
thereby possibly influencing cardiovascular disease indirectly.34 Given the uncertainty whether 
HRP acts as a (pro)renin receptor blocker or not, future studies should examine the exact 
function of the (pro)renin receptor in DM to define its role. In addition, to what degree prorenin 
– (pro)renin receptor interaction is physiologically relevant, given the nanomolar affinity of 
the receptor for prorenin and the picomolar levels of prorenin in blood,32 is still a matter of 
debate and requires further research. Therefore, the concept of prorenin – (pro)renin receptor 
interaction and subsequent sequelae in DM still remain unclear and are possibly unrelated to 
the RAAS.35 Blockade of the (pro)renin receptor does not hold great therapeutic promise, since 
(pro)renin receptor knockout mice die at an early age.36
Also, in chapters 16, 17 and 18 we demonstrated promising effects of the renin inhibitor 
aliskiren on the reduction of diabetic cardiovascular pathology, at least within the animal 
model. In clinical practice, adequate blood pressure lowering effects of aliskiren have been 
demonstrated.37 Two weeks after ending aliskiren treatment beneficial effects on blood pressure 
were still present as well as reduced plasma renin activity.38 This cannot solely be explained 
because of the long half-life of aliskiren in plasma, but could also point to the accumulation of 
aliskiren in the kidney with subsequent suppression of tissue RAAS.39 Suppression of discordant 
tissue RAAS was thought to result in better long-term cardiovascular outcomes. However, large 
randomized controlled trials showed disappointing results with no additional benefits and even 
adverse effects like renal dysfunction and hypotension especially when dual RAAS blockade 
was present, as demonstrated for diabetic patients with cardiovascular disease,40 as well as for 
patients with acute obstructive CAD,41 and heart failure patients.42,43 These findings suggest that 
maximal RAAS blockade in high risk patients is deleterious because of renal failure.44 This is 
called the “nephrocentric” reaction to almost complete RAAS blockade.45 Possibly, aliskiren has 
more beneficial effects early on in cardiovascular disease development. Indeed in a small pilot 
study, aliskiren demonstrated favorable effects on endothelial function as well as on myocardial 
function after three months of treatment in DM patients under stable glycemic control and with 
mild essential hypertension, independent from the blood pressure lowering effect,46 possibly 
because of increased NO availability.47 This would point again to differences in disease state: 
early versus advanced cardiovascular disease, as this thesis also clearly demonstrates.
The exact mechanism of an overactive RAAS on cardiovascular disease development is still 
incompletely understood.48 Although double RAAS blockade with an ACE inhibitor or an Ang 
II type 1 receptor blocker in combination with a mineralocorticoid receptor antagonist has 
proven to be very beneficial for the treatment of heart failure; double RAAS blockade with 
both a renin inhibitor and an ACE inhibitor or an Ang II type 1 receptor blocker has proven to 
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be detrimental. However, the ten-year results of renin inhibition need to be awaited and the 
treatment in specific patient populations might be beneficial. Especially the disease spectrum 
of hypertension, diastolic dysfunction and heart failure with preserved ejection fraction is 
of interest, in which endothelial dysfunction is thought to play a crucial role. Indeed, plasma 
angiotensinogen might be a useful biomarker of this disease spectrum, as well as a potential 
therapeutic target.49 The combination of RAAS blockade therapy with measurement of both 
intrarenal and extrarenal RAAS activity50 and subsequent tailoring of optimal RAAS blockade 
therapy seems to be the next logical step in future studies. Finally, the role of (pro)renin 
receptor stimulation in the development of cardiovascular disease is ambiguous. Via indirect 
pathways related to cardiovascular risk factors it might have effects, which future studies need 
to resolve. Only selective blockade of this receptor may hold promise, because of its now known 
multifunctional connections to vital processes.
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Main conclusions and implications
Main conclusions and implications derived from Part I:
Peripheral arterial tonometry cannot predict patients at low risk of CAD in a clinical setting, most 
likely because of the presence of heterogeneous disease within the patients and because of the 
presence of uncontrollable variables in a clinical setting.
 A porcine model of CAD is a suitable model for the study of coronary conduit and microvascular 
dysfunction, for diagnostic and therapeutic interventions of CAD, as well as for the study of end-
organ pathology in cardiovascular disease. Therefore, this model could help to unravel disease 
processes involved in microvascular angina and heart failure. 
Coronary microvascular dysfunction shows a dysbalance of vasodilating and vasoconstricting 
mechanisms that changes over time in CAD development. Therefore, measurement of 
endothelial dysfunction at a single moment in time is not likely to predict dysfunction during 
later stages of the disease process.
Main conclusions and implications derived from Part II:
Endothelial function has several properties including a permeable barrier function, an anti-
thrombotic and anti-inflammatory defense, as well as the regulation of vascular tone. All of 
these properties can be impaired to some extent by coronary stenting in general.
Specifically PES, a first generation DES, can impair distal microvascular function under conditions 
of reduced NO bioavailability. This could be, at least partly, an explanation for the worse clinical 
outcomes for DM patients after first generation DES.
With the development of the BVS, endothelial dysfunction within the scaffold, resulting in 
neoatherosclerosis as well as dysfunction adjacent to the scaffold, still remains an issue, in 
particular in the presence of DM. This could be an explanation for the observations of increased 
scaffold thrombosis and restenosis in clinical practice, with DM patients having the greatest risk.
Main conclusions and implications derived from Part III:
DM patients are at increased risk of cardiovascular disease development, with an important 
role for an overactive RAAS. A discordant tissue RAAS is likely to play a role in specific end-
organ disease of DM. However, a role for prorenin – (pro)renin receptor interaction within this 
pathology has become questionable.
Urinary renin may represent renal RAAS activity in DM patients and its measurement can be used 
not only to reflect this activation but also to measure the success of RAAS blockade. Therefore, it 
could possibly guide therapy in selected patients to improve clinical outcome.
Renin inhibition can improve endothelial dysfunction and end-organ pathology related to diabetic 
cardiovascular disease, at least in an animal model with a highly activated RAAS. The clinical 
effects of renin inhibition in clinical practice are hampered by the “nephrocentric” reaction to 
almost complete RAAS blockade, but may show long-term benefit in selected patients.
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Abbreviations and acronyms
ACE  angiotensin-converting enzyme 
Ang II  angiotensin II
AT1   Ang II type 1 receptor
BMS  bare metal stents 
BVS  bioresorbable vascular scaffold
CAD  coronary artery disease
cGMP  cyclic guanoside monophosphate
COX-2  cyclooxygenase 2 
DES  drug-eluting stents 
DM  diabetes mellitus
EDCF  endothelium derived contracting factor
EDHF  endothelium derived hyperpolarizing factor
eNOS   endothelial nitric oxide synthase 
ETA   endothelin type A
ETB   endothelin type B 
ET-1  endothelin-1
HRP  handle region peptide
NIRS   near-infrared spectroscopy 
NO   nitric monoxide
OCT   optical coherence tomography 
PAT   peripheral arterial tonometry 
PCI   percutaneous coronary intervention
PES  paclitaxel eluting stent 
RAAS  renin angiotensin aldosterone system
TGF-β   transforming growth factor-β
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Curriculum vitae
De auteur van dit proefschrift, Mieke van den Heuvel, werd geboren op 29 december 1976 
te Oss. In 1995 behaalde zij aldaar haar VWO diploma aan het Titus Brandsma Lyceum. In 
hetzelfde jaar begon zij aan de studie Medische Biologie aan de universiteit van Utrecht. In 
2000 begon zij aldaar ook aan de studie Geneeskunde. In 2002 maakte zij voor het eerst kennis 
met de experimentele cardiologie in het laboratorium van Prof.dr. G. Pasterkamp tijdens een 
onderzoeksstage onder supervisie van Dr. J.I. Rotmans waarbij zij startte met onderzoek doen naar 
de pathologie van bloedvaten. Vanuit deze afdeling, deed zij in 2003 een extra onderzoeksstage 
te Stanford University in de VS, in het Cardiovascular Core Analysis Laboratory van Dr. A. Yeung. 
Hier maakte zij voor het eerst kennis met pathologie verbonden aan drug eluting stents. In 2004 
ronde zij haar studie Medische Biologie af en in 2005 de studie Geneeskunde. In 2006 was zij 
werkzaam als ANIOS interne geneeskunde / cardiologie eerst in het Sint Franciscus Gasthuis 
te Rotterdam, later in het Albert Schweitzer ziekenhuis te Dordrecht. In 2007 begon zij met 
haar promotieonderzoek op de afdelingen experimentele cardiologie en farmacologie van het 
Erasmus MC te Rotterdam met als promotoren Prof.dr. W.J. van der Giessen, na zijn overlijden 
Prof.dr. D.J. Duncker en Prof.dr. A.H.J. Danser. De resultaten van dit onderzoek zijn in dit 
proefschrift beschreven. Eind 2012 is zij begonnen met de opleiding cardiologie in het Erasmus 
MC na een korte periode als ANIOS cardiologie in het Sint Elisabeth Hospitaal te Willemstad in 
Curaçao en in het Erasmus MC te hebben gewerkt. Zij heeft de twee jaar vooropleiding interne 
geneeskunde in het Albert Schweitzer ziekenhuis gedaan onder supervisie van Dr. E.F.H. van 
Bommel en in 2015 de B-opleiding cardiologie, onder supervisie van Dr. E.J. van den Bos en Dr. 
M.J.M. Kofflard. Vanaf eind 2015 is zij bezig met de A-opleiding cardiologie in het Erasmus MC, 
onder supervisie van Dr. T.W. Galema en Dr. E.A. Dubois. Zij woont samen met Alexander Cupido 
te Rotterdam.
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PhD Portfolio
Name PhD student: Mieke van den Heuvel
Erasmus MC Department: Cardiology
Research School: COEUR
PhD Period: 2007 – 2017
Promotors: Prof.dr. D.J. Duncker
 Prof.dr. A.H.J. Danser
1. PhD training Year Workload (ECTS)
General academic skills
-Integrity in Research 2007 0.5
-Laboratory animal science 2007 4.5
-English biomedical writing and communication 2008 4
Research skills
-Statistics (NIHESS course) 2007, 2008 6
In-depth courses
-COEUR courses 2007 – 2011 6
-NHS Papendal PhD training course 2007 4
-Methodologie voor patientgebonden onderzoek 2007 2
Presentations
-Oral presentation, EASD 2007
-Oral presentation COEUR Research seminars 2007, 2011, 2012
-Oral presentation, TCT 2008
-Poster presentations, European Society of Cardiology 2008, 2009, 2010
-Poster presentation, American Heart Association 2009
-Poster presentation, European Society of Hypertension 2009
-Oral presentation, EuroPCR 2009
-Poster presentation, High Blood Pressure Counsil 2010
-Oral presentation, European Society of Hypertension 2011
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 (International) conferences
-EAS meeting 2007 1
-EASD, 43rd annual meeting 2007 1
-NHS Molecular Cardiology 2007 1
-NVVC-Voorjaarscongres 2007 1
-Pfizer HDL symposium 2007 0.5
-Vasculair Spreekuur 2007 0.5
-Cardiology and Vascular Medicine Update and Perspective 2007 – 2009 2
-COEUR research seminars 2007 – 2011 2 
-TCT conference 2008 1
-FIGON Dutch medicines days 2008 0.5
-ESC conference 2008 – 2010 3
-MIVAB 2008 – 2011 4
-DAS symposium 2009 1
-19th ESH meeting 2009 1
-AHA conference 2009 1
-EuroPCR conference 2009 1
-High Blood Pressure Counsil 2010 1
-9th Dutch German Joint meeting 2011 1
-NCCV conference 2011 0.5
-21st ESH meeting 2011 1
Seminars and workshops
-MolMed Writing successful grant proposals 2008 0.5
-Shear stress symposium 2008 0.5
-Geavanceerde beeldvormende technieken voor doctors 2009 0.5
-Pigs: “The missing link?” 2010 0.5
-Farewell symposium of Prof. J.A.E. Spaan 2010 0.5
-Diabetes Platform Erasmus MC 2010 0.5
-The first Bioresorbable Vascular Scaffold summit 2011 0.5
-Symposium Microcirculation in Health and Disease 2011 0.5
2. Teaching and organisation activities
-2nd year medical students: review writing 2009 2
-Organisation COEUR PhD day 2010 4
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3. Awards and grants
-Erasmus MC-grant: Pilot project 2007
Microvascular dysfunction in diabetes mellitus type 2 and its relation to metabolic control
-Travelgrant ESC counsil on Basic Cardiovascular Science 2008
-Prize for best poster, 19th   ESH meeting, Milan 2009
-Travelgrant EuroPCR, Barcelona, Erasmus Trustfonds 2009
-Prize for best poster, 13th DAS Symposium 2010
-Travelgrant High Blood Pressure Counsil, Washington
Nederlandse Vereniging voor Farmacologie 2010
-Dirk Durrer prize 2011
-Van Noordwijk stipendium, Kolff conference 2011
-3th prize Young Investigators Award, ACS platform 2011
-Travelgrant AHA, Orlando, Erasmus Trustfonds 2011
-Prize for best oral presentation,  2011
Nederlands Hypertensie Genootschap,
CardioVasculaire Conferentie
Total  62
x
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Publicatielijst
The effect of bioresorbable vascular scaffold implantation on distal coronary endothelial function in 
dyslipidemic swine with and without diabetes.
van den Heuvel M, Sorop O, van Ditzhuijzen NS, de Vries R, van Duin RWB, Krabbendam-Peters I, van Loon 
JE, de Maat MP, van Beusekom HM, van der Giessen WJ, Danser AHJ, Duncker DJ.
Int J Cardiol. 2018 Feb 1;252:44-51.
Neoatherosclerosis development following bioresorbable vascular scaffold implantation in diabetic and 
non-diabetic swine.
van Ditzhuijzen NS, Kurata M, van den Heuvel M, Sorop O, van Duin RWB, Krabbendam-Peters I, Ligthart 
J, Witberg K, Murawska M, Bouma B, Villiger M, Garcia-Garcia HM, Serruys PW, Zijlstra F, van Soest G, 
Duncker DJ, Regar E, van Beusekom HMM.
PLoS One. 2017 Sep 12;12(9):e0183419.
Serial Coronary Imaging of Early Atherosclerosis Development in Fast-Food-Fed Diabetic and Nondiabetic 
Swine.
Nienke S. van Ditzhuijzen, MSC, Mieke van den Heuvel, MD, Oana Sorop, PHD, Alexia Rossi, MD, PHD, 
Timothy Veldhof, MSC, Nico Bruining, PHD, Stefan Roest, BSC, Jurgen M.R. Ligthart, RT, Karen Th. Witberg, 
CCRN, Marcel L. Dijkshoorn, BSC, Koen Nieman, MD, PHD, Monique T. Mulder, PHD, Felix Zijlstra, MD, PHD, 
Dirk J. Duncker, MD, PHD, Heleen M.M. van Beusekom, PHD, Evelyn Regar, MD, PHD.
JACC Basic to Translational Science. 2016 Oct;449-6.
Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia.
Sorop O*, van den Heuvel M*, van Ditzhuijzen NS, de Beer VJ, Heinonen I, van Duin RW, Zhou Z, Koopmans 
SJ, Merkus D, van der Giessen WJ, Danser AH & Duncker DJ.
*Shared first authorship
Am J Physiol Heart Circ Physiol. 2016 Dec 1;311(6).
Peripheral arterial tonometry cannot detect patients at low risk of coronary artery disease.
van den Heuvel M, Sorop O, Musters PJ, van Domburg RT, Galema TW, Duncker DJ, van der Giessen WJ & 
Nieman K.
Neth Heart J. 2015 Sep;23(10):468-74.
Early systemic microvascular damage in pigs with atherogenic diabetes mellitus coincides with renal 
angiopoietin dysbalance.
Khairoun M, van den Heuvel M, van den Berg BM, Sorop O, de Boer R, van Ditzhuijzen NS, Bajema IM, 
Baelde HJ, Zandbergen M, Duncker DJ, Rabelink TJ, Reinders ME, van der Giessen WJ & Rotmans JI.
PLoS One. 2015 Apr 24;10(4).
The impact of Fourier-Domain optical coherence tomography catheter induced motion artefacts on 
quantitative measurements of a PLLA-based bioresorbable scaffold.
van Ditzhuijzen NS, Karanasos A, Bruining N, van den Heuvel M, Sorop O, Ligthart J, Witberg K, Garcia-
Garcia HM, Zijlstra F, Duncker DJ, van Beusekom HM & Regar E.
Int J Cardiovasc Imaging. 2014 Aug;30(6):1013-26.
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Combined renin inhibition/(pro)renin receptor blockade in diabetic retinopathy--a study in transgenic 
(mREN2)27 rats.
Batenburg WW, Verma A, Wang Y, Zhu P, van den Heuvel M, van Veghel R, Danser AH & Li Q.
PLoS One. 2014 Jun 26;9(6).
Deterioration of kidney function by the (pro)renin receptor blocker handle region peptide in aliskiren-
treated diabetic transgenic (mRen2)27 rats.
te Riet L, van den Heuvel M, Peutz-Kootstra CJ, van Esch JH, van Veghel R, Garrelds IM, Musterd-Bhaggoe 
U, Bouhuizen AM, Leijten FP, Danser AH & Batenburg WW.
Am J Physiol Renal Physiol. 2014 May 15;306(10).
The (pro)renin receptor blocker handle region peptide upregulates endothelium-derived contractile factors 
in aliskiren-treated diabetic transgenic (mREN2)27 rats.
Batenburg WW*, van den Heuvel M*, van Esch JH, van Veghel R, Garrelds IM, Leijten F & Danser AH.
*Shared first authorship
J Hypertens. 2013 Feb;31(2):292-302.
Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes.
van den Heuvel M*, Sorop O*, Koopmans SJ, Dekker R, de Vries R, van Beusekom HM, Eringa EC, Duncker 
DJ, Danser AH & van der Giessen WJ.
*Shared first authorship
Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1).
Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone 
system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, van den 
Meiracker AH & Danser AH.
J Hypertens. 2011 Nov;29(11):2147-55. 
Invasive coronary imaging in animal models of atherosclerosis.
van Ditzhuijzen NS*, van den Heuvel M*, Sorop O, van Duin RW, Krabbendam-Peters I, van Haeren R, 
Ligthart JM, Witberg KT, Duncker DJ, Regar E, van Beusekom HM & van der Giessen WJ.
*Shared first authorship
Neth Heart J. 2011 Oct;19(10):442-6.
Dietary saturated fat/cholesterol, but not unsaturated fat or starch, induces C-reactive protein associated 
early atherosclerosis and ectopic fat deposition in diabetic pigs.
Koopmans SJ, Dekker R, Ackermans MT, Sauerwein HP, Serlie MJ, van Beusekom HM, van den Heuvel M & 
van der Giessen WJ.
Cardiovasc Diabetol. 2011 Jul 14;10:64. 
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The Authors Reply.
Response to ‘Angiotensin II-induced phosphorylation of the sodium chloride cotransporter’.
Nils van der Lubbe, Mieke van den Heuvel, Robert Zietse, Ewout J. Hoorn, Alexander H.J. Danser.
Kidney International. 2011 June 79(12):1382.
On the origin of urinary angiotensin II.
van den Heuvel M, van Esch JH & Danser AH.
Hypertension. 2010 Oct;56(4).
Specific coronary drug-eluting stents interfere with distal microvascular function after single stent 
implantation in pigs.
van den Heuvel M, Sorop O, Batenburg WW, Bakker CL, de Vries R, Koopmans SJ, van Beusekom HM, 
Duncker DJ, Danser AH & van der Giessen WJ.
JACC Cardiovasc Interv. 2010 Jul;3(7):723-30. 
Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, 
sirolimus- and tacrolimus-eluting stents.
van Beusekom HM, Sorop O, van den Heuvel M, Onuma Y, Duncker DJ, Danser AH & van der Giessen WJ.
EuroIntervention. 2010 May;6(1):117-25.
Endothelial dysfunction after drug eluting stent implantation.
van den Heuvel M, Sorop O, van Beusekom HM & van der Giessen WJ.
Minerva Cardioangiol. 2009 Oct;57(5):629-43.
Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis?
van den Heuvel M, Batenburg WW & Danser AH.
Mol Cell Endocrinol. 2009 Apr 29;302(2):213-8.
Local overexpression of C-type natriuretic peptide ameliorates vascular adaptation of porcine hemodialysis 
grafts.
Rotmans JI, Verhagen HJ, Velema E, de Kleijn DP, van den Heuvel M, Kastelein JJ, Pasterkamp G, & 
Stroes ES.
Kidney Int. 2004 May;65(5):1897-905.
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Dankwoord
Promoveren doe je nooit alleen, maar met de steun van collega’s, vrienden en familie. Hierbij wil 
ik iedereen bedanken die bijgedragen heeft aan het tot stand komen van dit proefschrift. Zonder 
volledig te kunnen zijn, wil ik een aantal mensen in het bijzonder benoemen.
Nadat ik uit de klinische praktijk wist cardioloog te willen worden, ben ik op de afdeling 
experimentele cardiologie in het EMC gaan praten over promotieonderzoek. In een aangenaam 
gesprek met Wim, Dirk en Heleen werd mij duidelijk dat de afdeling meerdere projecten te 
bieden had en dat ik daar ook een eigen weg in kon bewandelen. Het laatste, in combinatie met 
het opzetten van een diabetes varkensmodel als een ziektemodel voor stent-studies, sprak me 
aan en sloot goed aan bij eerder onderzoek wat ik had gedaan.
In de maanden die volgden, bleek het opzetten van het model nog niet zo snel te gaan als 
ik zou willen, maar gelukkig kon ik uit eerder materiaal van pilots van Sietse Jan, Heleen en 
Oana putten. De vaatfunctie studies van Oana vond ik het meest interessant, die me dan ook in 
het “badjeslab” op de 14e verdieping binnen de afdeling farmacologie introduceerde. De sfeer 
daar en het zelf “prutsen” met vaatjes onder de microscoop verkregen uit slachthuisharten die 
ruimschoots voorhanden waren bevielen en hiermee was de samenwerking tussen de afdelingen 
experimentele cardiologie en farmacologie geboren. De loop der jaren kenmerkten zich doordat 
inmiddels meerdere projectjes gingen lopen en doordat ook het diabetes varkensmodel 
echt in Rotterdam zou gaan starten. Wat me altijd is bijgebleven is dat Wim eigenlijk in alles 
aanmoedigde en niet te veel stuurde zowel in experimenten, analyses, subsidie aanvragen, 
abstracts voor congressen als in manuscripten zodat ik het gevoel kreeg en altijd heb gehad 
mijn eigen promotie traject te bewandelen, wat misschien wel iets langer heeft geduurd dan 
gepland maar waarin ik alles heb afgerond waaraan ik ooit begonnen was. Ik kan me achteraf 
geen betere promotor voorstellen en ik hoop dat je tevreden geweest zou zijn met het resultaat. 
Wim bedankt!
Beste Jan, door de experimenten op het “badjeslab” kwam ik gedurende mijn onderzoeks-
jaren met veel plezier op jouw afdeling en ik ben ook erg blij dat al snel duidelijk werd dat 
mijn promotieonderzoek door twee promotoren zou worden ondersteund zodat de vaatfunctie 
experimenten een belangrijk onderdeel zouden vormen binnen mijn promotie traject. Het 
meedenken over de uitkomsten van de vaatfunctie stent-experimenten, maar ook het helpen 
met toekomst-ideeën zoals het isoleren van vaatjes uit bilbiopten, maar geeft wel aan dat er op 
de 14e altijd goed en breed mee werd gedacht. Uiteindelijk bleken de bilbiopten niet succesvol 
en heb ik samen met Wendy o.b.v. haar Nierstichting subsidie een aantal mooie experimenten 
kunnen doen die tot goede publicaties hebben geleid. Vanaf het moment van schrijven van het 
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review behorend bij dit project, het verrichten van de experimenten en tot aan het schrijven van 
de manuscripten o.b.v. de resultaten, stond alles in het teken van hoge efficiëntie en snelheid 
waarmee het voor elkaar kwam. Ik ken niemand die sneller uit geanalyseerde gegevens een 
manuscript kan destilleren, dan jij. De samenwerking en de sfeer op de afdeling was altijd 
prettig. Het discussiëren over resultaten was altijd leerzaam, hoewel ik wat betreft de RAAS 
experimenten vaak pas achteraf als jij het manuscript al zo’n beetje klaar had, door had wat 
ze nu eigenlijk betekenden. Ook het lab-uitje naar New York was memorabel. Uiteindelijk is de 
lange nasleep van dit promotie-traject niet helemaal wat jij wilde, maar ik denk dat het werk 
op zowel van de afdelingen farmacologie als experimentele cardiologie uiteindelijk wel zijn 
vruchten heeft afgeworpen. Jan, ik wil je graag bedanken voor de samenwerking en ik vind het 
een eer gewerkt te mogen hebben met een wereldwijde expert op het gebied van het RAAS en 
ik ben blij daar nu ook iets meer vanaf te weten.
Beste Dirk, na het overlijden van Wim werd jij mijn tweede promotor. Maar zoals gezegd was 
je al vanaf dag 1 van mijn promotieonderzoek betrokken en ook tussentijds was je altijd al 
bereid om mee te denken. Ik denk dat door je vriendelijke enthousiasme iedereen wel met je 
wil samenwerken, en ik dus ook. Ik ben blij en trots dat het diabetes varkensmodel nog altijd 
gebruikt wordt op de afdeling experimentele cardiologie en ik wil je hartelijk bedanken voor de 
steun en begeleiding tijdens het promotie-traject en met name voor je geduld in de afronding 
van het laatste deel. De discussies rondom de analyses van de resultaten en het schrijven van 
de manuscripten waren altijd leerzaam en ik heb het altijd kunnen waarderen dat je ruimte 
voor mij liet voor klinische uitstapjes zowel in de discussies van de manuscripten als voor het 
vaatfunctie onderzoek in de kliniek, als in het aangaan van samenwerkingen wat betreft het 
diabetes varkensmodel.
Geachte Prof. van Bavel, Prof. de Boer en Prof. Zijlstra, graag wil ik u allen bedanken voor de 
bereidheid om deel te nemen in de leescommissie voor de beoordeling van mijn proefschrift.
Beste Oana, zonder jouw hulp en steun was mijn promotieonderzoek waarschijnlijk niet tot stand 
gekomen. Je bent bij ieder van mijn projecten, die vanaf de 23ste gestart zijn, betrokken geweest 
inclusief de endotheel functie metingen in de kliniek. Hartelijk dank voor alle ondersteuning en 
prettige samenwerking en ook voor hulp in de afgelopen jaren voor de afronding van de laatste 
artikelen van dit boekje. Jouw voorliefde voor microvaatfunctie heb je op mij overgedragen en ik 
hoop dat je hier nog veel mensen in de toekomst voor kunt enthousiasmeren. Ik ben blij dat na 
al het harde werken om het diabetes varkensmodel in Rotterdam gestart te krijgen gelukt is en 
dat je daar met een groepje “sterke mannen” nog altijd verder aan werkt.
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Beste Wendy, naast Oana was ook jij een belangrijke steun en toeverlaat gedurende mijn 
promotie onderzoek. Als “koningin” van het “badjeslab” wist je alles over de in vitro vaatfunctie 
experimenten en het uitwerken daarvan. Het diabetes ratten project was een heel leuk project 
om samen aan te werken waarbij we de dieren maximaal efficiënt hebben gebruikt.
Beste Siete Jan, in de begin jaren heb ik geworsteld met jouw pilotdata van varkensmodellen 
met enige mate van cardiovasculaire ziekte. Uiteindelijk hebben we een bepaalde strategie 
overgenomen voor het model in Rotterdam maar ik begrijp nu beter dat ieder model zijn voors 
en tegens heeft. Hartelijk dank voor de altijd fijne samenwerking en je bereidheid om materiaal 
van je studies met ons te delen!
Op de 23ste heb ik tijdens de projecten met vele mensen samengewerkt: Heleen: bedankt voor 
je expertise in de histologie; Ilona: bedankt voor de kleuringen en metingen die je hebt gedaan; 
Richard: bedankt voor de hulp tijdens de dierexperimenten en succes met de afronding van je 
eigen promotie. Mensen die inmiddels vertrokken zijn: Charlotte: dank voor je hulp tijdens de 
dier experimenten en met de histologie; Rorry: bedankt voor je hulp bij de histologie;  Nienke: 
bedankt voor de samenwerking tijdens het diabetes varkens project en het schrijven van de 
bijbehorende manuscripten; Zhichao: bedankt voor je interesse in microvaatfunctie op het 
“badjeslab”. Daphne: bedankt voor het meedenken tijdens subsidie aanvragen, de analyses van 
data en tips voor presentaties. Rob: hartelijk dank voor je gezelligheid en ICT ondersteuning; 
Liesbeth: ook hartelijk dank voor je ICT ondersteuning en het veelvuldig activeren van mijn 
toegang tot de harde schijf van de 23ste; Monique: hartelijk dank voor de secretariële en 
administratieve ondersteuning. Elles: ook hartelijk dank voor de secretariële en administratieve 
ondersteuning in de tijd dat Wim er nog was. Mensen die bijdroegen aan de prettige werksfeer: 
Marc: hartelijk dank voor je gezelschap en steun tijdens de laatste onderzoeks-jaren; Elza: 
bedankt voor de gezelligheid inclusief road-trip door de Everglades en de Florida Keys; Maaike: 
hartelijk dank voor al je advies en ondersteuning; Martine: dank voor je gezelligheid; Andre: 
bedankt voor het zijn van de beste buurman die een promovenda zich kan wensen: altijd vrolijk, 
behendig in krav maga en altijd in voor een meloen cocktail! Bianca: bedankt als luisterend 
oor en gezellige buurvrouw; Tuncay: altijd rustig aanwezig en inmiddels allang gepromoveerd! 
Vincent: allang vertrokken maar hij blijft maar terugkeren naar de 23ste… In het begin waren we 
kamergenoten: bedankt daarvoor! Last but not least: de mensen van mijn laatste werkplek: 
Ruben, Jens en Maarten: er is weer meer plaats in de kamer!
Ook op de 14e heb ik met vele mensen samengewerkt: René: hartelijk dank voor alle “grote” 
vaatexperimenten en je rustige aanwezigheid; Richard: hartelijk dank voor alle hulp met de 
ratten experimenten en voor je gezellige praatjes. Ingrid: hartelijk dank  voor je snelle analyses 
van de urine en bloed monsters. Anton: bedankt voor het meedenken met experimenten en 
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fameuze farmacologie filmavonden en sinterklaasfeesten. Antoinette: hartelijk dank voor 
het meedenken met uitkomstresultaten. Birgitte: heel erg bedankt voor de secretariële en 
administratieve ondersteuning en de gezellige relaxte sfeer van de 14e. Mensen die inmiddels 
vertrokken zijn: Jeanette: ook hartelijk dank voor de hulp bij de analyses van de urine en plasma 
monsters. Joep: bedankt voor je hulp tijdens de ratten experimenten en voor de gezellige sfeer 
op het “badjeslab”, Ka Yi: bedankt voor de gezelligheid inclusief mijn eerste Chinese bruiloft.
Tijdens mijn onderzoekstijd had ik het geluk te kunnen samenwerken met meerdere mensen 
van ook andere afdelingen. Ton van den Meiracker: hartelijk dank voor je interesse in humane 
vaatfunctie experimenten, hoewel het afnemen van bilbiopten niet zo gemakkelijk bleek. Jurgen 
Lighthart en Karen Witberg: bedankt voor de in vivo vaatfunctie metingen. Etto Eringa: bedankt 
voor je hulp bij de Western Blot analyses. Joris Rotmans en Meriem Khairoun: hartelijk dank voor 
de glycocalyx metingen en de nier analyses. Janine Elshout en Moniek de Maat: hartelijk dank 
voor de plasma vWf metingen. Paul Musters en Tjebbe Galema voor het mogelijk maken van de 
endotheel functie metingen in de kliniek. Ron van Domburg en Magdalena Murawska: bedankt 
voor de statistische ondersteuning. Koen Nieman: bedankt voor je hulp en ondersteuning in de 
afronding van het perifere endotheel functie artikel.
Mijn opleiders, Tjebbe Galema en Eric Dubois, en mijn collega arts-assistenten wil ik bedanken 
voor de mogelijkheid die zij mij hebben gegeven tot de afronding van dit proefschrift tijdens de 
opleiding tot cardioloog.
Mijn paranimfen Karin en Diana wil ik bedanken voor hun ondersteuning tijdens de promotie 
plechtigheid, maar vooral voor hun vriendschap van afgelopen jaren en de garantie dat daarmee 
15 mei een feest gaat worden!
Natuurlijk kan ik ook de andere “In Viva” ladies niet vergeten: Evelyn, Maja, Michelle en Yvonne, 
bedankt voor de steun door jarenlange gezellige borrels, etentjes en uitjes!
Als laatste wil ik uiteraard ook mijn ouders en Alexander bedanken. Zonder jullie was het zeker 
niet gelukt!
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Addendum
De auteur wil Myrrhe van Spronsen, de artistieke vormgever van de illustraties van de kaft en in 
het proefschrift bedanken voor haar bijdrage.
De auteur erkent dankbaar de financiële ondersteuning voor het drukken van dit proefschrift 
door:
• Erasmus University Rotterdam
• Abbott Vascular Netherlands B.V.
• Boehringer Ingelheim B.V.
• Chipsoft B.V.
• Sanofi Nederland B.V.
• Servier Nederland Farma B.V.
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